{"1522b3c191730bb3161a610fadb3bf06095ab902": [["a1111111111 a1111111111 a1111111111 a1111111111 a1111111111IntroductionPatients increasingly receive treatment at facilities other than hospitals, including long-term health care facilities, due to the rapidly increasing aged population, who more often have chronic diseases [1, 2] Pneumonia occurring prior to hospital admission in patients who have had recent contact with health systems is termed healthcare-associated pneumonia (HCAP) [3] [4] [5] .", [["chronic diseases", "DISEASE", 258, 274], ["Pneumonia", "DISEASE", 282, 291], ["pneumonia", "DISEASE", 422, 431], ["HCAP", "DISEASE", 433, 437], ["patients", "ORGANISM", 333, 341], ["patients", "SPECIES", 333, 341], ["treatment", "TREATMENT", 101, 110], ["chronic diseases", "PROBLEM", 258, 274], ["Pneumonia", "PROBLEM", 282, 291], ["pneumonia (HCAP)", "PROBLEM", 422, 438], ["chronic", "OBSERVATION_MODIFIER", 258, 265], ["diseases", "OBSERVATION", 266, 274], ["Pneumonia", "OBSERVATION", 282, 291], ["pneumonia", "OBSERVATION", 422, 431]]], ["These patients are believed to be at increased risk for infection with multidrug-resistant (MDR) organisms [3, 4] , and is of particular concern in HCAP patients.", [["infection", "DISEASE", 56, 65], ["multidrug-resistant (MDR) organisms", "DISEASE", 71, 106], ["HCAP", "DISEASE", 148, 152], ["patients", "ORGANISM", 6, 14], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 153, 161], ["infection", "PROBLEM", 56, 65], ["multidrug-resistant (MDR) organisms", "PROBLEM", 71, 106], ["believed to be", "UNCERTAINTY", 19, 33], ["infection", "OBSERVATION", 56, 65], ["HCAP", "OBSERVATION", 148, 152]]], ["However, recent studies have indicated that many patients defined as having HCAP were not infected with MDR pathogens [6] [7] [8] [9] [10] .", [["patients", "ORGANISM", 49, 57], ["HCAP", "GENE_OR_GENE_PRODUCT", 76, 80], ["[6] [7] [8] [9", "SIMPLE_CHEMICAL", 118, 132], ["patients", "SPECIES", 49, 57], ["recent studies", "TEST", 9, 23], ["HCAP", "PROBLEM", 76, 80], ["MDR pathogens", "TEST", 104, 117]]], ["Even after excluding MDR pathogens, substantial differences in the etiological profile between community-acquired pneumonia (CAP) and HCAP groups have been noted in recent studies [11, 12] , indicating that HCAP settings might present unique risks of pneumonia.IntroductionThe incidence of viral pneumonia has increased during the past decade [13] .", [["pneumonia", "DISEASE", 114, 123], ["CAP", "DISEASE", 125, 128], ["pneumonia", "DISEASE", 251, 260], ["viral pneumonia", "DISEASE", 290, 305], ["MDR pathogens", "PROBLEM", 21, 34], ["community-acquired pneumonia (CAP) and HCAP groups", "PROBLEM", 95, 145], ["recent studies", "TEST", 165, 179], ["HCAP settings", "TREATMENT", 207, 220], ["pneumonia", "PROBLEM", 251, 260], ["viral pneumonia", "PROBLEM", 290, 305], ["substantial", "OBSERVATION_MODIFIER", 36, 47], ["differences", "OBSERVATION_MODIFIER", 48, 59], ["pneumonia", "OBSERVATION", 114, 123], ["CAP", "OBSERVATION_MODIFIER", 125, 128], ["HCAP", "OBSERVATION", 134, 138], ["HCAP", "OBSERVATION", 207, 211], ["pneumonia", "OBSERVATION", 251, 260], ["viral", "OBSERVATION_MODIFIER", 290, 295], ["pneumonia", "OBSERVATION", 296, 305], ["increased", "OBSERVATION_MODIFIER", 310, 319]]], ["In part, this apparent increase reflects improved diagnostic techniques, including polymerase chain reaction (PCR) [13] .", [["polymerase chain reaction", "PROBLEM", 83, 108], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["improved", "OBSERVATION_MODIFIER", 41, 49]]], ["Over the last decade, several studies have used PCR to establish the importance of viruses in the etiology of CAP, and have consistently demonstrated viruses to be the second most common etiological factor, accounting for 13-50% of diagnosed cases [7, 11, [13] [14] [15] [16] [17] [18] [19] [20] [21] .", [["CAP", "DISEASE", 110, 113], ["[13] [14] [15] [16] [17] [18] [19] [20] [21]", "SIMPLE_CHEMICAL", 256, 300], ["several studies", "TEST", 22, 37], ["PCR", "TEST", 48, 51], ["viruses", "PROBLEM", 83, 90], ["CAP", "PROBLEM", 110, 113], ["viruses", "PROBLEM", 150, 157], ["diagnosed cases", "TEST", 232, 247], ["viruses", "OBSERVATION", 83, 90], ["viruses", "OBSERVATION", 150, 157]]], ["In a recent systematic review and meta-analysis of viral CAP, no significant association between viral infection and increased mortality was observed, but mortality was increased in patients with a bacterial-viral coinfection [22] .", [["viral infection", "DISEASE", 97, 112], ["bacterial-viral coinfection", "DISEASE", 198, 225], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["viral CAP", "PROBLEM", 51, 60], ["viral infection", "PROBLEM", 97, 112], ["increased mortality", "PROBLEM", 117, 136], ["a bacterial-viral coinfection", "PROBLEM", 196, 225], ["viral CAP", "OBSERVATION", 51, 60], ["no", "UNCERTAINTY", 62, 64], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["viral", "OBSERVATION_MODIFIER", 97, 102], ["infection", "OBSERVATION", 103, 112], ["increased", "OBSERVATION_MODIFIER", 117, 126], ["mortality", "OBSERVATION", 127, 136], ["increased", "OBSERVATION_MODIFIER", 169, 178], ["viral coinfection", "OBSERVATION", 208, 225]]], ["However, its clinical implications are debatable, because most studies performed PCR using nasopharyngeal or oropharyngeal swabs [22] , which might yield a negative result in patients with lower respiratory tract viral infection [11, 23] .IntroductionUnlike CAP, the viral profile and the clinical implications thereof in HCAP are not well studied.", [["nasopharyngeal", "ANATOMY", 91, 105], ["oropharyngeal swabs", "ANATOMY", 109, 128], ["respiratory tract viral infection", "DISEASE", 195, 228], ["nasopharyngeal", "CANCER", 91, 105], ["patients", "ORGANISM", 175, 183], ["lower respiratory tract", "ORGANISM_SUBDIVISION", 189, 212], ["HCAP", "CANCER", 322, 326], ["patients", "SPECIES", 175, 183], ["PCR", "TEST", 81, 84], ["nasopharyngeal or oropharyngeal swabs", "TEST", 91, 128], ["lower respiratory tract viral infection", "PROBLEM", 189, 228], ["the viral profile", "TEST", 263, 280], ["HCAP", "PROBLEM", 322, 326], ["oropharyngeal", "ANATOMY", 109, 122], ["lower", "ANATOMY_MODIFIER", 189, 194], ["respiratory tract", "ANATOMY", 195, 212], ["CAP", "OBSERVATION_MODIFIER", 258, 261], ["HCAP", "OBSERVATION", 322, 326]]], ["Therefore, we performed this prospective study 1) to investigate the role of viral infection in patients with HCAP and CAP, using all available adequate respiratory specimens from our institution, and 2) to identify the seasonal variation in both groups of patients.Study design and patientsThis study was conducted at a tertiary referral hospital in Republic of Korea.", [["respiratory specimens", "ANATOMY", 153, 174], ["viral infection", "DISEASE", 77, 92], ["CAP", "DISEASE", 119, 122], ["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 257, 265], ["patients", "ORGANISM", 283, 291], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 257, 265], ["patients", "SPECIES", 283, 291], ["this prospective study", "TEST", 24, 46], ["viral infection", "PROBLEM", 77, 92], ["HCAP", "PROBLEM", 110, 114], ["CAP", "TREATMENT", 119, 122], ["Study design", "TEST", 266, 278], ["This study", "TEST", 291, 301], ["viral", "OBSERVATION_MODIFIER", 77, 82], ["infection", "OBSERVATION", 83, 92], ["seasonal variation", "OBSERVATION", 220, 238]]], ["All adult patients, who were admitted to the hospital with HCAP or CAP from January 1 to December 31, 2016, were prospectively recruited after providing written informed consent.", [["HCAP", "DISEASE", 59, 63], ["CAP", "DISEASE", 67, 70], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["HCAP", "PROBLEM", 59, 63], ["CAP", "PROBLEM", 67, 70], ["HCAP", "OBSERVATION", 59, 63]]], ["Patients were excluded from the study if they had pneumonia related to witnessed aspiration during eating or vomiting, obstructive pneumonia related to airway obstruction by a tumor, hospital-acquired (HAP), or ventilator-associated pneumonia (VAP).", [["airway", "ANATOMY", 152, 158], ["tumor", "ANATOMY", 176, 181], ["pneumonia", "DISEASE", 50, 59], ["vomiting", "DISEASE", 109, 117], ["obstructive pneumonia", "DISEASE", 119, 140], ["airway obstruction", "DISEASE", 152, 170], ["tumor", "DISEASE", 176, 181], ["HAP", "DISEASE", 202, 205], ["ventilator-associated pneumonia", "DISEASE", 211, 242], ["VAP", "DISEASE", 244, 247], ["Patients", "ORGANISM", 0, 8], ["airway", "PATHOLOGICAL_FORMATION", 152, 158], ["tumor", "CANCER", 176, 181], ["Patients", "SPECIES", 0, 8], ["the study", "TEST", 28, 37], ["pneumonia", "PROBLEM", 50, 59], ["witnessed aspiration", "PROBLEM", 71, 91], ["vomiting", "PROBLEM", 109, 117], ["obstructive pneumonia", "PROBLEM", 119, 140], ["airway obstruction", "PROBLEM", 152, 170], ["a tumor", "PROBLEM", 174, 181], ["ventilator-associated pneumonia", "PROBLEM", 211, 242], ["VAP", "PROBLEM", 244, 247], ["pneumonia", "OBSERVATION", 50, 59], ["aspiration", "OBSERVATION", 81, 91], ["obstructive", "OBSERVATION_MODIFIER", 119, 130], ["pneumonia", "OBSERVATION", 131, 140], ["airway", "ANATOMY", 152, 158], ["obstruction", "OBSERVATION", 159, 170], ["tumor", "OBSERVATION", 176, 181], ["pneumonia", "OBSERVATION", 233, 242]]], ["Patients who did not undergo any microbiological studies before antibiotic administration, who received any form of antibiotics for more than 24 hrs prior to our hospital or who refused to participate in this study were also excluded.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["any microbiological studies", "TEST", 29, 56], ["antibiotic administration", "TREATMENT", 64, 89], ["antibiotics", "TREATMENT", 116, 127], ["this study", "TEST", 204, 214]]], ["If a patient had multiple pneumonia episodes within the study period, only the first pneumonia episode was recorded.", [["pneumonia", "DISEASE", 26, 35], ["pneumonia", "DISEASE", 85, 94], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["multiple pneumonia episodes", "PROBLEM", 17, 44], ["the study", "TEST", 52, 61], ["the first pneumonia episode", "PROBLEM", 75, 102], ["multiple", "OBSERVATION_MODIFIER", 17, 25], ["pneumonia", "OBSERVATION", 26, 35], ["pneumonia", "OBSERVATION", 85, 94]]], ["The study was approved by the Institutional Review Board and Ethics Committee of Seoul National University Bundang Hospital (SNUBH) (IRB No.", [["The study", "TEST", 0, 9]]], ["B-1511-324-306) and was conducted in compliance with the Declaration of Helsinki.DefinitionsPneumonia was defined as the presence of new infiltrates on chest X-rays along with other suggestive signs and symptoms: cough, sputum, fever, chills, dyspnea, pleuritic chest pain, disturbance of consciousness, and crackles [3, 24] .", [["sputum", "ANATOMY", 220, 226], ["chest", "ANATOMY", 262, 267], ["B-1511-324-306", "CHEMICAL", 0, 14], ["Pneumonia", "DISEASE", 92, 101], ["cough", "DISEASE", 213, 218], ["fever", "DISEASE", 228, 233], ["chills", "DISEASE", 235, 241], ["dyspnea", "DISEASE", 243, 250], ["chest pain", "DISEASE", 262, 272], ["disturbance of consciousness", "DISEASE", 274, 302], ["Pneumonia", "PROBLEM", 92, 101], ["new infiltrates", "PROBLEM", 133, 148], ["chest X-rays", "TEST", 152, 164], ["other suggestive signs and symptoms", "PROBLEM", 176, 211], ["cough", "PROBLEM", 213, 218], ["sputum", "PROBLEM", 220, 226], ["fever", "PROBLEM", 228, 233], ["chills", "PROBLEM", 235, 241], ["dyspnea", "PROBLEM", 243, 250], ["pleuritic chest pain", "PROBLEM", 252, 272], ["disturbance of consciousness", "PROBLEM", 274, 302], ["crackles", "PROBLEM", 308, 316], ["Pneumonia", "OBSERVATION", 92, 101], ["new", "OBSERVATION_MODIFIER", 133, 136], ["infiltrates", "OBSERVATION", 137, 148], ["chest", "ANATOMY", 152, 157], ["cough", "OBSERVATION", 213, 218], ["pleuritic", "ANATOMY", 252, 261], ["chest", "ANATOMY", 262, 267], ["crackles", "OBSERVATION", 308, 316]]], ["The patients with HCAP had to fulfill any of the following: received intravenous therapy at home; received wound care or nursing care through a health care agency; or had intravenous medical therapy in the 30 days before pneumonia; or attended a hemodialysis clinic; or received intravenous chemotherapy in the 30 days before pneumonia; or admitted to a hospital for 2 or more days in the 90 days before pneumonia; or resided in a nursing home or a long-term care facility.", [["intravenous", "ANATOMY", 69, 80], ["wound", "ANATOMY", 107, 112], ["intravenous", "ANATOMY", 171, 182], ["intravenous", "ANATOMY", 279, 290], ["HCAP", "DISEASE", 18, 22], ["pneumonia", "DISEASE", 221, 230], ["pneumonia", "DISEASE", 326, 335], ["pneumonia", "DISEASE", 404, 413], ["patients", "ORGANISM", 4, 12], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 69, 80], ["wound", "PATHOLOGICAL_FORMATION", 107, 112], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 171, 182], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 279, 290], ["patients", "SPECIES", 4, 12], ["HCAP", "PROBLEM", 18, 22], ["intravenous therapy", "TREATMENT", 69, 88], ["wound care", "TREATMENT", 107, 117], ["nursing care", "TREATMENT", 121, 133], ["intravenous medical therapy", "TREATMENT", 171, 198], ["pneumonia", "PROBLEM", 221, 230], ["intravenous chemotherapy", "TREATMENT", 279, 303], ["pneumonia", "PROBLEM", 326, 335], ["pneumonia", "PROBLEM", 404, 413], ["pneumonia", "OBSERVATION", 221, 230], ["pneumonia", "OBSERVATION", 326, 335], ["pneumonia", "OBSERVATION", 404, 413]]], ["Patients were classified into the CAP if they did not fit the criteria for HCAP.Microbiological studiesMicrobiological samples were collected within 48 hr after diagnosis of pneumonia.", [["samples", "ANATOMY", 119, 126], ["HCAP", "DISEASE", 75, 79], ["pneumonia", "DISEASE", 174, 183], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["HCAP", "PROBLEM", 75, 79], ["Microbiological studies", "TEST", 80, 103], ["Microbiological samples", "TEST", 103, 126], ["pneumonia", "PROBLEM", 174, 183], ["HCAP", "OBSERVATION", 75, 79], ["pneumonia", "OBSERVATION", 174, 183]]], ["Microbiological studies included 2 or 3 sets of blood cultures and sputum or endotracheal aspirates for Gram staining and culturing.", [["blood cultures", "ANATOMY", 48, 62], ["sputum", "ANATOMY", 67, 73], ["endotracheal aspirates", "ANATOMY", 77, 99], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["sputum", "ORGANISM_SUBSTANCE", 67, 73], ["endotracheal aspirates", "MULTI-TISSUE_STRUCTURE", 77, 99], ["Microbiological studies", "TEST", 0, 23], ["blood cultures", "TEST", 48, 62], ["sputum", "TEST", 67, 73], ["endotracheal aspirates", "TEST", 77, 99], ["Gram staining", "TEST", 104, 117], ["culturing", "TEST", 122, 131], ["endotracheal", "ANATOMY", 77, 89]]], ["Urinary antigen tests for Streptococcus pneumoniae (Binax Inc., Portland, ME) and PCR tests for Mycoplasma pneumoniae (in-house developed nucleic acid sequence based amplification) were performed when indicated by the attending physician.", [["Urinary", "ANATOMY", 0, 7], ["Mycoplasma pneumoniae", "DISEASE", 96, 117], ["nucleic acid", "CHEMICAL", 138, 150], ["Urinary", "ORGANISM_SUBSTANCE", 0, 7], ["Streptococcus pneumoniae", "ORGANISM", 26, 50], ["Mycoplasma pneumoniae", "ORGANISM", 96, 117], ["Streptococcus pneumoniae", "SPECIES", 26, 50], ["Mycoplasma pneumoniae", "SPECIES", 96, 117], ["Streptococcus pneumoniae", "SPECIES", 26, 50], ["Mycoplasma pneumoniae", "SPECIES", 96, 117], ["Urinary antigen tests", "TEST", 0, 21], ["Streptococcus pneumoniae", "PROBLEM", 26, 50], ["PCR tests", "TEST", 82, 91], ["Mycoplasma pneumoniae", "PROBLEM", 96, 117], ["nucleic acid sequence", "TREATMENT", 138, 159]]], ["Bronchoalveolar lavage (BAL) fluid or thoracentesis was conducted if indicated for the diagnosis.", [["Bronchoalveolar lavage", "ANATOMY", 0, 22], ["BAL", "ANATOMY", 24, 27], ["Bronchoalveolar lavage (BAL) fluid", "TEST", 0, 34], ["thoracentesis", "TREATMENT", 38, 51], ["lavage", "OBSERVATION", 16, 22]]], ["All patients were tested for respiratory virus by multiplex reverse-transcription PCR (RT-PCR), using all available respiratory specimens.", [["respiratory specimens", "ANATOMY", 116, 137], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["respiratory virus", "PROBLEM", 29, 46], ["transcription PCR", "TEST", 68, 85], ["RT-PCR", "TEST", 87, 93], ["all available respiratory specimens", "TEST", 102, 137]]], ["If the patients had no sputum, RT-PCR was conducted on a nasopharyngeal specimen.", [["sputum", "ANATOMY", 23, 29], ["nasopharyngeal specimen", "ANATOMY", 57, 80], ["patients", "ORGANISM", 7, 15], ["nasopharyngeal specimen", "CANCER", 57, 80], ["patients", "SPECIES", 7, 15], ["sputum", "PROBLEM", 23, 29], ["RT-PCR", "TEST", 31, 37], ["a nasopharyngeal specimen", "TEST", 55, 80], ["nasopharyngeal", "ANATOMY", 57, 71]]], ["Respiratory virus multiplex RT-PCR was performed according to the xTAG respiratory viral panel (RVP) assay product insert instructions (Luminex Molecular Diagnostics, Toronto, Canada).", [["Respiratory virus", "SPECIES", 0, 17], ["Respiratory virus multiplex RT-PCR", "TEST", 0, 34], ["the xTAG respiratory viral panel", "TEST", 62, 94], ["RVP", "TEST", 96, 99]]], ["We considered that pneumonia was caused by a specific virus if respiratory viruses were detected in acceptable respiratory samples by RT-PCR [25] .", [["respiratory samples", "ANATOMY", 111, 130], ["pneumonia", "DISEASE", 19, 28], ["respiratory viruses", "DISEASE", 63, 82], ["pneumonia", "PROBLEM", 19, 28], ["a specific virus", "PROBLEM", 43, 59], ["respiratory viruses", "PROBLEM", 63, 82], ["PCR", "TEST", 137, 140], ["pneumonia", "OBSERVATION", 19, 28]]], ["Respiratory samples were considered acceptable when more than 25 polymorphonuclear cells and fewer than 10 squamous squamous epithelial cells were observed under low-power magnification were observed under low-power magnification [26] [27] [28] [29] [30] .Statistical analysisUnless otherwise specified, results are expressed as mean (standard deviation, SD) or median (range) for continuous variables and as percentage for categorical variables.", [["Respiratory samples", "ANATOMY", 0, 19], ["polymorphonuclear cells", "ANATOMY", 65, 88], ["squamous squamous epithelial cells", "ANATOMY", 107, 141], ["Respiratory samples", "CANCER", 0, 19], ["polymorphonuclear cells", "CELL", 65, 88], ["squamous squamous epithelial cells", "CELL", 107, 141], ["[26] [27] [28] [29", "SIMPLE_CHEMICAL", 230, 248], ["polymorphonuclear cells", "CELL_TYPE", 65, 88], ["squamous squamous epithelial cells", "CELL_TYPE", 107, 141], ["Respiratory samples", "TEST", 0, 19], ["polymorphonuclear cells", "TEST", 65, 88], ["squamous squamous epithelial cells", "TEST", 107, 141], ["continuous variables", "TEST", 381, 401], ["categorical variables", "TEST", 424, 445], ["squamous epithelial cells", "OBSERVATION", 116, 141]]], ["Student's t-test was used to compare continuous variables; chi-square or Fisher's exact tests were used to compare categorical variables.", [["Student's t-test", "TEST", 0, 16], ["Fisher's exact tests", "TEST", 73, 93]]], ["Variables with p < 0.1 in univariate analysis were entered into a multivariate logistic regression analysis to identify independent predictors of mortality.", [["univariate analysis", "TEST", 26, 45]]], ["Unless otherwise noted, all tests were 2-sided and performed at the 0.05 significance level.", [["all tests", "TEST", 24, 33]]], ["Analyses were performed using SPSS 20.0 (IBM Corp., Armonk, NY, USA).Baseline characteristicsAmong 2755 patients who visited the emergency department due to pneumonia during the 1-year study period, 507 patients were diagnosed with HCAP or CAP.", [["pneumonia", "DISEASE", 157, 166], ["HCAP", "DISEASE", 232, 236], ["CAP", "DISEASE", 240, 243], ["patients", "ORGANISM", 104, 112], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 104, 112], ["patients", "SPECIES", 203, 211], ["Analyses", "TEST", 0, 8], ["SPSS", "TEST", 30, 34], ["pneumonia", "PROBLEM", 157, 166], ["HCAP", "PROBLEM", 232, 236], ["CAP", "PROBLEM", 240, 243], ["pneumonia", "OBSERVATION", 157, 166], ["HCAP", "OBSERVATION", 232, 236], ["CAP", "OBSERVATION_MODIFIER", 240, 243]]], ["Fifty-five patients were excluded from the study because the microbiological specimens obtained prior to antibiotic administration were unacceptable (n = 37), or due to overlapping participation (n = 9); absence of RT-PCR results (n = 6); or withdrawal of informed consent (n = 3) (Fig 1) .", [["specimens", "ANATOMY", 77, 86], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["the study", "TEST", 39, 48], ["the microbiological specimens", "TEST", 57, 86], ["antibiotic administration", "TREATMENT", 105, 130], ["RT-PCR", "TEST", 215, 221]]], ["The baseline characteristics of 452 patients (HCAP: 224 patients; CAP: 228 patients) are shown in Table 1 .", [["patients", "ORGANISM", 36, 44], ["patients", "ORGANISM", 56, 64], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 36, 44], ["patients", "SPECIES", 56, 64], ["patients", "SPECIES", 75, 83], ["HCAP", "TEST", 46, 50], ["CAP", "TEST", 66, 69]]], ["Conventional microbiological studies, including blood culturing and sputum or endotracheal aspirate Gram staining and culturing, were conducted in all enrolled patients before or just after administration of antibiotics (within 1 hr).", [["blood", "ANATOMY", 48, 53], ["sputum", "ANATOMY", 68, 74], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["Conventional microbiological studies", "TEST", 0, 36], ["blood culturing", "TEST", 48, 63], ["sputum", "TEST", 68, 74], ["endotracheal aspirate Gram staining", "TEST", 78, 113], ["culturing", "TEST", 118, 127], ["antibiotics", "TREATMENT", 208, 219], ["endotracheal", "ANATOMY", 78, 90]]], ["BAL was conducted in 67 (14.8%) patients and additional diagnostic thoracentesis was performed in 19 (4.2%) patients.", [["BAL", "ANATOMY", 0, 3], ["BAL", "ORGANISM_SUBSTANCE", 0, 3], ["patients", "ORGANISM", 32, 40], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 108, 116], ["BAL", "TEST", 0, 3], ["additional diagnostic thoracentesis", "TEST", 45, 80], ["thoracentesis", "OBSERVATION", 67, 80]]], ["The proportions of patients who underwent BAL and thoracentesis were similar in the CAP and HCAP groups (BAL, 12.3% vs 17.4%, p = 0.125; thoracentesis, 3.5% vs 4.9%, p = 0.458).", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["BAL", "TEST", 42, 45], ["thoracentesis", "TREATMENT", 50, 63], ["HCAP groups", "TEST", 92, 103], ["BAL", "TEST", 105, 108], ["vs", "TEST", 116, 118], ["p", "TEST", 126, 127], ["thoracentesis", "TEST", 137, 150], ["p", "TEST", 166, 167], ["thoracentesis", "OBSERVATION", 50, 63], ["HCAP", "OBSERVATION", 92, 96]]], ["Pathogens related to pneumonia were identified in 235 (52.0%) patients.", [["pneumonia", "DISEASE", 21, 30], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["Pathogens", "PROBLEM", 0, 9], ["pneumonia", "PROBLEM", 21, 30], ["pneumonia", "OBSERVATION", 21, 30]]], ["Among them, 107 (23.7%) patients had bacterial pneumonia, while 87 (19.2%) patients had viral, and 41 (9.1%) patients had viral-bacterial coinfection.", [["pneumonia", "DISEASE", 47, 56], ["viral-bacterial coinfection", "DISEASE", 122, 149], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 109, 117], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 109, 117], ["bacterial pneumonia", "PROBLEM", 37, 56], ["viral", "TEST", 88, 93], ["viral-bacterial coinfection", "PROBLEM", 122, 149], ["bacterial", "OBSERVATION_MODIFIER", 37, 46], ["pneumonia", "OBSERVATION", 47, 56], ["bacterial coinfection", "OBSERVATION", 128, 149]]], ["(S1 Table) .Viral profiles in pneumoniaAmong the 452 enrolled patients, 430 (95.1%) patients were tested for respiratory viruses in sputum or endotracheal aspirates.", [["sputum", "ANATOMY", 132, 138], ["endotracheal aspirates", "ANATOMY", 142, 164], ["respiratory viruses", "DISEASE", 109, 128], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 84, 92], ["sputum", "ORGANISM_SUBSTANCE", 132, 138], ["endotracheal aspirates", "MULTI-TISSUE_STRUCTURE", 142, 164], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 84, 92], ["Viral profiles", "TEST", 12, 26], ["pneumoniaAmong", "TEST", 30, 44], ["respiratory viruses in sputum", "PROBLEM", 109, 138], ["endotracheal aspirates", "PROBLEM", 142, 164], ["respiratory", "ANATOMY", 109, 120], ["viruses", "OBSERVATION", 121, 128], ["sputum", "OBSERVATION", 132, 138], ["endotracheal", "ANATOMY", 142, 154], ["aspirates", "OBSERVATION", 155, 164]]], ["The remaining 22 (4.9%) patients underwent RT-PCR on nasopharyngeal specimens.", [["nasopharyngeal specimens", "ANATOMY", 53, 77], ["patients", "ORGANISM", 24, 32], ["nasopharyngeal specimens", "CANCER", 53, 77], ["patients", "SPECIES", 24, 32], ["RT-PCR", "TEST", 43, 49], ["nasopharyngeal specimens", "TEST", 53, 77], ["nasopharyngeal", "ANATOMY", 53, 67], ["specimens", "OBSERVATION", 68, 77]]], ["Additionally, BAL fluid RT-PCR was performed in 16 (3.5%) patients, and 4 (0.9%) patients underwent pleural effusion RT-PCR.", [["BAL fluid", "ANATOMY", 14, 23], ["pleural", "ANATOMY", 100, 107], ["pleural effusion", "DISEASE", 100, 116], ["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 81, 89], ["pleural", "ORGAN", 100, 107], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 81, 89], ["BAL fluid RT-PCR", "TEST", 14, 30], ["pleural effusion", "PROBLEM", 100, 116], ["PCR", "TEST", 120, 123], ["pleural", "ANATOMY", 100, 107], ["effusion", "OBSERVATION", 108, 116]]], ["Fifty-four (23.7%) of the patients with HCAP were found to have a viral infection; 31 (13.8%) patients had a pure viral infection and 23 (10.3%) patients had a viral-bacterial coinfection.", [["HCAP", "DISEASE", 40, 44], ["viral infection", "DISEASE", 66, 81], ["viral infection", "DISEASE", 114, 129], ["viral-bacterial coinfection", "DISEASE", 160, 187], ["patients", "ORGANISM", 26, 34], ["HCAP", "CANCER", 40, 44], ["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 145, 153], ["HCAP", "PROBLEM", 40, 44], ["a viral infection", "PROBLEM", 64, 81], ["a pure viral infection", "PROBLEM", 107, 129], ["a viral-bacterial coinfection", "PROBLEM", 158, 187], ["HCAP", "OBSERVATION", 40, 44], ["viral", "OBSERVATION_MODIFIER", 66, 71], ["infection", "OBSERVATION", 72, 81], ["viral", "OBSERVATION_MODIFIER", 114, 119], ["infection", "OBSERVATION", 120, 129], ["viral", "OBSERVATION_MODIFIER", 160, 165], ["bacterial coinfection", "OBSERVATION", 166, 187]]], ["In the CAP group, 74 (32.5%) patients had a viral infection, and the viral infection rate and viral-bacterial coinfection rates were 24.6% and 7.9% respectively.", [["viral infection", "DISEASE", 44, 59], ["viral infection", "DISEASE", 69, 84], ["viral-bacterial coinfection", "DISEASE", 94, 121], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["the CAP group", "TEST", 3, 16], ["a viral infection", "PROBLEM", 42, 59], ["the viral infection rate", "TEST", 65, 89], ["viral-bacterial coinfection rates", "TEST", 94, 127], ["CAP", "OBSERVATION_MODIFIER", 7, 10], ["viral", "OBSERVATION_MODIFIER", 44, 49], ["infection", "OBSERVATION", 50, 59], ["viral", "OBSERVATION_MODIFIER", 69, 74], ["infection", "OBSERVATION", 75, 84], ["bacterial coinfection", "OBSERVATION", 100, 121]]], ["The viral infection rate was significantly lower in the HCAP patients than in the CAP patients, irrespective of whether viral-bacterial infections were included (viral infection with viral-bacterial coinfection, p = 0.049, viral infection only, p = 0.004).", [["HCAP", "ANATOMY", 56, 60], ["viral infection", "DISEASE", 4, 19], ["CAP", "DISEASE", 82, 85], ["viral-bacterial infections", "DISEASE", 120, 146], ["viral infection", "DISEASE", 162, 177], ["viral-bacterial coinfection", "DISEASE", 183, 210], ["viral infection", "DISEASE", 223, 238], ["patients", "ORGANISM", 61, 69], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 61, 69], ["patients", "SPECIES", 86, 94], ["The viral infection rate", "TEST", 0, 24], ["viral-bacterial infections", "PROBLEM", 120, 146], ["viral infection", "PROBLEM", 162, 177], ["viral-bacterial coinfection", "PROBLEM", 183, 210], ["viral infection", "PROBLEM", 223, 238], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["infection", "OBSERVATION", 10, 19], ["significantly", "OBSERVATION_MODIFIER", 29, 42], ["lower", "OBSERVATION_MODIFIER", 43, 48], ["HCAP", "OBSERVATION", 56, 60], ["bacterial infections", "OBSERVATION", 126, 146], ["bacterial coinfection", "OBSERVATION", 189, 210]]], ["The respiratory viruses identified are summarized in Table 2 .", [["The respiratory viruses", "PROBLEM", 0, 23], ["respiratory viruses", "OBSERVATION", 4, 23]]], ["In both HCAP and CAP groups, influenza A was the most common respiratory virus, followed by entero-rhinovirus.", [["influenza A", "DISEASE", 29, 40], ["respiratory virus", "DISEASE", 61, 78], ["HCAP", "CANCER", 8, 12], ["influenza A", "ORGANISM", 29, 40], ["influenza A", "SPECIES", 29, 40], ["influenza", "PROBLEM", 29, 38], ["the most common respiratory virus", "PROBLEM", 45, 78], ["HCAP", "OBSERVATION", 8, 12], ["respiratory virus", "OBSERVATION", 61, 78]]], ["The general viral profile of patients with HCAP and CAP were similar, except for influenza A and adenovirus, which were higher in the CAP group than the HCAP (p = 0.040 andBacterial profiles in pneumoniaMore than half of the patients (64.9%) with HCAP received antibiotics at the healthcare facilities and 21 (20.8%) patients with CAP received any form of antibiotics prior to our hospital.", [["CAP", "DISEASE", 52, 55], ["CAP", "DISEASE", 134, 137], ["HCAP", "DISEASE", 153, 157], ["HCAP", "CHEMICAL", 247, 251], ["CAP", "DISEASE", 331, 334], ["patients", "ORGANISM", 29, 37], ["HCAP", "CANCER", 43, 47], ["influenza A", "ORGANISM", 81, 92], ["adenovirus", "ORGANISM", 97, 107], ["patients", "ORGANISM", 225, 233], ["patients", "ORGANISM", 317, 325], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 225, 233], ["patients", "SPECIES", 317, 325], ["influenza A", "SPECIES", 81, 92], ["adenovirus", "SPECIES", 97, 107], ["HCAP", "PROBLEM", 43, 47], ["CAP", "TEST", 52, 55], ["influenza A", "PROBLEM", 81, 92], ["adenovirus", "PROBLEM", 97, 107], ["the HCAP", "TEST", 149, 157], ["Bacterial profiles in pneumoniaMore", "PROBLEM", 172, 207], ["HCAP", "PROBLEM", 247, 251], ["antibiotics", "TREATMENT", 261, 272], ["CAP", "TREATMENT", 331, 334], ["antibiotics", "TREATMENT", 356, 367], ["viral", "OBSERVATION", 12, 17], ["HCAP", "OBSERVATION", 43, 47], ["higher", "OBSERVATION_MODIFIER", 120, 126], ["HCAP", "OBSERVATION", 153, 157]]], ["In contrast to viral infection, the proportion of bacterial pneumonia was significantly higher in patients with HCAP than in those with CAP (35.7% vs 11.8%, p < 0.001).", [["viral infection", "DISEASE", 15, 30], ["pneumonia", "DISEASE", 60, 69], ["HCAP", "DISEASE", 112, 116], ["CAP", "DISEASE", 136, 139], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["viral infection", "PROBLEM", 15, 30], ["bacterial pneumonia", "PROBLEM", 50, 69], ["HCAP", "PROBLEM", 112, 116], ["CAP", "TEST", 136, 139], ["viral", "OBSERVATION_MODIFIER", 15, 20], ["infection", "OBSERVATION", 21, 30], ["bacterial", "OBSERVATION_MODIFIER", 50, 59], ["pneumonia", "OBSERVATION", 60, 69], ["significantly", "OBSERVATION_MODIFIER", 74, 87], ["higher", "OBSERVATION_MODIFIER", 88, 94], ["HCAP", "OBSERVATION", 112, 116]]], ["Table 2 shows the bacterial pathogens in patients with HCAP or CAP.", [["HCAP", "DISEASE", 55, 59], ["CAP", "DISEASE", 63, 66], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["the bacterial pathogens", "PROBLEM", 14, 37], ["HCAP", "PROBLEM", 55, 59], ["CAP", "PROBLEM", 63, 66], ["bacterial", "OBSERVATION_MODIFIER", 18, 27], ["pathogens", "OBSERVATION", 28, 37], ["HCAP", "OBSERVATION", 55, 59], ["CAP", "OBSERVATION_MODIFIER", 63, 66]]], ["Pseudomonas aeruginosa and methicillinresistant Staphylococcus aureus (MRSA) were more frequently observed in HCAP than in CAP patients (p = 0.006 and p = 0.005, respectively).", [["HCAP", "ANATOMY", 110, 114], ["CAP", "DISEASE", 123, 126], ["Pseudomonas aeruginosa", "ORGANISM", 0, 22], ["methicillinresistant Staphylococcus aureus", "ORGANISM", 27, 69], ["MRSA", "CANCER", 71, 75], ["HCAP", "CANCER", 110, 114], ["patients", "ORGANISM", 127, 135], ["Pseudomonas aeruginosa", "SPECIES", 0, 22], ["Staphylococcus aureus", "SPECIES", 48, 69], ["MRSA", "SPECIES", 71, 75], ["patients", "SPECIES", 127, 135], ["Pseudomonas aeruginosa", "SPECIES", 0, 22], ["Staphylococcus aureus", "SPECIES", 48, 69], ["MRSA", "SPECIES", 71, 75], ["Pseudomonas aeruginosa", "PROBLEM", 0, 22], ["methicillinresistant Staphylococcus aureus", "PROBLEM", 27, 69], ["MRSA", "PROBLEM", 71, 75], ["HCAP", "PROBLEM", 110, 114], ["p", "TEST", 137, 138], ["Staphylococcus aureus", "OBSERVATION", 48, 69]]], ["The proportion of multi-bacterial and multidrug-resistant (MDR) bacterial infection was also higher in the HCAP than CAP group (p = 0.021 and p < 0.001, respectively).", [["bacterial infection", "DISEASE", 64, 83], ["multi-bacterial and multidrug-resistant (MDR) bacterial infection", "PROBLEM", 18, 83], ["multidrug", "OBSERVATION_MODIFIER", 38, 47], ["resistant", "OBSERVATION_MODIFIER", 48, 57], ["bacterial", "OBSERVATION_MODIFIER", 64, 73], ["infection", "OBSERVATION", 74, 83], ["higher", "OBSERVATION_MODIFIER", 93, 99], ["HCAP", "OBSERVATION", 107, 111]]], ["Empirical antimicrobial treatment regimens for HCAP or CAP are summarized in S3 Table.", [["HCAP", "CHEMICAL", 47, 51], ["CAP", "DISEASE", 55, 58], ["HCAP", "SIMPLE_CHEMICAL", 47, 51], ["Empirical antimicrobial treatment regimens", "TREATMENT", 0, 42], ["HCAP", "PROBLEM", 47, 51], ["CAP", "PROBLEM", 55, 58]]], ["Seasonal distribution of pneumonia Fig 2 shows the monthly distribution of viral and bacterial infection.", [["pneumonia", "DISEASE", 25, 34], ["viral and bacterial infection", "DISEASE", 75, 104], ["pneumonia Fig", "PROBLEM", 25, 38], ["viral and bacterial infection", "PROBLEM", 75, 104], ["pneumonia", "OBSERVATION", 25, 34], ["viral", "OBSERVATION", 75, 80], ["bacterial", "OBSERVATION_MODIFIER", 85, 94], ["infection", "OBSERVATION", 95, 104]]], ["In the HCAP group, bacterial infections were predominant during all 4 seasons, and were more common from February to April.", [["bacterial infections", "DISEASE", 19, 39], ["HCAP", "CANCER", 7, 11], ["bacterial infections", "PROBLEM", 19, 39], ["HCAP", "OBSERVATION", 7, 11], ["bacterial", "OBSERVATION_MODIFIER", 19, 28], ["infections", "OBSERVATION", 29, 39]]], ["The seasonal variation curve of viral infections was similar to that in the CAP group, but with a tendency to lag 1 month behind that in the CAP group.", [["viral infections", "DISEASE", 32, 48], ["CAP", "DISEASE", 141, 144], ["The seasonal variation curve", "PROBLEM", 0, 28], ["viral infections", "PROBLEM", 32, 48], ["seasonal", "OBSERVATION_MODIFIER", 4, 12], ["variation", "OBSERVATION_MODIFIER", 13, 22], ["curve", "OBSERVATION_MODIFIER", 23, 28], ["viral", "OBSERVATION_MODIFIER", 32, 37], ["infections", "OBSERVATION", 38, 48], ["CAP group", "OBSERVATION_MODIFIER", 76, 85], ["CAP", "OBSERVATION_MODIFIER", 141, 144]]], ["Fig 3 shows the distribution of each virus.", [["each virus", "PROBLEM", 32, 42], ["virus", "OBSERVATION", 37, 42]]], ["Generally, the viral seasonal distribution in the HCAP group was similar to that in the CAP group, except for adenovirus and human metapneumovirus.", [["HCAP", "ANATOMY", 50, 54], ["adenovirus and human metapneumovirus", "DISEASE", 110, 146], ["HCAP", "CANCER", 50, 54], ["adenovirus", "ORGANISM", 110, 120], ["human", "ORGANISM", 125, 130], ["metapneumovirus", "ORGANISM", 131, 146], ["human", "SPECIES", 125, 130], ["metapneumovirus", "SPECIES", 131, 146], ["adenovirus", "SPECIES", 110, 120], ["human metapneumovirus", "SPECIES", 125, 146], ["the viral seasonal distribution in the HCAP group", "PROBLEM", 11, 60], ["adenovirus", "PROBLEM", 110, 120], ["human metapneumovirus", "PROBLEM", 125, 146], ["viral", "OBSERVATION_MODIFIER", 15, 20], ["seasonal", "OBSERVATION_MODIFIER", 21, 29], ["distribution", "OBSERVATION_MODIFIER", 30, 42], ["HCAP", "OBSERVATION", 50, 54], ["metapneumovirus", "OBSERVATION", 131, 146]]], ["Of the 44 patients with influenza pneumonia, more than half (63.6%) had a history of influenza vaccination.Outcomes of pneumonia and predictors of mortalityThe median length of hospital stay (LOS) was 8.2 (range: 0.0-120.0) days.", [["influenza pneumonia", "DISEASE", 24, 43], ["influenza", "DISEASE", 85, 94], ["pneumonia", "DISEASE", 119, 128], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["influenza pneumonia", "PROBLEM", 24, 43], ["influenza vaccination", "PROBLEM", 85, 106], ["pneumonia", "PROBLEM", 119, 128], ["influenza", "OBSERVATION_MODIFIER", 24, 33], ["pneumonia", "OBSERVATION", 34, 43], ["influenza", "OBSERVATION", 85, 94], ["pneumonia", "OBSERVATION", 119, 128], ["median", "OBSERVATION_MODIFIER", 160, 166], ["length", "OBSERVATION_MODIFIER", 167, 173]]], ["Patients with HCAP had a significantly longer LOS than did patients with CAP (7.1 vs. 9.8 days, p = 0.009).", [["CAP", "DISEASE", 73, 76], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 59, 67], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 59, 67], ["HCAP", "PROBLEM", 14, 18], ["a significantly longer LOS", "PROBLEM", 23, 49], ["CAP", "TEST", 73, 76], ["HCAP", "OBSERVATION", 14, 18]]], ["Thirtyone (6.9%) patients died in the hospital; the HCAP group had a higher mortality than did the CAP group (DiscussionIn this study, we investigated the microbiological profile of patients with HCAP, focusing on viral infections.", [["HCAP", "DISEASE", 196, 200], ["viral infections", "DISEASE", 214, 230], ["patients", "ORGANISM", 17, 25], ["HCAP", "CANCER", 52, 56], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 182, 190], ["this study", "TEST", 123, 133], ["HCAP", "PROBLEM", 196, 200], ["viral infections", "PROBLEM", 214, 230], ["HCAP", "OBSERVATION", 196, 200], ["viral infections", "OBSERVATION", 214, 230]]], ["To date, only limited studies have evaluated the viral profile of patients with HCAP [11, 31, 32] .", [["HCAP", "DISEASE", 80, 84], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["limited studies", "TEST", 14, 29], ["HCAP", "PROBLEM", 80, 84], ["HCAP", "OBSERVATION", 80, 84]]], ["However, these studies only included patients with severe pneumonia requiring ICU care focusing on the CAP, which involved only a limited number of HCAP patients [32] .", [["pneumonia", "DISEASE", 58, 67], ["CAP", "DISEASE", 103, 106], ["HCAP", "DISEASE", 148, 152], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 153, 161], ["these studies", "TEST", 9, 22], ["severe pneumonia", "PROBLEM", 51, 67], ["ICU care", "TREATMENT", 78, 86], ["the CAP", "TEST", 99, 106], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["pneumonia", "OBSERVATION", 58, 67], ["HCAP", "OBSERVATION", 148, 152]]], ["Furthermore, they did not strictly control the respiratory sampling time and did not specified whether the patients received antibiotics and how long they received the antibiotics prior to admission [31] .", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["antibiotics", "TREATMENT", 125, 136], ["the antibiotics", "TREATMENT", 164, 179]]], ["Lastly, only limited respiratory specimens were used for detection of respiratory viruses, mainly nasopharyngeal swab [31, 32] .", [["respiratory specimens", "ANATOMY", 21, 42], ["nasopharyngeal swab", "ANATOMY", 98, 117], ["respiratory viruses", "DISEASE", 70, 89], ["nasopharyngeal swab", "ORGANISM_SUBSTANCE", 98, 117], ["limited respiratory specimens", "TEST", 13, 42], ["respiratory viruses", "PROBLEM", 70, 89], ["nasopharyngeal swab", "TEST", 98, 117], ["respiratory viruses", "OBSERVATION", 70, 89], ["nasopharyngeal", "ANATOMY", 98, 112]]], ["Therefore, the general trend and microbiological profile in HCAP remained unclear.", [["HCAP", "DISEASE", 60, 64], ["HCAP", "SIMPLE_CHEMICAL", 60, 64], ["microbiological profile", "TEST", 33, 56], ["HCAP", "PROBLEM", 60, 64], ["HCAP", "OBSERVATION", 60, 64]]], ["In the present study, we evaluated the role of respiratory viruses in patients with mild to severe HCAP, in comparison to that in patients with CAP, using all available respiratory specimens including sputum or endotracheal aspirate, BAL fluid or even pleural effusion.", [["respiratory specimens", "ANATOMY", 169, 190], ["sputum", "ANATOMY", 201, 207], ["endotracheal aspirate", "ANATOMY", 211, 232], ["BAL fluid", "ANATOMY", 234, 243], ["pleural effusion", "ANATOMY", 252, 268], ["respiratory viruses", "DISEASE", 47, 66], ["HCAP", "DISEASE", 99, 103], ["CAP", "DISEASE", 144, 147], ["pleural effusion", "DISEASE", 252, 268], ["patients", "ORGANISM", 70, 78], ["patients", "ORGANISM", 130, 138], ["endotracheal aspirate", "MULTI-TISSUE_STRUCTURE", 211, 232], ["pleural effusion", "PATHOLOGICAL_FORMATION", 252, 268], ["patients", "SPECIES", 70, 78], ["patients", "SPECIES", 130, 138], ["the present study", "TEST", 3, 20], ["respiratory viruses", "PROBLEM", 47, 66], ["mild to severe HCAP", "PROBLEM", 84, 103], ["CAP", "TEST", 144, 147], ["all available respiratory specimens", "TEST", 155, 190], ["sputum", "TEST", 201, 207], ["endotracheal aspirate", "TEST", 211, 232], ["BAL fluid", "TEST", 234, 243], ["pleural effusion", "PROBLEM", 252, 268], ["respiratory viruses", "OBSERVATION", 47, 66], ["mild", "OBSERVATION_MODIFIER", 84, 88], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["HCAP", "OBSERVATION", 99, 103], ["endotracheal", "ANATOMY", 211, 223], ["BAL fluid", "OBSERVATION", 234, 243], ["pleural", "ANATOMY", 252, 259], ["effusion", "OBSERVATION", 260, 268]]], ["Unlike previous studies [31] , microbiological results showed some differences in both groups.", [["previous studies", "TEST", 7, 23], ["microbiological results", "TEST", 31, 54]]], ["The overall viral infection rates were lower in the HCAP group (23.7%) than in the CAP group (32.5%).", [["viral infection", "DISEASE", 12, 27], ["HCAP", "DISEASE", 52, 56], ["CAP", "DISEASE", 83, 86], ["HCAP", "CANCER", 52, 56], ["The overall viral infection rates", "PROBLEM", 0, 33], ["the CAP group", "TEST", 79, 92], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["viral", "OBSERVATION_MODIFIER", 12, 17], ["infection", "OBSERVATION", 18, 27], ["lower", "OBSERVATION_MODIFIER", 39, 44], ["HCAP", "OBSERVATION", 52, 56]]], ["Most importantly, influenza A viral infection was significantly lower in the patients with HCAP than those with CAP (p = 0.040).", [["viral infection", "DISEASE", 30, 45], ["HCAP", "DISEASE", 91, 95], ["CAP", "DISEASE", 112, 115], ["influenza A viral", "ORGANISM", 18, 35], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["influenza", "PROBLEM", 18, 27], ["A viral infection", "PROBLEM", 28, 45], ["HCAP", "PROBLEM", 91, 95], ["CAP", "TEST", 112, 115], ["viral", "OBSERVATION_MODIFIER", 30, 35], ["infection", "OBSERVATION", 36, 45], ["HCAP", "OBSERVATION", 91, 95]]], ["In the previous multicenter study, bronchial asthma [odds ratio (OR) 4.006], male gender (OR 3.507) and age ! 50 years (OR 2.653) were the independent risk factors for influenza A viral pneumonia [33] .", [["bronchial", "ANATOMY", 35, 44], ["bronchial asthma", "DISEASE", 35, 51], ["viral pneumonia", "DISEASE", 180, 195], ["the previous multicenter study", "TEST", 3, 33], ["bronchial asthma", "PROBLEM", 35, 51], ["influenza", "PROBLEM", 168, 177], ["A viral pneumonia", "PROBLEM", 178, 195], ["bronchial", "ANATOMY", 35, 44], ["asthma", "OBSERVATION", 45, 51], ["viral", "OBSERVATION_MODIFIER", 180, 185], ["pneumonia", "OBSERVATION", 186, 195]]], ["Moreover, chronic lung diseases, such as bronchial asthma and chronic obstructive pulmonary disease, are well-known risk factors for viral infections [34, 35] .", [["lung", "ANATOMY", 18, 22], ["bronchial", "ANATOMY", 41, 50], ["pulmonary", "ANATOMY", 82, 91], ["chronic lung diseases", "DISEASE", 10, 31], ["bronchial asthma", "DISEASE", 41, 57], ["chronic obstructive pulmonary disease", "DISEASE", 62, 99], ["viral infections", "DISEASE", 133, 149], ["lung", "ORGAN", 18, 22], ["pulmonary", "ORGAN", 82, 91], ["chronic lung diseases", "PROBLEM", 10, 31], ["bronchial asthma", "PROBLEM", 41, 57], ["chronic obstructive pulmonary disease", "PROBLEM", 62, 99], ["viral infections", "PROBLEM", 133, 149], ["chronic", "OBSERVATION_MODIFIER", 10, 17], ["lung", "ANATOMY", 18, 22], ["diseases", "OBSERVATION", 23, 31], ["bronchial", "ANATOMY", 41, 50], ["asthma", "OBSERVATION", 51, 57], ["chronic", "OBSERVATION_MODIFIER", 62, 69], ["obstructive", "OBSERVATION_MODIFIER", 70, 81], ["pulmonary", "ANATOMY", 82, 91], ["disease", "OBSERVATION", 92, 99]]], ["In this study, the proportion of male was similar and the patients with CAP were younger.", [["CAP", "DISEASE", 72, 75], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["this study", "TEST", 3, 13]]], ["Patients with CAP had a higher prevalence of chronic lung disease than did patients with HCAP.", [["lung", "ANATOMY", 53, 57], ["CAP", "DISEASE", 14, 17], ["chronic lung disease", "DISEASE", 45, 65], ["HCAP", "DISEASE", 89, 93], ["Patients", "ORGANISM", 0, 8], ["lung", "ORGAN", 53, 57], ["patients", "ORGANISM", 75, 83], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 75, 83], ["CAP", "PROBLEM", 14, 17], ["chronic lung disease", "PROBLEM", 45, 65], ["HCAP", "PROBLEM", 89, 93], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["lung", "ANATOMY", 53, 57], ["disease", "OBSERVATION", 58, 65], ["HCAP", "OBSERVATION", 89, 93]]], ["Therefore, the CAP group may have had a higher chance of infection by respiratory viruses, especially influenza.", [["infection", "DISEASE", 57, 66], ["respiratory viruses", "DISEASE", 70, 89], ["influenza", "DISEASE", 102, 111], ["infection", "PROBLEM", 57, 66], ["respiratory viruses", "PROBLEM", 70, 89], ["influenza", "PROBLEM", 102, 111], ["infection", "OBSERVATION", 57, 66], ["respiratory viruses", "OBSERVATION", 70, 89]]], ["Furthermore, more than half of the HCAP patients (58.9%) were hospitalized for 2 or more days in the 90 days before pneumonia.", [["HCAP", "DISEASE", 35, 39], ["pneumonia", "DISEASE", 116, 125], ["HCAP", "CANCER", 35, 39], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["pneumonia", "PROBLEM", 116, 125], ["HCAP", "OBSERVATION", 35, 39], ["pneumonia", "OBSERVATION", 116, 125]]], ["Therefore, they may have had little opportunity of coming into contact with other patients who carried respiratory viruses [11] .", [["respiratory viruses", "DISEASE", 103, 122], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["respiratory viruses", "PROBLEM", 103, 122]]], ["Similar to previous studies [14, 17, 22, 36] , influenza A was the most commonly identified respiratory virus in CAP patients, and this was also true for the HCAP group.", [["influenza A", "DISEASE", 47, 58], ["respiratory virus", "DISEASE", 92, 109], ["CAP", "DISEASE", 113, 116], ["influenza A", "ORGANISM", 47, 58], ["patients", "ORGANISM", 117, 125], ["HCAP", "CANCER", 158, 162], ["patients", "SPECIES", 117, 125], ["previous studies", "TEST", 11, 27], ["influenza", "PROBLEM", 47, 56], ["respiratory virus", "PROBLEM", 92, 109], ["the HCAP group", "PROBLEM", 154, 168], ["respiratory virus", "OBSERVATION", 92, 109], ["HCAP", "OBSERVATION", 158, 162]]], ["Interestingly, more than half of the patients (63.6%) had a history of influenza vaccination.", [["influenza", "DISEASE", 71, 80], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["influenza vaccination", "PROBLEM", 71, 92], ["influenza", "OBSERVATION", 71, 80]]], ["Among them, influenza subtype H3N2 was detected in 5 (11.4%) patients and influenza A subtype H1N1 was found in 39 (88.6%) patients.", [["influenza subtype H3N2", "DISEASE", 12, 34], ["H1N1", "DISEASE", 94, 98], ["influenza subtype H3N2", "ORGANISM", 12, 34], ["patients", "ORGANISM", 61, 69], ["influenza A subtype H1N1", "ORGANISM", 74, 98], ["patients", "ORGANISM", 123, 131], ["influenza subtype H3N2", "SPECIES", 12, 34], ["patients", "SPECIES", 61, 69], ["influenza A subtype H1N1", "SPECIES", 74, 98], ["patients", "SPECIES", 123, 131], ["influenza A subtype H1N1", "SPECIES", 74, 98], ["influenza subtype H3N2", "PROBLEM", 12, 34], ["influenza A subtype H1N1", "PROBLEM", 74, 98]]], ["Most of the participants were elderly patients with mean age 70.5 years.", [["participants", "ORGANISM", 12, 24], ["patients", "ORGANISM", 38, 46], ["participants", "SPECIES", 12, 24], ["patients", "SPECIES", 38, 46]]], ["Several studies showed that vaccine efficacy against influenza was decreased with increasing age although there were several confounding factors [37, 38] .", [["influenza", "DISEASE", 53, 62], ["influenza", "ORGANISM", 53, 62], ["Several studies", "TEST", 0, 15], ["vaccine efficacy", "TREATMENT", 28, 44], ["influenza", "PROBLEM", 53, 62], ["several confounding factors", "PROBLEM", 117, 144]]], ["Since there was no available data for vaccine constituents, it is difficult to draw conclusions about the efficacy of influenza vaccine in this study.", [["vaccine constituents", "TREATMENT", 38, 58], ["influenza vaccine", "TREATMENT", 118, 135], ["this study", "TEST", 139, 149]]], ["Further studies are required to determine the relationship between the effectiveness of influenza vaccines and age.", [["influenza", "DISEASE", 88, 97], ["Further studies", "TEST", 0, 15], ["influenza vaccines", "TREATMENT", 88, 106]]], ["In this study, viral pneumonia itself was not found to affect the clinical prognosis, such as LOS and in-hospital mortality in either group.", [["pneumonia", "DISEASE", 21, 30], ["this study", "TEST", 3, 13], ["viral pneumonia", "PROBLEM", 15, 30], ["viral", "OBSERVATION_MODIFIER", 15, 20], ["pneumonia", "OBSERVATION", 21, 30]]], ["Recent studies of CAP have shown similar results [22, 31] , and we further showed that viral infection had no significant association with increased mortality in patients with HCAP.", [["viral infection", "DISEASE", 87, 102], ["HCAP", "DISEASE", 176, 180], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["Recent studies of CAP", "TEST", 0, 21], ["viral infection", "PROBLEM", 87, 102], ["increased mortality", "PROBLEM", 139, 158], ["HCAP", "PROBLEM", 176, 180], ["viral", "OBSERVATION_MODIFIER", 87, 92], ["infection", "OBSERVATION", 93, 102], ["increased", "OBSERVATION_MODIFIER", 139, 148], ["mortality", "OBSERVATION", 149, 158], ["HCAP", "OBSERVATION", 176, 180]]], ["Contradictory to the previous studies that reported viral-bacterial coinfection as an important risk factor for mortality in the CAP [22, 32] , no significant difference was noted in this study.", [["viral-bacterial coinfection", "DISEASE", 52, 79], ["CAP", "DISEASE", 129, 132], ["the previous studies", "TEST", 17, 37], ["viral-bacterial coinfection", "PROBLEM", 52, 79], ["the CAP", "TEST", 125, 132], ["significant difference", "PROBLEM", 147, 169], ["this study", "TEST", 183, 193], ["bacterial coinfection", "OBSERVATION", 58, 79], ["no", "UNCERTAINTY", 144, 146], ["significant", "OBSERVATION_MODIFIER", 147, 158], ["difference", "OBSERVATION", 159, 169]]], ["Most previous studies obtained samples for PCR via a nasopharyngeal or oropharyngeal swab [22, 39] , but this may lead to false results in cases of viral pneumonia [11, 23] .", [["samples", "ANATOMY", 31, 38], ["nasopharyngeal", "ANATOMY", 53, 67], ["oropharyngeal swab", "ANATOMY", 71, 89], ["viral pneumonia", "DISEASE", 148, 163], ["nasopharyngeal", "CANCER", 53, 67], ["Most previous studies", "TEST", 0, 21], ["PCR", "TEST", 43, 46], ["a nasopharyngeal or oropharyngeal swab", "TEST", 51, 89], ["viral pneumonia", "PROBLEM", 148, 163], ["nasopharyngeal", "ANATOMY", 53, 67], ["oropharyngeal", "ANATOMY", 71, 84], ["viral", "OBSERVATION_MODIFIER", 148, 153], ["pneumonia", "OBSERVATION", 154, 163]]], ["Easier access to a tertiary referral hospital, due to the healthcare system in Korea [40] , might be another reason for the similar prognosis of patients with viralbacterial coinfection, and viral and bacterial infections.", [["viralbacterial coinfection", "DISEASE", 159, 185], ["viral and bacterial infections", "DISEASE", 191, 221], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["viralbacterial coinfection", "PROBLEM", 159, 185], ["viral and bacterial infections", "PROBLEM", 191, 221], ["coinfection", "OBSERVATION", 174, 185], ["bacterial", "OBSERVATION_MODIFIER", 201, 210], ["infections", "OBSERVATION", 211, 221]]], ["One thing we have to mention here is that the results of this study should be interpreted with caution, because the true bacterial profile of these patients is not known.", [["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["this study", "TEST", 57, 67]]], ["In the present study, we enrolled only the patients who did not receive antibiotics for more than 24 hrs prior to our hospital to increase the yield of microbiological test.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["antibiotics", "TREATMENT", 72, 83], ["microbiological test", "TEST", 152, 172]]], ["Moreover, the conventional microbiological studies, including blood culturing and sputum or endotracheal aspirate Gram staining and culturing, were conducted before or within 1 hr after antibiotics administration.", [["blood", "ANATOMY", 62, 67], ["sputum", "ANATOMY", 82, 88], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["the conventional microbiological studies", "TEST", 10, 50], ["blood culturing", "TEST", 62, 77], ["sputum", "TEST", 82, 88], ["endotracheal aspirate Gram staining", "TEST", 92, 127], ["culturing", "TEST", 132, 141], ["antibiotics administration", "TREATMENT", 186, 212], ["endotracheal", "ANATOMY", 92, 104]]], ["However, we obtained low rates of bacterial detection similar to the previous studies [41] [42] [43] : bacterial pathogens were identified in 35.7% of patients with HCAP and in 11.8% of patients with CAP.", [["HCAP", "DISEASE", 165, 169], ["CAP", "DISEASE", 200, 203], ["[41] [42] [43]", "SIMPLE_CHEMICAL", 86, 100], ["patients", "ORGANISM", 151, 159], ["HCAP", "CANCER", 165, 169], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 151, 159], ["patients", "SPECIES", 186, 194], ["bacterial detection", "PROBLEM", 34, 53], ["the previous studies", "TEST", 65, 85], ["bacterial pathogens", "PROBLEM", 103, 122], ["HCAP", "TEST", 165, 169], ["CAP", "PROBLEM", 200, 203], ["HCAP", "OBSERVATION", 165, 169], ["CAP", "OBSERVATION", 200, 203]]], ["This could be the frailty of Gram staining and culture for bacterial detection.", [["Gram staining", "TEST", 29, 42], ["culture", "TEST", 47, 54], ["bacterial detection", "PROBLEM", 59, 78]]], ["There is a report that the use of multi-bacterial molecular testing approach approximately doubles pathogen detection in patients with pneumonia [44] .", [["pneumonia", "DISEASE", 135, 144], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["multi-bacterial molecular testing approach", "TREATMENT", 34, 76], ["pneumonia", "PROBLEM", 135, 144], ["pneumonia", "OBSERVATION", 135, 144]]], ["Particularly, they reported that PCR detected significantly more Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae than standard culture-based methods [44] .", [["Haemophilus influenzae", "DISEASE", 65, 87], ["Haemophilus influenzae", "ORGANISM", 65, 87], ["Streptococcus pneumoniae", "ORGANISM", 89, 113], ["Moraxella catarrhalis", "ORGANISM", 115, 136], ["Staphylococcus aureus", "ORGANISM", 138, 159], ["Escherichia coli", "ORGANISM", 161, 177], ["Klebsiella pneumoniae", "ORGANISM", 183, 204], ["Haemophilus influenzae", "SPECIES", 65, 87], ["Streptococcus pneumoniae", "SPECIES", 89, 113], ["Moraxella catarrhalis", "SPECIES", 115, 136], ["Staphylococcus aureus", "SPECIES", 138, 159], ["Escherichia coli", "SPECIES", 161, 177], ["Klebsiella pneumoniae", "SPECIES", 183, 204], ["Haemophilus influenzae", "SPECIES", 65, 87], ["Streptococcus pneumoniae", "SPECIES", 89, 113], ["Moraxella catarrhalis", "SPECIES", 115, 136], ["Staphylococcus aureus", "SPECIES", 138, 159], ["Escherichia coli", "SPECIES", 161, 177], ["Klebsiella pneumoniae", "SPECIES", 183, 204], ["PCR", "TEST", 33, 36], ["Haemophilus influenzae", "PROBLEM", 65, 87], ["Streptococcus pneumoniae", "PROBLEM", 89, 113], ["Moraxella catarrhalis", "PROBLEM", 115, 136], ["Staphylococcus aureus", "PROBLEM", 138, 159], ["Escherichia coli", "PROBLEM", 161, 177], ["Klebsiella pneumoniae", "PROBLEM", 183, 204], ["standard culture", "TEST", 210, 226], ["Streptococcus pneumoniae", "OBSERVATION", 89, 113], ["Moraxella catarrhalis", "OBSERVATION", 115, 136], ["Staphylococcus aureus", "OBSERVATION", 138, 159], ["Escherichia coli", "OBSERVATION", 161, 177], ["Klebsiella pneumoniae", "OBSERVATION", 183, 204]]], ["In this study, only 63 (26.8%) patients (24 patients with HCAP and 39 patients with CAP) were conducted PCR for Mycoplasma pneumoniae, and two patients with CAP showed positive results.", [["Mycoplasma pneumoniae", "DISEASE", 112, 133], ["CAP", "DISEASE", 157, 160], ["patients", "ORGANISM", 31, 39], ["patients", "ORGANISM", 44, 52], ["HCAP", "CANCER", 58, 62], ["patients", "ORGANISM", 70, 78], ["Mycoplasma pneumoniae", "ORGANISM", 112, 133], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 31, 39], ["patients", "SPECIES", 44, 52], ["patients", "SPECIES", 70, 78], ["Mycoplasma pneumoniae", "SPECIES", 112, 133], ["patients", "SPECIES", 143, 151], ["Mycoplasma pneumoniae", "SPECIES", 112, 133], ["this study", "TEST", 3, 13], ["HCAP", "PROBLEM", 58, 62], ["CAP", "TEST", 84, 87], ["PCR", "TEST", 104, 107], ["Mycoplasma pneumoniae", "PROBLEM", 112, 133], ["CAP", "TEST", 157, 160]]], ["We conducted this study according to our usual clinical practice and multi-bacterial PCR is currently not available in our hospital.", [["this study", "TEST", 13, 23], ["multi-bacterial PCR", "TEST", 69, 88]]], ["However, more timely and sensitive microbiological methods like PCR might be necessary to enable early bacterial detection and pathogen-directed therapy.DiscussionIn the present study, MRSA infection was the strongest predictor of in-hospital mortality, especially in HCAP patients (OR 10.0, 95% CI 1.331-75.619, p = 0.025) after adjusting for age, sex, BMI, smoking history, ECOG status and comorbidities.", [["MRSA infection", "DISEASE", 185, 199], ["HCAP", "DISEASE", 268, 272], ["patients", "ORGANISM", 273, 281], ["MRSA", "SPECIES", 185, 189], ["patients", "SPECIES", 273, 281], ["MRSA", "SPECIES", 185, 189], ["sensitive microbiological methods like PCR", "PROBLEM", 25, 67], ["early bacterial detection", "TEST", 97, 122], ["pathogen-directed therapy", "TREATMENT", 127, 152], ["the present study", "TEST", 166, 183], ["MRSA infection", "PROBLEM", 185, 199], ["CI", "TEST", 296, 298], ["comorbidities", "PROBLEM", 392, 405], ["HCAP", "OBSERVATION", 268, 272]]], ["Actually, it is well known that MRSA pneumonia results in numerous complications and high mortality rates [45] .", [["pneumonia", "DISEASE", 37, 46], ["MRSA", "SPECIES", 32, 36], ["MRSA pneumonia", "PROBLEM", 32, 46], ["numerous complications", "PROBLEM", 58, 80], ["high mortality rates", "PROBLEM", 85, 105], ["MRSA", "OBSERVATION_MODIFIER", 32, 36], ["pneumonia", "OBSERVATION", 37, 46], ["numerous", "OBSERVATION_MODIFIER", 58, 66], ["complications", "OBSERVATION", 67, 80]]], ["Furthermore, residency in a long-term care facility is identified as a risk factor for MRSA rather than hospitalization or prescription of antimicrobials in hospitals in the recent studies [46] .", [["MRSA", "DISEASE", 87, 91], ["MRSA", "SPECIES", 87, 91], ["MRSA", "SPECIES", 87, 91], ["a risk factor", "PROBLEM", 69, 82], ["MRSA", "PROBLEM", 87, 91], ["antimicrobials", "TREATMENT", 139, 153]]], ["We have confirmed that fact again in this study.DiscussionHCAP was removed from the updated 2016 HAP/VAP guidelines [10] , because many studies have reported that HCAP patients were not infected with MDR pathogens [6] [7] [8] [9] .", [["HCAP", "ORGANISM", 163, 167], ["patients", "ORGANISM", 168, 176], ["[6] [7] [8", "SIMPLE_CHEMICAL", 214, 224], ["patients", "SPECIES", 168, 176], ["this study", "TEST", 37, 47], ["VAP guidelines", "TREATMENT", 101, 115], ["many studies", "TEST", 131, 143], ["HCAP", "PROBLEM", 163, 167], ["MDR pathogens", "PROBLEM", 200, 213]]], ["However, in the present study, the HCAP patients showed significantly higher MDR bacterial infection rates.", [["bacterial infection", "DISEASE", 81, 100], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["the present study", "TEST", 12, 29], ["the HCAP", "TEST", 31, 39], ["significantly higher MDR bacterial infection rates", "PROBLEM", 56, 106], ["HCAP", "OBSERVATION", 35, 39], ["significantly", "OBSERVATION_MODIFIER", 56, 69], ["higher", "OBSERVATION_MODIFIER", 70, 76], ["MDR", "OBSERVATION_MODIFIER", 77, 80], ["bacterial", "OBSERVATION_MODIFIER", 81, 90], ["infection", "OBSERVATION", 91, 100]]], ["We performed a multivariate analysis adjusting for age, sex, BMI, performance status (ECOG ! 3), comorbidities, and pneumonia severity indexes (PSI, CURB 65 ! 3, qSOFA ! 2), and found that HCAP is the most important predictor for MDROs (OR 14.2, 95% CI 1.734-115.9, p = 0.013) unlike previous studies [6] [7] [8] [9] .", [["pneumonia", "DISEASE", 116, 125], ["MDROs", "DISEASE", 230, 235], ["HCAP", "SIMPLE_CHEMICAL", 189, 193], ["[6] [7] [8] [9]", "SIMPLE_CHEMICAL", 301, 316], ["a multivariate analysis", "TEST", 13, 36], ["comorbidities", "PROBLEM", 97, 110], ["pneumonia severity indexes", "PROBLEM", 116, 142], ["PSI", "TEST", 144, 147], ["CURB", "TEST", 149, 153], ["HCAP", "PROBLEM", 189, 193], ["MDROs", "TEST", 230, 235], ["CI", "TEST", 250, 252], ["previous studies", "TEST", 284, 300], ["comorbidities", "OBSERVATION", 97, 110], ["pneumonia", "OBSERVATION", 116, 125], ["HCAP", "OBSERVATION", 189, 193]]], ["Recently, the number of elderly patients with frequent hospital contacts has increased rapidly and many of these individuals are residing in nursing homes or long-term care facilities, especially in Korea [47] , and those HCAP patients might be prone to MDR bacterial infection [48] [49] [50] .", [["HCAP", "DISEASE", 222, 226], ["bacterial infection", "DISEASE", 258, 277], ["patients", "ORGANISM", 32, 40], ["individuals", "ORGANISM", 113, 124], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 227, 235], ["MDR bacterial infection", "PROBLEM", 254, 277]]], ["Such recent trends may explain why this study has shown results that are different from previous studies.", [["this study", "TEST", 35, 45], ["previous studies", "TEST", 88, 104], ["different", "OBSERVATION_MODIFIER", 73, 82]]], ["However, further studies with updated data are needed to confirm these findings.DiscussionOur study has several limitations.", [["further studies", "TEST", 9, 24], ["updated data", "TEST", 30, 42], ["DiscussionOur study", "TEST", 80, 99]]], ["First, a limited number of invasive respiratory specimens was available in this study.", [["respiratory specimens", "ANATOMY", 36, 57], ["respiratory specimens", "CANCER", 36, 57], ["invasive respiratory specimens", "TEST", 27, 57], ["this study", "TEST", 75, 85]]], ["However, BAL is not a preferred technique, because of its invasiveness [3, 10] , and good concordance has been found between the results of cultures of sputum and transtracheal aspirates, particularly when good-quality sputum specimens are obtained [27, 51, 52] .", [["BAL", "ANATOMY", 9, 12], ["sputum", "ANATOMY", 152, 158], ["transtracheal aspirates", "ANATOMY", 163, 186], ["sputum specimens", "ANATOMY", 219, 235], ["sputum", "ORGANISM_SUBSTANCE", 152, 158], ["transtracheal aspirates", "MULTI-TISSUE_STRUCTURE", 163, 186], ["BAL", "TEST", 9, 12], ["cultures of sputum", "TEST", 140, 158], ["transtracheal aspirates", "TEST", 163, 186], ["sputum specimens", "TEST", 219, 235], ["transtracheal", "ANATOMY", 163, 176], ["aspirates", "OBSERVATION", 177, 186]]], ["In this study, Gram staining and culturing of the expectorated sputum produced a relatively high yield, and sputum RT-PCR showed a similar effectiveness as the BAL fluid RT-PCR (87.5%).", [["sputum", "ANATOMY", 63, 69], ["this study", "TEST", 3, 13], ["Gram staining", "TEST", 15, 28], ["culturing", "TEST", 33, 42], ["the expectorated sputum", "TEST", 46, 69], ["sputum RT", "TEST", 108, 117], ["PCR", "TEST", 118, 121], ["the BAL fluid RT", "TEST", 156, 172], ["PCR", "TEST", 173, 176]]], ["Second, we only included admitted patients with HCAP or CAP, and pneumonia patients in an outpatient setting were not included.", [["HCAP", "DISEASE", 48, 52], ["CAP", "DISEASE", 56, 59], ["pneumonia", "DISEASE", 65, 74], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 75, 83], ["HCAP", "PROBLEM", 48, 52], ["CAP", "PROBLEM", 56, 59], ["pneumonia", "PROBLEM", 65, 74], ["HCAP", "OBSERVATION", 48, 52], ["CAP", "OBSERVATION_MODIFIER", 56, 59], ["pneumonia", "OBSERVATION", 65, 74]]], ["Previous studies that included outpatients reported that the viral pneumonia rate was as high as 36% [13] , and there may be a risk that our results underestimated the proportion of viral pneumonia.", [["pneumonia", "DISEASE", 67, 76], ["pneumonia", "DISEASE", 188, 197], ["outpatients", "ORGANISM", 31, 42], ["Previous studies", "TEST", 0, 16], ["the viral pneumonia rate", "TEST", 57, 81], ["viral pneumonia", "PROBLEM", 182, 197], ["viral", "OBSERVATION_MODIFIER", 61, 66], ["pneumonia", "OBSERVATION", 67, 76], ["viral", "OBSERVATION_MODIFIER", 182, 187], ["pneumonia", "OBSERVATION", 188, 197]]], ["Lastly, this study was conducted in only one tertiary referral hospital and thus may reflect this limited clinical context.", [["this study", "TEST", 8, 18], ["may reflect", "UNCERTAINTY", 81, 92]]], ["A prospective multicenter study of HCAP and CAP is needed to confirm out findings.ConclusionHCAP patients have a lower likelihood of viral infection than, and a similar viral profile and seasonal variations to patients with CAP.", [["HCAP", "DISEASE", 35, 39], ["CAP", "DISEASE", 44, 47], ["viral infection", "DISEASE", 133, 148], ["CAP", "DISEASE", 224, 227], ["HCAP", "CANCER", 35, 39], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 210, 218], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 210, 218], ["A prospective multicenter study", "TEST", 0, 31], ["HCAP", "PROBLEM", 35, 39], ["CAP", "TEST", 44, 47], ["viral infection", "PROBLEM", 133, 148], ["a similar viral profile", "PROBLEM", 159, 182], ["CAP", "PROBLEM", 224, 227], ["HCAP", "OBSERVATION", 35, 39], ["lower likelihood", "OBSERVATION_MODIFIER", 113, 129], ["viral", "OBSERVATION_MODIFIER", 133, 138], ["infection", "OBSERVATION", 139, 148]]], ["Viral infection did not affect the prognosis of patients with HCAP.", [["Viral infection", "DISEASE", 0, 15], ["HCAP", "DISEASE", 62, 66], ["Viral", "ORGANISM", 0, 5], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["Viral infection", "PROBLEM", 0, 15], ["HCAP", "PROBLEM", 62, 66], ["infection", "OBSERVATION", 6, 15], ["HCAP", "OBSERVATION", 62, 66]]], ["Rather, multi-bacterial or MDR bacterial infection was the most important concern in patients with HCAP.ConclusionSupporting information S1", [["bacterial infection", "DISEASE", 31, 50], ["HCAP", "DISEASE", 99, 103], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["multi-bacterial", "PROBLEM", 8, 23], ["MDR bacterial infection", "PROBLEM", 27, 50], ["HCAP", "PROBLEM", 99, 103], ["MDR", "OBSERVATION_MODIFIER", 27, 30], ["bacterial", "OBSERVATION_MODIFIER", 31, 40], ["infection", "OBSERVATION", 41, 50], ["HCAP", "OBSERVATION", 99, 103]]]], "420730f8f702dcc8d0784ab8a2f21283adc01ac7": [["Introductionare seeing that the epidemic has entered a plateau, and when the plateau ends it gives place to a 23 new epidemic growth phase.", [["plateau", "ANATOMY", 55, 62]]], ["We 24 analyze the interrelation between the date of maximum incidence and heightened incidence events 25 taking place before the projected maximum.", [["heightened incidence events", "PROBLEM", 74, 101]]], ["In Section 2, 26 we formulate the mathematical model and give some general results arising from it; in Section 3, 27 we describe the Mexico City data that is used to exemplify our model results and present a brief 28 analysis of the impact of mitigation measures.", [["mitigation measures", "TREATMENT", 243, 262]]], ["In Section 4, we use our proposed model to gen-29 erate scenarios that describe the impact of superspreading events associated with holidays, on the 30 shape of the epidemic curve, and explore the probable consequences of lifting mitigation measures.", [["superspreading events", "PROBLEM", 94, 115], ["lifting mitigation measures", "TREATMENT", 222, 249]]], ["Figure 1 : S , E, I a , I s , I r , R, D represent the populations of susceptible, exposed, asymptomatically infected, symptomatically infected, reported infected, recovered and dead individuals, respectively.", [["asymptomatically infected, symptomatically infected", "DISEASE", 92, 143], ["D", "SIMPLE_CHEMICAL", 39, 40], ["asymptomatically infected", "PROBLEM", 92, 117], ["symptomatically infected", "PROBLEM", 119, 143], ["asymptomatically", "OBSERVATION_MODIFIER", 92, 108], ["infected", "OBSERVATION", 109, 117], ["symptomatically", "OBSERVATION_MODIFIER", 119, 134], ["infected", "OBSERVATION", 135, 143], ["infected", "OBSERVATION_MODIFIER", 154, 162]]], ["Previous to the mitigation measures, the epidemic follows the dynamics represented by the blue diagram.", [["the mitigation measures", "TREATMENT", 12, 35], ["the blue diagram", "TEST", 86, 102], ["blue diagram", "OBSERVATION", 90, 102]]], ["Once the mitigation measures are implemented (on March 23 in the case of Mexico), the population splits into two: those who comply with the control measures (green box) and those who do not (orange box).", [["the mitigation measures", "TREATMENT", 5, 28], ["the control measures", "TREATMENT", 136, 156]]], ["The dashed line connecting the green and orange boxes represent the compliance-failure rate \u03c9(t).Introductionfollowing system of ordinary differential equations:IntroductionS N * \u2212 \u03b3E, I a = \u03c1\u03b3E \u2212 \u03b7 a I a , I s = (1 \u2212 \u03c1)\u03b3E \u2212 (\u03b7 s + \u03b4 s ) I s , I r = \u03b4 s I s \u2212 \u03b4 r I r , R = \u03b7 a I a + \u03b7 s I s + (1 \u2212 \u00b5) \u03b4 r I r , D = \u00b5\u03b4 r I r ,Introduction(2.", [["\u03b3E", "SIMPLE_CHEMICAL", 181, 183], ["\u03b3E \u2212", "SIMPLE_CHEMICAL", 220, 224], ["green and orange boxes", "DNA", 31, 53], ["The dashed line", "TREATMENT", 0, 15], ["failure rate", "PROBLEM", 79, 91], ["\u03c1", "TEST", 218, 219], ["E \u2212", "TEST", 221, 224], ["s", "PROBLEM", 234, 235], ["\u00b5", "TEST", 299, 300], ["D", "TEST", 312, 313], ["line", "OBSERVATION", 11, 15], ["green", "OBSERVATION_MODIFIER", 31, 36], ["failure", "OBSERVATION", 79, 86]]], ["1) where N * = S + E + I a + I s + R. Note that the I r compartment does not participate in transmission since, it is assumed, once confirmed, the cases are effectively isolated. b represents the effective contact rate, 1/\u03b3 the incubation period, \u03c1 the proportion of asymptomatically infected individuals, 1/\u03b7 a and 1/\u03b7 s the periods from symptoms onset to recovery for symptomatically and asymptomatically infected individuals, \u03b4 s the rate at which a symptomatically infected individuals becomes a reported (confirmed) case, 1/\u03b4 r the time from confirmation to recovery or death and \u00b5 is the proportion of those reported cases that die.", [["death", "DISEASE", 575, 580], ["asymptomatically infected individuals", "PROBLEM", 267, 304], ["symptoms", "PROBLEM", 339, 347], ["asymptomatically infected individuals", "PROBLEM", 390, 427], ["the rate", "TEST", 433, 441], ["a symptomatically infected individuals", "PROBLEM", 451, 489], ["death", "PROBLEM", 575, 580], ["asymptomatically", "OBSERVATION_MODIFIER", 267, 283], ["infected", "OBSERVATION", 284, 292]]], ["The basic reproductive number of the system 2.1 is given by:Introductionwhere the first term represents the number of new cases produced by asymptomatically infected individuals and the second term represents the number produced by symptomatically infected individuals.", [["asymptomatically infected individuals", "PROBLEM", 140, 177], ["symptomatically infected individuals", "PROBLEM", 232, 268], ["reproductive", "OBSERVATION_MODIFIER", 10, 22], ["number", "OBSERVATION_MODIFIER", 23, 29], ["new", "OBSERVATION_MODIFIER", 118, 121], ["asymptomatically", "OBSERVATION_MODIFIER", 140, 156], ["infected", "OBSERVATION", 157, 165], ["symptomatically", "OBSERVATION_MODIFIER", 232, 247], ["infected", "OBSERVATION", 248, 256]]], ["After mitigation measures are implemented (T ), the population is split into two groups: one constituted by those individuals who comply with the measures that is referred to as the confined group, and another constituted by those individuals who do not, that is called the unconfined group, either because they disobey the social-distancing guidelines or because they belong to an strategic sector of the economy.", [["mitigation measures", "TREATMENT", 6, 25]]], ["The dynamics in the second time interval are given by:IntroductionThe index i = 1 gives the population that complies with the control measures, while i = 2 indicates those who do not.", [["the control measures", "TREATMENT", 122, 142]]], ["Note that the compartments I r , R, 4 .", [["compartments", "ANATOMY", 14, 26]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)IntroductionThe copyright holder for this preprint this version posted July 24, 2020. . and D are common to both groups.", [["CC", "CHEMICAL", 0, 2], ["D", "SIMPLE_CHEMICAL", 294, 295], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["Following [5] , the effective contact rates are different for each group and are given by:Introduction3) assumes decreasing contact rates where the parameters q 2i \u2264 q 1i , i = 1, 2, represent a reduction in the baseline effective contact rate b.", [["a reduction", "TREATMENT", 193, 204]]], ["T is the time at which the effective contact rates start to act and \u03b8 j , j = 1, 2, are the duration of the contact reduction process.", [["the contact reduction process", "TREATMENT", 104, 133], ["contact reduction", "OBSERVATION", 108, 125]]], ["Finally, we define the compliance-failure rate \u03c9(t) as a step function, that is,Introductionwhere \u03ba > 1 is the increase in the compliance-failure rate relative to the baseline value \u03c9 0 (\u03ba = 1), 1 T * is the time at which the perturbation starts and \u03b8 \u03c9 is the duration of the perturbation.", [["failure rate", "PROBLEM", 34, 46], ["failure rate", "PROBLEM", 138, 150], ["the baseline value", "TEST", 163, 181], ["increase", "OBSERVATION_MODIFIER", 111, 119], ["failure", "OBSERVATION", 138, 145]]], ["This model 2 admits several periods during which \u03c9(t) may act but here we illustrate only one period.3The inclusion of short-term superspreading events into equations 2.3 and 2.4 renders scenarios 4 in which a plateau-like behavior appears.", [["equations", "TEST", 157, 166], ["short-term", "OBSERVATION_MODIFIER", 119, 129], ["plateau", "ANATOMY", 210, 217]]], ["We show three scenarios: (I) long plateau with slight 5 decrease and rebound; (II) shorter plateau with a later decreasing trend in the epidemic-curve; 6 (III) long plateau with a later decreasing epidemic-curve.", [["slight 5 decrease and rebound", "PROBLEM", 47, 76], ["the epidemic-curve", "TEST", 132, 150], ["long plateau", "PROBLEM", 160, 172], ["a later decreasing epidemic-curve", "PROBLEM", 178, 211], ["slight", "OBSERVATION_MODIFIER", 47, 53], ["decrease", "OBSERVATION_MODIFIER", 56, 64], ["decreasing", "OBSERVATION_MODIFIER", 186, 196], ["epidemic", "OBSERVATION_MODIFIER", 197, 205]]], ["Each scenario is subdivided into three 7 sub-cases defined as follows: 8 \u2022 Scenario X.a: Increase \u03ba = 3 of the baseline value \u03c9 0 .9\u2022 Scenario X.b: Increase \u03ba = 5 of the baseline value \u03c9 0 .10\u2022 Scenario X.c: Increase \u03ba = 7 of the baseline value \u03c9 0 .11where X = I, II, III.", [["the baseline value", "TEST", 107, 125], ["the baseline value", "TEST", 166, 184]]], ["Fixed parameter values are given in Table 15.", [["Fixed parameter values", "TEST", 0, 22]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)5The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161026 doi: medRxiv preprint 2.1 (I) Long plateau with slight decrease and rebound 1 Setting q 1i as in Table 1 , in (2.3) we put for both groups, \u03b8 1 of approximately two weeks and \u03b8 2 of 2 about 3 months with q 21 = 0.3 (decrease of 70% for the confined group), q 22 = 0.4 (decrease of 3 60% for the unconfined group).", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["Long plateau", "PROBLEM", 353, 365], ["slight decrease", "PROBLEM", 371, 386], ["rebound", "TEST", 391, 398], ["med", "ANATOMY", 105, 108], ["slight", "OBSERVATION_MODIFIER", 371, 377], ["decrease", "OBSERVATION", 378, 386]]], ["4 Figure 2 illustrates the case where the perturbed epidemic curve shows a slight decrease imme-5 diately after the perturbation relative to the baseline curve.", [["the perturbed epidemic curve", "TEST", 38, 66], ["a slight decrease imme", "PROBLEM", 73, 95], ["the baseline curve", "TEST", 141, 159], ["slight", "OBSERVATION_MODIFIER", 75, 81], ["decrease", "OBSERVATION_MODIFIER", 82, 90]]], ["Scenario Ic is the worst-case scenario where the growth rate keeps 7 growing.", [["the growth rate", "TEST", 45, 60]]], ["Scenario Ia illustrates the appearance of a plateau-like behavior followed first by a slight 8 decline and then growth again.", [["a plateau-like behavior", "PROBLEM", 42, 65], ["a slight 8 decline", "PROBLEM", 84, 102], ["plateau", "OBSERVATION", 44, 51], ["slight", "OBSERVATION_MODIFIER", 86, 92]]], ["The length of plateau is preserved for several weeks.", [["length", "OBSERVATION_MODIFIER", 4, 10], ["plateau", "OBSERVATION_MODIFIER", 14, 21], ["preserved", "OBSERVATION", 25, 34]]], ["Setting q 1i as in Table 1 , in (2.3) we put, as before, \u03b8 1 of about two weeks and \u03b8 2 of about three 11 months with q 21 = 0.3 (decrease of 70% for the confined group), q 22 = 0.3 (decrease of 70% for 12 the unconfined group).513 Figure 3 illustrates the case where the epidemic curve decreases after the end of the interval 14 of maximum incidence.", [["the epidemic curve", "PROBLEM", 268, 286]]], ["Scenario IIc is the worst-scenario since where after the perturbation, the 15 epidemic peak is pushed higher and later in time.", [["the perturbation", "TEST", 53, 69]]], ["Scenario IIa, on the other hand, is comparatively 16 benign.", [["Scenario IIa", "GENE_OR_GENE_PRODUCT", 0, 12], ["IIa", "OBSERVATION_MODIFIER", 9, 12], ["benign", "OBSERVATION", 53, 59]]], ["The peak is still reached as projected on the baseline case, and then the epidemic curve 17 decreases at a slower rate than the baseline.", [["the epidemic curve", "TEST", 70, 88], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["decreases", "OBSERVATION_MODIFIER", 92, 101]]], ["Finally, scenario IIb shows the appearance of a plateau-18 like behavior.", [["a plateau", "TEST", 46, 55], ["plateau", "OBSERVATION_MODIFIER", 48, 55]]], ["In this case, when the peak is reached, the incidence curve does not show a significant 19 decay but rather, enters a sustained phase of maximum incidence that lasts several weeks.", [["the incidence curve", "TEST", 40, 59], ["a significant 19 decay", "PROBLEM", 74, 96], ["sustained", "OBSERVATION_MODIFIER", 118, 127], ["phase", "OBSERVATION_MODIFIER", 128, 133], ["maximum", "OBSERVATION_MODIFIER", 137, 144]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)5The copyright holder for this preprint this version posted July 24, 2020.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["Figure 3 : Impact of high mobility, for 12 days, on the baseline epidemic curve (blue line).", [["the baseline epidemic curve (blue line", "TREATMENT", 52, 90], ["high mobility", "OBSERVATION_MODIFIER", 21, 34], ["blue line", "OBSERVATION", 81, 90]]], ["The increase period starts 23 days before of the baseline epidemic curve peak.", [["increase", "OBSERVATION_MODIFIER", 4, 12]]], ["(A) Newly reported cases proportion per day, and (B) daily deaths proportion per day.(III) Long plateau with decreasing epidemic-curve1 Set q 1i as in Table 1 , and, in (2.3) we put, for both groups, \u03b8 1 of about two weeks but now \u03b8 2 of 2 about four months with q 21 = 0.2 (confined group), q 22 = 0.3 (non-confined group).(III) Long plateau with decreasing epidemic-curve3 Figure 4 illustrate the case where the epidemic curve decreases after the peak.", [["deaths", "DISEASE", 59, 65], ["Set q 1i", "DNA", 136, 144], ["Long plateau", "PROBLEM", 91, 103], ["decreasing epidemic", "PROBLEM", 109, 128], ["Long plateau", "PROBLEM", 330, 342], ["decreasing epidemic-curve3", "TREATMENT", 348, 374], ["the epidemic curve", "TEST", 410, 428], ["decreasing", "OBSERVATION_MODIFIER", 109, 119], ["epidemic", "OBSERVATION", 120, 128], ["decreasing", "OBSERVATION_MODIFIER", 348, 358]]], ["Scenario IIIa 4 shows the appearance of a plateau that lasts some months after the date of the baseline peak.", [["a plateau", "PROBLEM", 40, 49], ["plateau", "OBSERVATION_MODIFIER", 42, 49]]], ["On 5 the other hand, scenarios IIIb and IIIc shows a runaway epidemic with a much higher peak than 6 that of the baseline curve.", [["a runaway epidemic", "PROBLEM", 51, 69]]], ["We start the 2 analysis with some context.", [["the 2 analysis", "TEST", 9, 23]]], ["On March 23, 2020, social distancing measures where implemented 3 in Mexico to slowdown the spread of COVID-19 pandemic, mainly focused in closing schools 4 and some non-essential activities.", [["non-essential activities", "OBSERVATION", 166, 190]]], ["These mea-6 sures aimed to \"flatten the curve\", meaning to lower the incidence to ensure that critical cases 7 would remain under manageable levels.", [["These mea", "TEST", 0, 9]]], ["On April 16, 2020, the federal government announced 8 that for Mexico City, the day of maximum incidence would occur on May 08-10, 2020 [8, 9] , and 9 consequently, the date for lifting mitigation measures was announced to start on June 01, 2020.17This plateau may have appeared as a consequence of two important holidays, children's day, and 18 mother's day, occurring approximately 10-14 days before the expected date for the peak of maxi-19 mum incidence .", [["children", "ORGANISM", 323, 331], ["children", "SPECIES", 323, 331], ["lifting mitigation measures", "TREATMENT", 178, 205]]], ["We postulate that these events are an important factor that explains the observed 20 quasi-stationary epidemic trend that the data shows at present (mid-July 2020).", [["the data", "TEST", 122, 130]]], ["In this section 21 we attempt an explanation of the probable causes of such behavior.", [["such behavior", "PROBLEM", 71, 84]]], ["Furthermore, we explore the Richards model is an extension of a simple logistic growth model that is an standard tool commonly used to predict cumulative COVID-19 cases in China (see, for example, [11] ).", [["a simple logistic growth model", "PROBLEM", 62, 92]]], ["In this model the curve of cumulative cases, C(t), is described by the solution of17where r is the epidemic growth rate, K is the final epidemic size, and a is a parameter that accounts 29 for the asymmetry of the epidemic curve.", [["the epidemic growth rate", "TEST", 95, 119], ["the epidemic curve", "TEST", 210, 228], ["epidemic", "OBSERVATION_MODIFIER", 136, 144], ["size", "OBSERVATION_MODIFIER", 145, 149]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161026 doi: medRxiv preprint [12, 13] .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Technical details can be found in Appendix A. We limit the fitting of the Richards curve 1 to April 30 since on that date an important event of increased transmission started that violated the 2 hypothesis that population conditions for transmission were essentially unchanged since March 23, 3 2020.", [["increased transmission", "PROBLEM", 144, 166], ["Appendix", "ANATOMY", 34, 42], ["unchanged", "OBSERVATION_MODIFIER", 267, 276]]], ["In terms of our model, unchanged conditions mean \u03c9(t) = \u03c9 0 for all t. both effective contact rates are q 11 = 0.6 (40% reduction in the confined group), q 12 = 0.7 (30% 26 reduction in the unconfined group), respectively.", [["unchanged", "OBSERVATION_MODIFIER", 23, 32]]], ["The duration \u03b8 2 and magnitudes (q 2i ) of the 27 second reductions (q 2i ) depend on the study scenario as described in the next section.28Once under confinement, individuals may abandon the isolation with a compliance-failure rate 29 \u03c9(t).", [["the 27 second reductions", "TREATMENT", 43, 67], ["the study scenario", "TEST", 86, 104], ["failure rate", "TEST", 220, 232]]], ["This is the parameter we use as a proxy for population mobility. \u03c9(t) is a time-dependent 30 rate: we assume that increased mobility lasts only for a period of \u03b8 \u03c9 days, with a background 31 compliance-failure rate \u03c9 0 that in atypical events is increased by a factor \u03ba (equation 2.4).", [["increased mobility", "PROBLEM", 114, 132], ["failure rate", "PROBLEM", 202, 214], ["atypical events", "PROBLEM", 227, 242], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["mobility", "OBSERVATION", 124, 132], ["increased", "OBSERVATION_MODIFIER", 246, 255]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["In Mexico, there were two important holidays (in terms of population mobility) within the 10 period of confinement: April 30, 2020, children's day, and May 10, 2020, mother's day.", [["children", "ORGANISM", 132, 140], ["children", "SPECIES", 132, 140]]], ["Population 11 mobility increased these days as evidenced by the intantaneous reproduction number (Figure 6 ).", [["mobility", "OBSERVATION_MODIFIER", 14, 22]]], ["12 Note that R t shows a slight increase just around April 30, 2020, and May 01, 2020.", [["a slight increase", "PROBLEM", 23, 40], ["slight", "OBSERVATION_MODIFIER", 25, 31], ["increase", "OBSERVATION_MODIFIER", 32, 40]]], ["We center 13 our attention on the effect of increased mobility within the period from April 29, 2020, to May 10, 14 2020.", [["increased mobility", "PROBLEM", 44, 62], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["mobility", "OBSERVATION", 54, 62]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 24, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Mexico City epidemic has shown a plateau-like behavior since middle-May ( Figure 8) .", [["plateau", "OBSERVATION_MODIFIER", 33, 40]]], ["As 1 Figure 6 shows, a significant increase in mobility occurred in the period from April 29, 2020, 2 to May 10, 2020.", [["a significant increase in mobility", "PROBLEM", 21, 55], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["increase", "OBSERVATION_MODIFIER", 35, 43], ["mobility", "OBSERVATION_MODIFIER", 47, 55]]], ["Figure 7 shows simulations for \u03ba = 3.", [["Figure", "TEST", 0, 6]]], ["We compare our results with the reported confirmed 6 cases and deaths per day.", [["deaths", "DISEASE", 63, 69]]], ["Blue and yellow bars represent 7 confirmed and suspect+confirmed cases, respectively.", [["Blue and yellow bars", "TEST", 0, 20], ["yellow bars", "OBSERVATION", 9, 20]]], ["This observed decrease in mortality is intriguing.", [["decrease", "OBSERVATION_MODIFIER", 14, 22], ["mortality", "OBSERVATION", 26, 35]]], ["It could be due 9 to enhanced treatment of grave cases, shifting of the morbidity towards age classes with a lower 10 risk of death or, perhaps, incomplete mortality records and reporting time delays.", [["death", "DISEASE", 126, 131], ["grave cases", "PROBLEM", 43, 54], ["a lower 10 risk of death", "PROBLEM", 107, 131]]], ["Since we are 11 comparing with the absolute number of deaths, testing has little impact in this case. measures.", [["deaths", "DISEASE", 54, 60], ["testing", "TEST", 62, 69]]], ["The concern is that an increase in the number of cases may occur as it has occurred in 15 the USA.", [["increase", "OBSERVATION_MODIFIER", 23, 31]]], ["In this section, we explore the possibility of this scenario for Mexico City.16Mexico's federal government developed an epidemiological panel to oversee the reactivation 17 11 .", [["an epidemiological panel", "TEST", 117, 141]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 24, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We model this process by updating the number of individuals at a fixed time (T * ) in equa-12 tion (2.2), as x 1 (t i ) = (1 \u2212 q)x 1 (t i\u22121 ) and x 2 (t i ) = qx 1 (t i\u22121 ) + x 2 (t i\u22121 ) where t i = T * , x 1 and x 2 13 represent the susceptible, exposed, asymptomatically infected and symptomatically infected for 14 the confined and unconfined groups, respectively. change from red to orange light).", [["equa", "TEST", 86, 90], ["qx", "TEST", 159, 161], ["asymptomatically infected", "PROBLEM", 257, 282], ["susceptible", "OBSERVATION", 235, 246], ["asymptomatically", "OBSERVATION_MODIFIER", 257, 273], ["infected", "OBSERVATION", 274, 282]]], ["We explore the short and medium-term effects of the lifting of the 19 mitigation measures on the epidemic curve.", [["the 19 mitigation measures", "TREATMENT", 63, 89]]], ["These curves are obtained for the parameters shown in Table 2 .", [["These curves", "TEST", 0, 12]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Solid lines are the baseline, while dotted 3 lines represent the perturbed system (after lifting restrictions on June 29, 2020).", [["Solid lines", "ANATOMY", 0, 11], ["Solid lines", "CELL", 0, 11], ["3 lines", "CELL", 43, 50], ["Solid lines", "CELL_LINE", 0, 11], ["lines", "OBSERVATION", 6, 11], ["baseline", "OBSERVATION_MODIFIER", 20, 28]]], ["Note that, as the 4 percentage of the confined population is decreased, the incidence increases to higher levels.", [["confined", "OBSERVATION_MODIFIER", 38, 46], ["population", "OBSERVATION", 47, 57], ["decreased", "OBSERVATION_MODIFIER", 61, 70], ["higher", "OBSERVATION_MODIFIER", 99, 105], ["levels", "OBSERVATION_MODIFIER", 106, 112]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 24, 2020. .4.2.2Lifting on June 29, 2020, with decreasing effective contact rate 1 We explore the scenario where the effective contact rate continues to decline even after partially lift-2 ing mitigation measures.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["2 ing mitigation measures", "TREATMENT", 452, 477], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Here, we consider that the effective contact rates in both groups decrease 3 until August 01, 2020, and then both remain constant.", [["constant", "OBSERVATION", 121, 129]]], ["For this scenario, we set q 11 = 0.6, q 21 = 0.1 4 (confined group), and q 12 = 0.7, q 22 = 0.2 (unconfined group).", [["this scenario", "TEST", 4, 17]]], ["Other parameter values are similar 5 to those employed in the above subsection.", [["Other parameter values", "TEST", 0, 22]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161026 doi: medRxiv preprintRemark:1 Figures 8 and 9 show that, as the percentage of the population under confinement decreases, the 2 number of new reported cases also increases.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["population", "OBSERVATION", 403, 413], ["confinement", "OBSERVATION_MODIFIER", 420, 431], ["decreases", "OBSERVATION_MODIFIER", 432, 441], ["new", "OBSERVATION_MODIFIER", 459, 462]]], ["A similar behavior is observed for the dynamics of 3 daily deaths.", [["deaths", "DISEASE", 59, 65]]], ["City, the federal government originally forecasted the peak of maximum incidence to occur by May 11 8-10 , 2020 and the date for lifting mitigation measures was set to start on June 1, 2020.", [["lifting mitigation measures", "TREATMENT", 129, 156]]], ["The peak, 12 however, occurred much later in the month as the data and independent models have shown [5, 6, 7].13The epidemic in Mexico City shows that it entered a period of constant incidence since around24A characteristic of our model that we think is worth underlining, is that the effective contact rates 25 are time-varying which, we think, constitutes a realistic approximation since we are looking at 26 population averages.", [["the data", "TEST", 58, 66], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["epidemic", "OBSERVATION_MODIFIER", 117, 125]]], ["For example, adopting safe behaviors, such as wearing face masks, involves 27 a learning process; it does not suddenly occur, rather it takes time for the face masks to be adopted 28 by a significant proportion of the general population.", [["the face masks", "TREATMENT", 151, 165]]], ["Our results indicate that after lifting mobility 29 restrictions, a decrease of the effective contact rate should continue in order to force the epidemic 30 curve to make a downward turn.", [["the effective contact rate", "TREATMENT", 80, 106]]], ["We interpret this continuing decrease in the effective contact rate 31 as related to the use of face masks, social-distancing, washing hands, etc.32Mathematical models are essential in the fight against COVID-19.", [["face masks", "TREATMENT", 96, 106], ["COVID", "TEST", 203, 208]]], ["They are tools for evaluating 33 mitigation measures, estimating mortality and incidence, and projecting scenarios to help public 34 health decision-makers in their very difficult and important task of controlling the epidemic.", [["33 mitigation measures", "TREATMENT", 30, 52]]], ["In this 35 paper, we have used mathematical models to evaluate and generate scenarios.", [["mathematical models", "TREATMENT", 31, 50]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 24, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 24, 2020. .17.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 24, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Let Y j , for j = 1, 2, ...n, be the number of observed new daily cases at time t j , with t j given in days since the first reported case started symptoms.", [["Let Y j", "GENE_OR_GENE_PRODUCT", 0, 7], ["t j", "TREATMENT", 91, 94], ["symptoms", "PROBLEM", 147, 155]]], ["We assume that Y j follows a Negative Binomial distribution with mean value X(t j |a, r, K) = C(t j |a, r, K) \u2212 C(t j\u22121 |a, r, K) and dispersion parameter \u03b1.", [["a", "TEST", 83, 84], ["K", "TEST", 89, 90], ["C", "TEST", 94, 95], ["j", "TEST", 98, 99], ["a", "TEST", 101, 102], ["K", "TEST", 107, 108], ["C", "TEST", 112, 113], ["j\u22121", "TEST", 116, 119], ["a", "TEST", 121, 122], ["K", "TEST", 127, 128], ["dispersion parameter", "TEST", 134, 154]]], ["Here, C(t|a, r, K) is the solution of Richards model presented in (3.1).", [["Richards model", "TEST", 38, 52]]], ["Assuming that, given the parameters, the observations Y 1 , Y 2 , . . . , Y n are conditionally independent, then(which was not certified by peer review)Var[Y j |a, r, K, \u03b1] = X(t j |a, r, K) + \u03b1X(t j |a, r, K) 2 (A.(which was not certified by peer review)2)(which was not certified by peer review)The Negative Binomial distribution allows to control the variability of the data by considering 4 over-dispersion which is common for epidemiological data.", [["a", "TEST", 162, 163], ["K", "TEST", 168, 169], ["\u03b1]", "TEST", 171, 173], ["j", "TEST", 180, 181], ["a", "TEST", 183, 184], ["K", "TEST", 189, 190], ["a", "TEST", 202, 203], ["Negative", "OBSERVATION_MODIFIER", 302, 310], ["Binomial distribution", "OBSERVATION", 311, 332]]], ["Then, the likelihood function, which represents how plausible is the data under the Negative Binomial assumption and Richards model if we knew the parameters, is given by \u03c0(y 1 , . . . , y n |\u03b8) = n j=1 \u0393(y j + \u03c4) \u0393(y j )\u0393(\u03c4) \u03c4 \u03c4 + C(t j |a, r, K) \u03c4 C(t j |a, r, K) \u03c4 + C(t j |a, r, K)6Consider that parameters a, r, K and \u03b1 as random variables.", [["j", "TEST", 207, 208], ["\u0393", "TEST", 214, 215], ["\u0393", "TEST", 221, 222], ["\u03c4", "TEST", 223, 224], ["\u03c4", "TEST", 226, 227], ["\u03c4", "TEST", 228, 229], ["j", "TEST", 236, 237], ["a", "TEST", 239, 240], ["K", "TEST", 245, 246], ["C", "TEST", 250, 251], ["j", "TEST", 254, 255], ["a", "TEST", 257, 258], ["K", "TEST", 263, 264], ["\u03c4", "TEST", 266, 267], ["a", "TEST", 277, 278], ["K", "TEST", 283, 284], ["parameters", "TEST", 300, 310], ["a", "TEST", 311, 312], ["K", "TEST", 317, 318], ["random variables", "TEST", 328, 344]]], ["Assuming prior independence, the joint prior distribution for vector \u03b8 is \u03c0(\u03b8) = \u03c0(a)\u03c0(r)\u03c0(K)\u03c0(\u03b1),6where \u03c0(a) is the probability density function (pdf) of a Uniform(0,2) distribution, \u03c0(r) is the 7 pdf of a Uniform(0, 2), \u03c0(K) is the pdf of a Uniform(K min , K max ), and \u03c0(\u03b1) is the pdf of a 8 Gamma(shape=2, scale=0.1).", [["\u03c0", "PROTEIN", 272, 273], ["\u03b1", "PROTEIN", 274, 275], ["the joint prior distribution", "TEST", 29, 57], ["vector", "TEST", 62, 68], ["K", "TEST", 91, 92], ["K max", "TEST", 259, 264], ["shape", "TEST", 301, 306], ["scale", "TEST", 310, 315], ["joint", "ANATOMY", 33, 38], ["density", "OBSERVATION", 129, 136], ["Uniform", "OBSERVATION_MODIFIER", 157, 164]]], ["To select the prior for parameter r, we consider that previous es-9 timations of r are close to 0.3 [11], and a Uniform(0,2) represents a weekly informative prior as it 10 allows for a wide range of values of r.", [["r.", "SPECIES", 209, 211]]], ["Also, there is no available prior information regarding the 11 final size of the outbreak K. This is a critical parameter in the model and, in order to avoid bias, 12 we assume a uniform prior over K min and K max .", [["K max", "TEST", 208, 213], ["no", "UNCERTAINTY", 15, 17]]], ["To set the upper bound for K, we consider a 15 fraction of the total population K max = N * 0.05, where N is the population size of Mexico.", [["size", "OBSERVATION_MODIFIER", 124, 128]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)14The copyright holder for this preprint this version posted July 24, 2020.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["Table 3 : Parameter median estimates and 95% posterior probability intervals for Richards model.", [["Parameter median estimates", "TREATMENT", 10, 36]]], ["Here, r is the growth rate, K is the final size of the outbreak and a is a scaling factor.", [["the growth rate", "TEST", 11, 26], ["a scaling factor", "PROBLEM", 73, 89], ["size", "OBSERVATION_MODIFIER", 43, 47], ["outbreak", "OBSERVATION", 55, 63]]], ["K is shown by completeness.14fraction was determined based on the observations of other cities such as the New York where the 1 total population size is similar to Mexico City. mean, variance, quantiles, etc. We refer the reader to [12] for more details on MCMC methods and 7 to [13] for an introduction to Bayesian inference with differential equations.", [["K", "CHEMICAL", 0, 1], ["K", "TEST", 0, 1], ["MCMC methods", "TEST", 257, 269], ["differential equations", "TEST", 331, 353], ["size", "OBSERVATION_MODIFIER", 145, 149]]], ["8 We estimate vector \u03b8 using data from Mexico City for two different periods, from February 22, 9 2020 to March 22, 2020, and from March 23, 2020 to April 30, 2020.", [["vector \u03b8", "DNA", 14, 22]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)19The copyright holder for this preprint this version posted July 24, 2020. . https://doi.org/10.1101/2020.07.23.20161026 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv", "TREATMENT", 329, 336], ["med", "ANATOMY", 105, 108]]]], "PMC7426458": [["One of these clocks is the environmental clock, which generates roughly 24-h changes in the light/dark (LD) cycle.", [["environmental clock", "OBSERVATION", 27, 46], ["roughly", "OBSERVATION_MODIFIER", 64, 71], ["24-h", "OBSERVATION_MODIFIER", 72, 76]]], ["The other clock is the endogenous biological clock, which among other rhythms generates roughly 24-h (circadian) rhythms in biological outputs such as the sleep/wake cycle.", [["biological outputs", "TEST", 124, 142], ["endogenous biological clock", "OBSERVATION", 23, 50]]], ["Prior to the introduction of artificial light at night, these two clocks were probably tightly synchronised (1, 2).", [["artificial light", "TREATMENT", 29, 45], ["probably", "UNCERTAINTY", 78, 86], ["tightly synchronised", "OBSERVATION_MODIFIER", 87, 107]]], ["Following industrialisation, however, people can more easily work outside of conventional daytime hours, and 15\u201320% of the working population now work shifts (3).", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44]]], ["The burden of shift work is striking: Shift workers are not only at increased risk of accidents (4), they are also disposed to developing numerous diseases, including certain cancers, coronary heart disease, stroke, and type-two diabetes (5).", [["cancers", "ANATOMY", 175, 182], ["coronary", "ANATOMY", 184, 192], ["heart", "ANATOMY", 193, 198], ["accidents", "DISEASE", 86, 95], ["cancers", "DISEASE", 175, 182], ["coronary heart disease", "DISEASE", 184, 206], ["stroke", "DISEASE", 208, 214], ["diabetes", "DISEASE", 229, 237], ["cancers", "CANCER", 175, 182], ["heart", "ORGAN", 193, 198], ["numerous diseases", "PROBLEM", 138, 155], ["certain cancers", "PROBLEM", 167, 182], ["coronary heart disease", "PROBLEM", 184, 206], ["stroke", "PROBLEM", 208, 214], ["type-two diabetes", "PROBLEM", 220, 237], ["numerous", "OBSERVATION_MODIFIER", 138, 146], ["diseases", "OBSERVATION", 147, 155], ["coronary heart", "ANATOMY", 184, 198], ["disease", "OBSERVATION", 199, 206], ["stroke", "OBSERVATION", 208, 214], ["diabetes", "OBSERVATION", 229, 237]]], ["Few studies have explored whether shift work makes individuals prone to neurodegenerative diseases (6, 7), but shift work frequently disrupts biological rhythms and sleep, and such disturbances propagate a slew of pathobiological changes that contribute to neurodegeneration (8).", [["neurodegenerative diseases", "DISEASE", 72, 98], ["neurodegeneration", "DISEASE", 257, 274], ["Few studies", "TEST", 0, 11], ["neurodegenerative diseases", "PROBLEM", 72, 98], ["such disturbances", "PROBLEM", 176, 193], ["pathobiological changes", "PROBLEM", 214, 237], ["neurodegeneration", "PROBLEM", 257, 274], ["neurodegenerative", "OBSERVATION_MODIFIER", 72, 89], ["diseases", "OBSERVATION", 90, 98], ["neurodegeneration", "OBSERVATION", 257, 274]]], ["While at the time of writing little is known about the effects of the 2019 novel coronavirus disease (COVID-19) pandemic on the lives of many shift workers, we would be remiss not to mention that many healthcare professionals at the frontlines of the outbreak are currently working long shifts in conditions that dispose them to developing COVID-19 (9).", [["coronavirus disease", "DISEASE", 81, 100], ["COVID-19", "CHEMICAL", 340, 348], ["novel coronavirus disease", "PROBLEM", 75, 100]]], ["Many of the chronic conditions associated with shift work are also associated with greater risk of poor outcomes in those with COVID-19 as well as other coronavirus and influenza infections (10\u201317).", [["coronavirus", "DISEASE", 153, 164], ["influenza infections", "DISEASE", 169, 189], ["coronavirus", "ORGANISM", 153, 164], ["the chronic conditions", "PROBLEM", 8, 30], ["poor outcomes", "PROBLEM", 99, 112], ["COVID", "TEST", 127, 132], ["other coronavirus and influenza infections", "PROBLEM", 147, 189], ["chronic", "OBSERVATION_MODIFIER", 12, 19], ["conditions", "OBSERVATION", 20, 30], ["coronavirus", "OBSERVATION", 153, 164], ["influenza", "OBSERVATION", 169, 178]]], ["Importantly, however, at present there is no strong evidence that people fully adapt to shift work (18).", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72], ["no strong evidence", "UNCERTAINTY", 42, 60]]], ["And considering that the unconventional schedules of shift workers also interrupt the lives of cohabiting non-shift workers, the burden of shift work is greater still.", [["greater", "OBSERVATION_MODIFIER", 153, 160]]], ["The purpose of this manuscript is therefore to summarise some ways by which we might be able to reduce this burden.Optimising Shift Work SchedulesOptimising shift work schedules is fundamental to the health and productivity of shift workers.", [["this burden", "PROBLEM", 103, 114]]], ["In general, it appears that most shift workers tolerate rapid, forward (clockwise) rotation schedules best (5).", [["forward (clockwise) rotation schedules", "TREATMENT", 63, 101]]], ["This autonomy helps account for differences between people in non-work responsibilities, tolerance to shift work, and commuting to and from work.Optimising Shift Work SchedulesChronotype is another tailoring variable that is particularly germane to optimising shift work schedules.", [["people", "ORGANISM", 52, 58], ["people", "SPECIES", 52, 58], ["shift work schedules", "TREATMENT", 260, 280]]], ["Chronotype is defined as interindividual differences in the phenotypic expression of behavioural outputs regulated by the circadian system (19), the most conspicuous of which is the timing of the sleep/wake cycle, and in industrialised societies there exist large differences between individuals in their chronotypes (20).", [["behavioural outputs", "PROBLEM", 85, 104], ["large differences between individuals", "PROBLEM", 258, 295], ["interindividual", "OBSERVATION_MODIFIER", 25, 40], ["differences", "OBSERVATION_MODIFIER", 41, 52], ["behavioural outputs", "OBSERVATION", 85, 104], ["most conspicuous", "OBSERVATION_MODIFIER", 149, 165], ["large", "OBSERVATION_MODIFIER", 258, 263], ["differences", "OBSERVATION_MODIFIER", 264, 275]]], ["Chronotype appears to modify the association between shift work schedules and risk of health problems (21), such that the health of early chronotypes may be especially negatively affected by working night shifts (22), whereas late chronotypes find working morning shifts particularly problematic (23).", [["shift work schedules", "TREATMENT", 53, 73], ["health problems", "PROBLEM", 86, 101]]], ["While it is not clear precisely why this interaction exists, shift workers who have closer alignment between their chronotypes and their work schedules appear to have more robust melatonin rhythms than their fellow shift workers, suggesting that they have better circadian system function (24).", [["melatonin", "CHEMICAL", 179, 188], ["melatonin", "SIMPLE_CHEMICAL", 179, 188]]], ["Shift workers who have chronotypes that are better matched to their work schedules may also sleep better (23), and it is increasingly clear that circadian system and sleep health are essential to perhaps all facets of human health (25, 26).Exposure to Light ::: Optimising Zeitgeber SchedulesRetinal light exposure is generally regarded as the most important stimulus in entraining the human circadian system (28), and changes in patterns of light exposure can rapidly and substantially shift circadian system timing (phase).", [["Retinal", "ANATOMY", 292, 299], ["human", "ORGANISM", 218, 223], ["Retinal", "MULTI-TISSUE_STRUCTURE", 292, 299], ["human", "ORGANISM", 386, 391], ["human", "SPECIES", 218, 223], ["human", "SPECIES", 386, 391], ["human", "SPECIES", 218, 223], ["human", "SPECIES", 386, 391], ["clear", "OBSERVATION", 134, 139], ["light exposure", "OBSERVATION", 300, 314]]], ["This is especially true of short-wavelength light, which most potently suppresses melatonin synthesis (29).", [["melatonin", "CHEMICAL", 82, 91], ["melatonin", "CHEMICAL", 82, 91], ["melatonin", "SIMPLE_CHEMICAL", 82, 91], ["melatonin synthesis", "TEST", 82, 101], ["short-wavelength light", "OBSERVATION_MODIFIER", 27, 49]]], ["The implication of this is that it is possible to bolster how well-shift workers adapt to work schedules through timely use of means to increase exposure to high-intensity, short-wavelength light at specific times of day (e.g., by using light-therapy lamps) and means to reduce exposure to such light at specific times of day (e.g., \u201cblue-blocking\u201d glasses and blue-light filtering apps on electronic devices).", [["short-wavelength light", "TREATMENT", 173, 195], ["light-therapy lamps", "TREATMENT", 237, 256], ["blocking\u201d glasses", "TREATMENT", 339, 356], ["blue", "TREATMENT", 361, 365], ["electronic devices", "TREATMENT", 390, 408]]], ["While not all studies that have used interventions to modify exposure to light in shift workers have proven beneficial, this inconsistency likely reflects marked heterogeneity in the methods used by researchers (30), as well as large variation between people in how they respond to light (31).Melatonin ::: Optimising Zeitgeber SchedulesDuring darkness, retinal photoreceptors no longer register exposure to light, relaying this to the central clock in the circadian system (the suprachiasmatic nucleus), which in turn signals the pineal gland to synthesise melatonin.", [["retinal photoreceptors", "ANATOMY", 354, 376], ["suprachiasmatic nucleus", "ANATOMY", 479, 502], ["pineal gland", "ANATOMY", 531, 543], ["Melatonin", "CHEMICAL", 293, 302], ["melatonin", "CHEMICAL", 558, 567], ["Melatonin", "CHEMICAL", 293, 302], ["melatonin", "CHEMICAL", 558, 567], ["people", "ORGANISM", 252, 258], ["Melatonin", "SIMPLE_CHEMICAL", 293, 302], ["retinal photoreceptors", "MULTI-TISSUE_STRUCTURE", 354, 376], ["suprachiasmatic nucleus", "MULTI-TISSUE_STRUCTURE", 479, 502], ["pineal gland", "ORGAN", 531, 543], ["melatonin", "SIMPLE_CHEMICAL", 558, 567], ["people", "SPECIES", 252, 258], ["all studies", "TEST", 10, 21], ["interventions", "TREATMENT", 37, 50], ["marked heterogeneity in the methods", "PROBLEM", 155, 190], ["Melatonin", "TREATMENT", 293, 302], ["likely reflects", "UNCERTAINTY", 139, 154], ["marked", "OBSERVATION_MODIFIER", 155, 161], ["heterogeneity", "OBSERVATION", 162, 175], ["large", "OBSERVATION_MODIFIER", 228, 233], ["variation", "OBSERVATION_MODIFIER", 234, 243], ["retinal", "ANATOMY", 354, 361], ["central clock", "OBSERVATION", 436, 449], ["circadian system", "ANATOMY", 457, 473], ["suprachiasmatic nucleus", "ANATOMY", 479, 502], ["pineal gland", "ANATOMY", 531, 543]]], ["Melatonin therefore acts as an endogenous marker of darkness, agonising its receptors in cells in numerous tissues to signal them to fulfil time-of-day-specific functions.", [["cells", "ANATOMY", 89, 94], ["tissues", "ANATOMY", 107, 114], ["Melatonin", "CHEMICAL", 0, 9], ["Melatonin", "CHEMICAL", 0, 9], ["Melatonin", "SIMPLE_CHEMICAL", 0, 9], ["cells", "CELL", 89, 94], ["tissues", "TISSUE", 107, 114], ["Melatonin", "TREATMENT", 0, 9], ["darkness", "PROBLEM", 52, 60]]], ["Simplistically, when the concentration of melatonin in the blood surpasses a certain threshold in humans who are melatonin-proficient, it is the biological night-time.", [["blood", "ANATOMY", 59, 64], ["melatonin", "CHEMICAL", 42, 51], ["melatonin", "CHEMICAL", 113, 122], ["melatonin", "CHEMICAL", 42, 51], ["melatonin", "CHEMICAL", 113, 122], ["melatonin", "SIMPLE_CHEMICAL", 42, 51], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["humans", "ORGANISM", 98, 104], ["melatonin", "SIMPLE_CHEMICAL", 113, 122], ["humans", "SPECIES", 98, 104], ["humans", "SPECIES", 98, 104], ["melatonin", "TREATMENT", 42, 51]]], ["Conversely, when the concentration of melatonin is below this threshold, it is the biological daytime.Melatonin ::: Optimising Zeitgeber SchedulesMelatonin supplementation can shift the phase of the circadian system (32).", [["melatonin", "CHEMICAL", 38, 47], ["Melatonin", "CHEMICAL", 102, 111], ["Melatonin", "CHEMICAL", 146, 155], ["melatonin", "CHEMICAL", 38, 47], ["Melatonin", "CHEMICAL", 102, 111], ["Melatonin", "CHEMICAL", 146, 155], ["melatonin", "SIMPLE_CHEMICAL", 38, 47], ["Melatonin", "SIMPLE_CHEMICAL", 102, 111], ["Melatonin", "SIMPLE_CHEMICAL", 146, 155], ["melatonin", "TREATMENT", 38, 47], ["Melatonin", "TREATMENT", 102, 111], ["Melatonin supplementation", "TREATMENT", 146, 171]]], ["Melatonin ingestion in the late biological afternoon tends to advance circadian phase, while ingestion in the early biological morning tends to delay it.", [["Melatonin", "CHEMICAL", 0, 9], ["Melatonin", "CHEMICAL", 0, 9], ["Melatonin", "SIMPLE_CHEMICAL", 0, 9], ["Melatonin ingestion", "PROBLEM", 0, 19]]], ["Melatonin is therefore a chronobiotic \u2013 an agent that can modify circadian phase.", [["Melatonin", "CHEMICAL", 0, 9], ["Melatonin", "CHEMICAL", 0, 9], ["Melatonin", "SIMPLE_CHEMICAL", 0, 9], ["Melatonin", "TREATMENT", 0, 9], ["a chronobiotic \u2013 an agent", "TREATMENT", 23, 48]]], ["When timed appropriately, light exposure and melatonin ingestion additively shift circadian phase (33).Exercise ::: Optimising Zeitgeber SchedulesA growing body of evidence also shows that exercise can shift circadian phase.", [["melatonin", "CHEMICAL", 45, 54], ["melatonin", "CHEMICAL", 45, 54], ["melatonin", "SIMPLE_CHEMICAL", 45, 54], ["light exposure", "PROBLEM", 26, 40], ["melatonin ingestion", "PROBLEM", 45, 64]]], ["More recent work has begun to clarify the precise nature of the relationship between exercise and circadian phase, showing that treadmill exercise done in the early biological morning or early biological afternoon advances circadian phase, whereas the same exercise done in the biological evening delays it (35).", [["treadmill exercise", "TEST", 128, 146]]], ["This relationship is therefore similar to how timing of exposure to light affects circadian phase, and timely exposure to both light and exercise can also additively shift circadian phase (36).Nutrition ::: Optimising Zeitgeber SchedulesThe influence of timing of food availability on patterns of activity in rats was documented as early as a century ago (37), and numerous studies of such \u201cfood anticipatory activity\u201d have since implicated nutrition as an influence on circadian system timing.", [["rats", "ORGANISM", 309, 313], ["rats", "SPECIES", 309, 313], ["circadian system timing", "TREATMENT", 470, 493]]], ["Whereas the LD cycle is the primary zeitgeber for the suprachiasmatic nucleus, some scientists have hypothesised that the eating/fasting cycle may be the primary time cue for some peripheral clocks in the circadian system.", [["suprachiasmatic nucleus", "ANATOMY", 54, 77], ["suprachiasmatic nucleus", "MULTI-TISSUE_STRUCTURE", 54, 77], ["the suprachiasmatic nucleus", "PROBLEM", 50, 77], ["some peripheral clocks in the circadian system", "PROBLEM", 175, 221], ["suprachiasmatic nucleus", "ANATOMY", 54, 77], ["peripheral clocks", "OBSERVATION", 180, 197], ["circadian system", "ANATOMY", 205, 221]]], ["We now know that changing the timing of food consumption rapidly alters the timing of gene transcription in peripheral clocks in mice, for example (38).", [["mice", "ORGANISM", 129, 133], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["gene transcription", "TREATMENT", 86, 104]]], ["Recent work has shown that this may be true of humans too, for changing meal timing independently shifts the expression of some genes in peripheral tissues as well as the timing of the blood glucose rhythm, without changing the phase of the melatonin rhythm (39).", [["peripheral tissues", "ANATOMY", 137, 155], ["blood", "ANATOMY", 185, 190], ["glucose", "CHEMICAL", 191, 198], ["melatonin", "CHEMICAL", 241, 250], ["glucose", "CHEMICAL", 191, 198], ["melatonin", "CHEMICAL", 241, 250], ["humans", "ORGANISM", 47, 53], ["peripheral tissues", "TISSUE", 137, 155], ["blood", "ORGANISM_SUBSTANCE", 185, 190], ["glucose", "SIMPLE_CHEMICAL", 191, 198], ["humans", "SPECIES", 47, 53], ["humans", "SPECIES", 47, 53], ["some genes in peripheral tissues", "PROBLEM", 123, 155], ["the blood glucose rhythm", "TEST", 181, 205], ["peripheral tissues", "ANATOMY", 137, 155]]], ["We acknowledge, however, that lack of control of variables such as LD cycles in most studies of the effects of nutrition on the human circadian system mean that this is arguably the only study of people that fulfils at least one of the criteria for diet to be classified as a zeitgeber (40).", [["human", "ORGANISM", 128, 133], ["people", "ORGANISM", 196, 202], ["human", "SPECIES", 128, 133], ["people", "SPECIES", 196, 202], ["human", "SPECIES", 128, 133], ["LD cycles", "TREATMENT", 67, 76]]], ["It could be that entrainment to LD cycles largely nullifies any zeitgeber effects of nutrition (41).Nutrition ::: Optimising Zeitgeber SchedulesSummarising the above, it is plausible that carefully timed exposure to light, melatonin ingestion, and exercise may result in additive shifts in the phase of the suprachiasmatic nucleus.", [["suprachiasmatic nucleus", "ANATOMY", 307, 330], ["melatonin", "CHEMICAL", 223, 232], ["melatonin", "CHEMICAL", 223, 232], ["melatonin", "SIMPLE_CHEMICAL", 223, 232], ["suprachiasmatic nucleus", "MULTI-TISSUE_STRUCTURE", 307, 330], ["LD cycles", "TREATMENT", 32, 41], ["melatonin ingestion", "PROBLEM", 223, 242], ["additive shifts", "OBSERVATION", 271, 286], ["suprachiasmatic nucleus", "ANATOMY", 307, 330]]], ["As eating/fasting cycles appear to affect the phases of some peripheral circadian clocks, we anticipate that coordinated changes in all of these variables could be used to expedite adaptation to new shift work schedules.", [["some peripheral circadian clocks", "PROBLEM", 56, 88], ["new shift work schedules", "TREATMENT", 195, 219], ["circadian clocks", "OBSERVATION", 72, 88]]], ["If one could estimate shift workers' circadian phases in real time and model how subsequent changes in zeitgeber schedules would influence their circadian systems, one could develop tools that use this information to expedite adaptation to shift schedule changes by providing personalised guidance and perhaps even individual-level changes in exposure to light.", [["changes in zeitgeber schedules", "TREATMENT", 92, 122], ["shift schedule changes", "TREATMENT", 240, 262]]], ["This may be a particularly fruitful topic for further study.Diet Timing in Shift Workers ::: Chrononutrition: The Importance of Diet TimingBeginning with preclinical research, studies of mice have shown that restricting food access to the dark period (the active phase for these nocturnal animals) may protect against the obesogenic effects of repeated 6-h advances in the LD cycle (48).", [["mice", "ORGANISM", 187, 191], ["mice", "SPECIES", 187, 191], ["mice", "SPECIES", 187, 191], ["further study", "TEST", 46, 59], ["these nocturnal animals", "TREATMENT", 273, 296]]], ["In addition, restricting food access to the active phase may also accelerate adaptation of circadian rhythms in core body temperature and locomotor activity to repeated 12-h changes in LD cycles (49).", [["body", "ANATOMY", 117, 121], ["body", "ORGANISM_SUBDIVISION", 117, 121], ["circadian rhythms", "TEST", 91, 108], ["core body temperature", "TEST", 112, 133], ["locomotor activity", "TEST", 138, 156]]], ["These findings imply that people would better cope with rotating shift work if they fixed their eating to the daytime, which is somewhat counterintuitive given that fixing eating time during shifting LD cycles might be expected to uncouple circadian rhythms between the suprachiasmatic nucleus and peripheral clocks.", [["suprachiasmatic nucleus", "ANATOMY", 270, 293], ["people", "ORGANISM", 26, 32], ["suprachiasmatic nucleus", "MULTI-TISSUE_STRUCTURE", 270, 293], ["peripheral clocks", "MULTI-TISSUE_STRUCTURE", 298, 315], ["people", "SPECIES", 26, 32], ["shifting LD cycles", "TREATMENT", 191, 209], ["suprachiasmatic nucleus", "ANATOMY", 270, 293], ["peripheral clocks", "OBSERVATION", 298, 315]]], ["It is, however, intuitive that restricting food access to the active phase may be preferable to restricting it to the rest phase, and findings from initial research on humans support this contention.Diet Timing in Shift Workers ::: Chrononutrition: The Importance of Diet TimingAmong healthy young men undergoing simulated night shift work for 4 days, those who confined their consumption of calorie-containing foods and drinks (i.e., the caloric period) to between breakfast at 07:00 and dinner at 19:00 had superior post-breakfast glucose tolerance after the intervention compared to men who had dinner at 19:00, a meal at 01:30, and breakfast at 07:00 (50).", [["glucose", "CHEMICAL", 533, 540], ["glucose", "CHEMICAL", 533, 540], ["humans", "ORGANISM", 168, 174], ["men", "ORGANISM", 298, 301], ["glucose", "SIMPLE_CHEMICAL", 533, 540], ["men", "ORGANISM", 586, 589], ["humans", "SPECIES", 168, 174], ["men", "SPECIES", 298, 301], ["men", "SPECIES", 586, 589], ["humans", "SPECIES", 168, 174], ["the intervention", "TREATMENT", 557, 573]]], ["Additional studies using larger sample sizes and investigating the effects of diet composition on a range of round-the-clock postprandial responses will be instructive.Time-Restricted Eating: Findings From Non-shift Workers ::: Chrononutrition: The Importance of Diet TimingStudies of adults undergoing time-restricted eating (TRE) also indicate that optimising nutrient timing is likely to be important to cardiometabolic health, although the participants in these studies have generally not been shift workers.", [["adults", "ORGANISM", 285, 291], ["participants", "SPECIES", 444, 456], ["Additional studies", "TEST", 0, 18], ["larger sample sizes", "TREATMENT", 25, 44], ["diet composition", "TREATMENT", 78, 94], ["sizes", "OBSERVATION_MODIFIER", 39, 44]]], ["We arbitrarily define TRE as consumption of all calorie-containing items within a period of 12 h or less each day.", [["calorie", "SIMPLE_CHEMICAL", 48, 55], ["TRE", "DNA", 22, 25], ["all calorie", "TREATMENT", 44, 55]]], ["Conversely, we define intermittent fasting as periodic abstinence from consumption of any calories for at least 24 h.Time-Restricted Eating: Findings From Non-shift Workers ::: Chrononutrition: The Importance of Diet TimingSkipping breakfast is one way to implement TRE, and doing so leads to late TRE.", [["TRE", "DNA", 266, 269], ["TRE", "DNA", 298, 301], ["intermittent fasting", "PROBLEM", 22, 42], ["any calories", "TREATMENT", 86, 98], ["Diet TimingSkipping breakfast", "TREATMENT", 212, 241]]], ["While breakfast-skipping is a controversial topic, epidemiologic studies have tended to associate breakfast consumption with lower risk of developing cardiometabolic diseases such as heart disease and type-two diabetes (53, 54).", [["heart", "ANATOMY", 183, 188], ["cardiometabolic diseases", "DISEASE", 150, 174], ["heart disease", "DISEASE", 183, 196], ["diabetes", "DISEASE", 210, 218], ["heart", "ORGAN", 183, 188], ["epidemiologic studies", "TEST", 51, 72], ["developing cardiometabolic diseases", "PROBLEM", 139, 174], ["heart disease", "PROBLEM", 183, 196], ["type-two diabetes", "PROBLEM", 201, 218], ["cardiometabolic diseases", "OBSERVATION", 150, 174], ["heart", "ANATOMY", 183, 188], ["disease", "OBSERVATION", 189, 196], ["diabetes", "OBSERVATION", 210, 218]]], ["However, controlled studies have not shown large effects of skipping breakfast on cardiometabolic health (55).", [["controlled studies", "TEST", 9, 27]]], ["For example, lean adults who skipped breakfast for 6 weeks inadvertently decreased their daily energy intakes, but this change was compensated by reductions in physical activity energy expenditure, resulting in no changes in energy balance or body composition (56).", [["body", "ANATOMY", 243, 247], ["body", "ORGANISM_SUBDIVISION", 243, 247], ["changes in energy balance", "PROBLEM", 214, 239], ["reductions", "OBSERVATION_MODIFIER", 146, 156], ["no", "UNCERTAINTY", 211, 213]]], ["A subsequent study implemented the same intervention but only included obese adults (57).", [["A subsequent study", "TEST", 0, 18], ["the same intervention", "TREATMENT", 31, 52]]], ["In this study, participants in the breakfast-skipping group expended less energy in the morning, but they did not burn fewer calories over the entire day.", [["participants", "SPECIES", 15, 27], ["this study", "TEST", 3, 13]]], ["Daily energy intake was similar in breakfast-skippers and breakfast eaters, and both groups gained weight during the study.", [["the study", "TEST", 113, 122]]], ["People who skipped breakfast did have higher insulinaemic responses to an oral glucose tolerance test, however.", [["oral", "ANATOMY", 74, 78], ["glucose", "CHEMICAL", 79, 86], ["glucose", "CHEMICAL", 79, 86], ["People", "ORGANISM", 0, 6], ["oral", "ORGANISM_SUBDIVISION", 74, 78], ["glucose", "SIMPLE_CHEMICAL", 79, 86], ["People", "SPECIES", 0, 6], ["higher insulinaemic responses", "PROBLEM", 38, 67], ["an oral glucose tolerance test", "TEST", 71, 101]]], ["These two rigorous studies show that skipping breakfast minimally affects energy balance but may negatively affect glycaemic regulation and some of its determinants.", [["These two rigorous studies", "TEST", 0, 26], ["skipping breakfast", "PROBLEM", 37, 55]]], ["As sleep timing did not differ between groups, breakfast skipping led to a form of late TRE, so these studies imply that late TRE may not be optimal for some aspects of cardiometabolic health.Time-Restricted Eating: Findings From Non-shift Workers ::: Chrononutrition: The Importance of Diet TimingSkipping breakfast imposes a relatively late caloric period, and an alternative is to shorten the caloric period by way of skipping dinner or having an early dinner.", [["TRE", "DNA", 88, 91], ["TRE", "DNA", 126, 129], ["late TRE", "PROBLEM", 83, 91], ["these studies", "TEST", 96, 109]]], ["Several recent carefully controlled experiments have shown that such early TRE may exert numerous positive effects on health.", [["TRE", "DNA", 75, 78], ["numerous", "OBSERVATION_MODIFIER", 89, 97], ["positive", "OBSERVATION", 98, 106]]], ["The first of these experiments reported that compared with a ~ 12-h daily caloric period for 5 weeks, 5 weeks of early TRE (~ 6-h daily caloric period, finished by 15:00) improved insulin sensitivity, blood pressure, appetite regulation, and a marker of oxidative stress in men who have prediabetes (58).", [["blood", "ANATOMY", 201, 206], ["prediabetes", "DISEASE", 287, 298], ["insulin", "GENE_OR_GENE_PRODUCT", 180, 187], ["blood", "ORGANISM_SUBSTANCE", 201, 206], ["men", "ORGANISM", 274, 277], ["men", "SPECIES", 274, 277], ["blood pressure", "TEST", 201, 215], ["prediabetes", "PROBLEM", 287, 298]]], ["The same group of scientists recently reported that in overweight adults, just 4 days of early TRE reduced mean 24-h blood glucose levels and improved metabolic flexibility, among other benefits (59, 60).Time-Restricted Eating: Findings From Non-shift Workers ::: Chrononutrition: The Importance of Diet TimingThese experiments did not compare early TRE to later TRE while keeping the caloric period fixed, however, and to our knowledge, only one study has done this to date (61).", [["blood", "ANATOMY", 117, 122], ["glucose", "CHEMICAL", 123, 130], ["glucose", "CHEMICAL", 123, 130], ["blood", "ORGANISM_SUBSTANCE", 117, 122], ["glucose", "SIMPLE_CHEMICAL", 123, 130], ["TRE", "DNA", 95, 98], ["TRE", "DNA", 350, 353], ["TRE", "DNA", 363, 366], ["blood glucose levels", "TEST", 117, 137], ["one study", "TEST", 443, 452], ["metabolic flexibility", "OBSERVATION", 151, 172]]], ["The study in question showed that 7 days of both early (08:00 to 17:00) and late (12:00 to 21:00) TRE improved oral glucose tolerance in men at high risk of developing type-two diabetes, although only early TRE lowered fasting glucose, suggest a small advantage of early TRE (61).", [["oral", "ANATOMY", 111, 115], ["glucose", "CHEMICAL", 116, 123], ["diabetes", "DISEASE", 177, 185], ["glucose", "CHEMICAL", 227, 234], ["glucose", "CHEMICAL", 116, 123], ["glucose", "CHEMICAL", 227, 234], ["oral", "ORGANISM_SUBDIVISION", 111, 115], ["glucose", "SIMPLE_CHEMICAL", 116, 123], ["men", "ORGANISM", 137, 140], ["glucose", "SIMPLE_CHEMICAL", 227, 234], ["TRE", "DNA", 207, 210], ["TRE", "DNA", 271, 274], ["men", "SPECIES", 137, 140], ["The study", "TEST", 0, 9], ["TRE improved oral glucose tolerance", "PROBLEM", 98, 133], ["two diabetes", "PROBLEM", 173, 185], ["early TRE lowered fasting glucose", "PROBLEM", 201, 234], ["diabetes", "OBSERVATION", 177, 185], ["small", "OBSERVATION_MODIFIER", 246, 251]]], ["While this hypothesis needs careful testing, we believe that early TRE may also enhance diet composition by reducing intakes of foods and drinks commonly consumed in the evening, such as processed snacks and alcohol.Time-Restricted Eating: Findings From Non-shift Workers ::: Chrononutrition: The Importance of Diet TimingTogether, these studies support the superiority of relatively early TRE in adults who have poor cardiometabolic health.", [["alcohol", "CHEMICAL", 208, 215], ["alcohol", "CHEMICAL", 208, 215], ["alcohol", "SIMPLE_CHEMICAL", 208, 215], ["TRE", "DNA", 67, 70], ["TRE", "DNA", 390, 393], ["careful testing", "TEST", 28, 43], ["early TRE", "PROBLEM", 61, 70], ["these studies", "TEST", 332, 345]]], ["However, non-self-selected TRE schedules may interfere with some social activities and be difficult to adhere to in the context of work schedules and family commitments (62, 63).", [["TRE", "DNA", 27, 30], ["non-self-selected TRE schedules", "TREATMENT", 9, 40]]], ["Letting people self-select their TRE periods helps mitigate these undesirable consequences.", [["people", "ORGANISM", 8, 14], ["TRE", "DNA", 33, 36], ["people", "SPECIES", 8, 14], ["these undesirable consequences", "PROBLEM", 60, 90]]], ["Indeed, 12 weeks of self-selected TRE minimised these issues in adults with metabolic syndrome, also reducing daily energy intake and potently improving numerous aspects of cardiometabolic health including bodyweight, waist circumference, and blood pressure (64).", [["blood", "ANATOMY", 243, 248], ["metabolic syndrome", "DISEASE", 76, 94], ["waist", "ORGANISM_SUBDIVISION", 218, 223], ["blood", "ORGANISM_SUBSTANCE", 243, 248], ["TRE", "DNA", 34, 37], ["metabolic syndrome", "PROBLEM", 76, 94], ["bodyweight", "TEST", 206, 216], ["waist circumference", "TEST", 218, 237], ["blood pressure", "TEST", 243, 257], ["metabolic syndrome", "OBSERVATION", 76, 94]]], ["Moreover, TRE led to more regular diet timing, which may independently be beneficial for cardiometabolic health (65).", [["TRE", "DNA", 10, 13]]], ["Interestingly, TRE also improved sleep timing regularity and increased how often participants self-reported restorative sleep.", [["TRE", "DNA", 15, 18], ["participants", "SPECIES", 81, 93], ["improved", "OBSERVATION_MODIFIER", 24, 32], ["sleep", "OBSERVATION", 33, 38], ["increased", "OBSERVATION_MODIFIER", 61, 70]]], ["However, this study was an unblinded, single-arm study with only 19 participants included in the data analysis (64).Time-Restricted Eating: Findings From Non-shift Workers ::: Chrononutrition: The Importance of Diet TimingBased on existing studies, TRE appears to be a safe strategy that is likely to reduce energy intake, which would be especially beneficial for people who have unavoidably sedentary lifestyles.", [["people", "ORGANISM", 364, 370], ["TRE", "DNA", 249, 252], ["participants", "SPECIES", 68, 80], ["people", "SPECIES", 364, 370], ["this study", "TEST", 9, 19], ["single-arm study", "TEST", 38, 54], ["the data analysis", "TEST", 93, 110], ["existing studies", "TEST", 231, 247]]], ["We hypothesise that fixing the timing of each worker's caloric period within regular hours each day supports metabolic health, and it is plausible that this may be especially important in workers who are subject to unpredictable changes in zeitgebers such as LD cycles (e.g., emergency service workers).", [["unpredictable changes in zeitgebers", "PROBLEM", 215, 250]]], ["We further speculate that each worker's biological daytime is the optimal time at which to fix the individual's caloric period, but self-selection of TRE schedules will help people adhere to TRE and avoid undesirable effects on social and family life.", [["people", "ORGANISM", 174, 180], ["TRE", "DNA", 150, 153], ["TRE", "DNA", 191, 194], ["people", "SPECIES", 174, 180], ["self-selection of TRE schedules", "TREATMENT", 132, 163]]], ["This said, scheduling TRE as early as is practical may maximise the beneficial cardiometabolic effects of TRE.Distribution of Energy and Macronutrient Intakes Within the Caloric Period: Findings From Non-shift Workers ::: Chrononutrition: The Importance of Diet TimingWhile a detailed discussion of this subject is beyond the scope of this review, several recent controlled studies have shown that when daily energy intake is fixed, the distributions of energy and macronutrient intakes within the caloric period strongly influence cardiometabolic health.", [["TRE", "DNA", 22, 25], ["TRE", "DNA", 106, 109], ["several recent controlled studies", "TEST", 348, 381]]], ["For example, one study divided overweight and obese women into two groups that consumed isocaloric weight loss diets for 12 weeks (66).", [["weight loss", "DISEASE", 99, 110], ["women", "ORGANISM", 52, 57], ["women", "SPECIES", 52, 57], ["one study", "TEST", 13, 22], ["isocaloric weight loss diets", "TREATMENT", 88, 116]]], ["The group that consumed half at breakfast lost more than twice as much bodyweight, more than twice as many centimetres off their waists, and had greater improvements in oral glucose tolerance.", [["oral", "ANATOMY", 169, 173], ["glucose", "CHEMICAL", 174, 181], ["glucose", "CHEMICAL", 174, 181], ["oral", "ORGANISM_SUBDIVISION", 169, 173], ["glucose", "SIMPLE_CHEMICAL", 174, 181]]], ["Subsequent work by the same scientists demonstrated that when energy intake is controlled, concentrating energy and carbohydrate intakes early in the day leads to enhanced appetite regulation, weight loss, and dramatic improvements in glycaemic control in adults with type-2 diabetes (67).", [["weight loss", "DISEASE", 193, 204], ["type-2 diabetes", "DISEASE", 268, 283], ["carbohydrate", "CHEMICAL", 116, 128], ["enhanced appetite regulation", "PROBLEM", 163, 191], ["weight loss", "PROBLEM", 193, 204], ["glycaemic control", "TREATMENT", 235, 252], ["type-2 diabetes", "PROBLEM", 268, 283], ["dramatic", "OBSERVATION_MODIFIER", 210, 218], ["improvements", "OBSERVATION_MODIFIER", 219, 231]]], ["This builds on research demonstrating that having carbohydrate-rich meals early in the day reduces 24-h glycaemia in adults with impaired fasting glucose and/or impaired glucose tolerance (68).Distribution of Energy and Macronutrient Intakes Within the Caloric Period: Findings From Non-shift Workers ::: Chrononutrition: The Importance of Diet TimingWhile these studies highlight the advantages of concentrating energy and carbohydrate intakes relatively early in the caloric period, we note that that intelligent inclusion of physical activity leads to acute improvements in postprandial responses to dietary events such that relatively high energy and carbohydrate intakes late in the biological day may not be so problematic if they bookend exercise (69).", [["impaired fasting glucose", "DISEASE", 129, 153], ["impaired glucose tolerance", "DISEASE", 161, 187], ["carbohydrate", "CHEMICAL", 50, 62], ["glucose", "CHEMICAL", 146, 153], ["glucose", "CHEMICAL", 170, 177], ["carbohydrate", "CHEMICAL", 424, 436], ["carbohydrate", "CHEMICAL", 655, 667], ["glucose", "SIMPLE_CHEMICAL", 146, 153], ["glucose", "SIMPLE_CHEMICAL", 170, 177], ["carbohydrate", "SIMPLE_CHEMICAL", 424, 436], ["carbohydrate-rich meals", "TREATMENT", 50, 73], ["impaired fasting glucose", "PROBLEM", 129, 153], ["impaired glucose tolerance", "PROBLEM", 161, 187], ["these studies", "TEST", 357, 370], ["carbohydrate intakes", "TREATMENT", 424, 444], ["dietary events", "PROBLEM", 603, 617], ["acute", "OBSERVATION_MODIFIER", 555, 560]]], ["And staying on the subject of exercise, there is tentative evidence that distribution of daily protein intake affects skeletal muscle protein synthetic responses to resistance training (70).", [["skeletal muscle", "ANATOMY", 118, 133], ["skeletal muscle", "TISSUE", 118, 133], ["daily protein intake", "PROBLEM", 89, 109], ["resistance training", "TREATMENT", 165, 184]]], ["As muscle protein synthesis is the main determinant of muscle protein balance, it is reasonable to assume that evenly dividing and spacing protein intakes between 3 and 4 daily dietary events may help maximise fat-free mass, a key determinant of cardiometabolic health (43).Sequence of Macronutrient Intakes Within Dietary Events: Findings From Non-shift Workers ::: Chrononutrition: The Importance of Diet TimingWe would be negligent to not mention that the sequence of macronutrient intakes within dietary events may also meaningfully affect postprandial responses.", [["muscle", "ANATOMY", 3, 9], ["muscle", "ANATOMY", 55, 61], ["fat", "ANATOMY", 210, 213], ["muscle", "ORGAN", 3, 9], ["muscle", "ORGAN", 55, 61], ["fat", "TISSUE", 210, 213], ["muscle protein synthesis", "TEST", 3, 27], ["muscle protein balance", "PROBLEM", 55, 77], ["spacing protein intakes", "PROBLEM", 131, 154], ["free mass", "PROBLEM", 214, 223], ["muscle", "ANATOMY", 55, 61], ["protein balance", "OBSERVATION", 62, 77], ["free", "OBSERVATION_MODIFIER", 214, 218], ["mass", "OBSERVATION", 219, 223]]], ["Several studies by one research group have shown that consuming carbohydrate last at a given dietary event (e.g., a full meal) dramatically reduces postprandial glycaemia and insulinaemia in adults who have prediabetes or type-two diabetes (71\u201373).", [["postprandial glycaemia", "DISEASE", 148, 170], ["insulinaemia", "DISEASE", 175, 187], ["prediabetes", "DISEASE", 207, 218], ["diabetes", "DISEASE", 231, 239], ["carbohydrate", "CHEMICAL", 64, 76], ["Several studies", "TEST", 0, 15], ["postprandial glycaemia", "PROBLEM", 148, 170], ["insulinaemia", "PROBLEM", 175, 187], ["prediabetes", "PROBLEM", 207, 218], ["type-two diabetes", "PROBLEM", 222, 239], ["postprandial glycaemia", "OBSERVATION", 148, 170]]], ["Shift workers who have poor glycaemic control may hence benefit from consuming carbohydrate-rich foods last at dietary events, when practical.Snacking in Shift Workers ::: Chrononutrition: The Importance of Diet TimingMost shift workers snack during night shifts.", [["carbohydrate", "CHEMICAL", 79, 91], ["carbohydrate", "SIMPLE_CHEMICAL", 79, 91]]], ["The problem is that night shifts often occur during the workers' biological night-times, and digestive and metabolic responses to dietary events are impaired during the biological night (74).", [["digestive", "ANATOMY", 93, 102], ["digestive", "ORGAN", 93, 102]]], ["As highlighted earlier, eating and/or drinking during the biological night-time may disrupt peripheral clocks.", [["peripheral clocks", "OBSERVATION", 92, 109]]], ["These snacks should also be convenient, minimally processed, micronutrient-dense, satiating, easy to digest, and minimally perishable, when applicable.Snacking in Shift Workers ::: Chrononutrition: The Importance of Diet TimingPreliminary research has shown that when 24-h energy and macronutrient intakes are controlled during simulated night shifts, a small snack (containing 10% of daily energy intake) may support cognitive function and performance in simulated driving compared with no snacking or a larger meal containing 30% of daily energy intake (75).", [["dense", "OBSERVATION_MODIFIER", 75, 80]]], ["In this instance, the small snack also reduced hunger to a comparable extent to the meal, without leading to significant digestive discomfort (76).", [["digestive", "ANATOMY", 121, 130], ["digestive", "ORGAN", 121, 130], ["reduced hunger", "PROBLEM", 39, 53], ["significant digestive discomfort", "PROBLEM", 109, 141], ["small", "OBSERVATION_MODIFIER", 22, 27], ["reduced", "OBSERVATION_MODIFIER", 39, 46], ["hunger", "OBSERVATION", 47, 53], ["significant", "OBSERVATION_MODIFIER", 109, 120], ["digestive", "OBSERVATION_MODIFIER", 121, 130], ["discomfort", "OBSERVATION", 131, 141]]], ["Glycaemic control is relatively easy to measure and predictive of many health outcomes, and some researchers have therefore focused on the effects of nocturnal snacking on glycaemic control.", [["Glycaemic control", "TREATMENT", 0, 17], ["nocturnal snacking", "TREATMENT", 150, 168], ["glycaemic control", "TREATMENT", 172, 189]]], ["Compared with a small midnight snack (~200 calories), a large midnight snack (~500 calories) impaired postprandial glycaemic responses at a subsequent breakfast at 08:30 during simulated shift work (77).", [["a small midnight snack", "TREATMENT", 14, 36], ["a large midnight snack", "TREATMENT", 54, 76], ["impaired postprandial glycaemic responses", "PROBLEM", 93, 134]]], ["Research such as this is informative, but we again need additional studies of workers in which the effects of dietary changes on metabolic parameters are measured around the clock.The Ketogenic Diet ::: Chrononutrition: The Importance of Diet CompositionStudies of mice have shown that the KD has chronobiotic actions on the clocks in multiple peripheral tissues, including the brain, gut, and liver (78\u201380).", [["peripheral tissues", "ANATOMY", 344, 362], ["brain", "ANATOMY", 378, 383], ["gut", "ANATOMY", 385, 388], ["liver", "ANATOMY", 394, 399], ["mice", "ORGANISM", 265, 269], ["peripheral tissues", "TISSUE", 344, 362], ["brain", "ORGAN", 378, 383], ["gut", "ORGAN", 385, 388], ["liver", "ORGAN", 394, 399], ["mice", "SPECIES", 265, 269], ["mice", "SPECIES", 265, 269], ["dietary changes", "PROBLEM", 110, 125], ["metabolic parameters", "TEST", 129, 149], ["chronobiotic actions", "TREATMENT", 297, 317], ["multiple", "ANATOMY_MODIFIER", 335, 343], ["peripheral tissues", "ANATOMY", 344, 362], ["brain", "ANATOMY", 378, 383], ["gut", "ANATOMY", 385, 388], ["liver", "ANATOMY", 394, 399]]], ["Interestingly, Tognini and colleagues found that a KD induced distinct changes in the liver and gut clocks in mice.", [["liver", "ANATOMY", 86, 91], ["gut", "ANATOMY", 96, 99], ["liver", "ORGAN", 86, 91], ["gut", "ORGANISM_SUBDIVISION", 96, 99], ["mice", "ORGANISM", 110, 114], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 110, 114], ["a KD induced distinct changes in the liver", "PROBLEM", 49, 91], ["distinct", "OBSERVATION_MODIFIER", 62, 70], ["changes", "OBSERVATION", 71, 78], ["liver", "ANATOMY", 86, 91], ["gut", "ANATOMY", 96, 99]]], ["Compared to a control diet, consumption of a KD produced greater amplitudes of clock gene transcription and their downstream products in the liver, as well as inducing 24-h oscillations in the transcription of many genes in the gut (78).", [["liver", "ANATOMY", 141, 146], ["gut", "ANATOMY", 228, 231], ["liver", "ORGAN", 141, 146], ["gut", "ORGANISM_SUBDIVISION", 228, 231], ["clock gene", "DNA", 79, 89], ["clock gene transcription", "TREATMENT", 79, 103], ["liver", "ANATOMY", 141, 146], ["gut", "ANATOMY", 228, 231]]], ["As disruption of the gut clock is associated with increased intestinal inflammation and permeability, as well as endotoxaemia (78, 81), if translatable to humans these results suggest that shift workers who follow a KD may protect themselves against some of the adverse consequences of consuming calories at suboptimal circadian phases.The Ketogenic Diet ::: Chrononutrition: The Importance of Diet CompositionMore generally, both the KD and less severe carbohydrate restriction may reduce some negative effects of shift work on metabolic health.", [["gut", "ANATOMY", 21, 24], ["intestinal", "ANATOMY", 60, 70], ["inflammation", "DISEASE", 71, 83], ["endotoxaemia", "DISEASE", 113, 125], ["carbohydrate", "CHEMICAL", 454, 466], ["gut", "ORGAN", 21, 24], ["intestinal", "ORGAN", 60, 70], ["humans", "ORGANISM", 155, 161], ["humans", "SPECIES", 155, 161], ["humans", "SPECIES", 155, 161], ["increased intestinal inflammation", "PROBLEM", 50, 83], ["endotoxaemia", "PROBLEM", 113, 125], ["less severe carbohydrate restriction", "TREATMENT", 442, 478], ["gut", "ANATOMY", 21, 24], ["associated with", "UNCERTAINTY", 34, 49], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["intestinal", "ANATOMY", 60, 70], ["inflammation", "OBSERVATION", 71, 83], ["permeability", "OBSERVATION_MODIFIER", 88, 100], ["endotoxaemia", "OBSERVATION", 113, 125]]], ["Shift workers are at an increased risk of impaired glucose tolerance and type-two diabetes, and restricting carbohydrate intake is likely to reduce fasting and postprandial glycaemia, both of which are precursory to numerous chronic diseases (e.g., some cardiovascular diseases, certain cancers, and dementia) (82\u201387).", [["cardiovascular", "ANATOMY", 254, 268], ["cancers", "ANATOMY", 287, 294], ["impaired glucose tolerance", "DISEASE", 42, 68], ["diabetes", "DISEASE", 82, 90], ["chronic diseases", "DISEASE", 225, 241], ["cardiovascular diseases", "DISEASE", 254, 277], ["cancers", "DISEASE", 287, 294], ["dementia", "DISEASE", 300, 308], ["glucose", "CHEMICAL", 51, 58], ["carbohydrate", "CHEMICAL", 108, 120], ["glucose", "SIMPLE_CHEMICAL", 51, 58], ["carbohydrate", "SIMPLE_CHEMICAL", 108, 120], ["cancers", "CANCER", 287, 294], ["impaired glucose tolerance", "PROBLEM", 42, 68], ["type-two diabetes", "PROBLEM", 73, 90], ["fasting and postprandial glycaemia", "PROBLEM", 148, 182], ["numerous chronic diseases", "PROBLEM", 216, 241], ["some cardiovascular diseases", "PROBLEM", 249, 277], ["certain cancers", "PROBLEM", 279, 294], ["dementia", "PROBLEM", 300, 308], ["impaired", "OBSERVATION_MODIFIER", 42, 50], ["glucose tolerance", "OBSERVATION", 51, 68], ["diabetes", "OBSERVATION", 82, 90], ["postprandial glycaemia", "OBSERVATION", 160, 182], ["numerous", "OBSERVATION_MODIFIER", 216, 224], ["chronic", "OBSERVATION_MODIFIER", 225, 232], ["diseases", "OBSERVATION", 233, 241], ["cardiovascular", "ANATOMY", 254, 268], ["diseases", "OBSERVATION", 269, 277]]], ["Preliminary evidence has shown that a multicomponent lifestyle intervention centred on the KD may also improve subjective sleep quality in adults who have poor glycaemic control (88), suggesting that sleep enhancement may mediate some of the reported benefits of the KD.The Ketogenic Diet ::: Chrononutrition: The Importance of Diet CompositionIn preclinical studies, ketone bodies themselves have been found to have pleiotropic beneficial physiological effects, including modulation of inflammation, tissue-specific suppression of mTOR signalling, and increased production of brain-derived neurotrophic factor (89\u201391).", [["tissue", "ANATOMY", 501, 507], ["brain", "ANATOMY", 577, 582], ["ketone", "CHEMICAL", 368, 374], ["inflammation", "DISEASE", 487, 499], ["ketone", "CHEMICAL", 368, 374], ["ketone", "SIMPLE_CHEMICAL", 368, 374], ["tissue", "TISSUE", 501, 507], ["mTOR", "GENE_OR_GENE_PRODUCT", 532, 536], ["brain-derived neurotrophic factor", "GENE_OR_GENE_PRODUCT", 577, 610], ["mTOR", "PROTEIN", 532, 536], ["brain-derived neurotrophic factor", "PROTEIN", 577, 610], ["a multicomponent lifestyle intervention", "TREATMENT", 36, 75], ["sleep enhancement", "PROBLEM", 200, 217], ["the KD", "PROBLEM", 263, 269], ["pleiotropic beneficial physiological effects", "PROBLEM", 417, 461], ["inflammation", "PROBLEM", 487, 499], ["mTOR signalling", "PROBLEM", 532, 547], ["increased production of brain", "PROBLEM", 553, 582], ["inflammation", "OBSERVATION", 487, 499], ["increased", "OBSERVATION_MODIFIER", 553, 562], ["brain", "ANATOMY", 577, 582]]], ["If translatable to humans, these systemic effects of ketone bodies imply that long-term consumption of a KD could reduce risk of certain cancers and neurodegenerative diseases such as Alzheimer's in shift workers, particularly those that are already at increased risk (92, 93).", [["cancers", "ANATOMY", 137, 144], ["ketone", "CHEMICAL", 53, 59], ["cancers", "DISEASE", 137, 144], ["neurodegenerative diseases", "DISEASE", 149, 175], ["Alzheimer's in shift workers", "DISEASE", 184, 212], ["ketone", "CHEMICAL", 53, 59], ["humans", "ORGANISM", 19, 25], ["ketone", "SIMPLE_CHEMICAL", 53, 59], ["cancers", "CANCER", 137, 144], ["humans", "SPECIES", 19, 25], ["humans", "SPECIES", 19, 25], ["ketone bodies", "TREATMENT", 53, 66], ["a KD", "PROBLEM", 103, 107], ["certain cancers", "PROBLEM", 129, 144], ["neurodegenerative diseases", "PROBLEM", 149, 175], ["Alzheimer's", "PROBLEM", 184, 195], ["certain", "OBSERVATION_MODIFIER", 129, 136], ["cancers", "OBSERVATION", 137, 144], ["neurodegenerative", "OBSERVATION_MODIFIER", 149, 166], ["diseases", "OBSERVATION", 167, 175]]], ["Increased production of ketone bodies may also account for some benefits of fasting and TRE.", [["ketone", "CHEMICAL", 24, 30], ["ketone", "CHEMICAL", 24, 30], ["ketone", "SIMPLE_CHEMICAL", 24, 30], ["TRE", "DNA", 88, 91], ["Increased production of ketone bodies", "PROBLEM", 0, 37], ["fasting and TRE", "PROBLEM", 76, 91], ["production", "OBSERVATION_MODIFIER", 10, 20], ["ketone bodies", "OBSERVATION", 24, 37], ["may also account for", "UNCERTAINTY", 38, 58]]], ["For example, early TRE led to greater morning beta-hydroxybutyrate levels compared to a 12-h caloric period (59).", [["beta-hydroxybutyrate", "CHEMICAL", 46, 66], ["beta-hydroxybutyrate", "CHEMICAL", 46, 66], ["beta-hydroxybutyrate", "SIMPLE_CHEMICAL", 46, 66], ["TRE", "DNA", 19, 22], ["early TRE", "PROBLEM", 13, 22], ["greater morning beta-hydroxybutyrate levels", "PROBLEM", 30, 73]]], ["However, there have not yet been any clinical trials of the KD in shift workers, and it will be interesting to explore how the combination of the KD and TRE and/or intermittent fasting interact to affect ketosis, metabolic regulation, and circadian biology in these people.Other Dietary Chronobiotics ::: Chrononutrition: The Importance of Diet CompositionIn addition to effects of dietary patterns on the circadian system, specific dietary compounds have chronobiotic actions.", [["ketosis", "DISEASE", 204, 211], ["people", "ORGANISM", 266, 272], ["TRE", "DNA", 153, 156], ["people", "SPECIES", 266, 272], ["intermittent fasting interact", "PROBLEM", 164, 193], ["ketosis", "PROBLEM", 204, 211], ["the circadian system", "TREATMENT", 402, 422], ["chronobiotic actions", "TREATMENT", 456, 476]]], ["A multitude of dietary compounds affects the circadian system and sleep (94, 95), and it is beyond the scope of this article to discuss them all.", [["dietary compounds", "TREATMENT", 15, 32], ["dietary compounds", "OBSERVATION", 15, 32]]], ["In the future, screens for novel chronobiotics and hypnotics may yield compounds that support the health and performance of these workers (96).", [["screens", "TEST", 15, 22], ["novel chronobiotics", "PROBLEM", 27, 46], ["hypnotics", "TREATMENT", 51, 60]]], ["Identifying agents that counter decrements in health and cognitive function incited by sleep disruption would also benefit shift workers.Caffeine ::: Chrononutrition: The Importance of Diet CompositionLargely by antagonising adenosine receptors, consumption of caffeine can improve alertness, attention, reaction time, and mood, as well as physical performance in tests of endurance, strength, and power (44).", [["Caffeine", "CHEMICAL", 137, 145], ["adenosine", "CHEMICAL", 225, 234], ["caffeine", "CHEMICAL", 261, 269], ["Caffeine", "CHEMICAL", 137, 145], ["adenosine", "CHEMICAL", 225, 234], ["caffeine", "CHEMICAL", 261, 269], ["Caffeine", "SIMPLE_CHEMICAL", 137, 145], ["adenosine", "SIMPLE_CHEMICAL", 225, 234], ["caffeine", "SIMPLE_CHEMICAL", 261, 269], ["adenosine receptors", "PROTEIN", 225, 244], ["Caffeine", "TREATMENT", 137, 145], ["antagonising adenosine receptors", "TREATMENT", 212, 244], ["caffeine", "TREATMENT", 261, 269]]], ["Studies of caffeine consumption by shift workers have consistently shown beneficial effects on multiple aspects of cognitive function, although whether this results in improved safety is not clear (97).", [["caffeine", "CHEMICAL", 11, 19], ["caffeine", "CHEMICAL", 11, 19], ["caffeine", "SIMPLE_CHEMICAL", 11, 19], ["caffeine consumption", "TREATMENT", 11, 31], ["cognitive function", "TEST", 115, 133]]], ["The trade-off is that caffeine consumption tends to prolong sleep latency, reduce slow-wave activity during sleep (which is important to numerous restorative processes), shorten sleep duration, fragment sleep, and worsen subjective sleep quality (98).", [["caffeine", "CHEMICAL", 22, 30], ["caffeine", "CHEMICAL", 22, 30], ["caffeine", "SIMPLE_CHEMICAL", 22, 30], ["caffeine consumption", "TREATMENT", 22, 42], ["sleep latency", "PROBLEM", 60, 73], ["slow-wave activity during sleep", "PROBLEM", 82, 113], ["fragment sleep", "PROBLEM", 194, 208]]], ["Consumed late in the day as coffee, caffeine also delays circadian phase (99).", [["caffeine", "CHEMICAL", 36, 44], ["caffeine", "CHEMICAL", 36, 44], ["caffeine", "SIMPLE_CHEMICAL", 36, 44], ["caffeine", "TREATMENT", 36, 44]]], ["Thus it is clear that while judicious caffeine intake can be used to help shift workers perform at work - especially when sleepy - mistimed caffeine intake may strongly degrade sleep, which is noteworthy given that many of the adverse consequences of shift work appear to relate to its detrimental effects on sleep (5).", [["caffeine", "CHEMICAL", 38, 46], ["caffeine", "CHEMICAL", 140, 148], ["caffeine", "CHEMICAL", 38, 46], ["caffeine", "CHEMICAL", 140, 148], ["caffeine", "SIMPLE_CHEMICAL", 38, 46], ["caffeine", "SIMPLE_CHEMICAL", 140, 148], ["judicious caffeine intake", "TREATMENT", 28, 53]]], ["It therefore seems prudent to recommend that shift workers generally stop consuming caffeine several hours before their main sleep period (more specific guidance on caffeine intake is provided in Table 1).Creatine Monohydrate ::: Chrononutrition: The Importance of Diet CompositionAntagonising adenosine receptors is one way to reduce the accumulation of pressure to sleep (sleep homeostasis), but another is to bolster the phosphorylation of adenosine.", [["caffeine", "CHEMICAL", 84, 92], ["caffeine", "CHEMICAL", 165, 173], ["Creatine", "CHEMICAL", 205, 213], ["adenosine", "CHEMICAL", 294, 303], ["adenosine", "CHEMICAL", 443, 452], ["caffeine", "CHEMICAL", 84, 92], ["caffeine", "CHEMICAL", 165, 173], ["Creatine", "CHEMICAL", 205, 213], ["adenosine", "CHEMICAL", 294, 303], ["adenosine", "CHEMICAL", 443, 452], ["caffeine", "SIMPLE_CHEMICAL", 84, 92], ["caffeine", "SIMPLE_CHEMICAL", 165, 173], ["Creatine", "SIMPLE_CHEMICAL", 205, 213], ["adenosine", "SIMPLE_CHEMICAL", 443, 452], ["adenosine receptors", "PROTEIN", 294, 313], ["caffeine", "TREATMENT", 84, 92], ["caffeine intake", "TREATMENT", 165, 180], ["Creatine Monohydrate", "TEST", 205, 225], ["Antagonising adenosine receptors", "TREATMENT", 281, 313], ["the accumulation of pressure to sleep (sleep homeostasis", "PROBLEM", 335, 391], ["the phosphorylation of adenosine", "TREATMENT", 420, 452], ["pressure", "OBSERVATION_MODIFIER", 355, 363]]], ["Creatine (creatine monohydrate, specifically), a safe and inexpensive dietary supplement that increases brain phosphocreatine stores, countering the accumulation of extracellular adenosine in the brain during extended wakefulness.", [["brain", "ANATOMY", 104, 109], ["extracellular", "ANATOMY", 165, 178], ["brain", "ANATOMY", 196, 201], ["Creatine", "CHEMICAL", 0, 8], ["creatine", "CHEMICAL", 10, 18], ["phosphocreatine", "CHEMICAL", 110, 125], ["adenosine", "CHEMICAL", 179, 188], ["Creatine", "CHEMICAL", 0, 8], ["creatine monohydrate", "CHEMICAL", 10, 30], ["phosphocreatine", "CHEMICAL", 110, 125], ["adenosine", "CHEMICAL", 179, 188], ["Creatine", "SIMPLE_CHEMICAL", 0, 8], ["creatine monohydrate", "SIMPLE_CHEMICAL", 10, 30], ["brain", "ORGAN", 104, 109], ["phosphocreatine", "SIMPLE_CHEMICAL", 110, 125], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 165, 178], ["adenosine", "SIMPLE_CHEMICAL", 179, 188], ["brain", "ORGAN", 196, 201], ["Creatine (creatine monohydrate", "TEST", 0, 30], ["a safe and inexpensive dietary supplement", "TREATMENT", 47, 88], ["brain phosphocreatine stores", "TREATMENT", 104, 132], ["extracellular adenosine in the brain", "PROBLEM", 165, 201], ["extracellular adenosine", "OBSERVATION", 165, 188], ["brain", "ANATOMY", 196, 201]]], ["A study of rats showed that adding creatine to the rats' chow for 4 weeks reduced the duration and slow-wave activity of the rats' sleep (100).", [["creatine", "CHEMICAL", 35, 43], ["creatine", "CHEMICAL", 35, 43], ["rats", "ORGANISM", 11, 15], ["creatine", "SIMPLE_CHEMICAL", 35, 43], ["rats", "ORGANISM", 51, 55], ["rats", "ORGANISM", 125, 129], ["rats", "SPECIES", 11, 15], ["rats", "SPECIES", 51, 55], ["rats", "SPECIES", 125, 129], ["A study of rats", "TEST", 0, 15], ["creatine", "TEST", 35, 43], ["wave activity", "OBSERVATION_MODIFIER", 104, 117]]], ["We do not currently know the effects of creatine supplementation on sleep in humans, however.", [["creatine", "CHEMICAL", 40, 48], ["creatine", "CHEMICAL", 40, 48], ["creatine", "SIMPLE_CHEMICAL", 40, 48], ["humans", "ORGANISM", 77, 83], ["humans", "SPECIES", 77, 83], ["humans", "SPECIES", 77, 83], ["creatine supplementation", "TREATMENT", 40, 64]]], ["Notably, while shorter sleep would generally be expected to impair health and performance, creatine supplementation has repeatedly been shown to enhance these variables in humans.", [["creatine", "CHEMICAL", 91, 99], ["creatine", "CHEMICAL", 91, 99], ["creatine", "SIMPLE_CHEMICAL", 91, 99], ["humans", "ORGANISM", 172, 178], ["humans", "SPECIES", 172, 178], ["humans", "SPECIES", 172, 178], ["creatine supplementation", "TREATMENT", 91, 115]]], ["Creatine supplementation routinely improves performance in - and adaptations to - many exercise tasks, and creatine has a number of therapeutic actions, including neuroprotective properties (101).Creatine Monohydrate ::: Chrononutrition: The Importance of Diet CompositionInterestingly, creatine supplementation may also acutely help protect against the deleterious consequences of sleep loss.", [["Creatine", "CHEMICAL", 0, 8], ["creatine", "CHEMICAL", 107, 115], ["Creatine", "CHEMICAL", 196, 204], ["creatine", "CHEMICAL", 287, 295], ["sleep loss", "DISEASE", 382, 392], ["Creatine", "CHEMICAL", 0, 8], ["creatine", "CHEMICAL", 107, 115], ["Creatine", "CHEMICAL", 196, 204], ["creatine", "CHEMICAL", 287, 295], ["Creatine", "SIMPLE_CHEMICAL", 0, 8], ["creatine", "SIMPLE_CHEMICAL", 107, 115], ["Creatine", "SIMPLE_CHEMICAL", 196, 204], ["creatine", "SIMPLE_CHEMICAL", 287, 295], ["Creatine supplementation", "TREATMENT", 0, 24], ["exercise tasks", "TEST", 87, 101], ["creatine", "TEST", 107, 115], ["Creatine Monohydrate", "TEST", 196, 216], ["creatine supplementation", "TREATMENT", 287, 311], ["sleep loss", "PROBLEM", 382, 392], ["sleep loss", "OBSERVATION", 382, 392]]], ["After sleep loss, creatine supplementation seems to offset deterioration in executive function, mood, reaction time, balance, and other motor skills (102\u2013104).", [["sleep loss", "DISEASE", 6, 16], ["creatine", "CHEMICAL", 18, 26], ["creatine", "CHEMICAL", 18, 26], ["creatine", "SIMPLE_CHEMICAL", 18, 26], ["sleep loss", "PROBLEM", 6, 16], ["creatine supplementation", "TREATMENT", 18, 42], ["offset deterioration in executive function", "PROBLEM", 52, 94]]], ["Although we expect creatine supplementation to be a useful strategy to help but this people cope with shift work, we are not aware of any research on this topic.", [["creatine", "CHEMICAL", 19, 27], ["creatine", "CHEMICAL", 19, 27], ["creatine", "SIMPLE_CHEMICAL", 19, 27], ["people", "ORGANISM", 85, 91], ["people", "SPECIES", 85, 91], ["creatine supplementation", "TREATMENT", 19, 43]]], ["We also note that there is some evidence that concurrent consumption of caffeine may reduce some of the ergogenic effects of creatine on physical performance (105), and additional studies are needed to better identify how the two compounds interact.Dietary Amino Acids ::: Chrononutrition: The Importance of Diet CompositionSeveral dietary amino acids may influence circadian rhythms and sleep.", [["caffeine", "CHEMICAL", 72, 80], ["creatine", "CHEMICAL", 125, 133], ["Amino Acids", "CHEMICAL", 257, 268], ["amino acids", "CHEMICAL", 340, 351], ["caffeine", "CHEMICAL", 72, 80], ["creatine", "CHEMICAL", 125, 133], ["Amino Acids", "CHEMICAL", 257, 268], ["amino acids", "CHEMICAL", 340, 351], ["caffeine", "SIMPLE_CHEMICAL", 72, 80], ["creatine", "SIMPLE_CHEMICAL", 125, 133], ["Amino Acids", "SIMPLE_CHEMICAL", 257, 268], ["amino acids", "AMINO_ACID", 340, 351], ["caffeine", "TREATMENT", 72, 80], ["creatine on physical performance", "TEST", 125, 157], ["additional studies", "TEST", 169, 187], ["Diet CompositionSeveral dietary amino acids", "TREATMENT", 308, 351], ["circadian rhythms", "TEST", 366, 383]]], ["For instance, L-tryptophan is a precursor to melatonin that researchers have studied with respect to circadian rhythms and sleep.", [["L-tryptophan", "CHEMICAL", 14, 26], ["melatonin", "CHEMICAL", 45, 54], ["L-tryptophan", "CHEMICAL", 14, 26], ["melatonin", "CHEMICAL", 45, 54], ["L-tryptophan", "SIMPLE_CHEMICAL", 14, 26], ["melatonin", "SIMPLE_CHEMICAL", 45, 54], ["L-tryptophan", "TREATMENT", 14, 26], ["melatonin", "TREATMENT", 45, 54], ["circadian rhythms", "TEST", 101, 118]]], ["As an example, there appears to be a temporal relationship between consumption of L-tryptophan in breast milk and infant urinary excretion of 6-sulfatoxymelatonin, the primary metabolite of melatonin (106).", [["breast milk", "ANATOMY", 98, 109], ["urinary", "ANATOMY", 121, 128], ["L-tryptophan", "CHEMICAL", 82, 94], ["6-sulfatoxymelatonin", "CHEMICAL", 142, 162], ["melatonin", "CHEMICAL", 190, 199], ["L-tryptophan", "CHEMICAL", 82, 94], ["6-sulfatoxymelatonin", "CHEMICAL", 142, 162], ["melatonin", "CHEMICAL", 190, 199], ["L-tryptophan", "SIMPLE_CHEMICAL", 82, 94], ["breast milk", "ORGANISM_SUBSTANCE", 98, 109], ["urinary", "ORGANISM_SUBDIVISION", 121, 128], ["6-sulfatoxymelatonin", "SIMPLE_CHEMICAL", 142, 162], ["melatonin", "SIMPLE_CHEMICAL", 190, 199], ["L-tryptophan in breast milk", "TREATMENT", 82, 109], ["infant urinary excretion", "TEST", 114, 138], ["sulfatoxymelatonin", "TREATMENT", 144, 162], ["melatonin", "TREATMENT", 190, 199], ["appears to be", "UNCERTAINTY", 21, 34], ["breast", "ANATOMY", 98, 104], ["urinary", "ANATOMY", 121, 128]]], ["Furthermore, infants fed L-tryptophan-enriched night-time formula seem to experience more consolidated sleep/wake patterns (107).", [["-tryptophan", "CHEMICAL", 26, 37], ["-tryptophan", "CHEMICAL", 26, 37], ["infants", "ORGANISM", 13, 20], ["L-tryptophan", "SIMPLE_CHEMICAL", 25, 37], ["infants", "SPECIES", 13, 20]]], ["Many studies of adults have also shown that ~ 2 g L-tryptophan each day enhances some sleep parameters, although it is not a potent hypnotic (108).", [["-tryptophan", "CHEMICAL", 51, 62], ["-tryptophan", "CHEMICAL", 51, 62], ["adults", "ORGANISM", 16, 22], ["L-tryptophan", "SIMPLE_CHEMICAL", 50, 62], ["Many studies", "TEST", 0, 12], ["some sleep parameters", "PROBLEM", 81, 102], ["a potent hypnotic", "PROBLEM", 123, 140], ["potent", "OBSERVATION_MODIFIER", 125, 131], ["hypnotic", "OBSERVATION_MODIFIER", 132, 140]]], ["To our knowledge, there are no rigorously controlled studies demonstrating that L-tryptophan affects circadian phase, however.Dietary Amino Acids ::: Chrononutrition: The Importance of Diet CompositionOverall, there has been little research on whether amino acids affect circadian system parameters.", [["L-tryptophan", "CHEMICAL", 80, 92], ["Amino Acids", "CHEMICAL", 134, 145], ["amino acids", "CHEMICAL", 252, 263], ["L-tryptophan", "CHEMICAL", 80, 92], ["Amino Acids", "CHEMICAL", 134, 145], ["amino acids", "CHEMICAL", 252, 263], ["L-tryptophan", "SIMPLE_CHEMICAL", 80, 92], ["Amino Acids", "SIMPLE_CHEMICAL", 134, 145], ["amino acids", "AMINO_ACID", 252, 263], ["rigorously controlled studies", "TEST", 31, 60], ["amino acids", "TEST", 252, 263], ["circadian system parameters", "TEST", 271, 298], ["no", "UNCERTAINTY", 28, 30]]], ["In a screen of whether amino acids affect light-induced shifts in the phase of wheel running activity in mice, L-serine increased the magnitude of phase shifts by 86%.", [["amino acids", "CHEMICAL", 23, 34], ["L-serine", "CHEMICAL", 111, 119], ["amino acids", "CHEMICAL", 23, 34], ["L-serine", "CHEMICAL", 111, 119], ["amino acids", "AMINO_ACID", 23, 34], ["mice", "ORGANISM", 105, 109], ["L-serine", "GENE_OR_GENE_PRODUCT", 111, 119], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 105, 109], ["amino acids", "TEST", 23, 34]]], ["This effect seems to translate to humans, as adults who consumed L-serine before bedtime experienced a greater advance in circadian phase in response to bright light exposure (109).", [["-serine", "CHEMICAL", 66, 73], ["humans", "ORGANISM", 34, 40], ["L-serine", "SIMPLE_CHEMICAL", 65, 73], ["humans", "SPECIES", 34, 40], ["humans", "SPECIES", 34, 40], ["L-serine", "TREATMENT", 65, 73]]], ["Another study reported that 1 week of L-ornithine supplementation delayed the plasma melatonin rhythm by 15 min (110).", [["plasma", "ANATOMY", 78, 84], ["L-ornithine", "CHEMICAL", 38, 49], ["melatonin", "CHEMICAL", 85, 94], ["L-ornithine", "CHEMICAL", 38, 49], ["melatonin", "CHEMICAL", 85, 94], ["L-ornithine", "SIMPLE_CHEMICAL", 38, 49], ["plasma", "ORGANISM_SUBSTANCE", 78, 84], ["melatonin", "SIMPLE_CHEMICAL", 85, 94], ["Another study", "TEST", 0, 13], ["L-ornithine supplementation", "TREATMENT", 38, 65], ["the plasma melatonin rhythm", "TREATMENT", 74, 101]]], ["However, LD cycles and meal timing were not fully controlled in these studies.", [["LD cycles", "TEST", 9, 18], ["meal timing", "TEST", 23, 34], ["these studies", "TEST", 64, 77]]], ["Interestingly, there is also preliminary evidence that regular L-ornithine supplementation (400 mg per day) may enhance sleep quality during stressful periods (111, 112).Dietary Amino Acids ::: Chrononutrition: The Importance of Diet CompositionL-glycine may too affect sleep.", [["L-ornithine", "CHEMICAL", 63, 74], ["Amino Acids", "CHEMICAL", 178, 189], ["glycine", "CHEMICAL", 247, 254], ["L-ornithine", "CHEMICAL", 63, 74], ["Amino Acids", "CHEMICAL", 178, 189], ["glycine", "CHEMICAL", 247, 254], ["L-ornithine", "SIMPLE_CHEMICAL", 63, 74], ["Amino Acids", "SIMPLE_CHEMICAL", 178, 189], ["glycine", "SIMPLE_CHEMICAL", 247, 254], ["regular L-ornithine supplementation", "TREATMENT", 55, 90], ["Diet CompositionL-glycine", "TREATMENT", 229, 254], ["too affect sleep", "PROBLEM", 259, 275]]], ["Consuming 3 g L-glycine an hour before bedtime appears to shorten sleep latency, increase sleep efficiency, and reduce daytime sleepiness in healthy adults, effects that appear to be mediated via the suprachiasmatic nucleus (113, 114).", [["suprachiasmatic nucleus", "ANATOMY", 200, 223], ["-glycine", "CHEMICAL", 15, 23], ["daytime sleepiness", "DISEASE", 119, 137], ["suprachiasmatic nucleus", "MULTI-TISSUE_STRUCTURE", 200, 223], ["sleep latency", "PROBLEM", 66, 79], ["increase sleep efficiency", "PROBLEM", 81, 106], ["daytime sleepiness in healthy adults", "PROBLEM", 119, 155], ["suprachiasmatic nucleus", "ANATOMY", 200, 223]]], ["Such supplementation also seems to diminish daytime fatigue and boost vigilance during sleep restriction (115), implying that L-glycine may both enhance sleep and the ability to cope with sleep loss.", [["fatigue", "DISEASE", 52, 59], ["-glycine", "CHEMICAL", 127, 135], ["sleep loss", "DISEASE", 188, 198], ["L-glycine", "SIMPLE_CHEMICAL", 126, 135], ["Such supplementation", "TREATMENT", 0, 20], ["daytime fatigue", "PROBLEM", 44, 59], ["sleep restriction", "TREATMENT", 87, 104], ["L-glycine", "TREATMENT", 126, 135], ["sleep loss", "PROBLEM", 188, 198]]], ["Given that L-glycine is safe, inexpensive, and may confer other health benefits (116), night shift workers could gain from supplementing with this amino acid.", [["-glycine", "CHEMICAL", 12, 20], ["amino acid", "CHEMICAL", 147, 157], ["L-glycine", "CHEMICAL", 11, 20], ["amino acid", "CHEMICAL", 147, 157], ["L-glycine", "SIMPLE_CHEMICAL", 11, 20], ["amino acid", "AMINO_ACID", 147, 157], ["this amino acid", "TREATMENT", 142, 157]]], ["At present, however, there has been little research on effects of this amino acid on sleep.Dietary Amino Acids ::: Chrononutrition: The Importance of Diet CompositionIn summary, it is plausible that supplementing with certain amino acids may help shift workers adapt more quickly to changes in their shifts and/or sleep better, but this is based on few studies that did not control zeitgeber cycles or explore whether the circadian timing of amino acid ingestion interacts with the circadian timing of light exposure.", [["amino acid", "CHEMICAL", 71, 81], ["Amino Acids", "CHEMICAL", 99, 110], ["amino acids", "CHEMICAL", 226, 237], ["amino acid", "CHEMICAL", 442, 452], ["amino acid", "CHEMICAL", 71, 81], ["Amino Acids", "CHEMICAL", 99, 110], ["amino acids", "CHEMICAL", 226, 237], ["amino acid", "CHEMICAL", 442, 452], ["amino acid", "AMINO_ACID", 71, 81], ["Amino Acids", "SIMPLE_CHEMICAL", 99, 110], ["amino acids", "AMINO_ACID", 226, 237], ["amino acid", "AMINO_ACID", 442, 452], ["this amino acid", "TREATMENT", 66, 81], ["certain amino acids", "TREATMENT", 218, 237], ["few studies", "TEST", 349, 360], ["amino acid ingestion", "PROBLEM", 442, 462], ["little", "OBSERVATION_MODIFIER", 36, 42], ["research", "OBSERVATION_MODIFIER", 43, 51]]], ["It will also be interesting to see whether concurrent consumption of different chronobiotic agents additively boosts circadian phase shifts.Using Novel Technologies to Better Personalise Guidance for Shift Workers ::: The FutureRapid recent advances in the development and uptake of digital technologies such as smartphones, apps, wearables, and artificial intelligence provide scientists with an unprecedented ability to comprehensively assess people's behaviours and health in free-living contexts.", [["people", "ORGANISM", 445, 451], ["people", "SPECIES", 445, 451], ["different chronobiotic agents", "TREATMENT", 69, 98]]], ["This app has already been used in multiple studies to monitor the circadian phenotypes of study participants, unveiling interesting insights into the effects of interventions such as TRE on human health (64, 117).Using Novel Technologies to Better Personalise Guidance for Shift Workers ::: The FutureAs data collected from digital devices are time-stamped, it is easier than ever to temporally map behavioural patterns and their biological sequelae, which could provide novel insights into the causes of changes in the health trajectories of shift workers.", [["human", "ORGANISM", 190, 195], ["TRE", "DNA", 183, 186], ["participants", "SPECIES", 96, 108], ["human", "SPECIES", 190, 195], ["human", "SPECIES", 190, 195], ["multiple studies", "TEST", 34, 50], ["interventions", "TREATMENT", 161, 174], ["digital devices", "TREATMENT", 324, 339], ["their biological sequelae", "PROBLEM", 424, 449]]], ["As it is not currently practical to assess an individual's melatonin rhythm on a daily basis, the integration of data from surrogate markers of circadian phase such as body temperature and sleep/wake cycles could be used to approximate the timing of the biological daytime.", [["body", "ANATOMY", 168, 172], ["melatonin", "CHEMICAL", 59, 68], ["melatonin", "CHEMICAL", 59, 68], ["melatonin", "SIMPLE_CHEMICAL", 59, 68], ["body", "ORGANISM_SUBDIVISION", 168, 172], ["circadian phase", "TEST", 144, 159], ["body temperature", "TEST", 168, 184], ["sleep/wake cycles", "TREATMENT", 189, 206]]], ["These cycles could be monitored ambiently using data from devices such as smartphones, and the data from the devices could then be used to inform individual shift workers about how to best implement TRE.", [["TRE", "DNA", 199, 202], ["smartphones", "TREATMENT", 74, 85]]], ["Where feasible, this process could be refined with the addition of round-the-clock measures of metabolic regulation, such as continuous glucose monitoring.Using Novel Technologies to Better Personalise Guidance for Shift Workers ::: The FutureAt a small scale, the feasibility of this type of approach has already been shown (118).", [["glucose", "CHEMICAL", 136, 143], ["glucose", "CHEMICAL", 136, 143], ["glucose", "SIMPLE_CHEMICAL", 136, 143], ["round-the-clock measures", "TREATMENT", 67, 91], ["metabolic regulation", "TREATMENT", 95, 115], ["continuous glucose monitoring", "TEST", 125, 154], ["round", "OBSERVATION_MODIFIER", 67, 72], ["small", "OBSERVATION_MODIFIER", 248, 253]]], ["Ultimately, implementing such methods at a large scale and including both shift workers and non-shift-working controls may help develop models that forecast transitions in the health of shift workers, as well as how to alter these trajectories.", [["a large scale", "TREATMENT", 41, 54]]], ["However, the data collection process will need to be relatively frictionless (for participants, at least) to achieve this.", [["participants", "SPECIES", 82, 94], ["the data collection process", "PROBLEM", 9, 36]]], ["With accurate monitoring in place, digital tools could then be implemented to improve the health and productivity of shift workers by optimising variables such as zeitgeber schedules in real time (Figure 1).Using Novel Technologies to Better Personalise Guidance for Shift Workers ::: The FutureInnovative technologies could also provide novel means of generating insightful data while minimising participant burden.", [["accurate monitoring", "TEST", 5, 24], ["The FutureInnovative technologies", "TREATMENT", 285, 318]]], ["For example, sensors commonly built into smartphones can now be used to monitor blood parameters such as haemoglobin that once required invasive testing (119).", [["blood", "ANATOMY", 80, 85], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 105, 116], ["blood parameters", "TEST", 80, 96], ["haemoglobin", "TEST", 105, 116], ["invasive testing", "TEST", 136, 152]]], ["Smartphones can also be used to monitor some exposures that are particularly relevant to shift workers, such as patterns of locomotion and exposure to light.", [["Smartphones", "TREATMENT", 0, 11]]], ["One problem, however, is that it would be especially useful to assess exposure to light at the level of the eye.", [["eye", "ANATOMY", 108, 111], ["eye", "ORGAN", 108, 111], ["eye", "ANATOMY", 108, 111]]], ["This requires new wearable devices, for smartphones are not suited to this, and many existing wearables that measure light exposure are frequently obstructed by clothing, confounding their data.", [["new wearable devices", "TREATMENT", 14, 34], ["smartphones", "TREATMENT", 40, 51]]], ["It is possible to make smart eyewear to estimate retinal light exposure, and such eyewear may be especially useful for another purpose.", [["retinal", "ANATOMY", 49, 56], ["retinal", "MULTI-TISSUE_STRUCTURE", 49, 56], ["retinal", "ANATOMY", 49, 56], ["light exposure", "OBSERVATION", 57, 71]]], ["The utility of all of these monitoring technologies may be enhanced by the addition of the ability to digitally \u201cenvirotype\u201d individuals, ambiently tracking information about their environments to better understand the interaction between environment and phenotype (120).", [["these monitoring technologies", "TEST", 22, 51]]], ["Building camera technology into eyewear is one way to accomplish this.Using Novel Technologies to Better Personalise Guidance for Shift Workers ::: The FutureMeanwhile, digital phenotyping \u2013 assessing changes in people's phenotypes using data from digital devices \u2013 has already been used to identify patients' disease trajectories in neurological disorders such as schizophrenia (121).", [["neurological", "ANATOMY", 334, 346], ["neurological disorders", "DISEASE", 334, 356], ["schizophrenia", "DISEASE", 365, 378], ["people", "ORGANISM", 212, 218], ["patients", "ORGANISM", 300, 308], ["people", "SPECIES", 212, 218], ["patients", "SPECIES", 300, 308], ["digital phenotyping", "TEST", 169, 188], ["changes in people's phenotypes", "PROBLEM", 201, 231], ["digital devices", "TREATMENT", 248, 263], ["patients' disease trajectories in neurological disorders", "PROBLEM", 300, 356], ["schizophrenia", "PROBLEM", 365, 378]]], ["Ultimately, use of multimodal novel sensors that analyse biofluids including interstitial fluid (e.g., continuous glucose monitoring), saliva, sweat, and tears may prove particularly useful in monitoring variables such as dietary intakes and associated changes in metabolites (123).", [["interstitial fluid", "ANATOMY", 77, 95], ["sweat", "ANATOMY", 143, 148], ["glucose", "CHEMICAL", 114, 121], ["glucose", "SIMPLE_CHEMICAL", 114, 121], ["saliva", "ORGANISM_SUBSTANCE", 135, 141], ["sweat", "ORGANISM_SUBDIVISION", 143, 148], ["multimodal novel sensors", "TREATMENT", 19, 43], ["interstitial fluid", "PROBLEM", 77, 95], ["continuous glucose monitoring", "TEST", 103, 132], ["tears", "PROBLEM", 154, 159], ["associated changes in metabolites", "PROBLEM", 242, 275], ["interstitial", "ANATOMY_MODIFIER", 77, 89], ["fluid", "OBSERVATION", 90, 95]]], ["However, the development of these sensors poses substantial challenges related to biofouling, accuracy, power, usability, calibration, and data security.Using Novel Technologies to Better Personalise Guidance for Shift Workers ::: The FutureThese tools are promising approaches to forecasting changes in behaviours and health, and we hope they will help healthcare professionals intervene before individuals succumb to disease.", [["biofouling", "OBSERVATION_MODIFIER", 82, 92]]], ["We foresee that using sophisticated computational methods such as deep learning to concurrently analyse individuals' behavioural, health, and environmental data from multimodal sources will eventually enhance personalisation of guidance for individual shift workers (124).Applying Behavioural Science to Support Better Health Decisions by Shift Workers ::: The FutureEven if shift workers understand precisely which behaviours they should enact to improve their health, they are prone to a variety of factors that impair decision making, such as circadian system misalignment and sleep loss (125, 126).", [["sleep loss", "DISEASE", 580, 590], ["sophisticated computational methods", "TREATMENT", 22, 57], ["circadian system misalignment", "PROBLEM", 546, 575], ["sleep loss", "PROBLEM", 580, 590]]], ["It is therefore imperative to support the ability of these people to make smart decisions, and this requires applying principles from behavioural science, particularly at the level of the organisations that employ shift workers.Applying Behavioural Science to Support Better Health Decisions by Shift Workers ::: The FutureSignificantly, many new technologies are strikingly habit-forming, and this exemplifies the power of applying behavioural science principles to shape behaviour.", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65], ["behavioural science", "TREATMENT", 134, 153], ["new", "OBSERVATION_MODIFIER", 343, 346]]], ["We believe that technologies that deliver adaptive interventions to both help people avoid poor health decisions during states of vulnerability and support good health decisions during states of opportunity will be particularly advantageous (128).Applying Behavioural Science to Support Better Health Decisions by Shift Workers ::: The FutureThe built environment also affects health in numerous ways (129), and given that shift workers are prone to health problems, it is particularly critical to pay attention to optimising the workplaces of these people.", [["people", "ORGANISM", 78, 84], ["people", "ORGANISM", 550, 556], ["people", "SPECIES", 78, 84], ["people", "SPECIES", 550, 556], ["adaptive interventions", "TREATMENT", 42, 64]]], ["As shift workers commonly experience circadian system disruption and do not gain tolerance to such disruption (130), it may be valuable to create workplaces that allow close control over exposure to light, and intelligent use of \u201csmart\u201d lighting systems may benefit these individuals.", [["circadian system disruption", "PROBLEM", 37, 64], ["such disruption", "PROBLEM", 94, 109], ["\u201csmart\u201d lighting systems", "TREATMENT", 229, 253]]], ["We also anticipate the development of closed-loop devices that will personalise light exposure at the level of the individual.Applying Behavioural Science to Support Better Health Decisions by Shift Workers ::: The FutureThe built environment influences physical activity.", [["closed-loop devices", "TREATMENT", 38, 57], ["closed", "OBSERVATION", 38, 44], ["loop devices", "OBSERVATION", 45, 57]]], ["Furthermore, workplace interventions to promote healthier diets, such as offering free fruit and labelling meals, have sometimes been shown to facilitate healthy dietary choices (132, 133).", [["interventions", "TREATMENT", 23, 36], ["labelling meals", "TREATMENT", 97, 112]]], ["Simple changes in the placement of food in eating areas affect food selection too (134), and these changes can be leveraged to support the health of shift workers.", [["Simple changes", "PROBLEM", 0, 14], ["the placement of food", "TREATMENT", 18, 39], ["placement", "OBSERVATION_MODIFIER", 22, 31]]], ["Similarly, if workers are using products such as melatonin supplements and blue-light-blocking glasses to shift the phases of their circadian systems, it makes sense to help them acquire efficacious products.Applying Behavioural Science to Support Better Health Decisions by Shift Workers ::: The FutureIt is also clear that social life is a strong influence on many shift workers' health behaviours, including their diets.", [["melatonin", "CHEMICAL", 49, 58], ["melatonin", "CHEMICAL", 49, 58], ["melatonin", "SIMPLE_CHEMICAL", 49, 58], ["products", "TREATMENT", 32, 40], ["melatonin supplements", "TREATMENT", 49, 70], ["blue-light-blocking glasses", "TREATMENT", 75, 102]]], ["As stress strongly affects dietary choices in many people and shift workers often report high stress and abnormal dietary behaviours (136), interventions to nurture the resilience of shift workers and to improve workers' self-regulation skills may support their dietary choices.", [["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["high stress", "PROBLEM", 89, 100], ["abnormal dietary behaviours", "PROBLEM", 105, 132]]], ["Shift workers could also benefit from other types of social support, including provision of additional childcare, as well as groups and events designed to minimise conflicts between their work and non-work activities.Applying Behavioural Science to Support Better Health Decisions by Shift Workers ::: The FutureEducating shift workers about how to sleep better is likely to be pivotal to their well-being, and shift work workplaces should have spaces for sleepy workers to nap.", [["social support", "TREATMENT", 53, 67]]], ["It is of course important to identify workers who have sleep disorders too, and simple screening tools such as brief questionnaires can be used for this (138).", [["sleep disorders", "DISEASE", 55, 70], ["sleep disorders", "PROBLEM", 55, 70]]], ["It may too be useful to screen for people who are simply not suited to certain shift schedules, for people differ substantially in how they tolerate shift work.", [["people", "ORGANISM", 35, 41], ["people", "ORGANISM", 100, 106], ["people", "SPECIES", 35, 41], ["people", "SPECIES", 100, 106]]], ["Certain characteristics associate with better shift work tolerance, including robust general health; young age; male sex; not having children; low languidity and neuroticism; high extraversion, flexibility in sleeping habits, and internal locus of control; and a chronotype that is neither very early nor very late (18).", [["low languidity", "DISEASE", 143, 157], ["neuroticism", "DISEASE", 162, 173], ["children", "ORGANISM", 133, 141], ["children", "SPECIES", 133, 141], ["low languidity", "PROBLEM", 143, 157], ["neuroticism", "PROBLEM", 162, 173], ["high extraversion", "PROBLEM", 175, 192], ["flexibility in sleeping habits", "PROBLEM", 194, 224], ["internal locus of control", "PROBLEM", 230, 255]]], ["To estimate chronotype, a study by Vetter and colleagues used a shift work-specific version of the Munich Chronotype Questionnaire (140), and this approach may be useful to help personalise work schedules for shift workers.", [["a study", "TEST", 24, 31]]], ["Nonetheless, it would be useful to develop additional questionnaires designed specifically to identify appropriate shift schedules, as well as to track how workers respond to these schedules.Applying Behavioural Science to Support Better Health Decisions by Shift Workers ::: The FutureFinally, it is worth noting that many workplace wellness programmes that have been tested have not yielded impressive results (141).", [["these schedules", "TREATMENT", 175, 190]]], ["Assessing the effects of workplace interventions is difficult for numerous reasons, not the least of which are enforcing blinding and randomisation of participants.", [["participants", "SPECIES", 151, 163], ["workplace interventions", "TREATMENT", 25, 48]]], ["To date, marked heterogeneity between studies has made it challenging to assess the utility of workplace interventions for shift workers (30).", [["marked heterogeneity between studies", "PROBLEM", 9, 45], ["workplace interventions", "TREATMENT", 95, 118], ["marked", "OBSERVATION_MODIFIER", 9, 15], ["heterogeneity", "OBSERVATION", 16, 29]]], ["And as is so often the case, the participants included in many of these studies did not comprise a diversity of ages and races, nor did the scientists attempt to define determinants of which workers responded positively to the interventions.", [["participants", "SPECIES", 33, 45], ["these studies", "TEST", 66, 79], ["the interventions", "TREATMENT", 223, 240]]], ["None of this means that it is not possible to implement effective programmes, however, and we hope that lacklustre results to date do not stymie continued efforts to improve on workplace interventions by better incorporating principles from behavioural science.Using Alternatives to Traditional Study Designs to Better Personalise Guidance for Shift Workers ::: The FutureTo assess the efficacy of interventions to improve shift-worker health, it may make sense to use alternatives to many of the hitherto-used study designs.", [["workplace interventions", "TREATMENT", 177, 200], ["interventions", "TREATMENT", 398, 411], ["not possible", "UNCERTAINTY", 30, 42]]], ["Recently, studies applying \u201cBig Data\u201d approaches have contributed to some advances in efforts to personalise medicine.", [["personalise medicine", "TREATMENT", 97, 117]]], ["However, it may be advantageous to concurrently carry out studies that use a \u201cSmall Data\u201d paradigm \u2013 for example, using n-of-1 approaches to more rapidly assess how individual workers are responding to a given intervention and to forecast which of them are at risk of health trajectory transitions towards disease (142).ConclusionsA large proportion of the workforce works shifts, and these individuals are integral to sustaining functional societies.", [["intervention", "TREATMENT", 210, 222], ["large", "OBSERVATION_MODIFIER", 333, 338], ["proportion", "OBSERVATION_MODIFIER", 339, 349]]], ["However, the study of how to support the long-term health and well-being of these people has been somewhat neglected, and a relatively small proportion of relevant studies has included shift workers as participants.", [["people", "ORGANISM", 82, 88], ["people", "SPECIES", 82, 88], ["participants", "SPECIES", 202, 214], ["the study", "TEST", 9, 18], ["small", "OBSERVATION_MODIFIER", 135, 140]]], ["While the type of personalised interventions to support shift workers that we have discussed in this article are bound to produce logistical headaches for employers, the onus should be on supporting the long-term the health and performance of their employees.", [["headaches", "DISEASE", 141, 150], ["personalised interventions", "TREATMENT", 18, 44], ["logistical headaches", "PROBLEM", 130, 150]]], ["The acute difficulties arising from implementing customised shift schedule systems and suchlike may be more than made up for by the lasting benefits of these systems on health, safety, and productivity.", [["The acute difficulties", "PROBLEM", 0, 22], ["customised shift schedule systems", "TREATMENT", 49, 82], ["acute", "OBSERVATION_MODIFIER", 4, 9], ["difficulties", "OBSERVATION", 10, 22]]], ["We note also that as shift work increases the likelihood of adverse pregnancy outcomes and may lead to epigenetic modifications in parents that could plausibly affect the epigenetics and hence health of their children, supporting the health of shift workers could one day have critical effects on the well-being of future generations (143, 144).ConclusionsScientists now have an unprecedented ability to identify ways of helping shift workers.", [["children", "ORGANISM", 209, 217], ["children", "SPECIES", 209, 217], ["adverse pregnancy outcomes", "PROBLEM", 60, 86], ["epigenetic modifications", "PROBLEM", 103, 127]]]], "a9dee13fda3ced0266934acdee7f68ec5fd64e53": [["IntroductionThe leukocyte-common antigen (L-CA, CD45) is a family of tyrosine phosphatases uniquely and abundantly expressed by cells of hematopoietic origin (for review, see Thomas, 1989) .", [["leukocyte", "ANATOMY", 16, 25], ["cells", "ANATOMY", 128, 133], ["hematopoietic", "ANATOMY", 137, 150], ["tyrosine", "CHEMICAL", 69, 77], ["tyrosine", "CHEMICAL", 69, 77], ["leukocyte", "CELL", 16, 25], ["L-CA", "GENE_OR_GENE_PRODUCT", 42, 46], ["CD45", "GENE_OR_GENE_PRODUCT", 48, 52], ["cells", "CELL", 128, 133], ["leukocyte-common antigen", "PROTEIN", 16, 40], ["L-CA", "PROTEIN", 42, 46], ["CD45", "PROTEIN", 48, 52], ["tyrosine phosphatases", "PROTEIN", 69, 90], ["The leukocyte", "TEST", 12, 25], ["tyrosine phosphatases", "TEST", 69, 90], ["leukocyte", "ANATOMY", 16, 25], ["hematopoietic origin", "OBSERVATION", 137, 157]]], ["Different cell types express family members in a precise manner that is controlled during both cell lineage differentiation and activation.", [["cell", "ANATOMY", 10, 14], ["cell lineage", "ANATOMY", 95, 107], ["cell", "CELL", 10, 14], ["cell", "CELL", 95, 99], ["cell types", "OBSERVATION", 10, 20], ["cell lineage differentiation", "OBSERVATION", 95, 123]]], ["L-CA is encoded by a single gene located in a syntenic region found on chromosome 1 in both humans and mice (Ralph et al., 1987; Hall et al., 1988; Saga et al., 1988; Seldin et al., 1988; Johnson et al., 1989) .", [["chromosome 1", "ANATOMY", 71, 83], ["L-CA", "GENE_OR_GENE_PRODUCT", 0, 4], ["chromosome 1", "CELLULAR_COMPONENT", 71, 83], ["humans", "ORGANISM", 92, 98], ["mice", "ORGANISM", 103, 107], ["L-CA", "PROTEIN", 0, 4], ["syntenic region", "DNA", 46, 61], ["chromosome 1", "DNA", 71, 83], ["humans", "SPECIES", 92, 98], ["mice", "SPECIES", 103, 107], ["humans", "SPECIES", 92, 98], ["mice", "SPECIES", 103, 107], ["CA", "OBSERVATION", 2, 4]]], ["The family is generated by differential splicing of three consecutive exons that encode sequences near the amino terminus of the molecule.", [["amino", "CHEMICAL", 107, 112], ["exons", "DNA", 70, 75], ["amino terminus", "PROTEIN", 107, 121], ["amino", "ANATOMY_MODIFIER", 107, 112], ["terminus", "ANATOMY_MODIFIER", 113, 121], ["molecule", "ANATOMY", 129, 137]]], ["A total of eight possible mRNAs can be generated, of which six have been isolated as cDNAs (Barclay et al., 1967; Ralph et al., 1987; Saga et al., 1987; Streuli et al., 1987; Thomas et al., 1967) .IntroductionThe mature glycoprotein is composed of an aminoterminal external domain, a single membrane-spanning region, and a very large cytoplasmic domain (Thomas et al., 1985) .", [["membrane", "ANATOMY", 291, 299], ["cytoplasmic", "ANATOMY", 334, 345], ["membrane", "CELLULAR_COMPONENT", 291, 299], ["cytoplasmic", "ORGANISM_SUBSTANCE", 334, 345], ["mRNAs", "RNA", 26, 31], ["cDNAs", "DNA", 85, 90], ["mature glycoprotein", "PROTEIN", 213, 232], ["aminoterminal external domain", "PROTEIN", 251, 280], ["single membrane-spanning region", "PROTEIN", 284, 315], ["cytoplasmic domain", "PROTEIN", 334, 352], ["The mature glycoprotein", "TREATMENT", 209, 232], ["an aminoterminal external domain", "PROBLEM", 248, 280], ["a single membrane-spanning region", "PROBLEM", 282, 315], ["a very large cytoplasmic domain", "PROBLEM", 321, 352], ["mature", "OBSERVATION_MODIFIER", 213, 219], ["glycoprotein", "OBSERVATION", 220, 232], ["aminoterminal", "OBSERVATION_MODIFIER", 251, 264], ["external domain", "OBSERVATION", 265, 280], ["very", "OBSERVATION_MODIFIER", 323, 327], ["large", "OBSERVATION_MODIFIER", 328, 333], ["cytoplasmic domain", "OBSERVATION", 334, 352]]], ["The external domain, based on protein biochemistry, interspecies sequence comparison, and genomic structure, can be divided into four subdomains (Thomas, 1989) .", [["external domain", "PROTEIN", 4, 19], ["The external domain", "TEST", 0, 19], ["protein biochemistry", "TEST", 30, 50], ["interspecies sequence comparison", "TEST", 52, 84], ["external domain", "ANATOMY", 4, 19]]], ["The region at the amino terminus is predicted to be a random protein structure containing O-linked carbohydrate sites.", [["amino", "CHEMICAL", 18, 23], ["O", "CHEMICAL", 90, 91], ["carbohydrate", "CHEMICAL", 99, 111], ["amino terminus", "AMINO_ACID", 18, 32], ["amino terminus", "PROTEIN", 18, 32], ["O-linked carbohydrate sites", "PROTEIN", 90, 117], ["a random protein structure", "PROBLEM", 52, 78], ["region", "ANATOMY_MODIFIER", 4, 10], ["amino terminus", "OBSERVATION", 18, 32], ["carbohydrate sites", "OBSERVATION", 99, 117]]], ["The O-linked carbohydrate region is followed by two separate cysteine clusters and then a short spacer region before the membrane-spanning region.", [["membrane", "ANATOMY", 121, 129], ["O", "CHEMICAL", 4, 5], ["carbohydrate", "CHEMICAL", 13, 25], ["cysteine", "CHEMICAL", 61, 69], ["membrane", "CELLULAR_COMPONENT", 121, 129], ["O-linked carbohydrate region", "PROTEIN", 4, 32], ["short spacer region", "DNA", 90, 109], ["membrane-spanning region", "PROTEIN", 121, 145], ["a short spacer region", "TREATMENT", 88, 109], ["short spacer", "OBSERVATION_MODIFIER", 90, 102], ["membrane", "OBSERVATION_MODIFIER", 121, 129]]], ["The differential use of the three variable exons results in changes in the O-linked carbohydrate region.", [["O", "CHEMICAL", 75, 76], ["carbohydrate", "CHEMICAL", 84, 96], ["exons", "DNA", 43, 48], ["O-linked carbohydrate region", "PROTEIN", 75, 103]]], ["Since the regulation of alternative splicing of L-CA mRNA is a highly regulated event, it appears likely that the carbohydrate structures are of functional importance.IntroductionIt was recently demonstrated that the cytoplasmic domain of L-CA contains tyrosine phosphatase activity Tonks et al., 1988; Ostergaard et al., 1989) .", [["cytoplasmic", "ANATOMY", 217, 228], ["tyrosine", "CHEMICAL", 253, 261], ["carbohydrate", "CHEMICAL", 114, 126], ["tyrosine", "CHEMICAL", 253, 261], ["L-CA", "GENE_OR_GENE_PRODUCT", 48, 52], ["cytoplasmic", "ORGANISM_SUBSTANCE", 217, 228], ["L-CA contains tyrosine phosphatase", "GENE_OR_GENE_PRODUCT", 239, 273], ["L-CA mRNA", "RNA", 48, 57], ["cytoplasmic domain", "PROTEIN", 217, 235], ["L-CA", "PROTEIN", 239, 243], ["tyrosine phosphatase", "PROTEIN", 253, 273], ["L-CA mRNA", "TREATMENT", 48, 57], ["the cytoplasmic domain of L-CA", "TEST", 213, 243], ["tyrosine phosphatase activity", "PROBLEM", 253, 282], ["L", "ANATOMY_MODIFIER", 48, 49], ["-CA mRNA", "OBSERVATION", 49, 57], ["appears likely", "UNCERTAINTY", 90, 104]]], ["This activity is likely to be important for cellular function since sequence comparison between species shows a remarkable degree of conservation: 65% over 700 amino acids.", [["cellular", "ANATOMY", 44, 52], ["amino acids", "CHEMICAL", 160, 171], ["amino acids", "CHEMICAL", 160, 171], ["cellular", "CELL", 44, 52], ["amino acids", "AMINO_ACID", 160, 171], ["amino acids", "TEST", 160, 171], ["likely to be", "UNCERTAINTY", 17, 29]]], ["The large cytoplasmic domain of L-CA is divided into two 300 amino acid tandem repeats that share 35% identical residues.", [["cytoplasmic", "ANATOMY", 10, 21], ["amino acid", "CHEMICAL", 61, 71], ["amino acid", "CHEMICAL", 61, 71], ["cytoplasmic", "ORGANISM_SUBSTANCE", 10, 21], ["L-CA", "GENE_OR_GENE_PRODUCT", 32, 36], ["cytoplasmic domain", "PROTEIN", 10, 28], ["L-CA", "PROTEIN", 32, 36], ["The large cytoplasmic domain of L-CA", "PROBLEM", 0, 36], ["amino acid tandem repeats", "TREATMENT", 61, 86], ["large", "OBSERVATION_MODIFIER", 4, 9], ["cytoplasmic domain", "OBSERVATION", 10, 28]]], ["Each subdomain is approximately 35% homologous to another tyrosine phosphatase, PTPase 1B .", [["tyrosine", "CHEMICAL", 58, 66], ["tyrosine", "CHEMICAL", 58, 66], ["PTPase 1B", "GENE_OR_GENE_PRODUCT", 80, 89], ["tyrosine phosphatase", "PROTEIN", 58, 78], ["PTPase 1B", "PROTEIN", 80, 89], ["another tyrosine phosphatase", "TEST", 50, 78]]], ["This suggests that both cytoplasmic subdomains will have tyrosine phosphatase activity, but with different substrate specificity and perhaps different regulation.IntroductionThe function of L-CA has been a long-standing puzzle.", [["cytoplasmic subdomains", "ANATOMY", 24, 46], ["tyrosine", "CHEMICAL", 57, 65], ["L-CA", "CHEMICAL", 190, 194], ["tyrosine", "CHEMICAL", 57, 65], ["cytoplasmic", "ORGANISM_SUBSTANCE", 24, 35], ["tyrosine", "AMINO_ACID", 57, 65], ["L-CA", "GENE_OR_GENE_PRODUCT", 190, 194], ["cytoplasmic subdomains", "PROTEIN", 24, 46], ["tyrosine phosphatase", "PROTEIN", 57, 77], ["L-CA", "PROTEIN", 190, 194], ["both cytoplasmic subdomains", "PROBLEM", 19, 46], ["tyrosine phosphatase activity", "PROBLEM", 57, 86], ["a long-standing puzzle", "TREATMENT", 204, 226], ["cytoplasmic subdomains", "OBSERVATION", 24, 46], ["tyrosine phosphatase", "OBSERVATION", 57, 77]]], ["The recent demonstration of tyrosine phosphatase activity suggests that L-CA may be involved in the regulation of hematopoietic cell growth.", [["hematopoietic cell", "ANATOMY", 114, 132], ["tyrosine", "CHEMICAL", 28, 36], ["L-CA", "CHEMICAL", 72, 76], ["tyrosine", "CHEMICAL", 28, 36], ["tyrosine", "AMINO_ACID", 28, 36], ["L-CA", "SIMPLE_CHEMICAL", 72, 76], ["hematopoietic cell", "CELL", 114, 132], ["tyrosine phosphatase", "PROTEIN", 28, 48], ["L-CA", "PROTEIN", 72, 76], ["tyrosine phosphatase activity", "TEST", 28, 57], ["L-CA", "PROBLEM", 72, 76], ["hematopoietic cell growth", "PROBLEM", 114, 139], ["tyrosine phosphatase", "OBSERVATION", 28, 48], ["hematopoietic cell growth", "OBSERVATION", 114, 139]]], ["This has been supported by studies using antibodies to L-CA that have implicated this family in the activation and proliferation of lymphocytes.", [["lymphocytes", "ANATOMY", 132, 143], ["L-CA", "GENE_OR_GENE_PRODUCT", 55, 59], ["lymphocytes", "CELL", 132, 143], ["antibodies", "PROTEIN", 41, 51], ["L-CA", "PROTEIN", 55, 59], ["lymphocytes", "CELL_TYPE", 132, 143], ["antibodies", "TREATMENT", 41, 51], ["proliferation of lymphocytes", "PROBLEM", 115, 143], ["lymphocytes", "ANATOMY", 132, 143]]], ["The proliferative response induced by the lectin phytohemagglutinin or the cross-linked anti-CD3 antibody can be modulated using monoclonal antibodies to L-CA (Bernabeu et al., 1987; Martorell et al., 1987) .", [["lectin phytohemagglutinin", "GENE_OR_GENE_PRODUCT", 42, 67], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 88, 96], ["lectin phytohemagglutinin", "PROTEIN", 42, 67], ["cross-linked anti-CD3 antibody", "PROTEIN", 75, 105], ["monoclonal antibodies", "PROTEIN", 129, 150], ["The proliferative response", "PROBLEM", 0, 26], ["the lectin phytohemagglutinin", "TEST", 38, 67], ["the cross-linked anti-CD3 antibody", "TREATMENT", 71, 105], ["monoclonal antibodies", "TEST", 129, 150], ["proliferative response", "OBSERVATION", 4, 26]]], ["Similarly, modulatory effects are also seen by cross-linking L-CA to other surface glycoproteins (Ledbetter et al., 1988) .", [["surface", "ANATOMY", 75, 82], ["L-CA", "GENE_OR_GENE_PRODUCT", 61, 65], ["L-CA", "PROTEIN", 61, 65], ["surface glycoproteins", "PROTEIN", 75, 96], ["modulatory effects", "OBSERVATION", 11, 29]]], ["Anti-L-CA antibodies can inhibit cytolysis by NK cell or cytotoxic T lymphocytes; they can also inhibit B lymphocyte proliferation and antibody production (Seaman et al, 1981; Nakayama et al., 1982; Newman et al., 1983; Harp et al., 1984; Yakura et al., 1986; Mittler et al., 1987) .", [["NK cell", "ANATOMY", 46, 53], ["cytotoxic T lymphocytes", "ANATOMY", 57, 80], ["B lymphocyte", "ANATOMY", 104, 116], ["Anti-L-CA antibodies", "GENE_OR_GENE_PRODUCT", 0, 20], ["NK cell", "CELL", 46, 53], ["cytotoxic T lymphocytes", "CELL", 57, 80], ["B lymphocyte", "CELL", 104, 116], ["Anti-L-CA antibodies", "PROTEIN", 0, 20], ["NK cell", "CELL_TYPE", 46, 53], ["cytotoxic T lymphocytes", "CELL_TYPE", 57, 80], ["B lymphocyte", "CELL_TYPE", 104, 116], ["Anti-L-CA antibodies", "TEST", 0, 20], ["cytolysis", "PROBLEM", 33, 42], ["NK cell", "PROBLEM", 46, 53], ["cytotoxic T lymphocytes", "PROBLEM", 57, 80], ["B lymphocyte proliferation", "PROBLEM", 104, 130], ["antibody production", "TEST", 135, 154], ["lymphocyte proliferation", "OBSERVATION", 106, 130]]], ["Direct evidence, however, that L-CA is involved in leukocyte cell growth has been difficult to obtain.", [["leukocyte cell", "ANATOMY", 51, 65], ["L-CA", "SIMPLE_CHEMICAL", 31, 35], ["leukocyte cell", "CELL", 51, 65], ["L-CA", "PROTEIN", 31, 35], ["leukocyte cell growth", "PROBLEM", 51, 72], ["leukocyte cell", "OBSERVATION", 51, 65]]], ["To investigate the function of L-CA, we generated mouse T cell clones deficient in their expression of surface L-CA (L-CA-).", [["T cell clones", "ANATOMY", 56, 69], ["surface", "ANATOMY", 103, 110], ["L-CA", "GENE_OR_GENE_PRODUCT", 31, 35], ["mouse", "ORGANISM", 50, 55], ["T cell clones", "CELL", 56, 69], ["surface L-CA", "GENE_OR_GENE_PRODUCT", 103, 115], ["L-CA", "GENE_OR_GENE_PRODUCT", 117, 121], ["L-CA", "PROTEIN", 31, 35], ["mouse T cell clones", "CELL_LINE", 50, 69], ["surface L-CA", "PROTEIN", 103, 115], ["L-CA", "PROTEIN", 117, 121], ["mouse", "SPECIES", 50, 55], ["mouse", "SPECIES", 50, 55], ["L-CA", "PROBLEM", 31, 35], ["mouse T cell clones deficient", "PROBLEM", 50, 79], ["L-CA", "TEST", 117, 121], ["L", "ANATOMY_MODIFIER", 31, 32], ["CA", "ANATOMY", 33, 35]]], ["We report here that these clones are altered in their capacity to divide in response to antigen and provide evidence that L-CA is involved in the initiation of signals required for cell division.ResultsDerivation and Characterization of L-CA-Deficient T Cell Clones Mutational analysis has been a powerful tool in deciphering protein functions.", [["clones", "ANATOMY", 26, 32], ["cell", "ANATOMY", 181, 185], ["clones", "CELL", 26, 32], ["L-CA", "GENE_OR_GENE_PRODUCT", 122, 126], ["cell", "CELL", 181, 185], ["L-CA", "PROTEIN", 122, 126], ["L-CA", "PROTEIN", 237, 241], ["these clones", "PROBLEM", 20, 32], ["ResultsDerivation", "TEST", 195, 212], ["Characterization", "TEST", 217, 233], ["L-CA", "TEST", 237, 241], ["Deficient T Cell Clones Mutational analysis", "PROBLEM", 242, 285], ["Cell Clones", "OBSERVATION", 254, 265]]], ["We directed these methods toward the understanding of the function of L-CA.", [["L-CA", "GENE_OR_GENE_PRODUCT", 70, 74], ["L-CA", "PROTEIN", 70, 74]]], ["We chose to mutate mouse T cell clones because they maintain normal physiology and do not display a transformed phenotype.", [["T cell clones", "ANATOMY", 25, 38], ["mouse", "ORGANISM", 19, 24], ["T cell clones", "CELL", 25, 38], ["mouse T cell clones", "CELL_LINE", 19, 38], ["mouse", "SPECIES", 19, 24], ["mouse", "SPECIES", 19, 24], ["a transformed phenotype", "PROBLEM", 98, 121]]], ["T cell clones were mutated with N-methyl-N'-nitro-Nnitrosoguanidine, and L-CA-cells were selected by treating with antibody directed against a common L-CA determinant and rabbit complement.", [["T cell clones", "ANATOMY", 0, 13], ["L-CA-cells", "ANATOMY", 73, 83], ["N-methyl-N'-nitro-Nnitrosoguanidine", "CHEMICAL", 32, 67], ["N-methyl-N'-nitro-Nnitrosoguanidine", "CHEMICAL", 32, 67], ["T cell clones", "CELL", 0, 13], ["N-methyl-N'-nitro-Nnitrosoguanidine", "SIMPLE_CHEMICAL", 32, 67], ["L-CA-cells", "CELL", 73, 83], ["L-CA", "CANCER", 150, 154], ["rabbit", "ORGANISM", 171, 177], ["T cell clones", "CELL_LINE", 0, 13], ["L-CA-cells", "CELL_LINE", 73, 83], ["L-CA determinant", "PROTEIN", 150, 166], ["rabbit", "SPECIES", 171, 177], ["rabbit", "SPECIES", 171, 177], ["T cell clones", "PROBLEM", 0, 13], ["N-methyl", "TREATMENT", 32, 40], ["nitro", "TREATMENT", 44, 49], ["Nnitrosoguanidine", "TREATMENT", 50, 67], ["L-CA-cells", "TREATMENT", 73, 83], ["antibody", "TREATMENT", 115, 123], ["cell clones", "OBSERVATION", 2, 13]]], ["In one experiment, one (6) Analysis of clonally isolated populations of cells.", [["cells", "ANATOMY", 72, 77], ["cells", "CELL", 72, 77], ["clonally isolated populations of cells", "PROBLEM", 39, 77], ["populations of cells", "OBSERVATION", 57, 77]]], ["A.E7-M2-2, -3, and -11 were isolated from negatively sorted cells, and A.E7-M2-1P was isolated from positively sorted cells.", [["cells", "ANATOMY", 60, 65], ["cells", "ANATOMY", 118, 123], ["A.E7-M2-2", "GENE_OR_GENE_PRODUCT", 0, 9], ["-3", "GENE_OR_GENE_PRODUCT", 11, 13], ["cells", "CELL", 60, 65], ["A.E7-M2-1P", "CELL", 71, 81], ["cells", "CELL", 118, 123], ["A.E7-M2-2, -3, and -11", "DNA", 0, 22], ["negatively sorted cells", "CELL_TYPE", 42, 65], ["A.E7", "PROTEIN", 71, 75], ["M2", "PROTEIN", 76, 78], ["1P", "PROTEIN", 79, 81], ["positively sorted cells", "CELL_TYPE", 100, 123], ["A.E7", "TEST", 0, 4], ["A.E7", "TEST", 71, 75], ["positively sorted cells", "PROBLEM", 100, 123], ["sorted cells", "OBSERVATION", 111, 123]]], ["A.E7-M2-D3 was cloned directly from A.E7-M2 population.", [["A.E7-M2", "CELL", 36, 43], ["A.E7", "DNA", 0, 4], ["M2", "PROTEIN", 5, 7], ["D3", "DNA", 8, 10], ["A.E7-M2 population", "CELL_LINE", 36, 54]]], ["Cells were stained with anti-L-CA W2.3 and a fluoresceinated second antibody.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["anti-L-CA", "GENE_OR_GENE_PRODUCT", 24, 33], ["anti-L", "PROTEIN", 24, 30], ["CA W2.3", "PROTEIN", 31, 38], ["fluoresceinated second antibody", "PROTEIN", 45, 76], ["Cells", "TEST", 0, 5], ["anti-L", "TEST", 24, 30], ["CA", "TEST", 31, 33], ["a fluoresceinated second antibody", "TEST", 43, 76]]], ["Each line was stained with secondary antibody alone as a negative control.", [["secondary antibody", "PROTEIN", 27, 45], ["Each line", "TREATMENT", 0, 9], ["secondary antibody", "TREATMENT", 27, 45]]], ["The negative control for A.E7-M2-2 is shown.", [["A.E7", "PROTEIN", 25, 29], ["M2", "PROTEIN", 30, 32], ["A.E7", "TEST", 25, 29], ["negative", "OBSERVATION", 4, 12]]], ["Cells were analyzed on a Secton-Dickinson FACS 440.Resultsculture of a T cell clone, A.E7 (I-Ek restricted and specific for pigeon cytochrome c), contained a cluster of cells that appeared to be abnormal in morphology and growth.", [["Cells", "ANATOMY", 0, 5], ["T cell clone", "ANATOMY", 71, 83], ["cells", "ANATOMY", 169, 174], ["Cells", "CELL", 0, 5], ["T cell clone", "CELL", 71, 83], ["A.E7", "CELL", 85, 89], ["I-Ek", "GENE_OR_GENE_PRODUCT", 91, 95], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 131, 143], ["cells", "CELL", 169, 174], ["T cell clone", "CELL_LINE", 71, 83], ["A.E7", "PROTEIN", 85, 89], ["I-Ek", "PROTEIN", 91, 95], ["pigeon cytochrome c", "PROTEIN", 124, 143], ["pigeon", "SPECIES", 124, 130], ["a T cell clone", "PROBLEM", 69, 83], ["pigeon cytochrome c", "PROBLEM", 124, 143], ["a cluster of cells", "PROBLEM", 156, 174], ["abnormal in morphology", "PROBLEM", 195, 217], ["cell clone", "OBSERVATION", 73, 83], ["growth", "OBSERVATION_MODIFIER", 222, 228]]], ["This culture, termed A.E7-M2, was expanded and examined by flow cytometry ( Figure 1A ).", [["A.E7-M2", "ANATOMY", 21, 28], ["A.E7-M2", "CELL", 21, 28], ["A.E7", "DNA", 21, 25], ["M2", "CELL_LINE", 26, 28], ["This culture", "TEST", 0, 12], ["flow cytometry", "TEST", 59, 73]]], ["It is apparent that approximately half of the population of cells failed to react with anti-L-CA antibody W2.3.", [["cells", "ANATOMY", 60, 65], ["cells", "CELL", 60, 65], ["anti-L-CA", "GENE_OR_GENE_PRODUCT", 87, 96], ["anti-L", "PROTEIN", 87, 93], ["CA antibody W2", "PROTEIN", 94, 108], ["anti-L-CA antibody W2", "TREATMENT", 87, 108], ["approximately", "OBSERVATION_MODIFIER", 20, 33], ["half", "OBSERVATION_MODIFIER", 34, 38]]], ["Individual T cells were isolated and expanded either by limiting dilution cloning directly from the A.E7-M2 line or by cloning after positive and negative selection by cell sorting.", [["T cells", "ANATOMY", 11, 18], ["A.E7-M2 line", "ANATOMY", 100, 112], ["cell", "ANATOMY", 168, 172], ["T cells", "CELL", 11, 18], ["A.E7-M2 line", "CELL", 100, 112], ["cell", "CELL", 168, 172], ["T cells", "CELL_TYPE", 11, 18], ["A.E7-M2 line", "CELL_LINE", 100, 112], ["Individual T cells", "PROBLEM", 0, 18], ["cell sorting", "TEST", 168, 180]]], ["The clones isolated by positive cell sorting, for example, A.E7-M2-1P (Figure lB), appeared to be identical to the parent line by morphology, growth parameters, and cell surface molecules (data not shown).", [["clones", "ANATOMY", 4, 10], ["cell", "ANATOMY", 32, 36], ["cell surface", "ANATOMY", 165, 177], ["clones", "CELL", 4, 10], ["cell", "CELL", 32, 36], ["cell", "CELL", 165, 169], ["A.E7", "PROTEIN", 59, 63], ["M2", "PROTEIN", 64, 66], ["1P", "PROTEIN", 67, 69], ["Figure lB", "PROTEIN", 71, 80], ["cell surface molecules", "PROTEIN", 165, 187], ["The clones", "TEST", 0, 10], ["positive cell sorting", "TEST", 23, 44], ["A.E7", "TEST", 59, 63], ["growth parameters", "TEST", 142, 159], ["cell surface molecules", "TEST", 165, 187], ["positive cell sorting", "OBSERVATION", 23, 44]]], ["Six L-CA-clones were isolated by cloning directly from the A.E7-M2 line and 11 clones were isolated by cloning after negative selection.", [["L-CA-clones", "ANATOMY", 4, 15], ["A.E7-M2 line", "ANATOMY", 59, 71], ["clones", "ANATOMY", 79, 85], ["L-CA-clones", "CELL", 4, 15], ["A.E7-M2 line", "CELL", 59, 71], ["clones", "CELL", 79, 85], ["L-CA-clones", "CELL_LINE", 4, 15], ["A.E7", "DNA", 59, 63], ["M2 line", "CELL_LINE", 64, 71], ["Six L-CA-clones", "PROBLEM", 0, 15], ["clones", "OBSERVATION", 9, 15]]], ["One clone from the di-rect cloning, A.E7-M2-D3, and three clones from the negatively sorted cloning, A.E7-M2-2, -3, and -11, were examined further.", [["clone", "ANATOMY", 4, 9], ["clone", "CELL", 4, 9], ["A.E7-M2-2", "GENE_OR_GENE_PRODUCT", 101, 110], ["-3", "GENE_OR_GENE_PRODUCT", 112, 114], ["A.E7", "DNA", 36, 40], ["M2", "DNA", 41, 43], ["A.E7-M2-2, -3, and -11", "DNA", 101, 123], ["A.E7", "TEST", 36, 40], ["A.E7", "TEST", 101, 105]]], ["As shown in Figure 16 , these cells were completely negative for L-CA as determined by flow cytometry using the antibody 13/2.3.", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["L-CA", "SIMPLE_CHEMICAL", 65, 69], ["L-CA", "PROTEIN", 65, 69], ["antibody 13/2.3", "PROTEIN", 112, 127], ["these cells", "TEST", 24, 35], ["L-CA", "PROBLEM", 65, 69], ["flow cytometry", "TEST", 87, 101], ["the antibody", "TEST", 108, 120]]], ["Identical results were obtained with either 3OFll.l or MV9.3.4HL.2 monoclonal antibodies, which also recognize common epitopes on L-CA.", [["L-CA", "SIMPLE_CHEMICAL", 130, 134], ["MV9", "PROTEIN", 55, 58], ["HL.2 monoclonal antibodies", "PROTEIN", 62, 88], ["epitopes", "PROTEIN", 118, 126], ["L-CA", "PROTEIN", 130, 134], ["MV9", "TEST", 55, 58], ["monoclonal antibodies", "TEST", 67, 88], ["L", "ANATOMY_MODIFIER", 130, 131], ["-CA", "ANATOMY", 131, 134]]], ["Also, the anti-allotypic antibody 104-2, which recognizes the Ly-5.2 determinant, failed to stain (data not shown).", [["anti-allotypic antibody 104", "PROTEIN", 10, 37], ["Ly-5.2 determinant", "PROTEIN", 62, 80], ["the anti-allotypic antibody", "TEST", 6, 33], ["the Ly", "TEST", 58, 64]]], ["This indicates that the lack of L-CA detection was not merely due to the loss of the antigenic epitope.ResultsTo confirm the flow cytometry data, immunoprecipitation of surface-labeled cells was performed.", [["surface", "ANATOMY", 169, 176], ["cells", "ANATOMY", 185, 190], ["L-CA", "GENE_OR_GENE_PRODUCT", 32, 36], ["surface", "CELLULAR_COMPONENT", 169, 176], ["cells", "CELL", 185, 190], ["L-CA", "PROTEIN", 32, 36], ["antigenic epitope", "PROTEIN", 85, 102], ["surface-labeled cells", "CELL_LINE", 169, 190], ["L-CA detection", "PROBLEM", 32, 46], ["the loss of the antigenic epitope", "PROBLEM", 69, 102], ["the flow cytometry data", "TEST", 121, 144], ["immunoprecipitation of surface-labeled cells", "TEST", 146, 190], ["antigenic epitope", "OBSERVATION", 85, 102]]], ["Although analysis of the immunoprecipitate by SDS-PAGE showed no detectable surface-labeled L-CA from the L-CAclones, a single band at approximately 180,000 M, is im- bodies used were: anti-L-CA (1312.3) (lanes l-4); anti Pgpl (IM7.8.1) (lanes 5-8); and total 200cell lysates (lanes 9-12).", [["surface", "ANATOMY", 76, 83], ["lysates", "ANATOMY", 268, 275], ["L-CA", "GENE_OR_GENE_PRODUCT", 92, 96], ["anti-L-CA", "SIMPLE_CHEMICAL", 185, 194], ["surface-labeled L-CA", "PROTEIN", 76, 96], ["L-CAclones", "PROTEIN", 106, 116], ["anti Pgpl", "PROTEIN", 217, 226], ["the immunoprecipitate", "TEST", 21, 42], ["SDS", "TEST", 46, 49], ["a single band", "TEST", 118, 131], ["anti-L-CA", "TEST", 185, 194], ["lanes l", "TEST", 205, 212], ["anti Pgpl (IM7", "TEST", 217, 231], ["total 200cell lysates", "TREATMENT", 254, 275], ["L", "ANATOMY_MODIFIER", 106, 107], ["-CAclones", "ANATOMY", 107, 116]]], ["The ceils were: A.E7 (lanes 1, 5, and 9); A.E7-M2-2 (lanes 2, 6, and 10); A.E7-M2-3 (lanes 3, 7, and 11); and A.E7- M2-11 (lanes 4,8, and 12) .", [["M2", "PROTEIN", 79, 81], ["A.E7", "DNA", 110, 114], ["M2-11", "DNA", 116, 121], ["A.E7", "TEST", 42, 46], ["lanes", "TEST", 53, 58], ["A.E7", "TEST", 74, 78], ["lanes", "TEST", 85, 90], ["A.E7", "TEST", 110, 114], ["lanes", "TEST", 123, 128]]], ["The arrow marks the position of the high molecular weight protein seen in lane 9 and not found in lanes W-12.", [["high molecular weight protein", "PROTEIN", 36, 65], ["position", "OBSERVATION_MODIFIER", 20, 28], ["high", "OBSERVATION_MODIFIER", 36, 40]]], ["The arrow denotes the position of the higher molecular weight band found in the AE7 parent but not the mutant cell lines.", [["cell lines", "ANATOMY", 110, 120], ["AE7", "GENE_OR_GENE_PRODUCT", 80, 83], ["cell lines", "CELL", 110, 120], ["AE7 parent", "CELL_LINE", 80, 90], ["mutant cell lines", "CELL_LINE", 103, 120], ["cell lines", "OBSERVATION", 110, 120]]], ["The gel was exposed for 7 days.", [["The gel", "TREATMENT", 0, 7]]], ["(B) Northern blot analysis.", [["Northern blot analysis", "TEST", 4, 26]]], ["Totat RNA was prepared and 5 trg was electrophoresed per lane.", [["Totat RNA", "RNA", 0, 9], ["Totat RNA", "TREATMENT", 0, 9]]], ["The gel was blotted onto Zetaprobe (BioFtad) and hybridized with a fulllength L-CA cDNA (Thomas et al., 1987) .", [["Zetaprobe", "SIMPLE_CHEMICAL", 25, 34], ["BioFtad", "SIMPLE_CHEMICAL", 36, 43], ["Zetaprobe", "PROTEIN", 25, 34], ["BioFtad", "PROTEIN", 36, 43], ["fulllength L-CA cDNA", "DNA", 67, 87], ["The gel", "TREATMENT", 0, 7], ["Zetaprobe (BioFtad", "TREATMENT", 25, 43], ["a fulllength L-CA cDNA", "TREATMENT", 65, 87]]], ["The The filter was exposed overnight. normal size mRNA were found in the parent and L-CAcells ( Figure 36 ).", [["L-CAcells", "ANATOMY", 84, 93], ["L-CAcells", "CELL", 84, 93], ["normal size mRNA", "RNA", 38, 54], ["The The filter", "TREATMENT", 0, 14], ["filter", "OBSERVATION", 8, 14], ["size", "OBSERVATION_MODIFIER", 45, 49], ["mRNA", "OBSERVATION_MODIFIER", 50, 54], ["L", "ANATOMY_MODIFIER", 84, 85]]], ["SDS-PAGE of immunoprecipitated L-CA from parent A.E7 cells, labeled overnight with [%]methionine, revealed two molecular weight species of 180,000 and 180,000 M,.", [["A.E7 cells", "ANATOMY", 48, 58], ["methionine", "CHEMICAL", 86, 96], ["[%]methionine", "CHEMICAL", 83, 96], ["L-CA", "GENE_OR_GENE_PRODUCT", 31, 35], ["parent A.E7 cells", "CELL", 41, 58], ["[%]methionine", "SIMPLE_CHEMICAL", 83, 96], ["immunoprecipitated L-CA", "PROTEIN", 12, 35], ["parent A.E7 cells", "CELL_LINE", 41, 58], ["SDS", "TEST", 0, 3], ["methionine", "TREATMENT", 86, 96], ["two molecular weight species", "TEST", 107, 135]]], ["However, each of the L-CA-mutant clones contained only the 180,000 M, form, albeit in lesser amounts.", [["-CA", "GENE_OR_GENE_PRODUCT", 22, 25], ["L-CA-mutant clones", "CELL_LINE", 21, 39], ["mutant clones", "PROBLEM", 26, 39], ["mutant clones", "OBSERVATION", 26, 39], ["lesser", "OBSERVATION_MODIFIER", 86, 92]]], ["These data indicate that neither the transcription nor the translation of L-CA is impaired, but the defect is in the maturation and surface expression of the glycoprotein.ResultsThy-l, Fgp-1, and CD4 were examined by flow cytometry (Figure 4 ).", [["surface", "ANATOMY", 132, 139], ["L-CA", "GENE_OR_GENE_PRODUCT", 74, 78], ["surface", "CELLULAR_COMPONENT", 132, 139], ["Fgp-1", "GENE_OR_GENE_PRODUCT", 185, 190], ["CD4", "GENE_OR_GENE_PRODUCT", 196, 199], ["L-CA", "PROTEIN", 74, 78], ["glycoprotein", "PROTEIN", 158, 170], ["-l", "PROTEIN", 181, 183], ["Fgp", "PROTEIN", 185, 188], ["CD4", "PROTEIN", 196, 199], ["the defect", "PROBLEM", 96, 106], ["Fgp", "TEST", 185, 188], ["CD4", "TEST", 196, 199], ["flow cytometry", "TEST", 217, 231], ["impaired", "OBSERVATION", 82, 90], ["defect", "OBSERVATION", 100, 106]]], ["Unlike surface L-CA, there was no detectable difference in the expression of these glycoproteins between the A.E7 parent and the L-CA-T cell clones.", [["surface", "ANATOMY", 7, 14], ["L-CA-T cell clones", "ANATOMY", 129, 147], ["surface L-CA", "GENE_OR_GENE_PRODUCT", 7, 19], ["L-CA-T cell clones", "CELL", 129, 147], ["surface L-CA", "PROTEIN", 7, 19], ["glycoproteins", "PROTEIN", 83, 96], ["A.E7 parent", "CELL_LINE", 109, 120], ["L-CA-T cell clones", "CELL_LINE", 129, 147], ["Unlike surface L-CA", "PROBLEM", 0, 19], ["these glycoproteins", "PROBLEM", 77, 96], ["surface", "OBSERVATION_MODIFIER", 7, 14], ["L-CA", "OBSERVATION", 15, 19], ["no", "UNCERTAINTY", 31, 33], ["detectable", "OBSERVATION_MODIFIER", 34, 44], ["difference", "OBSERVATION_MODIFIER", 45, 55], ["T cell clones", "OBSERVATION", 134, 147]]], ["The combined immunoprecipitation and flow cytometry data strongly suggest that the defect in the L-CA-clones is specific to the L-CA glycoprotein.ResultsAnalysis of the Proliferative Capacity of L-CA T Cell Clones To determine whether or not the defect was specific forResultsThe L-CA-clones were visibly different from the parent L-CA, the expression of the cell surface molecules LFA-1, line (data not shown).", [["L-CA-clones", "ANATOMY", 97, 108], ["L-CA-clones", "ANATOMY", 280, 291], ["cell surface", "ANATOMY", 359, 371], ["L-CA", "GENE_OR_GENE_PRODUCT", 97, 101], ["L-CA glycoprotein", "GENE_OR_GENE_PRODUCT", 128, 145], ["L-CA-clones", "CELL", 280, 291], ["L-CA", "GENE_OR_GENE_PRODUCT", 331, 335], ["cell", "CELL", 359, 363], ["LFA-1", "GENE_OR_GENE_PRODUCT", 382, 387], ["L-CA-clones", "DNA", 97, 108], ["L-CA glycoprotein", "PROTEIN", 128, 145], ["L-CA T Cell Clones", "CELL_LINE", 195, 213], ["L-CA-clones", "CELL_LINE", 280, 291], ["CA", "PROTEIN", 333, 335], ["cell surface molecules", "PROTEIN", 359, 381], ["LFA", "PROTEIN", 382, 385], ["The combined immunoprecipitation", "TEST", 0, 32], ["flow cytometry data", "TEST", 37, 56], ["the defect in the L-CA-clones", "PROBLEM", 79, 108], ["the Proliferative Capacity", "TEST", 165, 191], ["L-CA T Cell Clones", "TREATMENT", 195, 213], ["the defect", "PROBLEM", 242, 252], ["The L-CA-clones", "TEST", 276, 291], ["the cell surface molecules LFA", "TEST", 355, 385], ["line (data", "TEST", 389, 399], ["flow cytometry", "OBSERVATION", 37, 51], ["defect", "OBSERVATION", 83, 89], ["Proliferative", "OBSERVATION_MODIFIER", 169, 182], ["defect", "OBSERVATION", 246, 252], ["clones", "OBSERVATION", 285, 291], ["CA", "OBSERVATION", 333, 335]]], ["While a few scattered cells were IL-2 CONCENTRATlON [U/ml] similar in shape to the parent line, most cells were larger and spherical.", [["cells", "ANATOMY", 22, 27], ["cells", "ANATOMY", 101, 106], ["cells", "CELL", 22, 27], ["IL-2", "GENE_OR_GENE_PRODUCT", 33, 37], ["cells", "CELL", 101, 106], ["IL", "PROTEIN", 33, 35], ["a few scattered cells", "PROBLEM", 6, 27], ["IL", "TEST", 33, 35], ["few", "OBSERVATION_MODIFIER", 8, 11], ["scattered", "OBSERVATION_MODIFIER", 12, 21], ["cells", "OBSERVATION", 22, 27], ["parent line", "OBSERVATION", 83, 94], ["larger", "OBSERVATION_MODIFIER", 112, 118], ["spherical", "OBSERVATION_MODIFIER", 123, 132]]], ["In contrast, the parent line contained between 20%~50% cells with amoeboid morphology.", [["cells", "ANATOMY", 55, 60], ["cells", "CELL", 55, 60], ["the parent line", "TREATMENT", 13, 28], ["amoeboid morphology", "OBSERVATION", 66, 85]]], ["The L-CA-clone cultures also contained more cellular debris and a higher frequency of dead cells.", [["L-CA-clone cultures", "ANATOMY", 4, 23], ["cellular debris", "ANATOMY", 44, 59], ["cells", "ANATOMY", 91, 96], ["L-CA-clone cultures", "CELL", 4, 23], ["cellular", "CELL", 44, 52], ["cells", "CELL", 91, 96], ["L-CA-clone cultures", "CELL_LINE", 4, 23], ["dead cells", "CELL_TYPE", 86, 96], ["The L-CA-clone cultures", "TEST", 0, 23], ["cellular debris", "PROBLEM", 44, 59], ["dead cells", "PROBLEM", 86, 96], ["more", "OBSERVATION_MODIFIER", 39, 43], ["cellular debris", "OBSERVATION", 44, 59], ["higher", "OBSERVATION_MODIFIER", 66, 72], ["dead cells", "OBSERVATION", 86, 96]]], ["This is reflected in total cell growth.", [["cell", "ANATOMY", 27, 31], ["cell", "CELL", 27, 31], ["total cell growth", "PROBLEM", 21, 38], ["total cell", "OBSERVATION", 21, 31], ["growth", "OBSERVATION_MODIFIER", 32, 38]]], ["Table 1 displays the number of cells obtained at the end of a series of biweekly passages.", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36]]], ["Consistently, the mutant cell lines gave approximately 4-fold fewer cells.ResultsTo examine the growth parameters between the parent and mutant cells, we compared the proliferative response to antigen and IL-2 ( Figure 5 ).", [["cell lines", "ANATOMY", 25, 35], ["cells", "ANATOMY", 68, 73], ["cells", "ANATOMY", 144, 149], ["cell lines", "CELL", 25, 35], ["cells", "CELL", 68, 73], ["mutant cells", "CELL", 137, 149], ["IL-2", "GENE_OR_GENE_PRODUCT", 205, 209], ["mutant cell lines", "CELL_LINE", 18, 35], ["mutant cells", "CELL_LINE", 137, 149], ["IL", "PROTEIN", 205, 207], ["the mutant cell lines", "PROBLEM", 14, 35], ["the growth parameters", "TEST", 92, 113], ["antigen", "TEST", 193, 200], ["cell lines", "OBSERVATION", 25, 35], ["fewer cells", "OBSERVATION", 62, 73]]], ["As expected, both the parent and the L-CA-clones failed to respond when only the spleen filler cells were present ( Figure 5A ).", [["L-CA-clones", "ANATOMY", 37, 48], ["spleen filler cells", "ANATOMY", 81, 100], ["L-CA-clones", "CELL", 37, 48], ["spleen filler cells", "CELL", 81, 100], ["L-CA-clones", "CELL_LINE", 37, 48], ["spleen filler cells", "CELL_TYPE", 81, 100], ["the L-CA-clones", "PROBLEM", 33, 48], ["spleen", "ANATOMY", 81, 87], ["filler cells", "OBSERVATION", 88, 100]]], ["Remarkably, when the specific antigen pigeon cytochrome c was added to the cultures, all the L-CA-clones failed to respond appropriately (Figure 58 ).", [["cultures", "ANATOMY", 75, 83], ["pigeon", "ORGANISM", 38, 44], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 45, 57], ["pigeon cytochrome c", "PROTEIN", 38, 57], ["L-CA-clones", "CELL_LINE", 93, 104], ["pigeon", "SPECIES", 38, 44], ["pigeon", "SPECIES", 38, 44], ["the specific antigen pigeon cytochrome c", "TREATMENT", 17, 57], ["the cultures", "TEST", 71, 83]]], ["The L-CA-clones failed to respond even to doses as high as 1 mg/ml.", [["L-CA-clones", "ANATOMY", 4, 15], ["L-CA-clones", "CELL", 4, 15], ["L-CA-clones", "CELL_LINE", 4, 15], ["The L-CA", "TEST", 0, 8]]], ["In comparison, both the parent and the L-CA-clones proliferate in response to 11-2, although the response is weaker for the L-CA-clones (Fig- ure 5C).", [["L-CA-clones", "ANATOMY", 39, 50], ["L-CA-clones", "ANATOMY", 124, 135], ["L-CA-clones", "CELL", 39, 50], ["L-CA-clones", "CELL_LINE", 39, 50], ["L-CA-clones", "CELL_LINE", 124, 135], ["the L-CA", "TEST", 120, 128], ["clones proliferate", "OBSERVATION", 44, 62]]], ["In five separate experiments, the response of the L-CA-clones to antigen was on average 9% of the response of the parent, while the response to IL-2 was 77%.", [["L-CA-clones", "ANATOMY", 50, 61], ["L-CA-clones", "CELL", 50, 61], ["IL-2", "GENE_OR_GENE_PRODUCT", 144, 148], ["L-CA-clones", "CELL_LINE", 50, 61], ["IL", "PROTEIN", 144, 146], ["IL", "TEST", 144, 146]]], ["The IL-2 source for the experiments shown in Figure 5 was from phorbol-stimulated EL-4 cells, however, similar results were obtained if recombinant IL-2 was used ( Figure 6B ).", [["EL-4 cells", "ANATOMY", 82, 92], ["phorbol", "CHEMICAL", 63, 70], ["phorbol", "CHEMICAL", 63, 70], ["IL-2", "GENE_OR_GENE_PRODUCT", 4, 8], ["phorbol", "SIMPLE_CHEMICAL", 63, 70], ["EL-4 cells", "CELL", 82, 92], ["IL-2", "GENE_OR_GENE_PRODUCT", 148, 152], ["IL", "PROTEIN", 4, 6], ["phorbol-stimulated EL-4 cells", "CELL_LINE", 63, 92], ["IL", "PROTEIN", 148, 150], ["the experiments", "TEST", 20, 35], ["phorbol", "TEST", 63, 70]]], ["In a dose response assay, the L-CA-clones did respond to 11-2, but the response was not as great as that of the AE7 parent.", [["L-CA-clones", "ANATOMY", 30, 41], ["AE7", "GENE_OR_GENE_PRODUCT", 112, 115], ["L-CA-clones", "CELL_LINE", 30, 41], ["a dose response assay", "TEST", 3, 24], ["the L-CA", "TEST", 26, 34]]], ["Examination of the ~55 chain of the IL-2 receptor by flow cytometry indicated that the mutant not only expressed this component but that the L-CA-clone increased the surface expression to a greater degree than that of the parent after stimulation with antigen and IL-2 (Table 2 ).", [["surface", "ANATOMY", 166, 173], ["IL-2 receptor", "GENE_OR_GENE_PRODUCT", 36, 49], ["L-CA", "GENE_OR_GENE_PRODUCT", 141, 145], ["surface", "CELLULAR_COMPONENT", 166, 173], ["IL-2", "GENE_OR_GENE_PRODUCT", 264, 268], ["IL-2 receptor", "PROTEIN", 36, 49], ["L-CA-clone", "CELL_LINE", 141, 151], ["IL", "PROTEIN", 264, 266], ["Examination", "TEST", 0, 11], ["flow cytometry", "TEST", 53, 67], ["the L-CA-clone", "PROBLEM", 137, 151], ["antigen and IL", "TREATMENT", 252, 266], ["surface", "OBSERVATION_MODIFIER", 166, 173], ["greater degree", "OBSERVATION_MODIFIER", 190, 204]]], ["This indicates that the diminished growth was not due to the lack of the IL-2 receptor in the L-CAclones.", [["IL-2 receptor", "GENE_OR_GENE_PRODUCT", 73, 86], ["L-CAclones", "CANCER", 94, 104], ["IL-2 receptor", "PROTEIN", 73, 86], ["the diminished growth", "PROBLEM", 20, 41], ["the IL", "TREATMENT", 69, 75], ["diminished", "OBSERVATION_MODIFIER", 24, 34], ["growth", "OBSERVATION", 35, 41]]], ["When antigen and IL-2 were added simultans ously to the cultures, the proliferative response of the parent and the mutant clones was always less than when only IL-2 was present ( Figure 5D ).", [["cultures", "ANATOMY", 56, 64], ["clones", "ANATOMY", 122, 128], ["IL-2", "GENE_OR_GENE_PRODUCT", 17, 21], ["clones", "CELL", 122, 128], ["IL-2", "GENE_OR_GENE_PRODUCT", 160, 164], ["IL", "PROTEIN", 17, 19], ["mutant clones", "CELL_LINE", 115, 128], ["IL", "PROTEIN", 160, 162], ["the cultures", "TEST", 52, 64], ["the mutant clones", "PROBLEM", 111, 128]]], ["Since the L-CA-clones fail to respond to antigen, our ability to grow these cells in vitro is presumably a result of the addition of an exoge nous IL-2 source. a Fluorescence was measured by flow cytometry using a Becton-Dickinson FACS 440.", [["L-CA-clones", "ANATOMY", 10, 21], ["cells", "ANATOMY", 76, 81], ["L-CA-clones", "CELL", 10, 21], ["cells", "CELL", 76, 81], ["IL-2", "GENE_OR_GENE_PRODUCT", 147, 151], ["L-CA-clones", "CELL_LINE", 10, 21], ["the L-CA", "TEST", 6, 14], ["antigen", "TEST", 41, 48], ["an exoge nous IL", "TREATMENT", 133, 149], ["a Fluorescence", "TEST", 160, 174], ["flow cytometry", "TEST", 191, 205]]], ["Fluorescent intensity was measured on a four-log scale and was divided into 255 channels. b Cells were stimulated with antigen and IL-2 on day 1.", [["Cells", "ANATOMY", 92, 97], ["Cells", "CELL", 92, 97], ["IL-2", "GENE_OR_GENE_PRODUCT", 131, 135], ["IL", "PROTEIN", 131, 133], ["Fluorescent intensity", "TEST", 0, 21], ["antigen", "TEST", 119, 126], ["intensity", "OBSERVATION_MODIFIER", 12, 21]]], ["For each experiment, IL-2 receptor was measured on the last day prior to stimulation (day 15 and day 13 of the previous stimulation for experiments 1 and 2. respectively) and then either day 6 or day 5 poststimulation.ResultsTo determine whether the L-CA-cells expressed the afi T cell antigen receptor-CD3 complex, the cells were analyzed by flow cytometry using a recently described monoclonal antibody to a framework determinant on the a8 T cell receptor (Figure 7 ) (Kubo et al., 1989) .", [["L-CA-cells", "ANATOMY", 250, 260], ["cells", "ANATOMY", 320, 325], ["a8 T cell", "ANATOMY", 439, 448], ["IL-2 receptor", "GENE_OR_GENE_PRODUCT", 21, 34], ["L-CA-cells", "CELL", 250, 260], ["afi T cell antigen receptor", "GENE_OR_GENE_PRODUCT", 275, 302], ["CD3", "GENE_OR_GENE_PRODUCT", 303, 306], ["cells", "CELL", 320, 325], ["a8 T cell receptor", "GENE_OR_GENE_PRODUCT", 439, 457], ["IL-2 receptor", "PROTEIN", 21, 34], ["L-CA-cells", "CELL_LINE", 250, 260], ["afi T cell antigen receptor", "PROTEIN", 275, 302], ["CD3 complex", "PROTEIN", 303, 314], ["monoclonal antibody", "PROTEIN", 385, 404], ["a8 T cell receptor", "PROTEIN", 439, 457], ["IL-2 receptor", "TREATMENT", 21, 34], ["the previous stimulation", "TREATMENT", 107, 131], ["the L-CA-cells", "TEST", 246, 260], ["flow cytometry", "TEST", 343, 357], ["a recently described monoclonal antibody", "PROBLEM", 364, 404]]], ["There was no detectable difference between the parent and mutant cells, indicating that lack of proliferation to antigen was not due to the failure to express the a8 T cell antigen receptor-CD3 complex.ResultsSince the L-CA-clones expressed CD3, it was of interest to determine whether or not they would proliferate in response to an anti-CD3 antibody.", [["cells", "ANATOMY", 65, 70], ["a8 T cell", "ANATOMY", 163, 172], ["L-CA-clones", "ANATOMY", 219, 230], ["cells", "CELL", 65, 70], ["a8 T cell antigen receptor", "GENE_OR_GENE_PRODUCT", 163, 189], ["CD3", "GENE_OR_GENE_PRODUCT", 190, 193], ["L-CA-clones", "CELL", 219, 230], ["CD3", "GENE_OR_GENE_PRODUCT", 241, 244], ["anti-CD3 antibody", "GENE_OR_GENE_PRODUCT", 334, 351], ["mutant cells", "CELL_LINE", 58, 70], ["a8 T cell antigen receptor", "PROTEIN", 163, 189], ["CD3 complex", "PROTEIN", 190, 201], ["L-CA-clones", "CELL_LINE", 219, 230], ["CD3", "PROTEIN", 241, 244], ["anti-CD3 antibody", "PROTEIN", 334, 351], ["detectable difference between the parent and mutant cells", "PROBLEM", 13, 70], ["proliferation to antigen", "PROBLEM", 96, 120], ["the failure", "PROBLEM", 136, 147], ["the L-CA", "TEST", 215, 223], ["an anti-CD3 antibody", "TREATMENT", 331, 351], ["no", "UNCERTAINTY", 10, 12], ["detectable", "OBSERVATION_MODIFIER", 13, 23], ["difference", "OBSERVATION", 24, 34]]], ["As shown in Figure 8 , while the parent responded to doses as low as 20 nglml, the A&'-M2-2 clone failed to respond to any dose.", [["A&'-M2-2 clone", "CELL_LINE", 83, 97]]], ["We interpret these data to mean that signaling through the antigen receptor-CD3 complexes is impaired in the L-CAclones.Analysis of an L-CA+ RevertantConfirmation that the diminished antigen-induced proliferative response of the L-CA-cells was a result of the failure to express surface L-CA was obtained by the analysis of an L-CA+ revertant.", [["L-CA-cells", "ANATOMY", 229, 239], ["surface", "ANATOMY", 279, 286], ["CD3", "GENE_OR_GENE_PRODUCT", 76, 79], ["L-CAclones", "CANCER", 109, 119], ["antigen", "GENE_OR_GENE_PRODUCT", 183, 190], ["L-CA-cells", "CELL", 229, 239], ["surface L-CA", "GENE_OR_GENE_PRODUCT", 279, 291], ["L-CA", "GENE_OR_GENE_PRODUCT", 327, 331], ["antigen receptor", "PROTEIN", 59, 75], ["CD3 complexes", "PROTEIN", 76, 89], ["L-CA-cells", "CELL_LINE", 229, 239], ["surface L-CA", "PROTEIN", 279, 291], ["L-CA+ revertant", "CELL_LINE", 327, 342], ["these data", "TEST", 13, 23], ["the antigen receptor", "TEST", 55, 75], ["Analysis", "TEST", 120, 128], ["an L-CA", "TEST", 132, 139], ["the diminished antigen", "PROBLEM", 168, 190], ["the L-CA-cells", "PROBLEM", 225, 239], ["the failure", "PROBLEM", 256, 267], ["surface L-CA", "TEST", 279, 291], ["the analysis", "TEST", 308, 320], ["diminished", "OBSERVATION_MODIFIER", 172, 182], ["proliferative", "OBSERVATION_MODIFIER", 199, 212]]], ["In one of the L-CA-clones, AR-M2-11, a spontaneous revertant arose, A.E7-M2-llR, which was detected by the change in morphology and increased cell growth rate.", [["L-CA-clones", "ANATOMY", 14, 25], ["cell", "ANATOMY", 142, 146], ["L-CA-clones", "CELL", 14, 25], ["AR-M2", "GENE_OR_GENE_PRODUCT", 27, 32], ["A.E7-M2-llR", "CELL", 68, 79], ["cell", "CELL", 142, 146], ["L-CA-clones", "CELL_LINE", 14, 25], ["AR", "PROTEIN", 27, 29], ["M2", "PROTEIN", 30, 32], ["A.E7", "PROTEIN", 68, 72], ["M2", "PROTEIN", 73, 75], ["llR", "PROTEIN", 76, 79], ["AR", "TEST", 27, 29], ["M2", "TEST", 30, 32], ["a spontaneous revertant", "PROBLEM", 37, 60], ["A.E7", "TEST", 68, 72], ["the change in morphology", "PROBLEM", 103, 127], ["increased cell growth rate", "PROBLEM", 132, 158], ["llR", "ANATOMY", 76, 79], ["change", "OBSERVATION_MODIFIER", 107, 113], ["morphology", "OBSERVATION_MODIFIER", 117, 127], ["increased cell", "OBSERVATION", 132, 146], ["growth rate", "OBSERVATION", 147, 158]]], ["Cells were isolated and examined by flow cytometry and confirmed to be L-CA+ ( Figure 9A ).", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["L-CA", "PROTEIN", 71, 75], ["flow cytometry", "TEST", 36, 50], ["L-CA", "TEST", 71, 75]]], ["The L-CA+ revertant cells, when analyzed for proliferation, regained their ability to divide in response to antigen and anti-CD3 ( Figures 9B and SC) .", [["cells", "ANATOMY", 20, 25], ["L-CA", "GENE_OR_GENE_PRODUCT", 4, 8], ["cells", "CELL", 20, 25], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 120, 128], ["SC", "CELL", 146, 148], ["L-CA+ revertant cells", "CELL_LINE", 4, 25], ["anti-CD3", "PROTEIN", 120, 128], ["The L-CA+ revertant cells", "TREATMENT", 0, 25], ["proliferation", "PROBLEM", 45, 58], ["antigen", "TEST", 108, 115], ["anti-CD3", "TEST", 120, 128], ["Figures", "TEST", 131, 138], ["L", "ANATOMY_MODIFIER", 4, 5], ["revertant cells", "OBSERVATION", 10, 25]]], ["This, therefore, indicates that the L-CA-mutant, A.E7-M2-11, has a functional T cell receptor-CD3 complex but requires the L-CAglycoprotein for the induction of the proliferative response.", [["T cell", "ANATOMY", 78, 84], ["L-CA", "GENE_OR_GENE_PRODUCT", 36, 40], ["A.E7-M2", "GENE_OR_GENE_PRODUCT", 49, 56], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 78, 93], ["CD3", "GENE_OR_GENE_PRODUCT", 94, 97], ["L-CAglycoprotein", "GENE_OR_GENE_PRODUCT", 123, 139], ["L-CA", "PROTEIN", 36, 40], ["A.E7", "PROTEIN", 49, 53], ["M2", "PROTEIN", 54, 56], ["T cell receptor", "PROTEIN", 78, 93], ["CD3 complex", "PROTEIN", 94, 105], ["L-CAglycoprotein", "PROTEIN", 123, 139], ["the L-CA", "TEST", 32, 40], ["A.E7", "TEST", 49, 53], ["the L-CAglycoprotein", "TREATMENT", 119, 139]]], ["The revertant was identified at the fifteenth passage postcloning and the A.E%MP-11 clone was still entirely L-CAat the twelfth passage ( Figures 1B and 2) .", [["MP-11 clone", "CELL", 78, 89], ["A.E%MP-11 clone", "DNA", 74, 89], ["the A.E%MP", "TEST", 70, 80]]], ["Therefore, since the L-CA+ cells have a selective growth advantage over the L-CA-cells, the appearance of the L-CA+ revertant could not be due to a contamination during cloning.", [["L-CA+ cells", "ANATOMY", 21, 32], ["L-CA-cells", "ANATOMY", 76, 86], ["L-CA", "GENE_OR_GENE_PRODUCT", 21, 25], ["L-CA-cells", "CELL", 76, 86], ["L-CA", "GENE_OR_GENE_PRODUCT", 110, 114], ["L-CA+ cells", "CELL_LINE", 21, 32], ["L-CA-cells", "CELL_LINE", 76, 86], ["L-CA+ revertant", "CELL_LINE", 110, 125], ["the L-CA+ cells", "PROBLEM", 17, 32], ["a contamination", "PROBLEM", 146, 161], ["selective", "OBSERVATION_MODIFIER", 40, 49], ["growth", "OBSERVATION_MODIFIER", 50, 56], ["L", "ANATOMY_MODIFIER", 110, 111], ["contamination", "OBSERVATION", 148, 161]]], ["It should also be noted that since the L-CA+ cells do have a selective growth advantage, it is not surprising that revertants are identified.DiscussionThe L-CA-T cell clones proliferated very poorly in response to antigen and had a diminished proliferative capacity in response to 11.2.", [["L-CA+ cells", "ANATOMY", 39, 50], ["L-CA-T cell clones", "ANATOMY", 155, 173], ["L-CA", "GENE_OR_GENE_PRODUCT", 39, 43], ["L-CA-T cell clones", "CELL", 155, 173], ["L-CA+ cells", "CELL_LINE", 39, 50], ["L-CA-T cell clones", "CELL_LINE", 155, 173], ["the L-CA+ cells", "PROBLEM", 35, 50], ["a selective growth advantage", "PROBLEM", 59, 87], ["The L-CA-T cell clones", "TEST", 151, 173], ["antigen", "TEST", 214, 221], ["a diminished proliferative capacity", "PROBLEM", 230, 265], ["selective", "OBSERVATION_MODIFIER", 61, 70], ["growth", "OBSERVATION_MODIFIER", 71, 77], ["not surprising", "UNCERTAINTY", 95, 109], ["diminished", "OBSERVATION_MODIFIER", 232, 242], ["proliferative capacity", "OBSERVATION", 243, 265]]], ["The data strongly suggest that the failure of the L-CA-clones to respond to signaling was owing to the lack of the L-CA glycoprotein.", [["L-CA-clones", "ANATOMY", 50, 61], ["L-CA", "GENE_OR_GENE_PRODUCT", 50, 54], ["L-CA glycoprotein", "GENE_OR_GENE_PRODUCT", 115, 132], ["L-CA-clones", "CELL_LINE", 50, 61], ["L-CA glycoprotein", "PROTEIN", 115, 132], ["The data", "TEST", 0, 8], ["the failure of the L-CA-clones", "PROBLEM", 31, 61], ["failure", "OBSERVATION", 35, 42]]], ["The L-CA-cells expressed the a3 T cell antigen receptor-CD3 complex, CD4, LFA-1, Thy-l, Pgp-1, and the IL-2 receptor in amounts equivalent to the parent clone.", [["L-CA-cells", "ANATOMY", 4, 14], ["clone", "ANATOMY", 153, 158], ["L-CA-cells", "CELL", 4, 14], ["a3 T cell antigen receptor", "GENE_OR_GENE_PRODUCT", 29, 55], ["CD3", "GENE_OR_GENE_PRODUCT", 56, 59], ["CD4", "GENE_OR_GENE_PRODUCT", 69, 72], ["LFA-1", "GENE_OR_GENE_PRODUCT", 74, 79], ["Thy-l", "GENE_OR_GENE_PRODUCT", 81, 86], ["Pgp-1", "GENE_OR_GENE_PRODUCT", 88, 93], ["IL-2 receptor", "GENE_OR_GENE_PRODUCT", 103, 116], ["clone", "CELL", 153, 158], ["L-CA-cells", "CELL_LINE", 4, 14], ["a3 T cell antigen receptor", "PROTEIN", 29, 55], ["CD3 complex", "PROTEIN", 56, 67], ["CD4", "PROTEIN", 69, 72], ["LFA", "PROTEIN", 74, 77], ["Thy-l", "PROTEIN", 81, 86], ["Pgp", "PROTEIN", 88, 91], ["IL-2 receptor", "PROTEIN", 103, 116], ["parent clone", "CELL_LINE", 146, 158], ["The L-CA-cells", "TEST", 0, 14], ["CD4", "TEST", 69, 72], ["LFA", "TEST", 74, 77], ["Thy-l", "TEST", 81, 86], ["Pgp", "TEST", 88, 91], ["the IL-2 receptor", "TREATMENT", 99, 116], ["a3 T cell", "OBSERVATION", 29, 38]]], ["Furthermore, the only distinguishable difference of total A.E7DiscussionA.E7-M2-2DiscussionA.E7-MZ-11 surface-labeled lysates between the parent and mutant cells was a single high molecular weight protein, which is most likely L-CA.", [["surface", "ANATOMY", 102, 109], ["lysates", "ANATOMY", 118, 125], ["cells", "ANATOMY", 156, 161], ["A.E7DiscussionA.E7-M2-2DiscussionA.E7-MZ-11 surface-labeled", "CHEMICAL", 58, 117], ["lysates", "ORGANISM_SUBSTANCE", 118, 125], ["mutant cells", "CELL", 149, 161], ["A.E7DiscussionA.E7", "PROTEIN", 58, 76], ["M2", "PROTEIN", 77, 79], ["2DiscussionA.E7", "PROTEIN", 80, 95], ["mutant cells", "CELL_TYPE", 149, 161], ["high molecular weight protein", "PROTEIN", 175, 204], ["L-CA", "PROTEIN", 227, 231], ["total A.E7DiscussionA.E7", "TEST", 52, 76], ["MZ", "TEST", 96, 98], ["mutant cells", "PROBLEM", 149, 161], ["a single high molecular weight protein", "PROBLEM", 166, 204], ["most likely", "UNCERTAINTY", 215, 226], ["-CA", "OBSERVATION", 228, 231]]], ["This indicates that the defect in the L-CA-cells was specific for the L-CA glycoprotein.", [["L-CA-cells", "ANATOMY", 38, 48], ["L-CA-cells", "CELL", 38, 48], ["L-CA glycoprotein", "GENE_OR_GENE_PRODUCT", 70, 87], ["L-CA-cells", "CELL_LINE", 38, 48], ["L-CA glycoprotein", "PROTEIN", 70, 87], ["the defect in the L-CA-cells", "PROBLEM", 20, 48], ["the L-CA glycoprotein", "PROBLEM", 66, 87], ["defect", "OBSERVATION", 24, 30]]], ["Further evidence that the proliferative defect in the mutant cells was due to the failure to express properly the L-CA glycoprotein was obtained by the analysis of a L-CA+ revertant.", [["cells", "ANATOMY", 61, 66], ["mutant cells", "CELL", 54, 66], ["L-CA glycoprotein", "GENE_OR_GENE_PRODUCT", 114, 131], ["L-CA", "GENE_OR_GENE_PRODUCT", 166, 170], ["mutant cells", "CELL_LINE", 54, 66], ["L-CA glycoprotein", "PROTEIN", 114, 131], ["L-CA+ revertant", "CELL_LINE", 166, 181], ["the proliferative defect in the mutant cells", "PROBLEM", 22, 66], ["the failure", "PROBLEM", 78, 89], ["the analysis", "TEST", 148, 160], ["proliferative", "OBSERVATION_MODIFIER", 26, 39], ["defect", "OBSERVATION", 40, 46], ["mutant cells", "OBSERVATION", 54, 66]]], ["These cells proliferated in response to antigen, cross-linked CD3, and IL-2 in a manner similar to the parent clone.", [["cells", "ANATOMY", 6, 11], ["clone", "ANATOMY", 110, 115], ["cells", "CELL", 6, 11], ["CD3", "GENE_OR_GENE_PRODUCT", 62, 65], ["IL-2", "GENE_OR_GENE_PRODUCT", 71, 75], ["clone", "CELL", 110, 115], ["CD3", "PROTEIN", 62, 65], ["IL", "PROTEIN", 71, 73], ["parent clone", "CELL_LINE", 103, 115], ["These cells", "PROBLEM", 0, 11], ["antigen", "TEST", 40, 47], ["IL", "TEST", 71, 73]]], ["It is highly unlikely that a double revertant would be obtained simultaneously for two separate mutations and therefore, the most straightforward interpretation is that the increase in proliferation is due to the reexpression of surface L-CA glycoprotein.", [["surface", "ANATOMY", 229, 236], ["surface L-CA glycoprotein", "GENE_OR_GENE_PRODUCT", 229, 254], ["surface L-CA glycoprotein", "PROTEIN", 229, 254], ["a double revertant", "TREATMENT", 27, 45], ["the increase in proliferation", "PROBLEM", 169, 198], ["the reexpression of surface L-CA glycoprotein", "PROBLEM", 209, 254], ["highly unlikely", "UNCERTAINTY", 6, 21], ["increase", "OBSERVATION_MODIFIER", 173, 181], ["proliferation", "OBSERVATION", 185, 198]]], ["The expression of the T cell receptor-CD3 complex and CD4 indicates that the recognition of antigen should not have been impaired in L-CAcells.", [["T cell", "ANATOMY", 22, 28], ["L-CAcells", "ANATOMY", 133, 142], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 22, 37], ["CD3", "GENE_OR_GENE_PRODUCT", 38, 41], ["CD4", "GENE_OR_GENE_PRODUCT", 54, 57], ["L-CAcells", "CELL", 133, 142], ["T cell receptor", "PROTEIN", 22, 37], ["CD3 complex", "PROTEIN", 38, 49], ["CD4", "PROTEIN", 54, 57], ["L-CAcells", "CELL_TYPE", 133, 142], ["the T cell receptor", "TEST", 18, 37], ["impaired in L-CAcells", "PROBLEM", 121, 142]]], ["It is significant that the L-CA-cells express LFA-1, Pgp-1, and Thy-l as well.", [["L-CA-cells", "ANATOMY", 27, 37], ["LFA-1", "GENE_OR_GENE_PRODUCT", 46, 51], ["Pgp-1", "GENE_OR_GENE_PRODUCT", 53, 58], ["Thy-l", "GENE_OR_GENE_PRODUCT", 64, 69], ["L-CA-cells", "CELL_LINE", 27, 37], ["LFA", "PROTEIN", 46, 49], ["Pgp", "PROTEIN", 53, 56], ["Thy-l", "PROTEIN", 64, 69], ["the L-CA", "TEST", 23, 31], ["LFA", "TEST", 46, 49], ["Pgp", "TEST", 53, 56], ["significant", "OBSERVATION_MODIFIER", 6, 17], ["LFA", "ANATOMY", 46, 49], ["-l", "ANATOMY_MODIFIER", 67, 69]]], ["LFA-1 and Pgp-1 are thought to be involved in cell adhesion advents (Springer et al., 1987; Goldstein et al., 1989; Stamenkovic et al., 1989) .", [["cell", "ANATOMY", 46, 50], ["LFA-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["Pgp-1", "GENE_OR_GENE_PRODUCT", 10, 15], ["cell", "CELL", 46, 50], ["LFA", "PROTEIN", 0, 3], ["Pgp-1", "PROTEIN", 10, 15], ["LFA", "TEST", 0, 3], ["thought to be", "UNCERTAINTY", 20, 33], ["cell adhesion", "OBSERVATION", 46, 59]]], ["Antibod- Dashes indicate identical residues; the kinases are compared with c-src and the phosphatases with human L-CA.", [["c-src", "GENE_OR_GENE_PRODUCT", 75, 80], ["human", "ORGANISM", 107, 112], ["L-CA", "ORGANISM", 113, 117], ["Antibod", "PROTEIN", 0, 7], ["kinases", "PROTEIN", 49, 56], ["c", "PROTEIN", 75, 76], ["src", "PROTEIN", 77, 80], ["phosphatases", "PROTEIN", 89, 101], ["human L-CA", "PROTEIN", 107, 117], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["Antibod", "TEST", 0, 7], ["identical residues", "PROBLEM", 25, 43], ["the kinases", "TEST", 45, 56], ["c-src", "TEST", 75, 80], ["the phosphatases", "TEST", 85, 101], ["human L-CA", "TREATMENT", 107, 117], ["identical residues", "OBSERVATION", 25, 43]]], ["The asterisk denotes the tyrosine phosphorylation site in C-SIC and /c/r.", [["tyrosine", "CHEMICAL", 25, 33], ["tyrosine", "CHEMICAL", 25, 33], ["tyrosine", "AMINO_ACID", 25, 33], ["C-SIC", "GENE_OR_GENE_PRODUCT", 58, 63], ["tyrosine phosphorylation site", "PROTEIN", 25, 54], ["SIC", "PROTEIN", 60, 63], ["the tyrosine phosphorylation site", "TREATMENT", 21, 54], ["tyrosine phosphorylation", "OBSERVATION", 25, 49]]], ["The sequences are: c-src (Hunter, 1987) ; /c/r (Marth et al., 1988) ; c-fgr (Katamine et al., 1988) ; c-yes (Sukegawa et al., 1987) ; human, mouse, and rat L-CA (Thomas, 1989) ; and human LAR (Streuli et al., 1988) .", [["c-src", "GENE_OR_GENE_PRODUCT", 19, 24], ["human", "ORGANISM", 134, 139], ["mouse", "ORGANISM", 141, 146], ["rat", "ORGANISM", 152, 155], ["L-CA", "CELL", 156, 160], ["human", "ORGANISM", 182, 187], ["LAR", "GENE_OR_GENE_PRODUCT", 188, 191], ["src", "PROTEIN", 21, 24], ["human", "SPECIES", 134, 139], ["mouse", "SPECIES", 141, 146], ["rat", "SPECIES", 152, 155], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 134, 139], ["mouse", "SPECIES", 141, 146], ["human", "SPECIES", 182, 187]]], ["The single letter amino acid code is used.Discussionies to Thy-l have been shown to cause mouse T cells to proliferate, and proliferation requires the coexpression of the T cell receptor-CD3 complex (Gunter et al., 1987) .", [["T cells", "ANATOMY", 96, 103], ["T cell", "ANATOMY", 171, 177], ["amino acid", "CHEMICAL", 18, 28], ["amino acid", "CHEMICAL", 18, 28], ["amino acid", "AMINO_ACID", 18, 28], ["mouse", "ORGANISM", 90, 95], ["T cells", "CELL", 96, 103], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 171, 186], ["CD3", "GENE_OR_GENE_PRODUCT", 187, 190], ["Thy-l", "PROTEIN", 59, 64], ["mouse T cells", "CELL_TYPE", 90, 103], ["T cell receptor", "PROTEIN", 171, 186], ["CD3 complex", "PROTEIN", 187, 198], ["mouse", "SPECIES", 90, 95], ["mouse", "SPECIES", 90, 95], ["The single letter amino acid code", "TREATMENT", 0, 33], ["mouse T cells", "PROBLEM", 90, 103]]], ["Therefore, the normal expression of many of the glycoproteins known to be involved in recognition, adherence, and signal transduction further indicates that the lack of L-CA surface expression is the cause of the proliferative defect.", [["surface", "ANATOMY", 174, 181], ["L-CA", "GENE_OR_GENE_PRODUCT", 169, 173], ["glycoproteins", "PROTEIN", 48, 61], ["L-CA", "PROTEIN", 169, 173], ["the glycoproteins", "PROBLEM", 44, 61], ["L-CA surface expression", "PROBLEM", 169, 192], ["the proliferative defect", "PROBLEM", 209, 233], ["normal", "OBSERVATION", 15, 21], ["proliferative defect", "OBSERVATION", 213, 233]]], ["The L-CA mutant clones synthesize a protein recognized by the 13/2.3 antibody, however, the protein is not transported to the cell surface (Figures 2 and 3) .", [["cell surface", "ANATOMY", 126, 138], ["L-CA mutant clones", "CELL", 4, 22], ["cell surface", "CELLULAR_COMPONENT", 126, 138], ["L-CA mutant clones", "CELL_LINE", 4, 22], ["13/2.3 antibody", "PROTEIN", 62, 77], ["a protein", "TEST", 34, 43], ["the protein", "TEST", 88, 99], ["Figures", "TEST", 140, 147]]], ["This suggests that the mutation causes a specific retention of L-CA at some stage of transport and may be similar to mutations described for influenza hemagglutinin protein, the El viral coat protein of coronavirus, and the low density lipoprotein receptor (Gething et al., 1988; Machamer and Rose, 1987; Pathak et al., 1988) .", [["L-CA", "GENE_OR_GENE_PRODUCT", 63, 67], ["influenza hemagglutinin protein", "GENE_OR_GENE_PRODUCT", 141, 172], ["coronavirus", "ORGANISM", 203, 214], ["low density lipoprotein receptor", "GENE_OR_GENE_PRODUCT", 224, 256], ["L-CA", "PROTEIN", 63, 67], ["influenza hemagglutinin protein", "PROTEIN", 141, 172], ["El viral coat protein", "PROTEIN", 178, 199], ["low density lipoprotein receptor", "PROTEIN", 224, 256], ["the mutation", "PROBLEM", 19, 31], ["a specific retention of L-CA", "PROBLEM", 39, 67], ["mutations", "PROBLEM", 117, 126], ["influenza hemagglutinin protein", "PROBLEM", 141, 172], ["the El viral coat protein", "TEST", 174, 199], ["coronavirus", "PROBLEM", 203, 214], ["retention", "OBSERVATION_MODIFIER", 50, 59], ["low density", "OBSERVATION_MODIFIER", 224, 235]]], ["Structural mutations have been described for these proteins that cause a specific retention in the biosynthetic pathway.", [["Structural mutations", "PROBLEM", 0, 20], ["these proteins", "PROBLEM", 45, 59], ["a specific retention", "PROBLEM", 71, 91]]], ["Since it is still formally possible that the mutation in the L-CA-cells effects L-CA and some other unknown component of the T cell receptor-CD3 complex, we are currently conducting experiments to transfect the complete L-CA cDNA into the L-CA-cells to determine whether or not this will also correct the proliferative defect.", [["L-CA-cells", "ANATOMY", 61, 71], ["T cell", "ANATOMY", 125, 131], ["L-CA-cells", "ANATOMY", 239, 249], ["L-CA-cells", "CELL", 61, 71], ["L-CA", "GENE_OR_GENE_PRODUCT", 80, 84], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 125, 140], ["CD3", "GENE_OR_GENE_PRODUCT", 141, 144], ["L-CA-cells", "CELL", 239, 249], ["L-CA-cells", "CELL_LINE", 61, 71], ["L-CA", "PROTEIN", 80, 84], ["T cell receptor", "PROTEIN", 125, 140], ["CD3 complex", "PROTEIN", 141, 152], ["L-CA cDNA", "DNA", 220, 229], ["L-CA-cells", "CELL_LINE", 239, 249], ["the mutation", "PROBLEM", 41, 53], ["L-CA", "PROBLEM", 80, 84], ["the proliferative defect", "PROBLEM", 301, 325], ["still formally possible", "UNCERTAINTY", 12, 35], ["proliferative defect", "OBSERVATION", 305, 325]]], ["If expression of L-CA by transfection does not correct the proliferative defect, then this would indicate that some other component of the T cell receptor complex is also effected in these cells.", [["T cell", "ANATOMY", 139, 145], ["cells", "ANATOMY", 189, 194], ["L-CA", "GENE_OR_GENE_PRODUCT", 17, 21], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 139, 154], ["cells", "CELL", 189, 194], ["L-CA", "PROTEIN", 17, 21], ["T cell receptor complex", "PROTEIN", 139, 162], ["the proliferative defect", "PROBLEM", 55, 79], ["the T cell receptor complex", "PROBLEM", 135, 162], ["proliferative defect", "OBSERVATION", 59, 79], ["T cell", "OBSERVATION", 139, 145]]], ["However, the most likely explanation for the proliferative defect described here is the failure to properly express the L-CA glycoprotein.DiscussionLymphocyte Division and vroslne Phosphorylatlon These data yield two observations that first appear to be surprising.", [["vroslne Phosphorylatlon", "CHEMICAL", 172, 195], ["vroslne Phosphorylatlon", "CHEMICAL", 172, 195], ["L-CA glycoprotein", "GENE_OR_GENE_PRODUCT", 120, 137], ["vroslne Phosphorylatlon", "SIMPLE_CHEMICAL", 172, 195], ["L-CA glycoprotein", "PROTEIN", 120, 137], ["the proliferative defect", "PROBLEM", 41, 65], ["the failure", "PROBLEM", 84, 95], ["the L-CA glycoprotein", "PROBLEM", 116, 137], ["DiscussionLymphocyte Division", "TREATMENT", 138, 167], ["vroslne Phosphorylatlon", "TREATMENT", 172, 195], ["most likely explanation for", "UNCERTAINTY", 13, 40], ["proliferative", "OBSERVATION_MODIFIER", 45, 58], ["defect", "OBSERVATION", 59, 65]]], ["L-CA is expressed by all leukocytes, so it was not anticipated that a negative L-CA phenotype would dramatically effect specific antigen signaling through the T cell receptor-CD3 complex.", [["leukocytes", "ANATOMY", 25, 35], ["T cell", "ANATOMY", 159, 165], ["L-CA", "GENE_OR_GENE_PRODUCT", 0, 4], ["leukocytes", "CELL", 25, 35], ["antigen", "GENE_OR_GENE_PRODUCT", 129, 136], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 159, 174], ["CD3", "GENE_OR_GENE_PRODUCT", 175, 178], ["L-CA", "PROTEIN", 0, 4], ["leukocytes", "CELL_TYPE", 25, 35], ["T cell receptor", "PROTEIN", 159, 174], ["CD3 complex", "PROTEIN", 175, 186], ["a negative L-CA phenotype", "PROBLEM", 68, 93], ["CA", "OBSERVATION", 2, 4], ["all", "OBSERVATION_MODIFIER", 21, 24], ["leukocytes", "OBSERVATION", 25, 35]]], ["However, this is reasonable if one assumes that T cells have evolved from primitive cell types that at one time were not antigen-specific.", [["T cells", "ANATOMY", 48, 55], ["cell", "ANATOMY", 84, 88], ["T cells", "CELL", 48, 55], ["primitive cell", "CELL", 74, 88], ["T cells", "CELL_TYPE", 48, 55], ["primitive cell types", "CELL_TYPE", 74, 94], ["T cells", "PROBLEM", 48, 55], ["primitive cell types", "PROBLEM", 74, 94], ["primitive cell types", "OBSERVATION", 74, 94]]], ["It is possible that T cells have adapted antigen-specific triggering for cell division utilizing molecules that are generally used in leukocyte cell division.", [["T cells", "ANATOMY", 20, 27], ["cell", "ANATOMY", 73, 77], ["leukocyte cell", "ANATOMY", 134, 148], ["T cells", "CELL", 20, 27], ["cell", "CELL", 73, 77], ["leukocyte cell", "CELL", 134, 148], ["T cells", "CELL_TYPE", 20, 27], ["T cells", "PROBLEM", 20, 27], ["cell division utilizing molecules", "TREATMENT", 73, 106], ["leukocyte cell", "OBSERVATION", 134, 148]]], ["This is supported by the observation that the L-CA tyrosine phosphatase domain is highly conserved throughout invertebrate and vertebrate evolution, indicating that this domain is extremely important in some aspect of cell physiology, such as cell cycling (R. J. Matthews and M. L. Thomas, unpublished data) .DiscussionThe lack of L-CA on the cell surface resulted in the failure of the cells to divide in response to antigen.", [["cell", "ANATOMY", 218, 222], ["cell", "ANATOMY", 243, 247], ["cell surface", "ANATOMY", 343, 355], ["cells", "ANATOMY", 387, 392], ["tyrosine", "CHEMICAL", 51, 59], ["tyrosine", "CHEMICAL", 51, 59], ["cell", "CELL", 218, 222], ["cell", "CELL", 243, 247], ["L-CA", "SIMPLE_CHEMICAL", 331, 335], ["cell surface", "CELLULAR_COMPONENT", 343, 355], ["cells", "CELL", 387, 392], ["L-CA tyrosine phosphatase domain", "PROTEIN", 46, 78], ["L-CA", "PROTEIN", 331, 335], ["the L-CA tyrosine phosphatase domain", "TEST", 42, 78], ["cell physiology", "PROBLEM", 218, 233], ["the cell surface", "TREATMENT", 339, 355], ["the failure of the cells", "PROBLEM", 368, 392], ["cell physiology", "OBSERVATION", 218, 233], ["failure", "OBSERVATION", 372, 379]]], ["Since this, presumably, is due to the failure of the proper signals being transduced to the tyrosine phosphatase domain, it is logical to conclude that antigen-induced cell proliferation requires the dephosphorylation of a tyrosine residue.", [["cell", "ANATOMY", 168, 172], ["tyrosine", "CHEMICAL", 92, 100], ["tyrosine", "CHEMICAL", 223, 231], ["tyrosine", "CHEMICAL", 92, 100], ["tyrosine", "CHEMICAL", 223, 231], ["antigen", "GENE_OR_GENE_PRODUCT", 152, 159], ["cell", "CELL", 168, 172], ["tyrosine", "AMINO_ACID", 223, 231], ["tyrosine phosphatase domain", "PROTEIN", 92, 119], ["the failure", "PROBLEM", 34, 45], ["the tyrosine phosphatase domain", "TEST", 88, 119], ["antigen-induced cell proliferation", "PROBLEM", 152, 186], ["a tyrosine residue", "PROBLEM", 221, 239], ["failure", "OBSERVATION", 38, 45], ["cell proliferation", "OBSERVATION", 168, 186], ["tyrosine residue", "OBSERVATION", 223, 239]]], ["Many growth factor receptors have a tyrosine kinase domain.", [["tyrosine", "CHEMICAL", 36, 44], ["tyrosine", "CHEMICAL", 36, 44], ["growth factor receptors", "PROTEIN", 5, 28], ["tyrosine kinase domain", "PROTEIN", 36, 58], ["Many growth factor receptors", "PROBLEM", 0, 28], ["a tyrosine kinase domain", "TREATMENT", 34, 58], ["tyrosine kinase", "OBSERVATION", 36, 51]]], ["It is thought, therefore, that tyrosine phosphorylation is also required for the induction into cell cycle.", [["cell", "ANATOMY", 96, 100], ["tyrosine", "CHEMICAL", 31, 39], ["tyrosine", "CHEMICAL", 31, 39], ["tyrosine", "AMINO_ACID", 31, 39], ["cell", "CELL", 96, 100], ["tyrosine phosphorylation", "TREATMENT", 31, 55], ["the induction into cell cycle", "TREATMENT", 77, 106]]], ["These two observations may at first appear to be incongruous.", [["incongruous", "OBSERVATION", 49, 60]]], ["However, the src gene family of tyrosine kinases is regulated by the phosphorylation of a tyrosine residue near the carboxyl terminus (Hunter, 1987) .", [["tyrosine", "CHEMICAL", 32, 40], ["tyrosine", "CHEMICAL", 90, 98], ["tyrosine", "CHEMICAL", 32, 40], ["tyrosine", "CHEMICAL", 90, 98], ["carboxyl", "CHEMICAL", 116, 124], ["src", "GENE_OR_GENE_PRODUCT", 13, 16], ["tyrosine", "AMINO_ACID", 32, 40], ["tyrosine", "AMINO_ACID", 90, 98], ["src gene family", "PROTEIN", 13, 28], ["tyrosine kinases", "PROTEIN", 32, 48], ["carboxyl terminus", "PROTEIN", 116, 133], ["tyrosine kinases", "TREATMENT", 32, 48], ["a tyrosine residue", "PROBLEM", 88, 106]]], ["Dephosphorylation at this site causes an increase in tyrosine kinase activity (Cooper and King, 1988; Cartwright et al., 1987; Amrein and Sefton, 1988; Marth et al., 1988) .", [["tyrosine", "CHEMICAL", 53, 61], ["tyrosine", "CHEMICAL", 53, 61], ["tyrosine", "AMINO_ACID", 53, 61], ["tyrosine kinase", "PROTEIN", 53, 68], ["Dephosphorylation at this site", "PROBLEM", 0, 30], ["an increase in tyrosine kinase activity", "PROBLEM", 38, 77], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["tyrosine kinase", "OBSERVATION", 53, 68]]], ["It is possible, therefore, that L-CA functions by regulating tyrosine kinase activity.", [["tyrosine", "CHEMICAL", 61, 69], ["tyrosine", "CHEMICAL", 61, 69], ["L-CA", "GENE_OR_GENE_PRODUCT", 32, 36], ["tyrosine", "AMINO_ACID", 61, 69], ["L-CA", "PROTEIN", 32, 36], ["tyrosine kinase", "PROTEIN", 61, 76], ["tyrosine kinase activity", "TREATMENT", 61, 85]]], ["Dephosphorylation of unknown kinase would cause an increase in the tyrosine kinase activity, thus initializing a cascade of events that results in cell cycling.", [["cell", "ANATOMY", 147, 151], ["tyrosine", "CHEMICAL", 67, 75], ["tyrosine", "CHEMICAL", 67, 75], ["tyrosine", "AMINO_ACID", 67, 75], ["cell", "CELL", 147, 151], ["tyrosine kinase", "PROTEIN", 67, 82], ["Dephosphorylation of unknown kinase", "PROBLEM", 0, 35], ["an increase in the tyrosine kinase activity", "PROBLEM", 48, 91], ["cell cycling", "PROBLEM", 147, 159], ["increase", "OBSERVATION_MODIFIER", 51, 59], ["tyrosine kinase activity", "OBSERVATION", 67, 91]]], ["It is interesting, therefore, that Ostergaard et al. (1989) have indicated that Ick, a member of the src gene family, is a substrate for L-CA.", [["Ick", "GENE_OR_GENE_PRODUCT", 80, 83], ["src", "GENE_OR_GENE_PRODUCT", 101, 104], ["L-CA", "GENE_OR_GENE_PRODUCT", 137, 141], ["Ick", "PROTEIN", 80, 83], ["src gene family", "DNA", 101, 116], ["L-CA", "PROTEIN", 137, 141]]], ["They have observed that position 505 in Ick, the regulatory tyrosine site, is not phosphorylated in L-CA+ lymphomas but is phosphorylated in L-CA-lymphoma mutants.", [["L-CA+ lymphomas", "ANATOMY", 100, 115], ["L-CA-lymphoma", "ANATOMY", 141, 154], ["tyrosine", "CHEMICAL", 60, 68], ["lymphomas", "DISEASE", 106, 115], ["lymphoma", "DISEASE", 146, 154], ["tyrosine", "CHEMICAL", 60, 68], ["Ick", "GENE_OR_GENE_PRODUCT", 40, 43], ["tyrosine", "AMINO_ACID", 60, 68], ["L-CA", "GENE_OR_GENE_PRODUCT", 100, 104], ["L-CA-lymphoma", "CANCER", 141, 154], ["Ick", "DNA", 40, 43], ["regulatory tyrosine site", "DNA", 49, 73], ["CA", "PROTEIN", 102, 104], ["L-CA", "PROTEIN", 141, 145], ["lymphomas", "PROBLEM", 106, 115], ["phosphorylated", "PROBLEM", 123, 137], ["lymphoma mutants", "PROBLEM", 146, 162], ["lymphomas", "OBSERVATION", 106, 115], ["lymphoma mutants", "OBSERVATION", 146, 162]]], ["The Ick tyrosine kinase has been identified in complexes with CD4 and CD8 and is a candidate for signaling through the T cell antigen receptor (Rudd et al., 1988; Veillette et al., 1988) .", [["T cell", "ANATOMY", 119, 125], ["tyrosine", "CHEMICAL", 8, 16], ["tyrosine", "CHEMICAL", 8, 16], ["Ick tyrosine kinase", "GENE_OR_GENE_PRODUCT", 4, 23], ["CD4", "GENE_OR_GENE_PRODUCT", 62, 65], ["CD8", "GENE_OR_GENE_PRODUCT", 70, 73], ["T cell antigen receptor", "GENE_OR_GENE_PRODUCT", 119, 142], ["Ick tyrosine kinase", "PROTEIN", 4, 23], ["CD4", "PROTEIN", 62, 65], ["CD8", "PROTEIN", 70, 73], ["T cell antigen receptor", "PROTEIN", 119, 142], ["The Ick tyrosine kinase", "TREATMENT", 0, 23], ["CD4", "TEST", 62, 65]]], ["It is possible that a failure to activate Ick by dephosphorylation accounts for the results obtained here.", [["Ick", "GENE_OR_GENE_PRODUCT", 42, 45], ["Ick", "PROTEIN", 42, 45], ["a failure", "PROBLEM", 20, 29], ["failure", "OBSERVATION", 22, 29]]], ["The sequence around position 505 in Ick is highly conserved in all members of the src gene family ( Figure 10 ).", [["Ick", "GENE_OR_GENE_PRODUCT", 36, 39], ["src", "GENE_OR_GENE_PRODUCT", 82, 85], ["Ick", "DNA", 36, 39], ["src gene family", "DNA", 82, 97]]], ["It is interesting to note, therefore, that a similar sequence is to be found near the carboxyl terminus of the second L-CA subdomain ( Figure 10 ).L-CA ActivationSince the interactions for the external domain of L-CA may be important in activating the tyrosine phosphatase domains, a question arises regarding the ligand for the external domain.", [["tyrosine", "CHEMICAL", 252, 260], ["carboxyl", "CHEMICAL", 86, 94], ["tyrosine", "CHEMICAL", 252, 260], ["L-CA", "SIMPLE_CHEMICAL", 147, 151], ["L-CA", "GENE_OR_GENE_PRODUCT", 212, 216], ["carboxyl terminus", "PROTEIN", 86, 103], ["L-CA subdomain", "PROTEIN", 118, 132], ["L-CA", "PROTEIN", 147, 151], ["external domain", "PROTEIN", 193, 208], ["L-CA", "PROTEIN", 212, 216], ["tyrosine phosphatase domains", "PROTEIN", 252, 280], ["external domain", "PROTEIN", 329, 344], ["the external domain of L-CA", "TREATMENT", 189, 216], ["the tyrosine phosphatase domains", "TEST", 248, 280], ["carboxyl", "ANATOMY_MODIFIER", 86, 94]]], ["Evidence exists that the carbohydrate structures are an important functional moiety of the L-CA glycoprotein (reviewed in Thomas, 1989) .", [["carbohydrate", "CHEMICAL", 25, 37], ["L-CA glycoprotein", "GENE_OR_GENE_PRODUCT", 91, 108], ["L-CA glycoprotein", "PROTEIN", 91, 108], ["the carbohydrate structures", "PROBLEM", 21, 48]]], ["Briefly stated, the external domain of L-CA is heavily glycosylated, bearing many N-linked and O-linked carbohydrates, and is a major surface glycoprotein on lymphocytes, comprising approximately 10% of the cell surface.", [["surface", "ANATOMY", 134, 141], ["lymphocytes", "ANATOMY", 158, 169], ["cell surface", "ANATOMY", 207, 219], ["N", "CHEMICAL", 82, 83], ["O", "CHEMICAL", 95, 96], ["carbohydrates", "CHEMICAL", 104, 117], ["L-CA", "SIMPLE_CHEMICAL", 39, 43], ["O-linked carbohydrates", "SIMPLE_CHEMICAL", 95, 117], ["lymphocytes", "CELL", 158, 169], ["cell surface", "CELLULAR_COMPONENT", 207, 219], ["external domain", "PROTEIN", 20, 35], ["L-CA", "PROTEIN", 39, 43], ["N-linked and O-linked carbohydrates", "PROTEIN", 82, 117], ["major surface glycoprotein", "PROTEIN", 128, 154], ["lymphocytes", "CELL_TYPE", 158, 169], ["heavily glycosylated", "PROBLEM", 47, 67], ["heavily", "OBSERVATION_MODIFIER", 47, 54], ["glycosylated", "OBSERVATION", 55, 67], ["major", "OBSERVATION_MODIFIER", 128, 133], ["surface", "OBSERVATION_MODIFIER", 134, 141], ["glycoprotein", "OBSERVATION", 142, 154], ["lymphocytes", "OBSERVATION", 158, 169], ["cell surface", "OBSERVATION", 207, 219]]], ["Therefore, L-CA bears many of the carbohydrates of these cells.", [["cells", "ANATOMY", 57, 62], ["carbohydrates", "CHEMICAL", 34, 47], ["L-CA", "SIMPLE_CHEMICAL", 11, 15], ["cells", "CELL", 57, 62], ["L-CA", "PROTEIN", 11, 15]]], ["Furthermore, there are differences in L-CA carbohydrate structures between lymphocyte lineages, and these structures can change upon activation (Brown and Williams, 1982; Cook et al., 1987) .", [["lymphocyte", "ANATOMY", 75, 85], ["carbohydrate", "CHEMICAL", 43, 55], ["lymphocyte", "CELL", 75, 85], ["lymphocyte lineages", "CELL_TYPE", 75, 94], ["differences in L-CA carbohydrate structures between lymphocyte lineages", "PROBLEM", 23, 94], ["L", "ANATOMY_MODIFIER", 38, 39], ["lymphocyte lineages", "OBSERVATION", 75, 94]]], ["More compelling though, is the observation that the difference between family members is due to differential splicing of three exons that encode O-linked carbohydrate sites.", [["O", "CHEMICAL", 145, 146], ["carbohydrate", "CHEMICAL", 154, 166], ["exons", "DNA", 127, 132], ["O-linked carbohydrate sites", "DNA", 145, 172]]], ["Since the expression of these carbohydrate sites is controlled in a precise developmental and activational manner, this strongly suggests that the carbohydrates are of functional importance.", [["carbohydrate", "CHEMICAL", 30, 42], ["carbohydrates", "CHEMICAL", 147, 160], ["carbohydrate sites", "PROTEIN", 30, 48], ["these carbohydrate sites", "PROBLEM", 24, 48], ["carbohydrate sites", "OBSERVATION", 30, 48]]], ["It has also been shown that the carbohydrate groups from L-CA will block NK cell binding to targets (Gilbert et al., 1988) .", [["NK cell", "ANATOMY", 73, 80], ["carbohydrate", "CHEMICAL", 32, 44], ["L-CA", "SIMPLE_CHEMICAL", 57, 61], ["NK cell", "CELL", 73, 80], ["NK cell", "OBSERVATION", 73, 80]]], ["The carbohydrate residues on L-CA may interact with lectins on cell surfaces, and this cell-cell interaction is necessary for induction into cell cycling.", [["cell surfaces", "ANATOMY", 63, 76], ["cell", "ANATOMY", 87, 91], ["cell", "ANATOMY", 92, 96], ["cell", "ANATOMY", 141, 145], ["carbohydrate", "CHEMICAL", 4, 16], ["L-CA", "SIMPLE_CHEMICAL", 29, 33], ["lectins", "GENE_OR_GENE_PRODUCT", 52, 59], ["cell surfaces", "CELLULAR_COMPONENT", 63, 76], ["cell", "CELL", 87, 91], ["cell", "CELL", 92, 96], ["cell", "CELL", 141, 145], ["L-CA", "PROTEIN", 29, 33], ["lectins", "PROTEIN", 52, 59], ["The carbohydrate residues on L-CA", "TREATMENT", 0, 33], ["lectins on cell surfaces", "TREATMENT", 52, 76], ["carbohydrate residues", "OBSERVATION", 4, 25]]], ["While the data strongly suggest that carbohydrate groups on L-CA are functionally important, this does not eliminate the possibility that L-CA could be activated by other interactions (for example, interactions with a soluble ligand or movement in the cell membrane).MutagenesisThe A.E7 is a Tkl CD4+ clone, I-EK restricted, and specific for pigeon cytochrome c.", [["cell membrane", "ANATOMY", 252, 265], ["Tkl CD4+ clone", "ANATOMY", 292, 306], ["L-CA", "CHEMICAL", 138, 142], ["carbohydrate", "CHEMICAL", 37, 49], ["L-CA", "CHEMICAL", 60, 64], ["L-CA", "GENE_OR_GENE_PRODUCT", 60, 64], ["L-CA", "SIMPLE_CHEMICAL", 138, 142], ["cell membrane", "CELLULAR_COMPONENT", 252, 265], ["A.E7", "GENE_OR_GENE_PRODUCT", 282, 286], ["CD4", "GENE_OR_GENE_PRODUCT", 296, 299], ["I-EK", "GENE_OR_GENE_PRODUCT", 308, 312], ["pigeon", "ORGANISM", 342, 348], ["cytochrome c.", "GENE_OR_GENE_PRODUCT", 349, 362], ["L-CA", "PROTEIN", 60, 64], ["L-CA", "PROTEIN", 138, 142], ["A.E7", "DNA", 282, 286], ["CD4", "PROTEIN", 296, 299], ["pigeon cytochrome", "PROTEIN", 342, 359], ["pigeon", "SPECIES", 342, 348], ["pigeon", "SPECIES", 342, 348], ["carbohydrate groups", "PROBLEM", 37, 56], ["a soluble ligand", "TREATMENT", 216, 232], ["pigeon cytochrome c.", "PROBLEM", 342, 362], ["cell membrane", "OBSERVATION", 252, 265]]], ["The cells were passaged by culturing 5 x lo5 cells/ml in RPM1 1640 containing 50 FM 2-mercaptoethanoi and 10% fetal calf serum (FCS; Hyclone) with 2.5 x 106 CBA/J spleen cells/ml (irradiated with 3000 rads) and 100 pigeon cytochrome c (Sigma).", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 45, 50], ["fetal calf serum", "ANATOMY", 110, 126], ["spleen cells", "ANATOMY", 163, 175], ["RPM1 1640", "CHEMICAL", 57, 66], ["cells", "CELL", 4, 9], ["lo5 cells", "CELL", 41, 50], ["fetal calf", "ORGANISM_SUBSTANCE", 110, 120], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["FCS", "ORGANISM_SUBSTANCE", 128, 131], ["Hyclone", "ORGANISM_SUBSTANCE", 133, 140], ["spleen cells", "CELL", 163, 175], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 222, 234], ["Sigma", "GENE_OR_GENE_PRODUCT", 236, 241], ["pigeon cytochrome c", "PROTEIN", 215, 234], ["Sigma", "PROTEIN", 236, 241], ["calf", "SPECIES", 116, 120], ["culturing", "TEST", 27, 36], ["RPM1", "TEST", 57, 61], ["mercaptoethanoi", "TEST", 86, 101], ["fetal calf serum", "TEST", 110, 126], ["FCS", "TEST", 128, 131], ["Hyclone", "TEST", 133, 140], ["CBA/J spleen cells", "TEST", 157, 175], ["fetal calf", "ANATOMY", 110, 120], ["spleen", "ANATOMY", 163, 169]]], ["After 2 days cells were expanded 5-fold in media containing 5% filtered supernatant obtained from EL-4 ceils stimulated for 24 hr with 10 nglml phorbol myristate acetate (the EL-4 supernatant contains between 100-500 U/ml IL-2).", [["cells", "ANATOMY", 13, 18], ["supernatant", "ANATOMY", 72, 83], ["EL-4 ceils", "ANATOMY", 98, 108], ["supernatant", "ANATOMY", 180, 191], ["EL-4 ceils", "CHEMICAL", 98, 108], ["nglml phorbol myristate acetate", "CHEMICAL", 138, 169], ["phorbol myristate acetate", "CHEMICAL", 144, 169], ["cells", "CELL", 13, 18], ["EL-4 ceils", "CELL", 98, 108], ["phorbol myristate acetate", "SIMPLE_CHEMICAL", 144, 169], ["IL-2", "GENE_OR_GENE_PRODUCT", 222, 226], ["10 nglml phorbol myristate acetate", "TREATMENT", 135, 169]]], ["The A.E7 cells were passaged at 2 week intervals.", [["A.E7 cells", "ANATOMY", 4, 14], ["A.E7 cells", "CELL", 4, 14], ["A.E7 cells", "CELL_LINE", 4, 14], ["The A.E7 cells", "TREATMENT", 0, 14]]], ["A.E7 cells were taken at day 6 of passage and cellular debris removed by centrifugation through Ficoii gradients (Ficoii-Paque, Pharmacia).", [["A.E7 cells", "ANATOMY", 0, 10], ["cellular debris", "ANATOMY", 46, 61], ["A.E7 cells", "CELL", 0, 10], ["cellular", "CELL", 46, 54], ["Ficoii", "SIMPLE_CHEMICAL", 96, 102], ["A.E7 cells", "CELL_LINE", 0, 10], ["cellular debris", "PROBLEM", 46, 61], ["Ficoii gradients", "TREATMENT", 96, 112], ["cellular debris", "OBSERVATION", 46, 61]]], ["A total of 5 x 10' ceils was resuspended at IO' ceils/ml in complete media with 7.5 ug/ml N-methyl-N'nitro-N-nitrosoguanidine (Sigma) for 45 min at 3PC, 5% COs.", [["N-methyl-N'nitro-N-nitrosoguanidine", "CHEMICAL", 90, 125], ["N-methyl-N'nitro-N-nitrosoguanidine", "CHEMICAL", 90, 125], ["N-methyl-N'nitro-N-nitrosoguanidine", "SIMPLE_CHEMICAL", 90, 125], ["Sigma", "SIMPLE_CHEMICAL", 127, 132], ["A total of 5 x 10' ceils", "TREATMENT", 0, 24], ["methyl", "TREATMENT", 92, 98], ["N'nitro", "TREATMENT", 99, 106], ["N-nitrosoguanidine (Sigma)", "TREATMENT", 107, 133]]], ["After washing twice with Hanks balanced salt solution (HBSS) containing 2% FCS, cells were resuspended in 25 ml of complete media containing 5% EL-4 supernatant and incubated at 3pC.", [["cells", "ANATOMY", 80, 85], ["supernatant", "ANATOMY", 149, 160], ["EL-4", "CHEMICAL", 144, 148], ["cells", "CELL", 80, 85], ["Hanks balanced salt solution (HBSS)", "TREATMENT", 25, 60], ["2% FCS", "TREATMENT", 72, 78], ["cells", "TREATMENT", 80, 85], ["complete media", "TREATMENT", 115, 129]]], ["5% CO*.", [["CO", "CHEMICAL", 3, 5]]], ["After 6 days, cellular debris was removed by centrifugation through Ficoll gradients and the ceils were treated at 10' ceils/ml with a I:50 dilution of i3/2.3 ascites (Trowbridge, 1976) for 46 min on ice, followed by treatment with 1:50 dilution rabbit anti-rat immunoglobuiin (United States Biochemical) for 45 min on ice.", [["cellular", "ANATOMY", 14, 22], ["ceils", "ANATOMY", 93, 98], ["ascites", "ANATOMY", 159, 166], ["ascites", "DISEASE", 159, 166], ["immunoglobuiin", "CHEMICAL", 262, 276], ["cellular", "CELL", 14, 22], ["rabbit", "ORGANISM", 246, 252], ["anti-rat immunoglobuiin", "SIMPLE_CHEMICAL", 253, 276], ["rabbit", "SPECIES", 246, 252], ["rabbit", "SPECIES", 246, 252], ["cellular debris", "PROBLEM", 14, 29], ["Ficoll gradients", "TREATMENT", 68, 84], ["the ceils", "TREATMENT", 89, 98], ["ascites", "PROBLEM", 159, 166], ["cellular", "OBSERVATION_MODIFIER", 14, 22], ["debris", "OBSERVATION", 23, 29], ["Ficoll gradients", "OBSERVATION", 68, 84], ["ascites", "OBSERVATION", 159, 166]]], ["Cells were iysed by treating with 1:12 dilution rabbit complement (Cedarlane, low-toxM) for 45 min at m, washed once with HBSS, 2% FCS, and retreated with the i3/2.3 rabbit anti-rat immunogiobuiin and rabbit complement as above, except that the incubation times were 20 min, 20 min, and 30 min, respectively.", [["Cells", "ANATOMY", 0, 5], ["Cedarlane", "CHEMICAL", 67, 76], ["Cells", "CELL", 0, 5], ["rabbit", "ORGANISM", 48, 54], ["Cedarlane", "SIMPLE_CHEMICAL", 67, 76], ["rabbit", "ORGANISM", 166, 172], ["anti-rat", "ORGANISM", 173, 181], ["immunogiobuiin", "SIMPLE_CHEMICAL", 182, 196], ["rabbit", "ORGANISM", 201, 207], ["rabbit", "SPECIES", 48, 54], ["rabbit", "SPECIES", 166, 172], ["rabbit", "SPECIES", 201, 207], ["rabbit", "SPECIES", 48, 54], ["rabbit", "SPECIES", 166, 172], ["rabbit", "SPECIES", 201, 207], ["Cedarlane", "TREATMENT", 67, 76], ["low-toxM)", "TREATMENT", 78, 87], ["HBSS", "TREATMENT", 122, 126], ["2% FCS", "TREATMENT", 128, 134], ["the i3", "TREATMENT", 155, 161], ["rabbit anti-rat immunogiobuiin", "TREATMENT", 166, 196]]], ["Ceils were resuspended in 1 ml of complete media with 1 ConA.", [["Ceils", "ANATOMY", 0, 5], ["Ceils", "CELL", 0, 5], ["ConA", "GENE_OR_GENE_PRODUCT", 56, 60], ["Ceils", "TREATMENT", 0, 5]]], ["The next day, media were removed and cells were passaged as normal.", [["cells", "ANATOMY", 37, 42], ["cells", "CELL", 37, 42], ["media", "TREATMENT", 14, 19], ["cells", "TREATMENT", 37, 42], ["normal", "OBSERVATION", 60, 66]]], ["ConA was added to the cultures a day prior to passage for the first three passages.", [["ConA", "GENE_OR_GENE_PRODUCT", 0, 4], ["ConA", "PROTEIN", 0, 4], ["the cultures", "TEST", 18, 30]]], ["After the fourth passage, cells were selected again with one cycle of antibody and complement as above.", [["cells", "ANATOMY", 26, 31], ["cells", "CELL", 26, 31], ["antibody", "TREATMENT", 70, 78]]], ["Ceils were sorted and cloned after the tenth passage using a Becton-Dickinson FACS 440 staining with a second antibody of fluoresceinated goat anti-rat immunoglobulin and cloning by limiting dilution using 0.3 cells/well.", [["Ceils", "ANATOMY", 0, 5], ["cells", "ANATOMY", 210, 215], ["Ceils", "CELL", 0, 5], ["goat", "ORGANISM", 138, 142], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 152, 166], ["cells", "CELL", 210, 215], ["fluoresceinated goat anti-rat immunoglobulin", "PROTEIN", 122, 166], ["goat", "SPECIES", 138, 142], ["goat", "SPECIES", 138, 142], ["a second antibody of fluoresceinated goat anti-rat immunoglobulin", "TREATMENT", 101, 166]]], ["Flow Cytometry Ceils, 106, were washed once with PBS (10 mM Na phosphate [pH 7.41.", [["Na phosphate", "CHEMICAL", 60, 72], ["Na phosphate", "CHEMICAL", 60, 72], ["Na phosphate", "SIMPLE_CHEMICAL", 60, 72], ["Flow Cytometry Ceils", "TEST", 0, 20], ["PBS", "TEST", 49, 52], ["mM Na phosphate", "TEST", 57, 72], ["pH", "TEST", 74, 76]]], ["150 mM NaCI) containing 0.02% BSA and 2 mM NaNs (B-PBS), resuspended in 200 ui of monocionai antibody tissue culture supernatant and incubated for 30 min at room temperature.", [["tissue", "ANATOMY", 102, 108], ["supernatant", "ANATOMY", 117, 128], ["NaCI", "CHEMICAL", 7, 11], ["BSA", "CHEMICAL", 30, 33], ["NaNs", "CHEMICAL", 43, 47], ["NaCI", "CHEMICAL", 7, 11], ["NaNs", "CHEMICAL", 43, 47], ["NaCI", "SIMPLE_CHEMICAL", 7, 11], ["BSA", "SIMPLE_CHEMICAL", 30, 33], ["NaNs", "SIMPLE_CHEMICAL", 43, 47], ["B-PBS", "SIMPLE_CHEMICAL", 49, 54], ["0.02% BSA", "TREATMENT", 24, 33], ["2 mM NaNs (B-PBS)", "TREATMENT", 38, 55], ["monocionai antibody tissue culture", "TEST", 82, 116]]], ["The monoclonal antibodies used were: anti-L-CA, 13/2.3 (Trowbridge, 1978) 3OFll.l (Seaman et al., 1981) M119.3.4.", [["anti-L-CA", "SIMPLE_CHEMICAL", 37, 46], ["monoclonal antibodies", "PROTEIN", 4, 25], ["The monoclonal antibodies", "TEST", 0, 25]]], ["HL.2 (Springer et al., 1976) 104-2 (anti-Ly-5.2; Shen, 1961) anti-a-e+ T cell antigen receptor, H57-157 (Kubc et al., 1969 ). antiCD3, 1452Cll (Leoet al., 1987 . antiCD4, GK1.5 (Dialynas et al., 1963) anti-IL-2 receptor ~55, 7D4 (Malek et al., 1963) . anti-LFA-1, FD411.6 (Sarmiento et al., 1982) antiThy-1, HO-22-1 (Marshak-Rothstein et al., 1979) and anti-Pgpl, IM7.8.1 (Trowbridge et al., 1982) .", [["T cell", "ANATOMY", 71, 77], ["H57-157", "CHEMICAL", 96, 103], ["T cell antigen receptor", "GENE_OR_GENE_PRODUCT", 71, 94], ["antiCD4", "SIMPLE_CHEMICAL", 162, 169], ["IL-2 receptor", "GENE_OR_GENE_PRODUCT", 206, 219], ["anti-LFA-1", "GENE_OR_GENE_PRODUCT", 252, 262], ["antiThy-1", "GENE_OR_GENE_PRODUCT", 297, 306], ["anti-Pgpl", "GENE_OR_GENE_PRODUCT", 353, 362], ["T cell antigen receptor", "PROTEIN", 71, 94], ["LFA", "PROTEIN", 257, 260], ["anti-Pgpl", "PROTEIN", 353, 362], ["IM7", "PROTEIN", 364, 367], ["anti-Ly", "TEST", 36, 43], ["anti-a", "TEST", 61, 67], ["T cell antigen receptor", "TEST", 71, 94], ["H57", "TEST", 96, 99], ["anti-IL", "TREATMENT", 201, 208], ["anti-LFA", "TEST", 252, 260], ["antiThy", "TEST", 297, 304], ["HO", "TEST", 308, 310], ["Marshak", "TEST", 317, 324], ["anti-Pgpl", "TREATMENT", 353, 362], ["LFA", "ANATOMY", 257, 260]]], ["Cells were washed twice in B-PBS, resuspended in 200 nl of a 1:30 dilution of fluoresceinated goat anti-rat immunoglobulin (cross-reactive with mouse immunoglobulin), and incubated for 30 min at room temperature.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["goat", "ORGANISM", 94, 98], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 108, 122], ["mouse", "ORGANISM", 144, 149], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 150, 164], ["fluoresceinated goat anti-rat immunoglobulin", "PROTEIN", 78, 122], ["mouse immunoglobulin", "PROTEIN", 144, 164], ["goat", "SPECIES", 94, 98], ["mouse", "SPECIES", 144, 149], ["goat", "SPECIES", 94, 98], ["mouse", "SPECIES", 144, 149], ["Cells", "TEST", 0, 5], ["fluoresceinated goat anti-rat immunoglobulin", "TREATMENT", 78, 122], ["mouse immunoglobulin", "TREATMENT", 144, 164]]], ["Antibodies that were neither rat nor mouse were purified and coupled directly with fluorescein.", [["fluorescein", "CHEMICAL", 83, 94], ["fluorescein", "CHEMICAL", 83, 94], ["rat", "ORGANISM", 29, 32], ["mouse", "ORGANISM", 37, 42], ["fluorescein", "SIMPLE_CHEMICAL", 83, 94], ["rat", "SPECIES", 29, 32], ["mouse", "SPECIES", 37, 42], ["rat", "SPECIES", 29, 32], ["mouse", "SPECIES", 37, 42], ["Antibodies", "TEST", 0, 10], ["fluorescein", "TREATMENT", 83, 94]]], ["After washing twice with B-PBS, cells were resuspended in 300 nl of B-PBS containing 25 uglml propidium iodide and filtered through nytex.", [["cells", "ANATOMY", 32, 37], ["propidium iodide", "CHEMICAL", 94, 110], ["propidium iodide", "CHEMICAL", 94, 110], ["cells", "CELL", 32, 37], ["uglml propidium iodide", "SIMPLE_CHEMICAL", 88, 110], ["B-PBS, cells", "TREATMENT", 25, 37], ["B-PBS", "TREATMENT", 68, 73], ["25 uglml propidium iodide", "TREATMENT", 85, 110]]], ["Cells were analyzed using a Becton-Dickinson FACS 440.Mutagenesisimmunoprecipitation For surface labeling, cells were purified by centrifugation through Ficoli gradients, and 10' ceils were grown overnight at 2 x 10s ceiislmi with 5% EL-4 supernatant The next day cells were washed once with media, once with PBS without calcium or magnesium, and resuspended in 1 ml of PBS with 50 mM glucose, 0.5 ma/ml alucose oxidase, and 200 PI of 2.5 pglmi iactoperoxidase added.", [["Cells", "ANATOMY", 0, 5], ["surface", "ANATOMY", 89, 96], ["cells", "ANATOMY", 107, 112], ["cells", "ANATOMY", 264, 269], ["EL-4", "CHEMICAL", 234, 238], ["calcium", "CHEMICAL", 321, 328], ["magnesium", "CHEMICAL", 332, 341], ["glucose", "CHEMICAL", 385, 392], ["calcium", "CHEMICAL", 321, 328], ["magnesium", "CHEMICAL", 332, 341], ["glucose", "CHEMICAL", 385, 392], ["alucose", "CHEMICAL", 404, 411], ["Cells", "CELL", 0, 5], ["cells", "CELL", 107, 112], ["Ficoli", "SIMPLE_CHEMICAL", 153, 159], ["cells", "CELL", 264, 269], ["calcium", "SIMPLE_CHEMICAL", 321, 328], ["magnesium", "SIMPLE_CHEMICAL", 332, 341], ["glucose", "SIMPLE_CHEMICAL", 385, 392], ["alucose oxidase", "GENE_OR_GENE_PRODUCT", 404, 419], ["alucose oxidase", "PROTEIN", 404, 419], ["ceiislmi", "TEST", 217, 225], ["media", "TREATMENT", 292, 297], ["PBS", "TREATMENT", 309, 312], ["calcium", "TREATMENT", 321, 328], ["magnesium", "TREATMENT", 332, 341], ["PBS", "TREATMENT", 370, 373], ["50 mM glucose", "TREATMENT", 379, 392], ["pglmi iactoperoxidase", "TREATMENT", 439, 460]]], ["The reaction was initiated by the addition of 20 ul of 5 mCi/mi Nathymidine at 20 t&i/ml was added to each culture.", [["Nathymidine", "CHEMICAL", 64, 75], ["Nathymidine", "CHEMICAL", 64, 75], ["Nathymidine", "SIMPLE_CHEMICAL", 64, 75], ["mi Nathymidine", "TREATMENT", 61, 75], ["each culture", "TEST", 102, 114]]], ["Ceils were harvested at 72 hr.CDB-Stimulatedthe TCR-CDS complex; Drs. T. Ley and T. Deuel for discussions on tyrosine kinases; and G. Elliot for FACS analyses.", [["Ceils", "ANATOMY", 0, 5], ["TCR", "CHEMICAL", 48, 51], ["tyrosine", "CHEMICAL", 109, 117], ["tyrosine", "CHEMICAL", 109, 117], ["Ceils", "CELL", 0, 5], ["tyrosine", "AMINO_ACID", 109, 117], ["CDB", "PROTEIN", 30, 33], ["TCR", "PROTEIN", 48, 51], ["CDS complex", "PROTEIN", 52, 63], ["tyrosine kinases", "PROTEIN", 109, 125], ["tyrosine kinases", "TEST", 109, 125], ["FACS analyses", "TEST", 145, 158]]], ["We are particularly grateful to Drs. P Allen, E. Unanue, C. Weaver, and to members of our lab for comments on the manuscript; to the OJCWO for their helpful advice; and to Dr. E. Unanue for his support and encouragement.", [["his support", "TREATMENT", 190, 201]]], ["I. Trowbridge, S. Kimura, E. Boyse, and J. Ledbetter for gifts of monoclonal antibody cell lines and Dr. I. Trowbridge for communicating results prior to publication.", [["cell lines", "ANATOMY", 86, 96], ["cell lines", "CELL", 86, 96], ["monoclonal antibody cell lines", "CELL_LINE", 66, 96], ["monoclonal antibody cell lines", "TREATMENT", 66, 96], ["antibody cell lines", "OBSERVATION", 77, 96]]], ["This work was supported by grant Al 26363 from the U.S. Public Health Service and grants from the Council for Tobacco Research.", [["Al 26363", "CHEMICAL", 33, 41], ["Al 26363", "CHEMICAL", 33, 41]]], ["M. L. T. is the recipient of an Established Investigator Award from the American Heart Association.CDB-StimulatedThe costs of publication of this article were defrayed in part by the payment of page charges.", [["M. L.", "SPECIES", 0, 5], ["M. L. T.", "SPECIES", 0, 8], ["Heart", "ANATOMY", 81, 86]]]], "d1c1bfef3a23d732cc38e8ebf4f4b94cc477b7dc": [["PALAVRAS-CHAVECoronav\u00edrus;PALAVRAS-CHAVECOVID-19; Cirurgia colorretal;ResumoA pandemia pelo COVID-19 colocou o Brasil hoje numa situa\u00e7\u00e3o de destaque negativo, porque somos o segundo pa\u00eds com maior n\u00famero de casos no mundo.", [["CHAVECoronav\u00edrus", "TEST", 9, 25], ["PALAVRAS", "TEST", 26, 34], ["CHAVECOVID", "TEST", 35, 45]]], ["Ao finalizarmos o per\u00edodo de afastamento social, as atividades profissionais, incluindo as m\u00e9dicas, ser\u00e3o restabelecidas, e o especialista necessita estar atualizado a fim de prover o melhor n\u00edvel de trabalho, de maneira segura.", [["maneira segura", "DISEASE", 213, 227]]], ["Apesar de muitas das recomenda\u00e7\u00f5es estarem baseadas em opini\u00f5es e estudos sem muito grau de evid\u00eancia, sua divulga\u00e7\u00e3o nesse momento torna-se necess\u00e1ria, uma vez que a infec\u00e7\u00e3o pelo coronav\u00edrus afeta os resultados operat\u00f3rios.", [["sua divulga\u00e7\u00e3o", "TEST", 103, 117]]], ["Da mesma forma, devemos reconhecer a infec\u00e7\u00e3o viral precocemente, antes ou ap\u00f3s a cirurgia.", [["a cirurgia", "PROBLEM", 80, 90]]], ["Diversas medidas preventivas relacionadas aos procedimentos minimamente invasivos j\u00e1 foram descritas, real\u00e7ando o poder de dissemina\u00e7\u00e3o pelo aerossol gerado nesses procedimentos e no uso de instrumentos de energia.", [["Diversas", "TREATMENT", 0, 8]]], ["O presente artigo visou apresentar ao coloproctologista as recomenda\u00e7\u00f5es atuais e cuidados gerais para prevenir dissemina\u00e7\u00e3o da infec\u00e7\u00e3o, e como planejar o tratamento cir\u00fargico com mais seguran\u00e7a em termos de momento da cirurgia e aspectos t\u00e9cnicos espec\u00edficos.IntroductionIn humans, coronaviruses (from the RNA family) cause respiratory infections, such as influenza or severe syndromes (MERS, Middle East Respiratory Syndrome; SARS, Severe Acute Respiratory Syndrome).", [["respiratory", "ANATOMY", 326, 337], ["respiratory infections", "DISEASE", 326, 348], ["influenza", "DISEASE", 358, 367], ["MERS", "DISEASE", 389, 393], ["Middle East Respiratory Syndrome", "DISEASE", 395, 427], ["SARS", "DISEASE", 429, 433], ["Acute Respiratory Syndrome", "DISEASE", 442, 468], ["humans", "ORGANISM", 276, 282], ["coronaviruses", "ORGANISM", 284, 297], ["humans", "SPECIES", 276, 282], ["humans", "SPECIES", 276, 282], ["Middle East Respiratory Syndrome; SARS, Severe Acute Respiratory Syndrome)", "SPECIES", 395, 469], ["coronaviruses", "PROBLEM", 284, 297], ["respiratory infections", "PROBLEM", 326, 348], ["influenza", "PROBLEM", 358, 367], ["severe syndromes (MERS", "PROBLEM", 371, 393], ["Middle East Respiratory Syndrome", "PROBLEM", 395, 427], ["SARS", "PROBLEM", 429, 433], ["Severe Acute Respiratory Syndrome", "PROBLEM", 435, 468], ["respiratory", "ANATOMY", 326, 337], ["infections", "OBSERVATION", 338, 348], ["severe", "OBSERVATION_MODIFIER", 371, 377], ["Middle", "ANATOMY_MODIFIER", 395, 401], ["Respiratory Syndrome", "OBSERVATION", 407, 427], ["Severe", "OBSERVATION_MODIFIER", 435, 441], ["Acute", "OBSERVATION_MODIFIER", 442, 447], ["Respiratory Syndrome", "OBSERVATION", 448, 468]]], ["Since its appearance in China, in December of last year, the infection J o u r n a l P r e -p r o o f caused by the new coronavirus, SARS-CoV-2 (known as COVID-19), has spread rapidly and was declared a pandemic by the World Health Organization (WHO) in March of this year.", [["infection", "DISEASE", 61, 70], ["coronavirus", "DISEASE", 120, 131], ["SARS", "DISEASE", 133, 137], ["COVID-19", "CHEMICAL", 154, 162], ["coronavirus", "ORGANISM", 120, 131], ["SARS-CoV-2", "ORGANISM", 133, 143], ["SARS-CoV", "SPECIES", 133, 141], ["the infection", "PROBLEM", 57, 70], ["the new coronavirus", "PROBLEM", 112, 131], ["CoV", "TEST", 138, 141], ["COVID", "TEST", 154, 159], ["infection", "OBSERVATION", 61, 70], ["coronavirus", "OBSERVATION", 120, 131]]], ["[1] The disease spreads from person-to-person through droplets from the nose or mouth through speech, coughing or sneezing, or when people come into contact with contaminated objects and puts their hands on their eyes, nose or mouth.", [["nose", "ANATOMY", 72, 76], ["mouth", "ANATOMY", 80, 85], ["eyes", "ANATOMY", 213, 217], ["nose", "ANATOMY", 219, 223], ["mouth", "ANATOMY", 227, 232], ["sneezing", "DISEASE", 114, 122], ["nose", "ORGANISM_SUBDIVISION", 72, 76], ["mouth", "ORGANISM_SUBDIVISION", 80, 85], ["people", "ORGANISM", 132, 138], ["hands", "ORGANISM_SUBDIVISION", 198, 203], ["eyes", "ORGAN", 213, 217], ["nose", "ORGANISM_SUBDIVISION", 219, 223], ["mouth", "ORGANISM_SUBDIVISION", 227, 232], ["person", "SPECIES", 29, 35], ["person", "SPECIES", 39, 45], ["people", "SPECIES", 132, 138], ["The disease spreads", "PROBLEM", 4, 23], ["coughing", "PROBLEM", 102, 110], ["sneezing", "PROBLEM", 114, 122], ["disease", "OBSERVATION", 8, 15], ["nose", "ANATOMY", 72, 76], ["mouth", "ANATOMY", 80, 85], ["eyes", "ANATOMY", 213, 217], ["nose", "ANATOMY", 219, 223], ["mouth", "ANATOMY", 227, 232]]], ["Once infected, the average incubation period is 5.2 days (2\u221214 days), and the individual may remain asymptomatic or develop flu-like, general symptoms (weakness and body pain), digestive and other symptoms.", [["body", "ANATOMY", 165, 169], ["digestive", "ANATOMY", 177, 186], ["weakness", "DISEASE", 152, 160], ["pain", "DISEASE", 170, 174], ["body", "ORGANISM_SUBDIVISION", 165, 169], ["digestive", "ORGAN", 177, 186], ["asymptomatic", "PROBLEM", 100, 112], ["flu", "PROBLEM", 124, 127], ["general symptoms", "PROBLEM", 134, 150], ["weakness", "PROBLEM", 152, 160], ["body pain", "PROBLEM", 165, 174], ["digestive and other symptoms", "PROBLEM", 177, 205], ["infected", "OBSERVATION", 5, 13]]], ["While the vast majority recover without difficulties, around 1/6 of the patients can have the severe form of the disease, especially elderly individuals or those with comorbidities.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["difficulties", "PROBLEM", 40, 52], ["the disease", "PROBLEM", 109, 120], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["disease", "OBSERVATION", 113, 120]]], ["[2] It is currently known that, in addition to the profound pulmonary effects, there are digestive, neurological, renal and other alterations associated with the viremia.", [["pulmonary", "ANATOMY", 60, 69], ["digestive", "ANATOMY", 89, 98], ["neurological", "ANATOMY", 100, 112], ["renal", "ANATOMY", 114, 119], ["digestive, neurological, renal and other alterations", "DISEASE", 89, 141], ["viremia", "DISEASE", 162, 169], ["pulmonary", "ORGAN", 60, 69], ["digestive", "ORGAN", 89, 98], ["renal", "CANCER", 114, 119], ["the profound pulmonary effects", "PROBLEM", 47, 77], ["digestive, neurological, renal and other alterations", "PROBLEM", 89, 141], ["the viremia", "PROBLEM", 158, 169], ["profound", "OBSERVATION_MODIFIER", 51, 59], ["pulmonary", "ANATOMY", 60, 69], ["effects", "OBSERVATION", 70, 77], ["renal", "ANATOMY", 114, 119], ["viremia", "OBSERVATION", 162, 169]]], ["More than the infection itself, the health system is deeply affected, and the economic consequences are estimated to be devastating in the short term.IntroductionIn Brazil, the pandemic reached numbers compatible with our large population, making it one of the five countries with the highest number of diagnosed cases.", [["infection", "DISEASE", 14, 23], ["the infection itself", "PROBLEM", 10, 30], ["infection", "OBSERVATION", 14, 23], ["devastating", "OBSERVATION_MODIFIER", 120, 131], ["short term", "OBSERVATION_MODIFIER", 139, 149], ["large", "OBSERVATION_MODIFIER", 222, 227], ["population", "OBSERVATION", 228, 238]]], ["Consequently, several medical Collegiates have been concerned about discussing general recommendations for daily practice, even if it is based on the small number of published studies with a low level of scientific evidence.", [["published studies", "TEST", 166, 183]]], ["[3] [4] [5] [6] [7] [8] Therefore, colorectal surgeons need to adapt their practical activities to the new reality, considering the concerns related to the possibility of fecal transmission of the virus.", [["colorectal", "ANATOMY", 35, 45], ["fecal", "ANATOMY", 171, 176], ["[3] [4] [5] [6] [7] [8]", "SIMPLE_CHEMICAL", 0, 23], ["colorectal", "MULTI-TISSUE_STRUCTURE", 35, 45], ["fecal", "ORGANISM_SUBDIVISION", 171, 176], ["colorectal surgeons", "TREATMENT", 35, 54], ["fecal transmission of the virus", "PROBLEM", 171, 202]]], ["[9] In view of the several anticipated and expected changes in patient care, this report aimed to discuss the several recommendations published so far in our specialty.Suggested adaptations in outpatient careMany publications have suggested that when making an appointment, the patient should be asked about symptoms and contacts with possible carriers.", [["patient", "ORGANISM", 63, 70], ["patient", "ORGANISM", 278, 285], ["patient", "SPECIES", 63, 70], ["patient", "SPECIES", 278, 285], ["symptoms", "PROBLEM", 308, 316]]], ["When there is any cause for suspicion, the appointment should be postponed or carried out by telemedicine, reducing the risk of crossinfection.", [["crossinfection", "DISEASE", 128, 142], ["crossinfection", "PROBLEM", 128, 142]]], ["Patients should be advised to come without companions, if possible, and appointments should be scheduled at longer intervals, to avoid contact with many people.", [["Patients", "ORGANISM", 0, 8], ["people", "ORGANISM", 153, 159], ["Patients", "SPECIES", 0, 8], ["people", "SPECIES", 153, 159]]], ["Alcohol gel must be made available in the environment, which must be regularly ventilated and cleaned.Suggested adaptations in outpatient careThe contact with patients should be made with the use of gloves, and both the doctor and the patient should wear facial masks, in view of the possibility of occupational exposure and J o u r n a l P r e -p r o o f cross-infection even by asymptomatic carriers.", [["facial", "ANATOMY", 255, 261], ["Alcohol", "CHEMICAL", 0, 7], ["infection", "DISEASE", 362, 371], ["Alcohol", "SIMPLE_CHEMICAL", 0, 7], ["patients", "ORGANISM", 159, 167], ["patient", "ORGANISM", 235, 242], ["patients", "SPECIES", 159, 167], ["patient", "SPECIES", 235, 242], ["Alcohol gel", "TREATMENT", 0, 11], ["gloves", "TREATMENT", 199, 205], ["facial masks", "TREATMENT", 255, 267], ["occupational exposure", "PROBLEM", 299, 320], ["infection", "PROBLEM", 362, 371], ["infection", "OBSERVATION", 362, 371]]], ["[4, 6, 7] In spite of the criticisms, the use of telemedicine has received support due to the fact that it minimizes the risk of contact and exposure of the patient.Suggested adaptations in outpatient careThe Gastrointestinal Tract (TGI) is another target of SARS-CoV-2, a fact recognized by digestive symptoms and the presence of the virus in the stool.", [["digestive", "ANATOMY", 292, 301], ["stool", "ANATOMY", 348, 353], ["SARS", "DISEASE", 259, 263], ["patient", "ORGANISM", 157, 164], ["Gastrointestinal Tract", "MULTI-TISSUE_STRUCTURE", 209, 231], ["SARS-CoV-2", "ORGANISM", 259, 269], ["digestive", "ORGAN", 292, 301], ["stool", "ORGANISM_SUBSTANCE", 348, 353], ["patient", "SPECIES", 157, 164], ["SARS-CoV", "SPECIES", 259, 267], ["telemedicine", "TREATMENT", 49, 61], ["support", "TREATMENT", 75, 82], ["SARS", "PROBLEM", 259, 263], ["digestive symptoms", "PROBLEM", 292, 310], ["the virus in the stool", "PROBLEM", 331, 353], ["Gastrointestinal Tract", "ANATOMY", 209, 231], ["virus", "OBSERVATION", 335, 340], ["stool", "OBSERVATION", 348, 353]]], ["This is probably due to the high expression of ACE2 (angiotensin-converting enzyme) receptors by enterocytes, also present in the type II alveolar epithelium.", [["enterocytes", "ANATOMY", 97, 108], ["type II alveolar epithelium", "ANATOMY", 130, 157], ["angiotensin", "CHEMICAL", 53, 64], ["ACE2", "GENE_OR_GENE_PRODUCT", 47, 51], ["angiotensin-converting enzyme) receptors", "GENE_OR_GENE_PRODUCT", 53, 93], ["enterocytes", "CELL", 97, 108], ["alveolar epithelium", "TISSUE", 138, 157], ["ACE2", "PROTEIN", 47, 51], ["angiotensin-converting enzyme) receptors", "PROTEIN", 53, 93], ["enterocytes", "CELL_TYPE", 97, 108], ["ACE2 (angiotensin", "TREATMENT", 47, 64], ["probably due to", "UNCERTAINTY", 8, 23], ["enterocytes", "ANATOMY", 97, 108], ["type II", "OBSERVATION_MODIFIER", 130, 137], ["alveolar", "ANATOMY_MODIFIER", 138, 146], ["epithelium", "ANATOMY_MODIFIER", 147, 157]]], ["[10] Symptoms in the high and low GIT are common, although diagnosed later, with watery diarrhea being the most frequent one (20%), even in the absence of cough, shortness of breath, sore throat or fever.", [["GIT", "ANATOMY", 34, 37], ["diarrhea", "DISEASE", 88, 96], ["cough", "DISEASE", 155, 160], ["shortness of breath", "DISEASE", 162, 181], ["sore throat", "DISEASE", 183, 194], ["fever", "DISEASE", 198, 203], ["GIT", "CANCER", 34, 37], ["Symptoms", "PROBLEM", 5, 13], ["watery diarrhea", "PROBLEM", 81, 96], ["cough", "PROBLEM", 155, 160], ["shortness of breath", "PROBLEM", 162, 181], ["sore throat", "PROBLEM", 183, 194], ["fever", "PROBLEM", 198, 203], ["low GIT", "OBSERVATION_MODIFIER", 30, 37], ["cough", "OBSERVATION", 155, 160], ["fever", "OBSERVATION", 198, 203]]], ["Diarrhea can occur before or after the respiratory symptoms, especially among women, and lasts an average of 5 days (1\u221214) .", [["respiratory", "ANATOMY", 39, 50], ["Diarrhea", "DISEASE", 0, 8], ["respiratory symptoms", "DISEASE", 39, 59], ["women", "ORGANISM", 78, 83], ["women", "SPECIES", 78, 83], ["Diarrhea", "PROBLEM", 0, 8], ["the respiratory symptoms", "PROBLEM", 35, 59]]], ["Other complaints are nausea, vomiting and abdominal pain.", [["abdominal", "ANATOMY", 42, 51], ["nausea", "DISEASE", 21, 27], ["vomiting", "DISEASE", 29, 37], ["abdominal pain", "DISEASE", 42, 56], ["abdominal", "ORGANISM_SUBDIVISION", 42, 51], ["nausea", "PROBLEM", 21, 27], ["vomiting", "PROBLEM", 29, 37], ["abdominal pain", "PROBLEM", 42, 56], ["nausea", "OBSERVATION", 21, 27], ["abdominal", "ANATOMY", 42, 51], ["pain", "OBSERVATION", 52, 56]]], ["The presence of GIT symptoms increases the chance of testing positive for COVID-19 and the disease duration.", [["GIT", "ANATOMY", 16, 19], ["GIT", "ORGAN", 16, 19], ["GIT symptoms", "PROBLEM", 16, 28], ["testing", "TEST", 53, 60], ["COVID", "TEST", 74, 79], ["the disease duration", "PROBLEM", 87, 107], ["GIT", "ANATOMY", 16, 19], ["symptoms", "OBSERVATION", 20, 28], ["disease", "OBSERVATION", 91, 98]]], ["[11] As much as possible, we must differentiate between uninfected, potentially infected individuals and sick patients, aiming to differentiate treatment strategies.", [["individuals", "ORGANISM", 89, 100], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["treatment strategies", "TREATMENT", 144, 164]]], ["In COVID + patients, the treatment of respiratory symptoms must precede the oncological therapy (except in emergencies).", [["respiratory", "ANATOMY", 38, 49], ["respiratory symptoms", "DISEASE", 38, 58], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["respiratory symptoms", "PROBLEM", 38, 58], ["the oncological therapy", "TREATMENT", 72, 95]]], ["Patients with suspected disease must be observed and kept in isolation.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["suspected disease", "PROBLEM", 14, 31], ["disease", "OBSERVATION", 24, 31]]], ["The management of non-infected individuals must include protection for the team, considering the incubation period of the disease.", [["individuals", "ORGANISM", 31, 42], ["non-infected individuals", "PROBLEM", 18, 42], ["the disease", "PROBLEM", 118, 129], ["non-infected", "OBSERVATION", 18, 30], ["disease", "OBSERVATION", 122, 129]]], ["Thus, the preoperative screening process is essential to avoid nosocomial infection and to reduce individual risks.Should elective surgeries be delayed?While there is an increasing number of new cases and deaths, there is a recommendation to delay elective surgeries (including selected cancer cases) in order to provide medical resources and beds (including ICUs), increase the hospital areas that can be used, concentrate hospital activities for emergency care and, mainly, reduce the chances of cross-infection of doctors, patients and visitors.", [["cancer", "ANATOMY", 287, 293], ["infection", "DISEASE", 74, 83], ["deaths", "DISEASE", 205, 211], ["cancer", "DISEASE", 287, 293], ["cancer", "CANCER", 287, 293], ["patients", "ORGANISM", 526, 534], ["patients", "SPECIES", 526, 534], ["the preoperative screening process", "TEST", 6, 40], ["nosocomial infection", "PROBLEM", 63, 83], ["individual risks", "PROBLEM", 98, 114], ["elective surgeries", "TREATMENT", 122, 140], ["delay elective surgeries", "TREATMENT", 242, 266], ["emergency care", "TREATMENT", 448, 462], ["infection", "OBSERVATION", 74, 83], ["increasing", "OBSERVATION_MODIFIER", 170, 180], ["number", "OBSERVATION_MODIFIER", 181, 187], ["new", "OBSERVATION_MODIFIER", 191, 194], ["cases", "OBSERVATION", 195, 200]]], ["If the doctor and Depending on hospital conditions, the treatment of perianal abscesses, selected cases of hemorrhoidal thrombosis, infected pilonidal cyst and anal fissure associated with a lot of pain are procedures that can be considered without great risks.", [["perianal abscesses", "ANATOMY", 69, 87], ["hemorrhoidal", "ANATOMY", 107, 119], ["pilonidal cyst", "ANATOMY", 141, 155], ["anal fissure", "ANATOMY", 160, 172], ["abscesses", "DISEASE", 78, 87], ["thrombosis", "DISEASE", 120, 130], ["pilonidal cyst", "DISEASE", 141, 155], ["anal fissure", "DISEASE", 160, 172], ["pain", "DISEASE", 198, 202], ["perianal abscesses", "PATHOLOGICAL_FORMATION", 69, 87], ["pilonidal cyst", "PATHOLOGICAL_FORMATION", 141, 155], ["anal fissure", "PATHOLOGICAL_FORMATION", 160, 172], ["perianal abscesses", "PROBLEM", 69, 87], ["hemorrhoidal thrombosis", "PROBLEM", 107, 130], ["infected pilonidal cyst", "PROBLEM", 132, 155], ["anal fissure", "PROBLEM", 160, 172], ["a lot of pain", "PROBLEM", 189, 202], ["procedures", "TREATMENT", 207, 217], ["perianal", "ANATOMY", 69, 77], ["abscesses", "OBSERVATION", 78, 87], ["hemorrhoidal", "ANATOMY", 107, 119], ["thrombosis", "OBSERVATION", 120, 130], ["infected", "OBSERVATION_MODIFIER", 132, 140], ["pilonidal", "ANATOMY", 141, 150], ["cyst", "OBSERVATION", 151, 155], ["anal fissure", "ANATOMY", 160, 172]]], ["An alternative is to perform outpatient surgery under local anesthesia.", [["outpatient surgery", "TREATMENT", 29, 47], ["local anesthesia", "TREATMENT", 54, 70]]], ["[13] In any case, RT-PCR swab tests should always be performed.Should elective surgeries be delayed?In suspected patients, utmost care should be taken when handling stool in the rectal ampoule.", [["rectal ampoule", "ANATOMY", 178, 192], ["patients", "ORGANISM", 113, 121], ["stool", "ORGANISM_SUBSTANCE", 165, 170], ["rectal ampoule", "MULTI-TISSUE_STRUCTURE", 178, 192], ["patients", "SPECIES", 113, 121], ["RT-PCR swab tests", "TEST", 18, 35], ["elective surgeries", "TREATMENT", 70, 88], ["utmost care", "TREATMENT", 123, 134], ["rectal", "ANATOMY", 178, 184]]], ["The use of N95 masks and devices to evacuate smoke in all anorectal procedures are recommended.", [["anorectal", "ANATOMY", 58, 67], ["N95 masks", "TREATMENT", 11, 20], ["devices", "TREATMENT", 25, 32], ["all anorectal procedures", "TREATMENT", 54, 78]]], ["[14] Some professionals request a chest computed tomography 24\u221248 hours prior to larger procedures.", [["a chest computed tomography", "TEST", 32, 59], ["larger procedures", "TREATMENT", 81, 98], ["chest", "ANATOMY", 34, 39]]], ["[15] General recommendations and care measures during surgical procedures Any procedure performed on a COVID-19-positive or suspected patient must be performed in a specific room.", [["COVID-19", "GENE_OR_GENE_PRODUCT", 103, 111], ["patient", "ORGANISM", 134, 141], ["patient", "SPECIES", 134, 141], ["care measures", "TREATMENT", 33, 46], ["surgical procedures", "TREATMENT", 54, 73], ["Any procedure", "TREATMENT", 74, 87], ["a COVID", "TEST", 101, 108]]], ["Appropriate PPE (N95 masks, caps, gloves, facial protection, eyewear) must be used by the team, who must be trained to remove it at the end of the surgery.Should elective surgeries be delayed?To operate on COVID + or suspected patients, it is recommended that patients have an exclusive access to enter and leave the operating room.", [["facial", "ANATOMY", 42, 48], ["patients", "ORGANISM", 227, 235], ["patients", "ORGANISM", 260, 268], ["patients", "SPECIES", 227, 235], ["patients", "SPECIES", 260, 268], ["Appropriate PPE", "TREATMENT", 0, 15], ["N95 masks", "TREATMENT", 17, 26], ["caps", "TREATMENT", 28, 32], ["gloves", "TREATMENT", 34, 40], ["facial protection", "TREATMENT", 42, 59], ["the surgery", "TREATMENT", 143, 154], ["elective surgeries", "TREATMENT", 162, 180], ["facial", "ANATOMY", 42, 48], ["surgery", "OBSERVATION", 147, 154]]], ["A minimum number of people in the operating room is recommended, and orotracheal intubation and extubation should be performed by the anesthetist without the presence of the surgical team in the operating room, preferably under negative pressure.Should elective surgeries be delayed?The indication of negative pressure is based on a history of infection by other pathogens, allowing the air flow to enter the room, but not its escape into neighboring areas.", [["orotracheal", "ANATOMY", 69, 80], ["infection", "DISEASE", 344, 353], ["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26], ["orotracheal intubation", "TREATMENT", 69, 91], ["extubation", "TREATMENT", 96, 106], ["elective surgeries", "TREATMENT", 253, 271], ["infection", "PROBLEM", 344, 353], ["other pathogens", "PROBLEM", 357, 372], ["the air flow", "TEST", 383, 395], ["minimum", "OBSERVATION_MODIFIER", 2, 9], ["negative", "OBSERVATION", 301, 309], ["pressure", "OBSERVATION_MODIFIER", 310, 318], ["infection", "OBSERVATION", 344, 353], ["air flow", "OBSERVATION", 387, 395]]], ["[7] Regarding the energy units, the use of monopolar scalpels, ultrasonic dissectors and advanced bipolar devices should be minimized, in addition to using the lowest possible power for the desirable effect, aiming to reduce the occurrence of particle aerosolization.", [["bipolar", "DISEASE", 98, 105], ["the energy units", "TREATMENT", 14, 30], ["monopolar scalpels", "TREATMENT", 43, 61], ["ultrasonic dissectors", "TREATMENT", 63, 84], ["advanced bipolar devices", "TREATMENT", 89, 113], ["particle aerosolization", "TREATMENT", 243, 266], ["particle aerosolization", "OBSERVATION", 243, 266]]], ["The use of monopolar diathermy pens, along with smoke evacuation, can be helpful to prevent inhaling by the team members and assistance.", [["monopolar diathermy pens", "TREATMENT", 11, 35], ["smoke evacuation", "TREATMENT", 48, 64]]], ["[6] Open, laparoscopic or robotic abdominal operations more easily.", [["abdominal", "ANATOMY", 34, 43], ["abdominal", "ORGANISM_SUBDIVISION", 34, 43], ["laparoscopic", "TREATMENT", 10, 22], ["robotic abdominal operations", "TREATMENT", 26, 54], ["laparoscopic", "OBSERVATION", 10, 22], ["abdominal", "ANATOMY", 34, 43]]], ["Nevertheless, some believe that it is necessary to avoid laparoscopies due to the risk of viral spread during pneumoperitoneum.", [["laparoscopies", "TREATMENT", 57, 70], ["viral spread during pneumoperitoneum", "PROBLEM", 90, 126], ["viral", "OBSERVATION_MODIFIER", 90, 95], ["spread", "OBSERVATION", 96, 102], ["pneumoperitoneum", "OBSERVATION", 110, 126]]], ["As this chance has not been well evaluated, the initial recommendations for abandoning MIS procedures quickly lost strength.", [["abandoning MIS procedures", "TREATMENT", 76, 101]]], ["[6] It has been recognized that the benefits provided by MIS (shorter hospital stay, reduced complications, less contact with abdominal organs) are very useful in patients with possible respiratory function impairment, if they become infected.", [["abdominal organs", "ANATOMY", 126, 142], ["respiratory", "ANATOMY", 186, 197], ["respiratory function impairment", "DISEASE", 186, 217], ["abdominal", "ORGANISM_SUBDIVISION", 126, 135], ["organs", "ORGAN", 136, 142], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["reduced complications", "PROBLEM", 85, 106], ["respiratory function impairment", "PROBLEM", 186, 217], ["infected", "PROBLEM", 234, 242], ["abdominal organs", "ANATOMY", 126, 142], ["infected", "OBSERVATION", 234, 242]]], ["On the other hand, the release of aerosols during or after the end of the surgery can contaminate the environment.", [["aerosols", "TREATMENT", 34, 42], ["the surgery", "TREATMENT", 70, 81]]], ["Even during a laparotomy, care must be taken to completely evacuate all smoke resulting from the use of diathermy / electrocautery, including the use of rooms with negative pressure.", [["a laparotomy", "TREATMENT", 12, 24], ["care", "TREATMENT", 26, 30], ["diathermy / electrocautery", "TREATMENT", 104, 130], ["laparotomy", "OBSERVATION", 14, 24]]], ["[5] Generically, the main recommendations and care defended so far are listed here:Should elective surgeries be delayed?-Provide informed consent on the risk of exposure to the virus and its consequences.Should elective surgeries be delayed?-Adopt protective measures in open, laparoscopic or robotic procedures.Should elective surgeries be delayed?-Create pneumoperitoneum using the closed technique with Veress needle.Should elective surgeries be delayed?-Make tight incisions for portal introduction, to avoid the inadvertent passage of gases through the wall.Should elective surgeries be delayed?-Maintain minimum inflation pressure during the procedure, which allows the creation of sufficient operating field (8\u221212 mm/Hg).Should elective surgeries be delayed?-The MIS procedure must use devices to evacuate and filter the released CO2 that may contain aerosol particles (AirSeal iFS \u00ae System or LaparoshieldTM Laparoscopic Smoke Filtration System).Should elective surgeries be delayed?Before making the assistance incision (to remove the specimen), before a surgical conversion or before removing the trocars at the end of the surgery, the pneumoperitoneum must be emptied by a filtration system, to avoid leaks.", [["portal", "ANATOMY", 483, 489], ["wall", "ANATOMY", 558, 562], ["specimen", "ANATOMY", 1044, 1052], ["CO2", "CHEMICAL", 837, 840], ["Hg", "CHEMICAL", 724, 726], ["CO2", "CHEMICAL", 837, 840], ["portal", "MULTI-TISSUE_STRUCTURE", 483, 489], ["wall", "TISSUE", 558, 562], ["CO2", "SIMPLE_CHEMICAL", 837, 840], ["elective surgeries", "TREATMENT", 90, 108], ["the virus", "PROBLEM", 173, 182], ["elective surgeries", "TREATMENT", 211, 229], ["protective measures", "TREATMENT", 248, 267], ["laparoscopic", "TREATMENT", 277, 289], ["robotic procedures", "TREATMENT", 293, 311], ["elective surgeries", "TREATMENT", 319, 337], ["pneumoperitoneum", "PROBLEM", 357, 373], ["the closed technique", "TREATMENT", 380, 400], ["Veress needle", "TREATMENT", 406, 419], ["elective surgeries", "TREATMENT", 427, 445], ["tight incisions", "TREATMENT", 463, 478], ["portal introduction", "TREATMENT", 483, 502], ["elective surgeries", "TREATMENT", 570, 588], ["minimum inflation pressure", "TREATMENT", 610, 636], ["the procedure", "TREATMENT", 644, 657], ["elective surgeries", "TREATMENT", 735, 753], ["The MIS procedure", "TREATMENT", 766, 783], ["devices", "TREATMENT", 793, 800], ["the released CO2", "TREATMENT", 824, 840], ["aerosol particles", "TREATMENT", 858, 875], ["LaparoshieldTM Laparoscopic Smoke Filtration System", "TREATMENT", 901, 952], ["elective surgeries", "TREATMENT", 961, 979], ["the assistance incision", "TREATMENT", 1005, 1028], ["a surgical conversion", "TREATMENT", 1062, 1083], ["the trocars", "TREATMENT", 1103, 1114], ["the surgery", "TREATMENT", 1129, 1140], ["the pneumoperitoneum", "PROBLEM", 1142, 1162], ["a filtration system", "TREATMENT", 1182, 1201], ["leaks", "PROBLEM", 1212, 1217], ["pneumoperitoneum", "OBSERVATION", 357, 373], ["portal", "ANATOMY", 483, 489], ["wall", "ANATOMY_MODIFIER", 558, 562], ["aerosol particles", "OBSERVATION", 858, 875], ["pneumoperitoneum", "OBSERVATION", 1146, 1162], ["leaks", "OBSERVATION", 1212, 1217]]], ["The trocar orifice must be connected to the negative pressure suction with a water seal.Should elective surgeries be delayed?As the virus can be present in gastrointestinal cells (saliva, intestinal contents, blood), endoscopic procedures must be considered of high risk and the same energy precautions must be adopted.Should elective surgeries be delayed?Procedures that require additional CO2 insufflation (endoscopic mucosal resection and endoluminal procedures) should be indicated according to strict criteria and maximum care until the viral aerosolization properties are better known.J o u r n a l P r e -p r o o fIt is recommended to use negative pressure also in endoscopic rooms.", [["trocar orifice", "ANATOMY", 4, 18], ["gastrointestinal cells", "ANATOMY", 156, 178], ["saliva", "ANATOMY", 180, 186], ["intestinal", "ANATOMY", 188, 198], ["blood", "ANATOMY", 209, 214], ["mucosal", "ANATOMY", 420, 427], ["CO2", "CHEMICAL", 391, 394], ["CO2", "CHEMICAL", 391, 394], ["gastrointestinal cells", "CELL", 156, 178], ["saliva", "ORGANISM_SUBSTANCE", 180, 186], ["intestinal", "ORGAN", 188, 198], ["blood", "ORGANISM_SUBSTANCE", 209, 214], ["CO2", "SIMPLE_CHEMICAL", 391, 394], ["mucosal", "MULTI-TISSUE_STRUCTURE", 420, 427], ["gastrointestinal cells", "CELL_TYPE", 156, 178], ["The trocar orifice", "TREATMENT", 0, 18], ["the negative pressure suction", "TREATMENT", 40, 69], ["a water seal", "TREATMENT", 75, 87], ["elective surgeries", "TREATMENT", 95, 113], ["the virus", "PROBLEM", 128, 137], ["endoscopic procedures", "TREATMENT", 217, 238], ["high risk", "PROBLEM", 261, 270], ["the same energy precautions", "TREATMENT", 275, 302], ["elective surgeries", "TREATMENT", 326, 344], ["additional CO2 insufflation", "TREATMENT", 380, 407], ["endoscopic mucosal resection", "TREATMENT", 409, 437], ["endoluminal procedures", "TREATMENT", 442, 464], ["maximum care", "TREATMENT", 519, 531], ["the viral aerosolization properties", "TREATMENT", 538, 573], ["trocar orifice", "OBSERVATION", 4, 18], ["negative", "OBSERVATION_MODIFIER", 44, 52], ["pressure", "OBSERVATION_MODIFIER", 53, 61], ["suction", "OBSERVATION", 62, 69], ["water seal", "OBSERVATION_MODIFIER", 77, 87], ["virus", "OBSERVATION", 132, 137], ["gastrointestinal cells", "ANATOMY", 156, 178], ["intestinal", "ANATOMY", 188, 198], ["resection", "OBSERVATION", 428, 437], ["viral aerosolization", "OBSERVATION", 542, 562]]], ["Endoscopies should not be performed in the medical office due to the risk of contamination of the environment and the need for special protective materials, and the cleaning of surgical or endoscopic material used in a positive or suspected patient should be done separately from others.", [["patient", "ORGANISM", 241, 248], ["patient", "SPECIES", 241, 248], ["Endoscopies", "TEST", 0, 11], ["contamination of the environment", "PROBLEM", 77, 109], ["special protective materials", "TREATMENT", 127, 155], ["surgical or endoscopic material", "TREATMENT", 177, 208], ["contamination", "OBSERVATION", 77, 90]]]], "11cabe7adaeb9fbe438c6d6d3b753b1e2e0141b8": [["IntroductionThe World Health Organization (WHO) has lately stated that the present pandemic of coronavirus disease 2019 (COVID-19) is a public health crisis of international interest [1] .", [["coronavirus disease", "DISEASE", 95, 114], ["COVID-19", "CHEMICAL", 121, 129], ["coronavirus", "ORGANISM", 95, 106], ["coronavirus disease", "PROBLEM", 95, 114], ["COVID", "TEST", 121, 126], ["coronavirus disease", "OBSERVATION", 95, 114]]], ["As of May 27-5,500,000 COVID-19 infected patients had been registered globally, and more than 300,000 people had died from the virus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).IntroductionWith more than 18 million new cases per year worldwide, cancer affects a considerable proportion of the global population, and subjects affected by tumors are more vulnerable to infections owing to poor health status, concomitant chronic diseases, and immunosuppressive conditions provoked by both the tumors and antitumor therapies [2, 3] .", [["cancer", "ANATOMY", 276, 282], ["tumors", "ANATOMY", 368, 374], ["tumors", "ANATOMY", 522, 528], ["antitumor", "ANATOMY", 533, 542], ["acute respiratory syndrome coronavirus", "DISEASE", 154, 192], ["cancer", "DISEASE", 276, 282], ["tumors", "DISEASE", 368, 374], ["infections", "DISEASE", 398, 408], ["chronic diseases", "DISEASE", 450, 466], ["tumors", "DISEASE", 522, 528], ["patients", "ORGANISM", 41, 49], ["people", "ORGANISM", 102, 108], ["cancer", "CANCER", 276, 282], ["tumors", "CANCER", 368, 374], ["tumors", "CANCER", 522, 528], ["antitumor", "CANCER", 533, 542], ["patients", "SPECIES", 41, 49], ["people", "SPECIES", 102, 108], ["severe acute respiratory syndrome coronavirus", "SPECIES", 147, 192], ["SARS-CoV-2", "SPECIES", 196, 206], ["COVID", "TEST", 23, 28], ["the virus", "PROBLEM", 123, 132], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 147, 192], ["CoV", "TEST", 201, 204], ["cancer", "PROBLEM", 276, 282], ["tumors", "PROBLEM", 368, 374], ["infections", "PROBLEM", 398, 408], ["poor health status", "PROBLEM", 418, 436], ["concomitant chronic diseases", "PROBLEM", 438, 466], ["immunosuppressive conditions", "TREATMENT", 472, 500], ["the tumors", "PROBLEM", 518, 528], ["antitumor therapies", "TREATMENT", 533, 552], ["severe", "OBSERVATION_MODIFIER", 147, 153], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["respiratory syndrome", "OBSERVATION", 160, 180], ["cancer", "OBSERVATION", 276, 282], ["global", "OBSERVATION_MODIFIER", 324, 330], ["population", "OBSERVATION", 331, 341], ["tumors", "OBSERVATION", 368, 374], ["chronic", "OBSERVATION_MODIFIER", 450, 457], ["diseases", "OBSERVATION", 458, 466], ["tumors", "OBSERVATION", 522, 528]]], ["In addition, apart from altered host defenses, Table 1 .", [["altered host defenses", "PROBLEM", 24, 45], ["altered", "OBSERVATION_MODIFIER", 24, 31], ["host defenses", "OBSERVATION", 32, 45]]], ["Incidence and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cancer patients worldwide.StudySubjects FindingsAll/various countries/continentsWorldometer (2020) [11] All confirmed worldwide cases (>5 million)All/various countries/continentsCritical events in 48-54% of cancer patients vs. 16% in general population; death in 5.6-29% vs. 3.4%All/various countries/continentsHrusak et al. (2020) Various countries [12] 10,000, of which 2000 children analyzed 4 .5% with tumor, of which 88.9% asymptomatic or mildly symptomatic Asia Liang et al. (2020) China [10] 2007All/various countries/continentsTumor history in SARS-CoV vs. general population: 1% vs. 0.29% Subjects with tumor worsened more quickly (13 vs. 43 days until critical events) and were more critical (39% vs. 8%) In an analogue study, Yu et al. calculated the infection percentage of SARS-CoV-2 in subjects with tumors from a single institution at 0.79% (12 of 1524 patients).", [["cancer", "ANATOMY", 90, 96], ["cancer", "ANATOMY", 297, 303], ["tumor", "ANATOMY", 496, 501], ["Tumor", "ANATOMY", 625, 630], ["tumor", "ANATOMY", 702, 707], ["tumors", "ANATOMY", 904, 910], ["acute respiratory syndrome coronavirus", "DISEASE", 33, 71], ["cancer", "DISEASE", 90, 96], ["cancer", "DISEASE", 297, 303], ["death", "DISEASE", 344, 349], ["tumor", "DISEASE", 496, 501], ["Tumor", "DISEASE", 625, 630], ["SARS", "DISEASE", 642, 646], ["tumor", "DISEASE", 702, 707], ["infection", "DISEASE", 852, 861], ["SARS", "DISEASE", 876, 880], ["tumors", "DISEASE", 904, 910], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 75, 85], ["cancer", "CANCER", 90, 96], ["patients", "ORGANISM", 97, 105], ["cancer", "CANCER", 297, 303], ["patients", "ORGANISM", 304, 312], ["children", "ORGANISM", 467, 475], ["tumor", "CANCER", 496, 501], ["Tumor", "CANCER", 625, 630], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 642, 650], ["tumor", "CANCER", 702, 707], ["subjects", "ORGANISM", 890, 898], ["tumors", "CANCER", 904, 910], ["patients", "ORGANISM", 958, 966], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 304, 312], ["children", "SPECIES", 467, 475], ["patients", "SPECIES", 958, 966], ["severe acute respiratory syndrome coronavirus", "SPECIES", 26, 71], ["SARS-CoV", "SPECIES", 75, 83], ["SARS-CoV", "SPECIES", 642, 650], ["SARS-CoV", "SPECIES", 876, 884], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 26, 71], ["Critical events", "PROBLEM", 268, 283], ["cancer", "PROBLEM", 297, 303], ["general population", "TEST", 324, 342], ["death", "TEST", 344, 349], ["tumor", "PROBLEM", 496, 501], ["mildly symptomatic", "PROBLEM", 534, 552], ["SARS", "PROBLEM", 642, 646], ["general population", "TEST", 655, 673], ["tumor", "PROBLEM", 702, 707], ["an analogue study", "TEST", 808, 825], ["the infection percentage", "PROBLEM", 848, 872], ["SARS", "PROBLEM", 876, 880], ["CoV", "TEST", 881, 884], ["tumors", "PROBLEM", 904, 910], ["severity", "OBSERVATION_MODIFIER", 14, 22], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["respiratory syndrome", "OBSERVATION", 39, 59], ["cancer", "OBSERVATION", 90, 96], ["cancer", "OBSERVATION", 297, 303], ["tumor", "OBSERVATION", 496, 501], ["mildly", "OBSERVATION_MODIFIER", 534, 540], ["symptomatic", "OBSERVATION_MODIFIER", 541, 552], ["tumor", "OBSERVATION", 702, 707], ["infection", "OBSERVATION", 852, 861], ["tumors", "OBSERVATION", 904, 910]]], ["Seven of the 12 (58.3%) subjects had non-small cell lung carcinomas (NSCLC).", [["non-small cell lung carcinomas", "ANATOMY", 37, 67], ["NSCLC", "ANATOMY", 69, 74], ["non-small cell lung carcinomas", "DISEASE", 37, 67], ["NSCLC", "DISEASE", 69, 74], ["non-small cell lung carcinomas", "CANCER", 37, 67], ["NSCLC", "CANCER", 69, 74], ["non-small cell lung carcinomas", "PROBLEM", 37, 67], ["NSCLC", "PROBLEM", 69, 74], ["non-small cell", "OBSERVATION", 37, 51], ["lung", "ANATOMY", 52, 56], ["carcinomas", "OBSERVATION", 57, 67], ["NSCLC", "OBSERVATION", 69, 74]]], ["Five (41.7%) were being given chemotherapy with or without immunotherapy or radiotherapy.", [["chemotherapy", "TREATMENT", 30, 42], ["immunotherapy", "TREATMENT", 59, 72], ["radiotherapy", "TREATMENT", 76, 88]]], ["Three patients (25.0%) had a severe respiratory syndrome; one subject needed to be admitted to the intensive care unit [13] .All/various countries/continentsThese data were confirmed by Chen's paper, which proposed that among those infected with SARS-CoV-2, about 1% of subjects had tumors (3): this was 5-fold greater than the overall occurrence of cancer in China (201.7/100,000 persons) [14, 21] .All/various countries/continentsOther authors have re-analyzed the greatest case series described by the Chinese center for disease control and prevention (44,672 cases) , to evaluate the clinical risk factors correlated with death.", [["tumors", "ANATOMY", 283, 289], ["cancer", "ANATOMY", 350, 356], ["respiratory syndrome", "DISEASE", 36, 56], ["SARS", "DISEASE", 246, 250], ["tumors", "DISEASE", 283, 289], ["cancer", "DISEASE", 350, 356], ["death", "DISEASE", 626, 631], ["patients", "ORGANISM", 6, 14], ["SARS-CoV-2", "ORGANISM", 246, 256], ["subjects", "ORGANISM", 270, 278], ["tumors", "CANCER", 283, 289], ["cancer", "CANCER", 350, 356], ["patients", "SPECIES", 6, 14], ["SARS-CoV", "SPECIES", 246, 254], ["a severe respiratory syndrome", "PROBLEM", 27, 56], ["SARS", "TEST", 246, 250], ["CoV", "TEST", 251, 254], ["tumors", "PROBLEM", 283, 289], ["cancer", "PROBLEM", 350, 356], ["disease control", "TREATMENT", 524, 539], ["death", "PROBLEM", 626, 631], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["respiratory syndrome", "OBSERVATION", 36, 56], ["tumors", "OBSERVATION", 283, 289], ["cancer", "OBSERVATION", 350, 356]]], ["Tumors (RR = 2.926, 95%CI = 1.34-6.41) were the main risk factors for mortality of subjects with SARS-CoV-2 [15] .All/various countries/continentsA similar multi-center analysis was performed by Dai et al., employing subject information gathered from 14 hospitals in Hubei Province, China, in which they reported the clinical features and outcomes (development of severe respiratory syndrome, invasive mechanical ventilation, ICU admission, and death) of infected patients for 105 hospitalized subjects with tumors and 536 subjects without tumors.", [["Tumors", "ANATOMY", 0, 6], ["respiratory", "ANATOMY", 371, 382], ["tumors", "ANATOMY", 508, 514], ["tumors", "ANATOMY", 540, 546], ["Tumors", "DISEASE", 0, 6], ["SARS", "DISEASE", 97, 101], ["respiratory syndrome", "DISEASE", 371, 391], ["death", "DISEASE", 445, 450], ["tumors", "DISEASE", 508, 514], ["tumors", "DISEASE", 540, 546], ["Tumors", "CANCER", 0, 6], ["patients", "ORGANISM", 464, 472], ["tumors", "CANCER", 508, 514], ["tumors", "CANCER", 540, 546], ["patients", "SPECIES", 464, 472], ["Tumors", "TEST", 0, 6], ["RR", "TEST", 8, 10], ["CI", "TEST", 23, 25], ["SARS", "TEST", 97, 101], ["CoV", "TEST", 102, 105], ["A similar multi-center analysis", "TEST", 146, 177], ["severe respiratory syndrome", "PROBLEM", 364, 391], ["invasive mechanical ventilation", "TREATMENT", 393, 424], ["tumors", "PROBLEM", 508, 514], ["tumors", "PROBLEM", 540, 546], ["severe", "OBSERVATION_MODIFIER", 364, 370], ["respiratory syndrome", "OBSERVATION", 371, 391], ["without", "UNCERTAINTY", 532, 539], ["tumors", "OBSERVATION", 540, 546]]], ["The data demonstrated SARS-CoV-2 subjects with cancer had greater risks for all severe outcomes.", [["cancer", "ANATOMY", 47, 53], ["cancer", "DISEASE", 47, 53], ["SARS-CoV-2", "ORGANISM", 22, 32], ["cancer", "CANCER", 47, 53], ["The data", "TEST", 0, 8], ["SARS", "PROBLEM", 22, 26], ["cancer", "PROBLEM", 47, 53], ["all severe outcomes", "PROBLEM", 76, 95], ["cancer", "OBSERVATION", 47, 53]]], ["Subjects with hematological neoplasia, lung cancer, or metastatic cancer had the greatest incidence of critical events.", [["hematological neoplasia", "ANATOMY", 14, 37], ["lung cancer", "ANATOMY", 39, 50], ["metastatic cancer", "ANATOMY", 55, 72], ["hematological neoplasia", "DISEASE", 14, 37], ["lung cancer", "DISEASE", 39, 50], ["cancer", "DISEASE", 66, 72], ["hematological neoplasia", "CANCER", 14, 37], ["lung cancer", "CANCER", 39, 50], ["metastatic cancer", "CANCER", 55, 72], ["hematological neoplasia", "PROBLEM", 14, 37], ["lung cancer", "PROBLEM", 39, 50], ["metastatic cancer", "PROBLEM", 55, 72], ["critical events", "PROBLEM", 103, 118], ["hematological", "ANATOMY", 14, 27], ["neoplasia", "OBSERVATION", 28, 37], ["lung", "ANATOMY", 39, 43], ["cancer", "OBSERVATION", 44, 50], ["metastatic", "OBSERVATION_MODIFIER", 55, 65], ["cancer", "OBSERVATION", 66, 72], ["greatest", "OBSERVATION_MODIFIER", 81, 89]]], ["Non-metastatic cancer subjects presented with similar rates of critical events to subjects without tumors.", [["cancer", "ANATOMY", 15, 21], ["tumors", "ANATOMY", 99, 105], ["cancer", "DISEASE", 15, 21], ["tumors", "DISEASE", 99, 105], ["Non-metastatic cancer", "CANCER", 0, 21], ["tumors", "CANCER", 99, 105], ["Non-metastatic cancer", "PROBLEM", 0, 21], ["tumors", "PROBLEM", 99, 105], ["without", "UNCERTAINTY", 91, 98], ["tumors", "OBSERVATION", 99, 105]]], ["Patients who received surgery had higher risks of having critical events, while subjects submitted only to radiotherapy did not display relevant differences in critical events with respect to patients without cancer [22] .", [["cancer", "ANATOMY", 209, 215], ["cancer", "DISEASE", 209, 215], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 192, 200], ["cancer", "CANCER", 209, 215], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 192, 200], ["surgery", "TREATMENT", 22, 29], ["critical events", "PROBLEM", 57, 72], ["radiotherapy", "TREATMENT", 107, 119], ["cancer", "PROBLEM", 209, 215]]], ["An updated WHO report reported a mortality of 7.6% among patients with cancer [1], while according other studies, cancer subjects are at a higher risk of critical events in (48-54% of cases vs. 16% in the general population) and death (5.6-29% vs. 3.4% in the general population) [11] .All/various countries/continentsThe results on the frequency of SARS-CoV-2 infection in tumor subjects seem diverse, and effects greater than those reported so far may be found when this is evaluated in other geographic areas.", [["cancer", "ANATOMY", 71, 77], ["cancer", "ANATOMY", 114, 120], ["tumor", "ANATOMY", 374, 379], ["cancer", "DISEASE", 71, 77], ["cancer", "DISEASE", 114, 120], ["death", "DISEASE", 229, 234], ["SARS", "DISEASE", 350, 354], ["infection", "DISEASE", 361, 370], ["tumor", "DISEASE", 374, 379], ["patients", "ORGANISM", 57, 65], ["cancer", "CANCER", 71, 77], ["cancer", "CANCER", 114, 120], ["SARS-CoV-2", "ORGANISM", 350, 360], ["tumor", "CANCER", 374, 379], ["patients", "SPECIES", 57, 65], ["CoV-", "SPECIES", 355, 359], ["SARS-CoV-2", "SPECIES", 350, 360], ["cancer", "PROBLEM", 71, 77], ["cancer subjects", "PROBLEM", 114, 129], ["critical events", "PROBLEM", 154, 169], ["death", "TEST", 229, 234], ["SARS", "PROBLEM", 350, 354], ["CoV", "PROBLEM", 355, 358], ["2 infection in tumor subjects", "PROBLEM", 359, 388], ["cancer", "OBSERVATION", 71, 77], ["cancer", "OBSERVATION", 114, 120], ["infection", "OBSERVATION", 361, 370], ["tumor", "OBSERVATION", 374, 379], ["diverse", "OBSERVATION_MODIFIER", 394, 401]]], ["They evaluated relevant clinical and demographic information (age, sex, comorbidities, critical events, and death rate) from 5688 patients with SARS-CoV-2, and found 334 subjects (6%) with tumors in this group (57 breast, 56 prostate, 23 lung, 18 urothelial, and 16 colon cancer).", [["tumors", "ANATOMY", 189, 195], ["breast", "ANATOMY", 214, 220], ["prostate", "ANATOMY", 225, 233], ["lung", "ANATOMY", 238, 242], ["urothelial", "ANATOMY", 247, 257], ["colon cancer", "ANATOMY", 266, 278], ["death", "DISEASE", 108, 113], ["SARS", "DISEASE", 144, 148], ["tumors", "DISEASE", 189, 195], ["breast, 56 prostate, 23 lung, 18 urothelial, and 16 colon cancer", "DISEASE", 214, 278], ["patients", "ORGANISM", 130, 138], ["tumors", "CANCER", 189, 195], ["breast", "CANCER", 214, 220], ["prostate", "CANCER", 225, 233], ["lung", "CANCER", 238, 242], ["urothelial", "CANCER", 247, 257], ["colon cancer", "CANCER", 266, 278], ["patients", "SPECIES", 130, 138], ["SARS-CoV", "SPECIES", 144, 152], ["death rate", "TEST", 108, 118], ["SARS", "PROBLEM", 144, 148], ["CoV", "TEST", 149, 152], ["tumors", "PROBLEM", 189, 195], ["prostate", "TEST", 225, 233], ["16 colon cancer", "PROBLEM", 263, 278], ["tumors", "OBSERVATION", 189, 195], ["breast", "ANATOMY", 214, 220], ["prostate", "ANATOMY", 225, 233], ["lung", "ANATOMY", 238, 242], ["urothelial", "ANATOMY", 247, 257], ["colon", "ANATOMY", 266, 271], ["cancer", "OBSERVATION", 272, 278]]], ["Without correcting for age groups, subjects with tumors were intubated considerably more frequently, but the death rate was not significantly different.", [["tumors", "ANATOMY", 49, 55], ["tumors", "DISEASE", 49, 55], ["death", "DISEASE", 109, 114], ["tumors", "CANCER", 49, 55], ["tumors", "PROBLEM", 49, 55], ["intubated", "TREATMENT", 61, 70], ["the death rate", "TEST", 105, 119], ["tumors", "OBSERVATION", 49, 55], ["significantly different", "OBSERVATION_MODIFIER", 128, 151]]], ["After stratifying subjects by age, they demonstrated a significantly augmented risk of intubation in subjects with tumors if aged 66-80.", [["tumors", "ANATOMY", 115, 121], ["tumors", "DISEASE", 115, 121], ["tumors", "CANCER", 115, 121], ["intubation", "TREATMENT", 87, 97], ["tumors", "PROBLEM", 115, 121], ["intubation", "OBSERVATION", 87, 97]]], ["Unexpectedly, subjects with tumors who were younger than 50 years had a higher mortality percentage.", [["tumors", "ANATOMY", 28, 34], ["tumors", "DISEASE", 28, 34], ["tumors", "CANCER", 28, 34], ["tumors", "PROBLEM", 28, 34], ["tumors", "OBSERVATION", 28, 34]]], ["Moreover, the mortality of SARS-CoV-2 in tumor subjects was lower than that in subjects without tumors in age groups older than 50 years, although the difference was not statistically significant.", [["tumor", "ANATOMY", 41, 46], ["tumors", "ANATOMY", 96, 102], ["SARS", "DISEASE", 27, 31], ["tumor", "DISEASE", 41, 46], ["tumors", "DISEASE", 96, 102], ["SARS-CoV-2", "ORGANISM", 27, 37], ["tumor", "CANCER", 41, 46], ["tumors", "CANCER", 96, 102], ["SARS-CoV", "SPECIES", 27, 35], ["SARS", "PROBLEM", 27, 31], ["CoV", "TEST", 32, 35], ["tumors", "PROBLEM", 96, 102], ["tumor", "OBSERVATION", 41, 46], ["tumors", "OBSERVATION", 96, 102]]], ["The uncertain connection between SARS-CoV-2 and intubation or death is a drawback in this analysis.", [["death", "DISEASE", 62, 67], ["SARS-CoV", "SPECIES", 33, 41], ["intubation", "TREATMENT", 48, 58], ["death", "PROBLEM", 62, 67], ["this analysis", "TEST", 85, 98]]], ["Moreover, the heterogeneity of tumor forms and diverse stages of cancers may provoke some uncertainty in the interpretation of the data [20] .All/various countries/continentsIn contrast to data from China and the USA, a report from Italy suggested that 20% of subjects with SARS-CoV-2 had been treated for a tumor in the previous 5 years.", [["tumor", "ANATOMY", 31, 36], ["cancers", "ANATOMY", 65, 72], ["tumor", "ANATOMY", 308, 313], ["tumor", "DISEASE", 31, 36], ["cancers", "DISEASE", 65, 72], ["SARS", "DISEASE", 274, 278], ["tumor", "DISEASE", 308, 313], ["tumor", "CANCER", 31, 36], ["cancers", "CANCER", 65, 72], ["SARS-CoV", "ORGANISM", 274, 282], ["tumor", "CANCER", 308, 313], ["the heterogeneity of tumor", "PROBLEM", 10, 36], ["cancers", "PROBLEM", 65, 72], ["SARS", "PROBLEM", 274, 278], ["a tumor", "PROBLEM", 306, 313], ["heterogeneity", "OBSERVATION_MODIFIER", 14, 27], ["tumor", "OBSERVATION", 31, 36], ["diverse", "OBSERVATION_MODIFIER", 47, 54], ["stages", "OBSERVATION_MODIFIER", 55, 61], ["cancers", "OBSERVATION", 65, 72], ["tumor", "OBSERVATION", 308, 313]]], ["However, in this study, the detection of comorbidities was limited to subjects who died of SARS-CoV-2; therefore, differentiating between tumors as an independent risk factor for developing SARS-CoV-2 or as a risk factor for a bad prognosis is not possible [17] .All/various countries/continentsIn a different study performed on 355 Italian subjects, 20.3% had an active tumors, in addition to several other comorbidities.", [["tumors", "ANATOMY", 138, 144], ["tumors", "ANATOMY", 371, 377], ["SARS", "DISEASE", 91, 95], ["tumors", "DISEASE", 138, 144], ["SARS", "DISEASE", 190, 194], ["tumors", "DISEASE", 371, 377], ["tumors", "CANCER", 138, 144], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 190, 200], ["tumors", "CANCER", 371, 377], ["SARS-CoV", "SPECIES", 91, 99], ["this study", "TEST", 12, 22], ["comorbidities", "PROBLEM", 41, 54], ["SARS", "PROBLEM", 91, 95], ["CoV", "TEST", 96, 99], ["tumors", "PROBLEM", 138, 144], ["an independent risk factor", "PROBLEM", 148, 174], ["developing SARS", "PROBLEM", 179, 194], ["a bad prognosis", "PROBLEM", 225, 240], ["a different study", "TEST", 298, 315], ["an active tumors", "PROBLEM", 361, 377], ["several other comorbidities", "PROBLEM", 394, 421], ["tumors", "OBSERVATION", 138, 144], ["active", "OBSERVATION_MODIFIER", 364, 370], ["tumors", "OBSERVATION", 371, 377]]], ["Although a higher mean age (79.5 \u00b1 8.1 years) was registered within this group, separate analyses have demonstrated a death percentage estimated at 20% in subjects aged 80 and older [18] .All/various countries/continentsA specific analysis was performed on particular subsets of patients, such as those affected by onco-hematological pathologies.", [["onco-hematological", "ANATOMY", 315, 333], ["death", "DISEASE", 118, 123], ["onco-hematological pathologies", "DISEASE", 315, 345], ["patients", "ORGANISM", 279, 287], ["patients", "SPECIES", 279, 287], ["a death percentage", "TEST", 116, 134], ["A specific analysis", "TEST", 220, 239], ["onco-hematological pathologies", "PROBLEM", 315, 345]]], ["One might suppose subjects with immune system tumors, such as lymphomas and lymphoid leukemias, might be at augmented risk for contracting SARS-CoV2 with respect to patients with myeloid cancers, such as Acute Myeloid Leukemia and Myelodysplastic Syndromes (AML and MDS), but an evaluation found no such connection.", [["immune system tumors", "ANATOMY", 32, 52], ["lymphomas", "ANATOMY", 62, 71], ["lymphoid leukemias", "ANATOMY", 76, 94], ["myeloid cancers", "ANATOMY", 179, 194], ["Acute Myeloid Leukemia", "ANATOMY", 204, 226], ["AML", "ANATOMY", 258, 261], ["immune system tumors", "DISEASE", 32, 52], ["lymphomas", "DISEASE", 62, 71], ["lymphoid leukemias", "DISEASE", 76, 94], ["SARS", "DISEASE", 139, 143], ["myeloid cancers", "DISEASE", 179, 194], ["Acute Myeloid Leukemia", "DISEASE", 204, 226], ["Myelodysplastic Syndromes", "DISEASE", 231, 256], ["AML", "DISEASE", 258, 261], ["MDS", "DISEASE", 266, 269], ["immune system tumors", "CANCER", 32, 52], ["lymphomas", "CANCER", 62, 71], ["lymphoid leukemias", "CANCER", 76, 94], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 139, 148], ["patients", "ORGANISM", 165, 173], ["myeloid cancers", "CANCER", 179, 194], ["Acute Myeloid Leukemia", "CANCER", 204, 226], ["AML", "CANCER", 258, 261], ["patients", "SPECIES", 165, 173], ["immune system tumors", "PROBLEM", 32, 52], ["lymphomas", "PROBLEM", 62, 71], ["lymphoid leukemias", "PROBLEM", 76, 94], ["contracting SARS", "PROBLEM", 127, 143], ["myeloid cancers", "PROBLEM", 179, 194], ["Acute Myeloid Leukemia", "PROBLEM", 204, 226], ["Myelodysplastic Syndromes", "PROBLEM", 231, 256], ["AML", "PROBLEM", 258, 261], ["MDS", "PROBLEM", 266, 269], ["an evaluation", "TEST", 276, 289], ["such connection", "PROBLEM", 299, 314], ["immune system", "OBSERVATION_MODIFIER", 32, 45], ["tumors", "OBSERVATION", 46, 52], ["lymphomas", "OBSERVATION", 62, 71], ["lymphoid leukemias", "OBSERVATION", 76, 94], ["myeloid cancers", "OBSERVATION", 179, 194], ["Acute", "OBSERVATION_MODIFIER", 204, 209], ["Myeloid Leukemia", "OBSERVATION", 210, 226], ["Myelodysplastic Syndromes", "OBSERVATION", 231, 256]]], ["He et al. performed a cohort study at two centers in Wuhan, China, of 128 hospitalized patients with hematological neoplasia, 10% of whom contracted SARS-CoV-2, and of 226 health care providers, 16 of whom contracted SARS-CoV-2 and 11 of whom were hospitalized.", [["hematological neoplasia", "ANATOMY", 101, 124], ["hematological neoplasia", "DISEASE", 101, 124], ["SARS", "DISEASE", 149, 153], ["SARS", "DISEASE", 217, 221], ["patients", "ORGANISM", 87, 95], ["hematological neoplasia", "CANCER", 101, 124], ["patients", "SPECIES", 87, 95], ["a cohort study", "TEST", 20, 34], ["hematological neoplasia", "PROBLEM", 101, 124], ["hematological", "ANATOMY", 101, 114], ["neoplasia", "OBSERVATION", 115, 124]]], ["The case rate for SARS-CoV-2 in hospitalized subjects with hematological diseases was 10%, compared to 7% in health care providers.", [["hematological", "ANATOMY", 59, 72], ["SARS", "DISEASE", 18, 22], ["hematological diseases", "DISEASE", 59, 81], ["SARS-CoV-2", "ORGANISM", 18, 28], ["SARS-CoV", "SPECIES", 18, 26], ["The case rate", "TEST", 0, 13], ["SARS", "PROBLEM", 18, 22], ["CoV", "TEST", 23, 26], ["hematological diseases", "PROBLEM", 59, 81]]], ["Nevertheless, the 13 patients with hematological diseases had more serious SARS-CoV-2, and more from this group died from the illness.", [["hematological", "ANATOMY", 35, 48], ["hematological diseases", "DISEASE", 35, 57], ["SARS", "DISEASE", 75, 79], ["illness", "DISEASE", 126, 133], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["hematological diseases", "PROBLEM", 35, 57], ["the illness", "PROBLEM", 122, 133], ["illness", "OBSERVATION", 126, 133]]], ["The case fatality percentages were 62% and 0%, respectively [16] .All/various countries/continentsThe augmented case fatality rate of patients with hematological disorders and SARS-CoV-2 appears to be correlated essentially to bacterial infections.", [["hematological", "ANATOMY", 148, 161], ["hematological disorders", "DISEASE", 148, 171], ["SARS", "DISEASE", 176, 180], ["bacterial infections", "DISEASE", 227, 247], ["patients", "ORGANISM", 134, 142], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 176, 186], ["patients", "SPECIES", 134, 142], ["SARS-CoV", "SPECIES", 176, 184], ["The case fatality percentages", "TEST", 0, 29], ["hematological disorders", "PROBLEM", 148, 171], ["SARS", "PROBLEM", 176, 180], ["CoV", "TEST", 181, 184], ["bacterial infections", "PROBLEM", 227, 247], ["bacterial", "OBSERVATION_MODIFIER", 227, 236], ["infections", "OBSERVATION", 237, 247]]], ["This is consistent with a greater possibility of reduced granulocyte levels because of their disease or treatment.All/various countries/continentsRegarding the gravity of the infection in cancer patients and the high mortality rate in cancer patients, it should be borne in mind that patients with SARS-CoV-2 may struggle to overcome critical phases such as intubation; full intensive care support and life sustaining therapies cannot overcome the poor prognosis for certain high-risk populations affected by SARS-CoV-2 [23] [24] [25] .All/various countries/continentsA separate discussion must then be had in the field of pediatric oncology.", [["granulocyte", "ANATOMY", 57, 68], ["cancer", "ANATOMY", 188, 194], ["cancer", "ANATOMY", 235, 241], ["infection", "DISEASE", 175, 184], ["cancer", "DISEASE", 188, 194], ["cancer", "DISEASE", 235, 241], ["SARS", "DISEASE", 298, 302], ["SARS", "DISEASE", 509, 513], ["granulocyte", "CELL", 57, 68], ["cancer", "CANCER", 188, 194], ["patients", "ORGANISM", 195, 203], ["cancer", "CANCER", 235, 241], ["patients", "ORGANISM", 242, 250], ["patients", "ORGANISM", 284, 292], ["SARS-CoV-2", "ORGANISM", 298, 308], ["2 [23] [24] [25]", "SIMPLE_CHEMICAL", 518, 534], ["patients", "SPECIES", 195, 203], ["patients", "SPECIES", 242, 250], ["patients", "SPECIES", 284, 292], ["reduced granulocyte levels", "PROBLEM", 49, 75], ["their disease", "PROBLEM", 87, 100], ["treatment", "TREATMENT", 104, 113], ["the infection in cancer", "PROBLEM", 171, 194], ["the high mortality rate in cancer", "PROBLEM", 208, 241], ["SARS", "PROBLEM", 298, 302], ["intubation", "TREATMENT", 358, 368], ["full intensive care support", "TREATMENT", 370, 397], ["life sustaining therapies", "TREATMENT", 402, 427], ["certain high-risk populations", "PROBLEM", 467, 496], ["CoV", "TEST", 514, 517], ["consistent with", "UNCERTAINTY", 8, 23], ["greater", "OBSERVATION_MODIFIER", 26, 33], ["reduced", "OBSERVATION_MODIFIER", 49, 56], ["granulocyte levels", "OBSERVATION", 57, 75], ["disease", "OBSERVATION", 93, 100], ["infection", "OBSERVATION", 175, 184], ["cancer", "OBSERVATION", 188, 194]]], ["Hrusak et al. performed a flash survey on SARS-CoV-2 occurrence and gravity among children on antitumor treatments.", [["antitumor", "ANATOMY", 94, 103], ["SARS", "DISEASE", 42, 46], ["children", "ORGANISM", 82, 90], ["antitumor", "CANCER", 94, 103], ["children", "SPECIES", 82, 90], ["SARS-CoV", "SPECIES", 42, 50], ["a flash survey", "TEST", 24, 38], ["SARS", "PROBLEM", 42, 46], ["antitumor treatments", "TREATMENT", 94, 114]]], ["They collected data from 25 countries, and about 10,000 patients considered at risk were followed.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64]]], ["Over 200 of these children were tested, nine of whom were positive for SARS-CoV-2.", [["SARS", "DISEASE", 71, 75], ["children", "ORGANISM", 18, 26], ["SARS-CoV-2", "ORGANISM", 71, 81], ["children", "SPECIES", 18, 26], ["SARS-CoV", "SPECIES", 71, 79], ["SARS", "PROBLEM", 71, 75]]], ["Eight of the nine cases had an asymptomatic to mild infection [12] .All/various countries/continentsThe low percentage of infection in this population is rather unexpected, as it is reasonable to presume that pediatric subjects with tumors would be at least as vulnerable to infection as their healthy peers.", [["tumors", "ANATOMY", 233, 239], ["infection", "DISEASE", 52, 61], ["infection", "DISEASE", 122, 131], ["tumors", "DISEASE", 233, 239], ["infection", "DISEASE", 275, 284], ["tumors", "CANCER", 233, 239], ["mild infection", "PROBLEM", 47, 61], ["infection", "PROBLEM", 122, 131], ["tumors", "PROBLEM", 233, 239], ["infection", "PROBLEM", 275, 284], ["mild", "OBSERVATION_MODIFIER", 47, 51], ["infection", "OBSERVATION", 52, 61], ["low percentage", "OBSERVATION_MODIFIER", 104, 118], ["infection", "OBSERVATION", 122, 131], ["tumors", "OBSERVATION", 233, 239], ["infection", "OBSERVATION", 275, 284]]], ["SARS-CoV-2 does infect children in general, although the minor gravity of the infection increases the likelihood of underreporting in children.All/various countries/continentsThe mild infection experienced by three children in this report was in contrast to a formerly reported case.", [["SARS", "DISEASE", 0, 4], ["infection", "DISEASE", 78, 87], ["infection", "DISEASE", 184, 193], ["SARS-CoV-2", "ORGANISM", 0, 10], ["children", "ORGANISM", 23, 31], ["children", "ORGANISM", 134, 142], ["children", "ORGANISM", 215, 223], ["children", "SPECIES", 23, 31], ["children", "SPECIES", 134, 142], ["children", "SPECIES", 215, 223], ["SARS-CoV", "SPECIES", 0, 8], ["the infection", "PROBLEM", 74, 87], ["The mild infection", "PROBLEM", 175, 193], ["infection", "OBSERVATION", 78, 87], ["mild", "OBSERVATION_MODIFIER", 179, 183], ["infection", "OBSERVATION", 184, 193]]], ["An 8 year old child undergoing myelosuppressive chemotherapy for T-cell acute lymphoblastic leukemia in ALL in a Wuhan hospital presented with respiratory failure, necessitating mechanical ventilation.", [["T-cell acute lymphoblastic leukemia", "ANATOMY", 65, 100], ["ALL", "ANATOMY", 104, 107], ["respiratory", "ANATOMY", 143, 154], ["T-cell acute lymphoblastic leukemia", "DISEASE", 65, 100], ["ALL", "DISEASE", 104, 107], ["respiratory failure", "DISEASE", 143, 162], ["child", "ORGANISM", 14, 19], ["T-cell acute lymphoblastic leukemia", "CANCER", 65, 100], ["ALL", "CANCER", 104, 107], ["child", "SPECIES", 14, 19], ["myelosuppressive chemotherapy", "TREATMENT", 31, 60], ["T-cell acute lymphoblastic leukemia", "PROBLEM", 65, 100], ["respiratory failure", "PROBLEM", 143, 162], ["mechanical ventilation", "TREATMENT", 178, 200], ["cell", "OBSERVATION", 67, 71], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["lymphoblastic leukemia", "OBSERVATION", 78, 100], ["respiratory", "ANATOMY", 143, 154], ["failure", "OBSERVATION", 155, 162], ["mechanical ventilation", "OBSERVATION", 178, 200]]], ["During the disease, CRP and Interleukin (IL)-6) were only slightly increased, but ferritin concentrations were elevated (6417-15,758 ug/L).", [["CRP", "GENE_OR_GENE_PRODUCT", 20, 23], ["Interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 28, 46], ["ferritin", "GENE_OR_GENE_PRODUCT", 82, 90], ["CRP", "PROTEIN", 20, 23], ["Interleukin (IL)-6", "PROTEIN", 28, 46], ["ferritin", "PROTEIN", 82, 90], ["the disease", "PROBLEM", 7, 18], ["CRP", "TEST", 20, 23], ["Interleukin (IL)", "TEST", 28, 44], ["ferritin concentrations", "TEST", 82, 105], ["elevated", "PROBLEM", 111, 119], ["disease", "OBSERVATION", 11, 18], ["slightly", "OBSERVATION_MODIFIER", 58, 66], ["increased", "OBSERVATION_MODIFIER", 67, 76]]], ["This is evocative of characteristics of hemophagocytic lymphohistiocytosis, which has been reported to co-occur with infections [26] .All/various countries/continentsA description of the Italian experience at a major childhood cancer center in Lombardy has recently been presented [19] .", [["cancer", "ANATOMY", 227, 233], ["hemophagocytic lymphohistiocytosis", "DISEASE", 40, 74], ["infections", "DISEASE", 117, 127], ["cancer", "DISEASE", 227, 233], ["cancer", "CANCER", 227, 233], ["hemophagocytic lymphohistiocytosis", "PROBLEM", 40, 74], ["infections", "PROBLEM", 117, 127], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 40, 74], ["cancer", "OBSERVATION", 227, 233]]], ["This report described five positive cases in subjects with childhood tumors, all of whom had a benign course and survived.", [["childhood tumors", "ANATOMY", 59, 75], ["tumors", "DISEASE", 69, 75], ["childhood tumors", "CANCER", 59, 75], ["childhood tumors", "PROBLEM", 59, 75], ["tumors", "OBSERVATION", 69, 75], ["benign", "OBSERVATION_MODIFIER", 95, 101]]], ["Three subjects were treated at home, and two in hospital.All/various countries/continentsAs for a possible explanation for the different course that tends to occur in children, the quantitative and qualitative changes in cytokine delivery can cause a diverse immune responses, and may explain the diverse outcomes in specific patients.", [["children", "ORGANISM", 167, 175], ["patients", "ORGANISM", 326, 334], ["cytokine", "PROTEIN", 221, 229], ["children", "SPECIES", 167, 175], ["patients", "SPECIES", 326, 334], ["cytokine delivery", "TREATMENT", 221, 238]]], ["In fact, it has now been documented that pregnant women and children generally have a mild disease after SARS-CoV-2 infection, if not a fully asymptomatic one [27] .", [["SARS-CoV-2 infection", "DISEASE", 105, 125], ["women", "ORGANISM", 50, 55], ["children", "ORGANISM", 60, 68], ["CoV-2", "ORGANISM", 110, 115], ["women", "SPECIES", 50, 55], ["children", "SPECIES", 60, 68], ["a mild disease", "PROBLEM", 84, 98], ["SARS", "PROBLEM", 105, 109], ["CoV-2 infection", "PROBLEM", 110, 125], ["mild", "OBSERVATION_MODIFIER", 86, 90], ["disease", "OBSERVATION", 91, 98]]], ["These types of subjects have an immune response skewed toward a T-helper Type 2 cells (TH2) profile (controlled by the TH2 cells), with a particular production of cytokines like IL-4 and IL-10, while production of the pro-inflammatory cytokines in SARS-CoV-2 infection is characteristic of TH1 cells.All/various countries/continentsThis specific immunological setup could somewhat defend pediatric tumor subjects from the most critical clinical manifestations of the infection.All/various countries/continentsDespite the presence in the literature of sometimes discordant data, this discordance can probably be linked to the low number of samples collected, the heterogeneity of neoplastic pathologies, and ethnic differences.", [["T-helper Type 2 cells", "ANATOMY", 64, 85], ["TH2 cells", "ANATOMY", 119, 128], ["TH1 cells", "ANATOMY", 290, 299], ["tumor", "ANATOMY", 398, 403], ["samples", "ANATOMY", 639, 646], ["neoplastic", "ANATOMY", 679, 689], ["infection", "DISEASE", 259, 268], ["tumor", "DISEASE", 398, 403], ["infection", "DISEASE", 467, 476], ["T-helper Type 2 cells", "CELL", 64, 85], ["TH2", "CELL", 87, 90], ["TH2 cells", "CELL", 119, 128], ["IL-4", "GENE_OR_GENE_PRODUCT", 178, 182], ["IL-10", "GENE_OR_GENE_PRODUCT", 187, 192], ["SARS-CoV-2", "ORGANISM", 248, 258], ["TH1 cells", "CELL", 290, 299], ["tumor", "CANCER", 398, 403], ["samples", "CANCER", 639, 646], ["T-helper Type 2 cells", "CELL_TYPE", 64, 85], ["TH2 cells", "CELL_TYPE", 119, 128], ["cytokines", "PROTEIN", 163, 172], ["IL-4", "PROTEIN", 178, 182], ["IL-10", "PROTEIN", 187, 192], ["pro-inflammatory cytokines", "PROTEIN", 218, 244], ["TH1 cells", "CELL_TYPE", 290, 299], ["SARS-CoV-2", "SPECIES", 248, 258], ["an immune response", "PROBLEM", 29, 47], ["IL", "TEST", 178, 180], ["IL", "TEST", 187, 189], ["the pro-inflammatory cytokines", "TEST", 214, 244], ["SARS", "PROBLEM", 248, 252], ["CoV-2 infection", "PROBLEM", 253, 268], ["TH1 cells", "PROBLEM", 290, 299], ["pediatric tumor subjects", "PROBLEM", 388, 412], ["the infection", "PROBLEM", 463, 476], ["neoplastic pathologies", "PROBLEM", 679, 701], ["pro-inflammatory cytokines", "OBSERVATION", 218, 244], ["infection", "OBSERVATION", 259, 268], ["characteristic of", "UNCERTAINTY", 272, 289], ["TH1 cells", "OBSERVATION", 290, 299], ["tumor", "OBSERVATION", 398, 403], ["most critical", "OBSERVATION_MODIFIER", 422, 435], ["infection", "OBSERVATION", 467, 476], ["low", "OBSERVATION_MODIFIER", 625, 628], ["heterogeneity", "OBSERVATION_MODIFIER", 662, 675], ["neoplastic", "OBSERVATION_MODIFIER", 679, 689], ["pathologies", "OBSERVATION", 690, 701]]], ["It is likely that cancer patients have a different susceptibility to SARS-CoV-2 infection, a different course, and a different prognosis.Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsThe present data remain inadequate to explicate an irrefutable correlation between tumors and SARS-CoV2 infection or poorer outcomes.", [["cancer", "ANATOMY", 18, 24], ["Cancer", "ANATOMY", 180, 186], ["tumors", "ANATOMY", 278, 284], ["cancer", "DISEASE", 18, 24], ["SARS-CoV-2 infection", "DISEASE", 69, 89], ["SARS-CoV 2 Infection", "DISEASE", 156, 176], ["Cancer", "DISEASE", 180, 186], ["tumors", "DISEASE", 278, 284], ["SARS-CoV2 infection", "DISEASE", 289, 308], ["cancer", "CANCER", 18, 24], ["patients", "ORGANISM", 25, 33], ["SARS-CoV-2", "ORGANISM", 69, 79], ["SARS-CoV 2", "ORGANISM", 156, 166], ["Cancer", "CANCER", 180, 186], ["Patients", "ORGANISM", 187, 195], ["tumors", "CANCER", 278, 284], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 289, 298], ["patients", "SPECIES", 25, 33], ["Patients", "SPECIES", 187, 195], ["SARS-CoV", "SPECIES", 69, 77], ["SARS-CoV", "SPECIES", 156, 164], ["cancer", "PROBLEM", 18, 24], ["SARS", "PROBLEM", 69, 73], ["CoV-2 infection", "PROBLEM", 74, 89], ["SARS", "PROBLEM", 156, 160], ["CoV 2 Infection in Cancer", "PROBLEM", 161, 186], ["an irrefutable correlation between tumors", "PROBLEM", 243, 284], ["SARS", "PROBLEM", 289, 293], ["CoV2 infection", "PROBLEM", 294, 308], ["is likely", "UNCERTAINTY", 3, 12], ["cancer", "OBSERVATION", 18, 24], ["infection", "OBSERVATION", 80, 89], ["SARS", "OBSERVATION", 156, 160], ["CoV 2", "OBSERVATION_MODIFIER", 161, 166], ["Infection", "OBSERVATION", 167, 176], ["Cancer", "OBSERVATION", 180, 186], ["tumors", "OBSERVATION", 278, 284], ["infection", "OBSERVATION", 299, 308]]], ["However, some considerations and hypotheses can be formulated on the subject ( Figure 1 ).Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsThe mild infection experienced by three children in this report was in contrast to a formerly reported case.", [["Cancer", "ANATOMY", 133, 139], ["SARS-CoV 2 Infection", "DISEASE", 109, 129], ["Cancer", "DISEASE", 133, 139], ["infection", "DISEASE", 157, 166], ["SARS-CoV 2", "ORGANISM", 109, 119], ["Cancer", "CANCER", 133, 139], ["Patients", "ORGANISM", 140, 148], ["children", "ORGANISM", 188, 196], ["Patients", "SPECIES", 140, 148], ["children", "SPECIES", 188, 196], ["SARS-CoV 2 Infection in Cancer", "PROBLEM", 109, 139], ["The mild infection", "PROBLEM", 148, 166], ["SARS-CoV", "OBSERVATION", 109, 117], ["Infection", "OBSERVATION", 120, 129], ["Cancer", "OBSERVATION", 133, 139], ["mild", "OBSERVATION_MODIFIER", 152, 156], ["infection", "OBSERVATION", 157, 166]]], ["An 8 year old child undergoing myelosuppressive chemotherapy for T-cell acute lymphoblastic leukemia in ALL in a Wuhan hospital presented with respiratory failure, necessitating mechanical ventilation.", [["T-cell acute lymphoblastic leukemia", "ANATOMY", 65, 100], ["ALL", "ANATOMY", 104, 107], ["respiratory", "ANATOMY", 143, 154], ["T-cell acute lymphoblastic leukemia", "DISEASE", 65, 100], ["ALL", "DISEASE", 104, 107], ["respiratory failure", "DISEASE", 143, 162], ["child", "ORGANISM", 14, 19], ["T-cell acute lymphoblastic leukemia", "CANCER", 65, 100], ["ALL", "CANCER", 104, 107], ["child", "SPECIES", 14, 19], ["myelosuppressive chemotherapy", "TREATMENT", 31, 60], ["T-cell acute lymphoblastic leukemia", "PROBLEM", 65, 100], ["respiratory failure", "PROBLEM", 143, 162], ["mechanical ventilation", "TREATMENT", 178, 200], ["cell", "OBSERVATION", 67, 71], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["lymphoblastic leukemia", "OBSERVATION", 78, 100], ["respiratory", "ANATOMY", 143, 154], ["failure", "OBSERVATION", 155, 162], ["mechanical ventilation", "OBSERVATION", 178, 200]]], ["During the disease, CRP and Interleukin (IL)-6) were only slightly increased, but ferritin concentrations were elevated (6417-15,758 ug/L).", [["CRP", "GENE_OR_GENE_PRODUCT", 20, 23], ["Interleukin (IL)-6", "GENE_OR_GENE_PRODUCT", 28, 46], ["ferritin", "GENE_OR_GENE_PRODUCT", 82, 90], ["CRP", "PROTEIN", 20, 23], ["Interleukin (IL)-6", "PROTEIN", 28, 46], ["ferritin", "PROTEIN", 82, 90], ["the disease", "PROBLEM", 7, 18], ["CRP", "TEST", 20, 23], ["Interleukin (IL)", "TEST", 28, 44], ["ferritin concentrations", "TEST", 82, 105], ["elevated", "PROBLEM", 111, 119], ["disease", "OBSERVATION", 11, 18], ["slightly", "OBSERVATION_MODIFIER", 58, 66], ["increased", "OBSERVATION_MODIFIER", 67, 76]]], ["This is evocative of characteristics of hemophagocytic lymphohistiocytosis, which has been reported to co-occur with infections [26] .Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsA description of the Italian experience at a major childhood cancer center in Lombardy has recently been presented [19] .", [["Cancer", "ANATOMY", 177, 183], ["cancer", "ANATOMY", 253, 259], ["hemophagocytic lymphohistiocytosis", "DISEASE", 40, 74], ["infections", "DISEASE", 117, 127], ["Cancer", "DISEASE", 177, 183], ["cancer", "DISEASE", 253, 259], ["Cancer", "CANCER", 177, 183], ["cancer", "CANCER", 253, 259], ["hemophagocytic lymphohistiocytosis", "PROBLEM", 40, 74], ["infections", "PROBLEM", 117, 127], ["SARS-CoV 2 Infection", "PROBLEM", 153, 173], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 40, 74], ["SARS-CoV", "OBSERVATION", 153, 161], ["Infection", "OBSERVATION", 164, 173], ["Cancer", "OBSERVATION", 177, 183], ["cancer", "OBSERVATION", 253, 259]]], ["This report described five positive cases in subjects with childhood tumors, all of whom had a benign course and survived.", [["childhood tumors", "ANATOMY", 59, 75], ["tumors", "DISEASE", 69, 75], ["childhood tumors", "CANCER", 59, 75], ["childhood tumors", "PROBLEM", 59, 75], ["tumors", "OBSERVATION", 69, 75], ["benign", "OBSERVATION_MODIFIER", 95, 101]]], ["Three subjects were treated at home, and two in hospital.Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsAs for a possible explanation for the different course that tends to occur in children, the quantitative and qualitative changes in cytokine delivery can cause a diverse immune responses, and may explain the diverse outcomes in specific patients.", [["Cancer", "ANATOMY", 100, 106], ["SARS", "DISEASE", 76, 80], ["Infection", "DISEASE", 87, 96], ["Cancer", "DISEASE", 100, 106], ["Cancer", "CANCER", 100, 106], ["Patients", "ORGANISM", 107, 115], ["children", "ORGANISM", 193, 201], ["patients", "ORGANISM", 352, 360], ["cytokine", "PROTEIN", 247, 255], ["Patients", "SPECIES", 107, 115], ["children", "SPECIES", 193, 201], ["patients", "SPECIES", 352, 360], ["SARS-CoV 2 Infection in Cancer", "PROBLEM", 76, 106], ["cytokine delivery", "TREATMENT", 247, 264], ["SARS", "OBSERVATION", 76, 80], ["Infection", "OBSERVATION", 87, 96], ["Cancer", "OBSERVATION", 100, 106]]], ["In fact, it has now been documented that pregnant women and children generally have a mild disease after SARS-CoV-2 infection, if not a fully asymptomatic one [27] .", [["SARS-CoV-2 infection", "DISEASE", 105, 125], ["women", "ORGANISM", 50, 55], ["children", "ORGANISM", 60, 68], ["CoV-2", "ORGANISM", 110, 115], ["women", "SPECIES", 50, 55], ["children", "SPECIES", 60, 68], ["a mild disease", "PROBLEM", 84, 98], ["SARS", "PROBLEM", 105, 109], ["CoV-2 infection", "PROBLEM", 110, 125], ["mild", "OBSERVATION_MODIFIER", 86, 90], ["disease", "OBSERVATION", 91, 98]]], ["These types of subjects have an immune response skewed toward a T-helper Type 2 cells (TH2) profile (controlled by the TH2 cells), with a particular production of cytokines like IL-4 and IL-10, while production of the pro-inflammatory cytokines in SARS-CoV-2 infection is characteristic of TH1 cells.Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsThis specific immunological setup could somewhat defend pediatric tumor subjects from the most critical clinical manifestations of the infection.Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsDespite the presence in the literature of sometimes discordant data, this discordance can probably be linked to the low number of samples collected, the heterogeneity of neoplastic pathologies, and ethnic differences.", [["T-helper Type 2 cells", "ANATOMY", 64, 85], ["TH2 cells", "ANATOMY", 119, 128], ["TH1 cells", "ANATOMY", 290, 299], ["Cancer", "ANATOMY", 343, 349], ["tumor", "ANATOMY", 424, 429], ["Cancer", "ANATOMY", 546, 552], ["samples", "ANATOMY", 691, 698], ["neoplastic", "ANATOMY", 731, 741], ["infection", "DISEASE", 259, 268], ["SARS", "DISEASE", 319, 323], ["Infection", "DISEASE", 330, 339], ["Cancer", "DISEASE", 343, 349], ["tumor", "DISEASE", 424, 429], ["infection", "DISEASE", 493, 502], ["SARS-CoV 2 Infection", "DISEASE", 522, 542], ["Cancer", "DISEASE", 546, 552], ["T-helper Type 2 cells", "CELL", 64, 85], ["TH2", "CELL", 87, 90], ["TH2 cells", "CELL", 119, 128], ["IL-4", "GENE_OR_GENE_PRODUCT", 178, 182], ["IL-10", "GENE_OR_GENE_PRODUCT", 187, 192], ["SARS-CoV-2", "ORGANISM", 248, 258], ["TH1 cells", "CELL", 290, 299], ["Cancer", "CANCER", 343, 349], ["Patients", "ORGANISM", 350, 358], ["tumor", "CANCER", 424, 429], ["SARS-CoV 2", "ORGANISM", 522, 532], ["Cancer", "CANCER", 546, 552], ["Patients", "ORGANISM", 553, 561], ["samples", "CANCER", 691, 698], ["T-helper Type 2 cells", "CELL_TYPE", 64, 85], ["TH2 cells", "CELL_TYPE", 119, 128], ["cytokines", "PROTEIN", 163, 172], ["IL-4", "PROTEIN", 178, 182], ["IL-10", "PROTEIN", 187, 192], ["pro-inflammatory cytokines", "PROTEIN", 218, 244], ["TH1 cells", "CELL_TYPE", 290, 299], ["Patients", "SPECIES", 350, 358], ["Patients", "SPECIES", 553, 561], ["SARS-CoV-2", "SPECIES", 248, 258], ["an immune response", "PROBLEM", 29, 47], ["IL", "TEST", 178, 180], ["IL", "TEST", 187, 189], ["the pro-inflammatory cytokines", "TEST", 214, 244], ["SARS", "PROBLEM", 248, 252], ["CoV-2 infection", "PROBLEM", 253, 268], ["TH1 cells", "PROBLEM", 290, 299], ["SARS-CoV 2 Infection in Cancer", "PROBLEM", 319, 349], ["pediatric tumor subjects", "PROBLEM", 414, 438], ["the infection", "PROBLEM", 489, 502], ["SARS-CoV 2 Infection in Cancer", "PROBLEM", 522, 552], ["neoplastic pathologies", "PROBLEM", 731, 753], ["pro-inflammatory cytokines", "OBSERVATION", 218, 244], ["infection", "OBSERVATION", 259, 268], ["characteristic of", "UNCERTAINTY", 272, 289], ["TH1 cells", "OBSERVATION", 290, 299], ["SARS", "OBSERVATION", 319, 323], ["Infection", "OBSERVATION", 330, 339], ["Cancer", "OBSERVATION", 343, 349], ["tumor", "OBSERVATION", 424, 429], ["most critical", "OBSERVATION_MODIFIER", 448, 461], ["infection", "OBSERVATION", 493, 502], ["SARS-CoV", "OBSERVATION", 522, 530], ["Infection", "OBSERVATION", 533, 542], ["Cancer", "OBSERVATION", 546, 552], ["low", "OBSERVATION_MODIFIER", 677, 680], ["heterogeneity", "OBSERVATION_MODIFIER", 714, 727], ["neoplastic", "OBSERVATION_MODIFIER", 731, 741], ["pathologies", "OBSERVATION", 742, 753]]], ["It is likely that cancer patients have a different susceptibility to SARS-CoV-2 infection, a different course, and a different prognosis.Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsThe present data remain inadequate to explicate an irrefutable correlation between tumors and SARS-CoV2 infection or poorer outcomes.", [["cancer", "ANATOMY", 18, 24], ["Cancer", "ANATOMY", 180, 186], ["tumors", "ANATOMY", 278, 284], ["cancer", "DISEASE", 18, 24], ["SARS-CoV-2 infection", "DISEASE", 69, 89], ["SARS-CoV 2 Infection", "DISEASE", 156, 176], ["Cancer", "DISEASE", 180, 186], ["tumors", "DISEASE", 278, 284], ["SARS-CoV2 infection", "DISEASE", 289, 308], ["cancer", "CANCER", 18, 24], ["patients", "ORGANISM", 25, 33], ["SARS-CoV-2", "ORGANISM", 69, 79], ["SARS-CoV 2", "ORGANISM", 156, 166], ["Cancer", "CANCER", 180, 186], ["Patients", "ORGANISM", 187, 195], ["tumors", "CANCER", 278, 284], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 289, 298], ["patients", "SPECIES", 25, 33], ["Patients", "SPECIES", 187, 195], ["SARS-CoV", "SPECIES", 69, 77], ["SARS-CoV", "SPECIES", 156, 164], ["cancer", "PROBLEM", 18, 24], ["SARS", "PROBLEM", 69, 73], ["CoV-2 infection", "PROBLEM", 74, 89], ["SARS", "PROBLEM", 156, 160], ["CoV 2 Infection in Cancer", "PROBLEM", 161, 186], ["an irrefutable correlation between tumors", "PROBLEM", 243, 284], ["SARS", "PROBLEM", 289, 293], ["CoV2 infection", "PROBLEM", 294, 308], ["is likely", "UNCERTAINTY", 3, 12], ["cancer", "OBSERVATION", 18, 24], ["infection", "OBSERVATION", 80, 89], ["SARS", "OBSERVATION", 156, 160], ["CoV 2", "OBSERVATION_MODIFIER", 161, 166], ["Infection", "OBSERVATION", 167, 176], ["Cancer", "OBSERVATION", 180, 186], ["tumors", "OBSERVATION", 278, 284], ["infection", "OBSERVATION", 299, 308]]], ["SARS-CoV2's cellular entry receptor, angiotensin-converting enzyme 2 (ACE2) [28] , may be overexpressed in some tumors, including in pancreatic, cervical, and renal cancers [29] .", [["cellular", "ANATOMY", 12, 20], ["tumors", "ANATOMY", 112, 118], ["pancreatic", "ANATOMY", 133, 143], ["cervical", "ANATOMY", 145, 153], ["renal cancers", "ANATOMY", 159, 172], ["SARS", "DISEASE", 0, 4], ["angiotensin", "CHEMICAL", 37, 48], ["tumors", "DISEASE", 112, 118], ["pancreatic, cervical, and renal cancers", "DISEASE", 133, 172], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 0, 9], ["cellular", "CELL", 12, 20], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 37, 68], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["tumors", "CANCER", 112, 118], ["pancreatic", "CANCER", 133, 143], ["cervical", "ORGAN", 145, 153], ["renal cancers", "CANCER", 159, 172], ["SARS-CoV2's cellular entry receptor", "PROTEIN", 0, 35], ["angiotensin-converting enzyme 2", "PROTEIN", 37, 68], ["ACE2", "PROTEIN", 70, 74], ["SARS", "TEST", 0, 4], ["angiotensin", "TEST", 37, 48], ["enzyme", "TEST", 60, 66], ["some tumors", "PROBLEM", 107, 118], ["pancreatic, cervical, and renal cancers", "PROBLEM", 133, 172], ["tumors", "OBSERVATION", 112, 118], ["pancreatic", "ANATOMY", 133, 143], ["cervical", "ANATOMY", 145, 153], ["renal", "ANATOMY", 159, 164], ["cancers", "OBSERVATION", 165, 172]]], ["However, other experiments have suggested the expression of ACE2 is considerably reduced in prostate, liver, and breast tumors, with respect to normal contiguous tissues.Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsSpecific studies have been conducted in patients with renal papillary cell carcinoma and endometrial cancer.Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsACE2 is a component of the renin-angiotensin system, however the relationship between ACE2 and prognosis in UCEC (uterine corpus endometrial carcinoma) and KIRP (kidney renal papillary cell carcinoma) is not well-defined.", [["prostate", "ANATOMY", 92, 100], ["liver", "ANATOMY", 102, 107], ["breast tumors", "ANATOMY", 113, 126], ["tissues", "ANATOMY", 162, 169], ["Cancer", "ANATOMY", 213, 219], ["renal papillary cell carcinoma", "ANATOMY", 282, 312], ["endometrial cancer", "ANATOMY", 317, 335], ["Cancer", "ANATOMY", 379, 385], ["UCEC", "ANATOMY", 502, 506], ["uterine corpus endometrial carcinoma", "ANATOMY", 508, 544], ["KIRP", "ANATOMY", 550, 554], ["kidney renal papillary cell carcinoma", "ANATOMY", 556, 593], ["prostate, liver, and breast tumors", "DISEASE", 92, 126], ["SARS", "DISEASE", 189, 193], ["Cancer", "DISEASE", 213, 219], ["renal papillary cell carcinoma", "DISEASE", 282, 312], ["endometrial cancer", "DISEASE", 317, 335], ["Infection", "DISEASE", 366, 375], ["Cancer", "DISEASE", 379, 385], ["angiotensin", "CHEMICAL", 427, 438], ["UCEC", "DISEASE", 502, 506], ["uterine corpus endometrial carcinoma", "DISEASE", 508, 544], ["kidney renal papillary cell carcinoma", "DISEASE", 556, 593], ["ACE2", "GENE_OR_GENE_PRODUCT", 60, 64], ["prostate", "CANCER", 92, 100], ["liver", "ORGAN", 102, 107], ["breast tumors", "CANCER", 113, 126], ["tissues", "TISSUE", 162, 169], ["Cancer", "CANCER", 213, 219], ["Patients", "ORGANISM", 220, 228], ["patients", "ORGANISM", 268, 276], ["renal papillary cell carcinoma", "CANCER", 282, 312], ["endometrial cancer", "CANCER", 317, 335], ["SARS-CoV 2", "ORGANISM", 355, 365], ["Cancer", "CANCER", 379, 385], ["renin-angiotensin", "GENE_OR_GENE_PRODUCT", 421, 438], ["ACE2", "GENE_OR_GENE_PRODUCT", 480, 484], ["UCEC", "CANCER", 502, 506], ["uterine corpus endometrial carcinoma", "CANCER", 508, 544], ["KIRP", "CANCER", 550, 554], ["kidney renal papillary cell carcinoma", "CANCER", 556, 593], ["ACE2", "PROTEIN", 60, 64], ["renin", "PROTEIN", 421, 426], ["ACE2", "PROTEIN", 480, 484], ["Patients", "SPECIES", 220, 228], ["patients", "SPECIES", 268, 276], ["ACE2", "TEST", 60, 64], ["reduced in prostate, liver, and breast tumors", "PROBLEM", 81, 126], ["SARS-CoV 2 Infection in Cancer", "PROBLEM", 189, 219], ["Specific studies", "TEST", 228, 244], ["renal papillary cell carcinoma", "PROBLEM", 282, 312], ["endometrial cancer", "PROBLEM", 317, 335], ["SARS-CoV 2 Infection in Cancer", "PROBLEM", 355, 385], ["the renin-angiotensin system", "PROBLEM", 417, 445], ["ACE2", "TEST", 480, 484], ["prognosis in UCEC (uterine corpus endometrial carcinoma", "PROBLEM", 489, 544], ["KIRP (kidney renal papillary cell carcinoma", "PROBLEM", 550, 593], ["considerably", "OBSERVATION_MODIFIER", 68, 80], ["reduced", "OBSERVATION_MODIFIER", 81, 88], ["prostate", "ANATOMY", 92, 100], ["liver", "ANATOMY", 102, 107], ["breast", "ANATOMY", 113, 119], ["tumors", "OBSERVATION", 120, 126], ["normal", "OBSERVATION", 144, 150], ["contiguous tissues", "OBSERVATION", 151, 169], ["SARS", "OBSERVATION", 189, 193], ["Infection", "OBSERVATION_MODIFIER", 200, 209], ["Cancer", "OBSERVATION", 213, 219], ["renal", "ANATOMY", 282, 287], ["papillary cell carcinoma", "OBSERVATION", 288, 312], ["endometrial", "ANATOMY", 317, 328], ["cancer", "OBSERVATION", 329, 335], ["SARS-CoV", "OBSERVATION", 355, 363], ["Infection", "OBSERVATION", 366, 375], ["Cancer", "OBSERVATION", 379, 385], ["angiotensin system", "OBSERVATION", 427, 445], ["uterine", "ANATOMY", 508, 515], ["corpus endometrial", "ANATOMY", 516, 534], ["carcinoma", "OBSERVATION", 535, 544], ["kidney", "ANATOMY", 556, 562], ["renal", "ANATOMY", 563, 568], ["papillary cell carcinoma", "OBSERVATION", 569, 593]]], ["ACE2 is augmented in KIRP and UCEC, and increased ACE2 is associated with a favorable outcome.", [["KIRP", "ANATOMY", 21, 25], ["UCEC", "ANATOMY", 30, 34], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["KIRP", "GENE_OR_GENE_PRODUCT", 21, 25], ["UCEC", "CANCER", 30, 34], ["ACE2", "GENE_OR_GENE_PRODUCT", 50, 54], ["ACE2", "PROTEIN", 0, 4], ["KIRP", "CELL_LINE", 21, 25], ["ACE2", "PROTEIN", 50, 54], ["ACE2", "TREATMENT", 0, 4], ["increased ACE2", "PROBLEM", 40, 54], ["augmented", "OBSERVATION", 8, 17]]], ["The expression of ACE2 appears to be positively correlated with the amount of immune infiltration of macrophages in KIRP, CD4+T cells, B cells, neutrophils, and dendritic cell immune infiltration in UCEC.", [["macrophages", "ANATOMY", 101, 112], ["KIRP", "ANATOMY", 116, 120], ["CD4+T cells", "ANATOMY", 122, 133], ["B cells", "ANATOMY", 135, 142], ["neutrophils", "ANATOMY", 144, 155], ["dendritic cell", "ANATOMY", 161, 175], ["UCEC", "ANATOMY", 199, 203], ["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["macrophages", "CELL", 101, 112], ["KIRP", "GENE_OR_GENE_PRODUCT", 116, 120], ["CD4", "GENE_OR_GENE_PRODUCT", 122, 125], ["B cells", "CELL", 135, 142], ["neutrophils", "CELL", 144, 155], ["dendritic cell", "CELL", 161, 175], ["UCEC", "CELL", 199, 203], ["ACE2", "PROTEIN", 18, 22], ["macrophages", "CELL_TYPE", 101, 112], ["KIRP, CD4+T cells", "CELL_TYPE", 116, 133], ["B cells", "CELL_TYPE", 135, 142], ["neutrophils", "CELL_TYPE", 144, 155], ["UCEC", "CELL_TYPE", 199, 203], ["ACE2", "PROBLEM", 18, 22], ["immune infiltration of macrophages", "PROBLEM", 78, 112], ["KIRP", "TEST", 116, 120], ["CD4", "TEST", 122, 125], ["B cells", "TEST", 135, 142], ["neutrophils", "TEST", 144, 155], ["dendritic cell immune infiltration in UCEC", "PROBLEM", 161, 203], ["immune infiltration", "OBSERVATION", 78, 97], ["macrophages", "OBSERVATION", 101, 112], ["neutrophils", "ANATOMY", 144, 155], ["dendritic cell immune infiltration", "OBSERVATION", 161, 195]]], ["Increased ACE2 expression is correlated with a favorable prognosis in UCEC and KIRP.", [["UCEC", "ANATOMY", 70, 74], ["ACE2", "GENE_OR_GENE_PRODUCT", 10, 14], ["UCEC", "CANCER", 70, 74], ["KIRP", "GENE_OR_GENE_PRODUCT", 79, 83], ["ACE2", "PROTEIN", 10, 14], ["Increased ACE2 expression", "PROBLEM", 0, 25]]], ["What is more, it has been demonstrated that the expression of ACE2 is reduced in vivo and in vitro after SARS-Co-V2 infection.", [["infection", "DISEASE", 116, 125], ["ACE2", "GENE_OR_GENE_PRODUCT", 62, 66], ["Co-V2", "ORGANISM", 110, 115], ["ACE2", "PROTEIN", 62, 66], ["SARS", "PROBLEM", 105, 109], ["Co-V2 infection", "PROBLEM", 110, 125], ["reduced", "OBSERVATION_MODIFIER", 70, 77], ["infection", "OBSERVATION", 116, 125]]], ["In conclusion, cancer may make sufferers more vulnerable to SARS-CoV-2 infection in the cases of KIRP and UCEC, leading to a poorer prognosis [30] .Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsSimilar studies have been conducted in lung cancer, as these patients appear to be more susceptible to infection than normal subjects [31] .Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsThe gene expression level of ACE2 may indicate susceptibility to SARS-CoV-2 infection.", [["cancer", "ANATOMY", 15, 21], ["UCEC", "ANATOMY", 106, 110], ["Cancer", "ANATOMY", 191, 197], ["lung cancer", "ANATOMY", 245, 256], ["Cancer", "ANATOMY", 389, 395], ["cancer", "DISEASE", 15, 21], ["SARS", "DISEASE", 60, 64], ["infection", "DISEASE", 71, 80], ["UCEC", "DISEASE", 106, 110], ["SARS-CoV 2 Infection", "DISEASE", 167, 187], ["Cancer", "DISEASE", 191, 197], ["lung cancer", "DISEASE", 245, 256], ["infection", "DISEASE", 309, 318], ["SARS-CoV 2 Infection", "DISEASE", 365, 385], ["Cancer", "DISEASE", 389, 395], ["SARS-CoV-2 infection", "DISEASE", 469, 489], ["cancer", "CANCER", 15, 21], ["SARS-CoV-2", "ORGANISM", 60, 70], ["KIRP", "CANCER", 97, 101], ["UCEC", "CANCER", 106, 110], ["SARS-CoV 2", "ORGANISM", 167, 177], ["Cancer", "CANCER", 191, 197], ["Patients", "ORGANISM", 198, 206], ["lung cancer", "CANCER", 245, 256], ["patients", "ORGANISM", 267, 275], ["SARS-CoV 2", "ORGANISM", 365, 375], ["Cancer", "CANCER", 389, 395], ["Patients", "ORGANISM", 396, 404], ["ACE2", "GENE_OR_GENE_PRODUCT", 433, 437], ["SARS-CoV-2", "ORGANISM", 469, 479], ["ACE2", "PROTEIN", 433, 437], ["Patients", "SPECIES", 198, 206], ["patients", "SPECIES", 267, 275], ["Patients", "SPECIES", 396, 404], ["SARS-CoV", "SPECIES", 60, 68], ["SARS-CoV", "SPECIES", 365, 373], ["SARS-CoV-2", "SPECIES", 469, 479], ["cancer", "PROBLEM", 15, 21], ["SARS", "PROBLEM", 60, 64], ["CoV", "PROBLEM", 65, 68], ["2 infection", "PROBLEM", 69, 80], ["SARS-CoV 2 Infection in Cancer", "PROBLEM", 167, 197], ["Similar studies", "TEST", 206, 221], ["lung cancer", "PROBLEM", 245, 256], ["infection", "PROBLEM", 309, 318], ["SARS", "PROBLEM", 365, 369], ["CoV 2 Infection in Cancer", "PROBLEM", 370, 395], ["SARS", "PROBLEM", 469, 473], ["CoV-2 infection", "PROBLEM", 474, 489], ["cancer", "OBSERVATION", 15, 21], ["infection", "OBSERVATION", 71, 80], ["SARS-CoV", "OBSERVATION", 167, 175], ["Infection", "OBSERVATION", 178, 187], ["Cancer", "OBSERVATION", 191, 197], ["lung", "ANATOMY", 245, 249], ["cancer", "OBSERVATION", 250, 256], ["infection", "OBSERVATION", 309, 318], ["SARS", "OBSERVATION", 365, 369], ["CoV 2", "OBSERVATION_MODIFIER", 370, 375], ["Infection", "OBSERVATION", 376, 385], ["Cancer", "OBSERVATION", 389, 395], ["infection", "OBSERVATION", 480, 489]]], ["Transmembrane serine protease 2 (TMPRSS2) has a supportive action.Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsIn fact, SARS-CoV-2 infected hACE2 transgenic mice showed serious pulmonary alterations, comprising interstitial hemorrhage, protein exudation, lymphocytic infiltration, and alveolar epithelial cell growth [32] .", [["Cancer", "ANATOMY", 109, 115], ["pulmonary", "ANATOMY", 190, 199], ["interstitial", "ANATOMY", 224, 236], ["lymphocytic", "ANATOMY", 268, 279], ["alveolar epithelial cell", "ANATOMY", 298, 322], ["SARS", "DISEASE", 85, 89], ["Cancer", "DISEASE", 109, 115], ["pulmonary alterations", "DISEASE", 190, 211], ["interstitial hemorrhage", "DISEASE", 224, 247], ["serine", "CHEMICAL", 14, 20], ["Transmembrane serine protease 2", "GENE_OR_GENE_PRODUCT", 0, 31], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 33, 40], ["SARS-CoV 2", "ORGANISM", 85, 95], ["Cancer", "CANCER", 109, 115], ["SARS-CoV-2", "ORGANISM", 133, 143], ["hACE2 transgenic mice", "ORGANISM", 153, 174], ["pulmonary", "ORGAN", 190, 199], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 224, 236], ["alveolar epithelial cell", "CELL", 298, 322], ["Transmembrane serine protease 2", "PROTEIN", 0, 31], ["TMPRSS2", "PROTEIN", 33, 40], ["mice", "SPECIES", 170, 174], ["SARS-CoV", "SPECIES", 85, 93], ["SARS-CoV", "SPECIES", 133, 141], ["mice", "SPECIES", 170, 174], ["Transmembrane serine protease", "TREATMENT", 0, 29], ["a supportive action", "TREATMENT", 46, 65], ["SARS", "PROBLEM", 85, 89], ["CoV 2 Infection in Cancer", "PROBLEM", 90, 115], ["SARS", "TEST", 133, 137], ["CoV", "TEST", 138, 141], ["serious pulmonary alterations", "PROBLEM", 182, 211], ["interstitial hemorrhage", "PROBLEM", 224, 247], ["protein exudation", "PROBLEM", 249, 266], ["lymphocytic infiltration", "PROBLEM", 268, 292], ["alveolar epithelial cell growth", "PROBLEM", 298, 329], ["SARS", "OBSERVATION", 85, 89], ["CoV 2", "OBSERVATION_MODIFIER", 90, 95], ["Infection", "OBSERVATION", 96, 105], ["serious", "OBSERVATION_MODIFIER", 182, 189], ["pulmonary", "ANATOMY", 190, 199], ["alterations", "OBSERVATION", 200, 211], ["interstitial", "ANATOMY_MODIFIER", 224, 236], ["hemorrhage", "OBSERVATION", 237, 247], ["exudation", "OBSERVATION_MODIFIER", 257, 266], ["lymphocytic infiltration", "OBSERVATION", 268, 292], ["alveolar", "ANATOMY_MODIFIER", 298, 306], ["epithelial cell", "OBSERVATION", 307, 322], ["growth", "OBSERVATION_MODIFIER", 323, 329]]], ["SARS-CoV-2 infected TMPRSS2-KO mice displayed reduced inflammatory cytokine reactions to intranasal stimulation.", [["SARS-CoV-2", "ORGANISM", 0, 10], ["TMPRSS2-KO mice", "ORGANISM", 20, 35], ["TMPRSS2", "PROTEIN", 20, 27], ["inflammatory cytokine", "PROTEIN", 54, 75], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["infected TMPRSS2", "TEST", 11, 27], ["reduced inflammatory cytokine reactions", "PROBLEM", 46, 85], ["intranasal stimulation", "TREATMENT", 89, 111], ["reduced", "OBSERVATION_MODIFIER", 46, 53], ["inflammatory cytokine", "OBSERVATION", 54, 75]]], ["TMPRSS2 reduction modified the primary sites of infection and the virus spread within the airways, leading to a less critical immunopathology [33] .Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsIn another study, the correlation between gene expression of ACE2 and TMPRSS2 and outcomes in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) was explored [34] .", [["primary sites", "ANATOMY", 31, 44], ["airways", "ANATOMY", 90, 97], ["Cancer", "ANATOMY", 191, 197], ["lung adenocarcinoma", "ANATOMY", 300, 319], ["LUAD", "ANATOMY", 321, 325], ["lung squamous cell carcinoma", "ANATOMY", 331, 359], ["LUSC", "ANATOMY", 361, 365], ["infection", "DISEASE", 48, 57], ["SARS-CoV 2 Infection", "DISEASE", 167, 187], ["Cancer", "DISEASE", 191, 197], ["lung adenocarcinoma", "DISEASE", 300, 319], ["LUAD", "DISEASE", 321, 325], ["lung squamous cell carcinoma", "DISEASE", 331, 359], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 0, 7], ["airways", "MULTI-TISSUE_STRUCTURE", 90, 97], ["SARS-CoV 2", "ORGANISM", 167, 177], ["Cancer", "CANCER", 191, 197], ["Patients", "ORGANISM", 198, 206], ["ACE2", "GENE_OR_GENE_PRODUCT", 267, 271], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 276, 283], ["lung adenocarcinoma", "CANCER", 300, 319], ["LUAD", "CANCER", 321, 325], ["lung squamous cell carcinoma", "CANCER", 331, 359], ["LUSC", "CANCER", 361, 365], ["TMPRSS2", "PROTEIN", 0, 7], ["ACE2", "PROTEIN", 267, 271], ["TMPRSS2", "PROTEIN", 276, 283], ["Patients", "SPECIES", 198, 206], ["TMPRSS2 reduction", "TREATMENT", 0, 17], ["infection", "PROBLEM", 48, 57], ["the virus spread", "PROBLEM", 62, 78], ["a less critical immunopathology", "PROBLEM", 110, 141], ["SARS-CoV 2 Infection in Cancer", "PROBLEM", 167, 197], ["another study", "TEST", 209, 222], ["ACE2", "TEST", 267, 271], ["TMPRSS2", "PROBLEM", 276, 283], ["lung adenocarcinoma (LUAD)", "PROBLEM", 300, 326], ["lung squamous cell carcinoma", "PROBLEM", 331, 359], ["infection", "OBSERVATION", 48, 57], ["virus spread", "OBSERVATION", 66, 78], ["airways", "ANATOMY", 90, 97], ["less", "OBSERVATION_MODIFIER", 112, 116], ["critical", "OBSERVATION_MODIFIER", 117, 125], ["immunopathology", "OBSERVATION", 126, 141], ["SARS-CoV", "OBSERVATION", 167, 175], ["Infection", "OBSERVATION", 178, 187], ["Cancer", "OBSERVATION", 191, 197], ["lung", "ANATOMY", 300, 304], ["adenocarcinoma", "OBSERVATION", 305, 319], ["lung", "ANATOMY", 331, 335], ["squamous cell carcinoma", "OBSERVATION", 336, 359]]], ["Lung tumor subjects in each subtype and stage were found to be predisposed to SARS-CoV-2 infection, excluding the primitive subtype of LUSC.", [["Lung tumor", "ANATOMY", 0, 10], ["LUSC", "ANATOMY", 135, 139], ["Lung tumor", "DISEASE", 0, 10], ["SARS-CoV-2 infection", "DISEASE", 78, 98], ["LUSC", "DISEASE", 135, 139], ["Lung tumor", "CANCER", 0, 10], ["SARS-CoV-2", "ORGANISM", 78, 88], ["LUSC", "CANCER", 135, 139], ["SARS-CoV-2", "SPECIES", 78, 88], ["Lung tumor subjects", "PROBLEM", 0, 19], ["SARS", "PROBLEM", 78, 82], ["CoV", "PROBLEM", 83, 86], ["2 infection", "PROBLEM", 87, 98], ["tumor", "OBSERVATION", 5, 10], ["SARS", "OBSERVATION", 78, 82], ["CoV", "OBSERVATION_MODIFIER", 83, 86], ["infection", "OBSERVATION", 89, 98], ["primitive subtype", "OBSERVATION_MODIFIER", 114, 131], ["LUSC", "OBSERVATION", 135, 139]]], ["LUAD subjects are more vulnerable to SARS-CoV-2 infection than LUSC subjects.", [["SARS", "DISEASE", 37, 41], ["infection", "DISEASE", 48, 57], ["SARS-CoV-2", "ORGANISM", 37, 47], ["LUSC", "CANCER", 63, 67], ["SARS-CoV", "SPECIES", 37, 45], ["LUAD subjects", "PROBLEM", 0, 13], ["SARS", "PROBLEM", 37, 41], ["CoV", "PROBLEM", 42, 45], ["2 infection", "PROBLEM", 46, 57], ["LUSC subjects", "PROBLEM", 63, 76], ["infection", "OBSERVATION", 48, 57]]], ["TMPRSS2 may be a tumor suppressor gene, as it was severely reduced in LUAD and LUSC.Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsIndeed, the relationship between ACE2, cancer, and smoking may have importance, and a diverse possible justification for different vulnerabilities and outcomes in lung cancer subjects might be the greater smoking history in these patients [35] .", [["tumor", "ANATOMY", 17, 22], ["LUAD", "ANATOMY", 70, 74], ["LUSC", "ANATOMY", 79, 83], ["Cancer", "ANATOMY", 127, 133], ["cancer", "ANATOMY", 181, 187], ["lung cancer", "ANATOMY", 305, 316], ["tumor", "DISEASE", 17, 22], ["LUAD", "DISEASE", 70, 74], ["LUSC", "DISEASE", 79, 83], ["SARS-CoV 2 Infection", "DISEASE", 103, 123], ["Cancer", "DISEASE", 127, 133], ["cancer", "DISEASE", 181, 187], ["smoking", "CHEMICAL", 193, 200], ["lung cancer", "DISEASE", 305, 316], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 0, 7], ["tumor", "CANCER", 17, 22], ["LUAD", "CANCER", 70, 74], ["LUSC", "CANCER", 79, 83], ["SARS-CoV 2", "ORGANISM", 103, 113], ["Cancer", "CANCER", 127, 133], ["Patients", "ORGANISM", 134, 142], ["ACE2", "GENE_OR_GENE_PRODUCT", 175, 179], ["cancer", "CANCER", 181, 187], ["lung cancer", "CANCER", 305, 316], ["patients", "ORGANISM", 372, 380], ["TMPRSS2", "DNA", 0, 7], ["tumor suppressor gene", "DNA", 17, 38], ["ACE2", "PROTEIN", 175, 179], ["Patients", "SPECIES", 134, 142], ["patients", "SPECIES", 372, 380], ["TMPRSS2", "PROBLEM", 0, 7], ["a tumor suppressor gene", "TREATMENT", 15, 38], ["SARS-CoV 2 Infection in Cancer", "PROBLEM", 103, 133], ["cancer", "PROBLEM", 181, 187], ["different vulnerabilities", "PROBLEM", 263, 288], ["lung cancer", "PROBLEM", 305, 316], ["tumor", "OBSERVATION", 17, 22], ["severely", "OBSERVATION_MODIFIER", 50, 58], ["reduced", "OBSERVATION_MODIFIER", 59, 66], ["LUAD", "OBSERVATION", 70, 74], ["SARS-CoV", "OBSERVATION", 103, 111], ["Infection", "OBSERVATION", 114, 123], ["Cancer", "OBSERVATION", 127, 133], ["cancer", "OBSERVATION", 181, 187], ["lung", "ANATOMY", 305, 309], ["cancer", "OBSERVATION", 310, 316]]], ["Experimental findings have demonstrated that tobacco use considerably augments the gene expression of ACE2, which could lead to increased susceptibility to SARS-CoV2 in smokers [36] .", [["SARS-CoV2", "DISEASE", 156, 165], ["tobacco", "ORGANISM", 45, 52], ["ACE2", "GENE_OR_GENE_PRODUCT", 102, 106], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 156, 165], ["ACE2", "PROTEIN", 102, 106], ["tobacco", "SPECIES", 45, 52], ["increased susceptibility to SARS", "PROBLEM", 128, 160]]], ["Moreover, cigarette smoking is the main cause of chronic obstructive pulmonary disease, which has been recognized as an independent risk factor in critical SARS-CoV2 patients [37, 38] .Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsIn addition to the above, although not all tumor subjects should be considered equally immunocompromised, tumors are always connected with an increased expression of immunosuppressive cytokines, decreased pro-inflammatory danger signals, and an augmented functional immunosuppressive leukocyte population, which may cause a dampened immune system and augment the probability of infectious complications [39] .Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsSome specific cytokines may favor SARS-CoV2 infection, and at the same time have a role in neoplastic diseases.", [["pulmonary", "ANATOMY", 69, 78], ["Cancer", "ANATOMY", 228, 234], ["tumor", "ANATOMY", 286, 291], ["tumors", "ANATOMY", 349, 355], ["leukocyte", "ANATOMY", 527, 536], ["immune system", "ANATOMY", 576, 589], ["Cancer", "ANATOMY", 695, 701], ["neoplastic", "ANATOMY", 801, 811], ["smoking", "CHEMICAL", 20, 27], ["chronic obstructive pulmonary disease", "DISEASE", 49, 86], ["SARS-CoV2", "DISEASE", 156, 165], ["SARS-CoV 2 Infection", "DISEASE", 204, 224], ["Cancer", "DISEASE", 228, 234], ["tumor", "DISEASE", 286, 291], ["tumors", "DISEASE", 349, 355], ["SARS-CoV 2 Infection", "DISEASE", 671, 691], ["Cancer", "DISEASE", 695, 701], ["SARS-CoV2 infection", "DISEASE", 744, 763], ["neoplastic diseases", "DISEASE", 801, 820], ["cigarette", "ORGANISM", 10, 19], ["pulmonary", "ORGAN", 69, 78], ["patients", "ORGANISM", 166, 174], ["SARS-CoV 2", "ORGANISM", 204, 214], ["Cancer", "CANCER", 228, 234], ["Patients", "ORGANISM", 235, 243], ["tumor", "CANCER", 286, 291], ["tumors", "CANCER", 349, 355], ["leukocyte", "CELL", 527, 536], ["SARS-CoV 2", "ORGANISM", 671, 681], ["Cancer", "CANCER", 695, 701], ["Patients", "ORGANISM", 702, 710], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 744, 753], ["immunosuppressive cytokines", "PROTEIN", 409, 436], ["immunosuppressive leukocyte population", "CELL_TYPE", 509, 547], ["cytokines", "PROTEIN", 724, 733], ["patients", "SPECIES", 166, 174], ["Patients", "SPECIES", 235, 243], ["Patients", "SPECIES", 702, 710], ["chronic obstructive pulmonary disease", "PROBLEM", 49, 86], ["SARS-CoV 2 Infection in Cancer", "PROBLEM", 204, 234], ["all tumor subjects", "PROBLEM", 282, 300], ["immunocompromised", "PROBLEM", 330, 347], ["tumors", "PROBLEM", 349, 355], ["immunosuppressive cytokines", "TREATMENT", 409, 436], ["decreased pro-inflammatory danger signals", "PROBLEM", 438, 479], ["an augmented functional immunosuppressive leukocyte population", "PROBLEM", 485, 547], ["a dampened immune system", "PROBLEM", 565, 589], ["infectious complications", "PROBLEM", 621, 645], ["SARS-CoV 2 Infection in Cancer", "PROBLEM", 671, 701], ["SARS", "PROBLEM", 744, 748], ["CoV2 infection", "PROBLEM", 749, 763], ["neoplastic diseases", "PROBLEM", 801, 820], ["chronic", "OBSERVATION_MODIFIER", 49, 56], ["obstructive", "OBSERVATION_MODIFIER", 57, 68], ["pulmonary", "ANATOMY", 69, 78], ["disease", "OBSERVATION", 79, 86], ["SARS-CoV", "OBSERVATION", 204, 212], ["Infection", "OBSERVATION", 215, 224], ["Cancer", "OBSERVATION", 228, 234], ["tumor", "OBSERVATION", 286, 291], ["tumors", "OBSERVATION", 349, 355], ["increased", "OBSERVATION_MODIFIER", 385, 394], ["immunosuppressive cytokines", "OBSERVATION", 409, 436], ["decreased", "OBSERVATION_MODIFIER", 438, 447], ["pro-inflammatory", "OBSERVATION_MODIFIER", 448, 464], ["immunosuppressive leukocyte population", "OBSERVATION", 509, 547], ["infectious", "OBSERVATION_MODIFIER", 621, 631], ["SARS-CoV", "OBSERVATION", 671, 679], ["Infection", "OBSERVATION", 682, 691], ["Cancer", "OBSERVATION", 695, 701], ["infection", "OBSERVATION", 754, 763], ["neoplastic diseases", "OBSERVATION", 801, 820]]], ["For instance, IL-17 could be central to this process.", [["IL-17", "GENE_OR_GENE_PRODUCT", 14, 19], ["IL-17", "PROTEIN", 14, 19], ["IL", "TREATMENT", 14, 16]]], ["In the lung, the IL-17 cytokine is generated by TH17 cells in reaction to viruses.", [["lung", "ANATOMY", 7, 11], ["TH17 cells", "ANATOMY", 48, 58], ["lung", "ORGAN", 7, 11], ["IL-17", "GENE_OR_GENE_PRODUCT", 17, 22], ["TH17 cells", "CELL", 48, 58], ["IL-17 cytokine", "PROTEIN", 17, 31], ["TH17 cells", "CELL_TYPE", 48, 58], ["viruses", "PROBLEM", 74, 81], ["lung", "ANATOMY", 7, 11], ["TH17 cells", "OBSERVATION", 48, 58], ["viruses", "OBSERVATION", 74, 81]]], ["IL-17 stimulates signaling, which in turn induces the production of chemokines.", [["IL-17", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-17", "PROTEIN", 0, 5], ["chemokines", "PROTEIN", 68, 78], ["IL", "TREATMENT", 0, 2]]], ["These substances enroll immune system cells to the inflammation site.", [["immune system cells", "ANATOMY", 24, 43], ["inflammation", "DISEASE", 51, 63], ["immune system cells", "CELL", 24, 43], ["immune system cells", "CELL_TYPE", 24, 43], ["These substances", "TREATMENT", 0, 16], ["immune system cells", "TREATMENT", 24, 43], ["the inflammation site", "PROBLEM", 47, 68], ["inflammation", "OBSERVATION", 51, 63]]], ["The permanency of the virus causes a hyperactivity of the immune system which can provoke a cytokine storm [40] , and IL-17 stimulates, in synergy with IL-6, viral permanency by stopping apoptosis [41] .", [["immune system", "ANATOMY", 58, 71], ["hyperactivity", "DISEASE", 37, 50], ["IL-17", "GENE_OR_GENE_PRODUCT", 118, 123], ["IL-6", "GENE_OR_GENE_PRODUCT", 152, 156], ["cytokine", "PROTEIN", 92, 100], ["IL-17", "PROTEIN", 118, 123], ["IL-6", "PROTEIN", 152, 156], ["the virus", "PROBLEM", 18, 27], ["a hyperactivity of the immune system", "PROBLEM", 35, 71], ["a cytokine storm", "TREATMENT", 90, 106], ["IL", "TREATMENT", 118, 120], ["virus", "OBSERVATION", 22, 27]]], ["Other research has found that it is possible to clarify the biological mechanisms correlated with organ injury due to virus action via the IL-17 pathway [41] .", [["organ", "ANATOMY", 98, 103], ["organ injury", "DISEASE", 98, 110], ["organ", "ORGAN", 98, 103], ["IL-17", "GENE_OR_GENE_PRODUCT", 139, 144], ["IL", "PROTEIN", 139, 141], ["the biological mechanisms", "PROBLEM", 56, 81], ["organ injury", "PROBLEM", 98, 110], ["virus action", "TREATMENT", 118, 130]]], ["In addition to provoking a cytokine storm and blocking the programmed cell death of infected cells, it also appears to have the capability to augment the proliferation of some viruses by augmenting their virulence [42] .", [["cell", "ANATOMY", 70, 74], ["cells", "ANATOMY", 93, 98], ["cell", "CELL", 70, 74], ["cells", "CELL", 93, 98], ["cytokine", "PROTEIN", 27, 35], ["infected cells", "CELL_TYPE", 84, 98], ["a cytokine storm", "TREATMENT", 25, 41], ["infected cells", "PROBLEM", 84, 98], ["some viruses", "PROBLEM", 171, 183], ["cytokine storm", "OBSERVATION", 27, 41], ["cell death", "OBSERVATION", 70, 80], ["infected cells", "OBSERVATION", 84, 98]]], ["It has further been reported, in an experimental model, that viral persistence, by producing a persistent augmentation of IL-17, provokes ARDS (acute distress respiratory syndrome) [43] , just as it occurs in SARS-CoV-2 infection.", [["ARDS", "DISEASE", 138, 142], ["acute distress respiratory syndrome", "DISEASE", 144, 179], ["SARS-CoV-2 infection", "DISEASE", 209, 229], ["IL-17", "GENE_OR_GENE_PRODUCT", 122, 127], ["SARS-CoV-2", "ORGANISM", 209, 219], ["IL-17", "PROTEIN", 122, 127], ["SARS-CoV-2", "SPECIES", 209, 219], ["a persistent augmentation of IL", "TREATMENT", 93, 124], ["ARDS (acute distress respiratory syndrome", "PROBLEM", 138, 179], ["SARS", "PROBLEM", 209, 213], ["CoV", "PROBLEM", 214, 217], ["2 infection", "PROBLEM", 218, 229], ["viral persistence", "OBSERVATION", 61, 78], ["persistent", "OBSERVATION_MODIFIER", 95, 105], ["augmentation", "OBSERVATION_MODIFIER", 106, 118], ["ARDS", "OBSERVATION", 138, 142], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["respiratory syndrome", "OBSERVATION", 159, 179], ["SARS", "OBSERVATION", 209, 213], ["infection", "OBSERVATION", 220, 229]]], ["The augmented concentration of IL-17 could also be correlated with the hypercoagulation condition sometimes seen in SARS-CoV-2 subjects [44] .Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsMoreover, an elevated amount of TH17 lymphocytes released into the alveolar space has been described.", [["Cancer", "ANATOMY", 185, 191], ["TH17 lymphocytes", "ANATOMY", 232, 248], ["alveolar space", "ANATOMY", 267, 281], ["SARS", "DISEASE", 116, 120], ["SARS", "DISEASE", 161, 165], ["Cancer", "DISEASE", 185, 191], ["IL-17", "GENE_OR_GENE_PRODUCT", 31, 36], ["SARS-CoV-2", "ORGANISM", 116, 126], ["SARS-CoV 2", "ORGANISM", 161, 171], ["Cancer", "CANCER", 185, 191], ["Patients", "ORGANISM", 192, 200], ["TH17 lymphocytes", "CELL", 232, 248], ["alveolar space", "MULTI-TISSUE_STRUCTURE", 267, 281], ["IL", "PROTEIN", 31, 33], ["TH17 lymphocytes", "CELL_TYPE", 232, 248], ["Patients", "SPECIES", 192, 200], ["SARS-CoV", "SPECIES", 116, 124], ["SARS-CoV", "SPECIES", 161, 169], ["The augmented concentration of IL", "TREATMENT", 0, 33], ["the hypercoagulation condition", "PROBLEM", 67, 97], ["SARS", "TEST", 116, 120], ["CoV", "TEST", 121, 124], ["SARS", "PROBLEM", 161, 165], ["CoV 2 Infection in Cancer", "PROBLEM", 166, 191], ["an elevated amount of TH17 lymphocytes", "PROBLEM", 210, 248], ["concentration", "OBSERVATION_MODIFIER", 14, 27], ["hypercoagulation", "OBSERVATION", 71, 87], ["SARS", "OBSERVATION", 161, 165], ["CoV 2", "OBSERVATION_MODIFIER", 166, 171], ["Infection", "OBSERVATION", 172, 181], ["elevated", "OBSERVATION_MODIFIER", 213, 221], ["amount", "OBSERVATION_MODIFIER", 222, 228], ["TH17 lymphocytes", "OBSERVATION", 232, 248], ["alveolar", "ANATOMY_MODIFIER", 267, 275]]], ["At the same time, the role of IL-17 is well known in lung cancer, as IL-17 stimulates VEGF production in cancer cell lines [45] .", [["lung cancer", "ANATOMY", 53, 64], ["cancer cell lines", "ANATOMY", 105, 122], ["lung cancer", "DISEASE", 53, 64], ["cancer", "DISEASE", 105, 111], ["IL-17", "GENE_OR_GENE_PRODUCT", 30, 35], ["lung cancer", "CANCER", 53, 64], ["IL-17", "GENE_OR_GENE_PRODUCT", 69, 74], ["VEGF", "GENE_OR_GENE_PRODUCT", 86, 90], ["cancer cell lines", "CELL", 105, 122], ["IL-17", "PROTEIN", 30, 35], ["IL-17", "PROTEIN", 69, 74], ["VEGF", "PROTEIN", 86, 90], ["cancer cell lines", "CELL_LINE", 105, 122], ["lung cancer", "PROBLEM", 53, 64], ["IL", "TEST", 69, 71], ["VEGF production in cancer cell lines", "PROBLEM", 86, 122], ["lung", "ANATOMY", 53, 57], ["cancer", "OBSERVATION", 58, 64], ["cancer cell lines", "OBSERVATION", 105, 122]]], ["This action is supported by the STAT3-G\u03b1-Interacting Vesicle-Associated Protein (GIV) pathway, and is stopped when cells are exposed to small interfering RNA (siRNA) [46] .", [["cells", "ANATOMY", 115, 120], ["STAT3", "GENE_OR_GENE_PRODUCT", 32, 37], ["G\u03b1-Interacting Vesicle-Associated Protein", "GENE_OR_GENE_PRODUCT", 38, 79], ["GIV", "GENE_OR_GENE_PRODUCT", 81, 84], ["cells", "CELL", 115, 120], ["STAT3", "PROTEIN", 32, 37], ["G\u03b1-Interacting Vesicle-Associated Protein", "PROTEIN", 38, 79], ["GIV", "PROTEIN", 81, 84], ["small interfering RNA", "PROBLEM", 136, 157], ["small", "OBSERVATION_MODIFIER", 136, 141], ["interfering RNA", "OBSERVATION", 142, 157]]], ["It has been reported that patients with augmented concentrations of IL-17 were less likely to survive and had increased angiogenesis with respect to healthy controls [47] .", [["patients", "ORGANISM", 26, 34], ["IL-17", "GENE_OR_GENE_PRODUCT", 68, 73], ["IL", "PROTEIN", 68, 70], ["patients", "SPECIES", 26, 34], ["augmented concentrations of IL", "TREATMENT", 40, 70], ["increased angiogenesis", "PROBLEM", 110, 132], ["increased", "OBSERVATION_MODIFIER", 110, 119], ["angiogenesis", "OBSERVATION", 120, 132]]], ["Similarly, exposure of diverse NSCLC cell lines to IL-17 increased neo-angiogenesis and augmented in vivo cancer proliferation in SCID mice via a C-X-C chemokine receptor (CXCR-2)-dependent mechanism.", [["NSCLC cell lines", "ANATOMY", 31, 47], ["cancer", "ANATOMY", 106, 112], ["NSCLC", "DISEASE", 31, 36], ["cancer", "DISEASE", 106, 112], ["NSCLC cell lines", "CELL", 31, 47], ["IL-17", "GENE_OR_GENE_PRODUCT", 51, 56], ["cancer", "CANCER", 106, 112], ["SCID mice", "ORGANISM", 130, 139], ["C-X-C chemokine receptor", "GENE_OR_GENE_PRODUCT", 146, 170], ["CXCR-2", "GENE_OR_GENE_PRODUCT", 172, 178], ["NSCLC cell lines", "CELL_LINE", 31, 47], ["IL-17", "PROTEIN", 51, 56], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 135, 139], ["diverse NSCLC cell lines", "TREATMENT", 23, 47], ["IL", "TEST", 51, 53], ["increased neo-angiogenesis", "PROBLEM", 57, 83], ["augmented in vivo cancer proliferation", "PROBLEM", 88, 126], ["a C-X-C chemokine receptor", "TREATMENT", 144, 170], ["CXCR", "TEST", 172, 176], ["dependent mechanism", "PROBLEM", 180, 199], ["diverse", "OBSERVATION_MODIFIER", 23, 30], ["NSCLC cell lines", "OBSERVATION", 31, 47], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["neo-angiogenesis", "OBSERVATION", 67, 83], ["cancer proliferation", "OBSERVATION", 106, 126]]], ["In fact, IL-17 increased numerous pro-angiogenic CXC chemokines, including CXCL1, CXCL5, CXCL6, and CXCL8.", [["IL-17", "GENE_OR_GENE_PRODUCT", 9, 14], ["CXC", "GENE_OR_GENE_PRODUCT", 49, 52], ["CXCL1", "GENE_OR_GENE_PRODUCT", 75, 80], ["CXCL5", "GENE_OR_GENE_PRODUCT", 82, 87], ["CXCL6", "GENE_OR_GENE_PRODUCT", 89, 94], ["CXCL8", "GENE_OR_GENE_PRODUCT", 100, 105], ["IL-17", "PROTEIN", 9, 14], ["pro-angiogenic CXC chemokines", "PROTEIN", 34, 63], ["CXCL1", "PROTEIN", 75, 80], ["CXCL5", "PROTEIN", 82, 87], ["CXCL6", "PROTEIN", 89, 94], ["CXCL8", "PROTEIN", 100, 105], ["IL", "TEST", 9, 11], ["numerous pro-angiogenic CXC chemokines", "TEST", 25, 63], ["CXCL1", "TEST", 75, 80], ["CXCL5", "TEST", 82, 87], ["CXCL6", "TEST", 89, 94], ["CXCL8", "TEST", 100, 105], ["pro-angiogenic", "OBSERVATION_MODIFIER", 34, 48], ["CXC chemokines", "OBSERVATION", 49, 63], ["CXCL1", "ANATOMY", 75, 80], ["CXCL5", "ANATOMY", 82, 87], ["CXCL8", "ANATOMY", 100, 105]]], ["Blocking IL-17 with monoclonal antibodies abrogated this up-regulation, and could be theoretically advantageous in subjects with SARS-CoV-2 infection.Pathophysiology of SARS-CoV 2 Infection in Cancer PatientsAnti-IL-17 use is well established and approved in psoriatic arthritis, and has demonstrated a therapeutic action not only in several tumor forms [48] , but also in the therapy of lung infections due to the H1N1 virus [47] , ARDS [49] , and pulmonary fibrosis [50] .", [["Cancer", "ANATOMY", 193, 199], ["tumor", "ANATOMY", 342, 347], ["lung", "ANATOMY", 388, 392], ["pulmonary", "ANATOMY", 449, 458], ["SARS-CoV-2 infection", "DISEASE", 129, 149], ["SARS-CoV 2 Infection", "DISEASE", 169, 189], ["Cancer", "DISEASE", 193, 199], ["psoriatic arthritis", "DISEASE", 259, 278], ["tumor", "DISEASE", 342, 347], ["lung infections", "DISEASE", 388, 403], ["ARDS", "DISEASE", 433, 437], ["pulmonary fibrosis", "DISEASE", 449, 467], ["IL-17", "GENE_OR_GENE_PRODUCT", 9, 14], ["SARS-CoV-2", "ORGANISM", 129, 139], ["SARS-CoV 2", "ORGANISM", 169, 179], ["Cancer", "CANCER", 193, 199], ["IL-17", "GENE_OR_GENE_PRODUCT", 213, 218], ["tumor", "CANCER", 342, 347], ["lung", "ORGAN", 388, 392], ["H1N1 virus", "ORGANISM", 415, 425], ["pulmonary", "ORGAN", 449, 458], ["IL-17", "PROTEIN", 9, 14], ["monoclonal antibodies", "PROTEIN", 20, 41], ["Patients", "SPECIES", 200, 208], ["H1N1 virus", "SPECIES", 415, 425], ["SARS-CoV", "SPECIES", 129, 137], ["SARS-CoV", "SPECIES", 169, 177], ["H1N1 virus", "SPECIES", 415, 425], ["Blocking IL", "TEST", 0, 11], ["monoclonal antibodies", "TREATMENT", 20, 41], ["SARS", "PROBLEM", 129, 133], ["CoV-2 infection", "PROBLEM", 134, 149], ["SARS", "PROBLEM", 169, 173], ["CoV 2 Infection in Cancer", "PROBLEM", 174, 199], ["Anti-IL", "TREATMENT", 208, 215], ["psoriatic arthritis", "PROBLEM", 259, 278], ["lung infections", "PROBLEM", 388, 403], ["the H1N1 virus", "PROBLEM", 411, 425], ["ARDS", "PROBLEM", 433, 437], ["pulmonary fibrosis", "PROBLEM", 449, 467], ["infection", "OBSERVATION", 140, 149], ["SARS", "OBSERVATION", 169, 173], ["CoV 2", "OBSERVATION_MODIFIER", 174, 179], ["Infection", "OBSERVATION", 180, 189], ["Cancer", "OBSERVATION", 193, 199], ["psoriatic", "ANATOMY", 259, 268], ["arthritis", "OBSERVATION", 269, 278], ["lung", "ANATOMY", 388, 392], ["infections", "OBSERVATION", 393, 403], ["pulmonary", "ANATOMY", 449, 458], ["fibrosis", "OBSERVATION", 459, 467]]], ["If a study was able to determine that IL17 target therapy can both control tumor diseases and lead to resolution of SARS-CoV-2 infection, it could be applied as a treatment for SARS-CoV-2 patients with lung cancer [51] .Diagnostic Challenges in the Recognition of SARS-CoV-2 Infection and Neoplastic Disease in Cancer-Infected PatientsThe presence of a neoplastic disease can complicate some diagnostic elements of SARS-CoV-2 infection, such as respiratory distress syndrome.", [["tumor", "ANATOMY", 75, 80], ["lung cancer", "ANATOMY", 202, 213], ["Cancer", "ANATOMY", 311, 317], ["neoplastic", "ANATOMY", 353, 363], ["respiratory", "ANATOMY", 445, 456], ["tumor", "DISEASE", 75, 80], ["SARS-CoV-2 infection", "DISEASE", 116, 136], ["SARS-CoV-2", "DISEASE", 177, 187], ["lung cancer", "DISEASE", 202, 213], ["SARS-CoV-2 Infection", "DISEASE", 264, 284], ["Neoplastic Disease", "DISEASE", 289, 307], ["Cancer", "DISEASE", 311, 317], ["neoplastic disease", "DISEASE", 353, 371], ["SARS-CoV-2 infection", "DISEASE", 415, 435], ["respiratory distress syndrome", "DISEASE", 445, 474], ["IL17", "GENE_OR_GENE_PRODUCT", 38, 42], ["tumor", "CANCER", 75, 80], ["SARS-CoV-2", "ORGANISM", 116, 126], ["SARS-CoV-2", "ORGANISM", 177, 187], ["patients", "ORGANISM", 188, 196], ["lung cancer", "CANCER", 202, 213], ["SARS-CoV-2", "ORGANISM", 264, 274], ["Cancer", "CANCER", 311, 317], ["Patients", "ORGANISM", 327, 335], ["SARS-CoV-2", "ORGANISM", 415, 425], ["IL17", "PROTEIN", 38, 42], ["patients", "SPECIES", 188, 196], ["Patients", "SPECIES", 327, 335], ["SARS-CoV", "SPECIES", 116, 124], ["SARS-CoV", "SPECIES", 264, 272], ["SARS-CoV-2", "SPECIES", 415, 425], ["a study", "TEST", 3, 10], ["IL17 target therapy", "TREATMENT", 38, 57], ["tumor diseases", "PROBLEM", 75, 89], ["SARS", "PROBLEM", 116, 120], ["CoV-2 infection", "PROBLEM", 121, 136], ["a treatment", "TREATMENT", 161, 172], ["SARS", "PROBLEM", 177, 181], ["lung cancer", "PROBLEM", 202, 213], ["SARS", "PROBLEM", 264, 268], ["CoV", "PROBLEM", 269, 272], ["Infection", "PROBLEM", 275, 284], ["Neoplastic Disease in Cancer", "PROBLEM", 289, 317], ["a neoplastic disease", "PROBLEM", 351, 371], ["SARS", "PROBLEM", 415, 419], ["CoV-2 infection", "PROBLEM", 420, 435], ["respiratory distress syndrome", "PROBLEM", 445, 474], ["tumor", "OBSERVATION", 75, 80], ["infection", "OBSERVATION", 127, 136], ["lung", "ANATOMY", 202, 206], ["cancer", "OBSERVATION", 207, 213], ["SARS", "OBSERVATION", 264, 268], ["Infection", "OBSERVATION", 275, 284], ["Neoplastic", "OBSERVATION_MODIFIER", 289, 299], ["Cancer", "OBSERVATION", 311, 317], ["Infected", "OBSERVATION_MODIFIER", 318, 326], ["neoplastic", "OBSERVATION", 353, 363], ["SARS", "OBSERVATION", 415, 419], ["infection", "OBSERVATION", 426, 435], ["respiratory", "OBSERVATION", 445, 456], ["distress syndrome", "OBSERVATION", 457, 474]]], ["Both SARS-CoV-2 and tumor non-SARS-CoV-2 conditions, such as superior vena cava obstruction, lung metastasis, or upper airway tumors, can provoke breathlessness and distress.", [["tumor", "ANATOMY", 20, 25], ["superior vena cava", "ANATOMY", 61, 79], ["lung", "ANATOMY", 93, 97], ["upper airway tumors", "ANATOMY", 113, 132], ["tumor", "DISEASE", 20, 25], ["superior vena cava obstruction", "DISEASE", 61, 91], ["lung metastasis", "DISEASE", 93, 108], ["airway tumors", "DISEASE", 119, 132], ["breathlessness", "DISEASE", 146, 160], ["SARS-CoV-2", "ORGANISM", 5, 15], ["tumor", "CANCER", 20, 25], ["vena cava", "MULTI-TISSUE_STRUCTURE", 70, 79], ["lung", "ORGAN", 93, 97], ["upper airway tumors", "CANCER", 113, 132], ["SARS-CoV", "SPECIES", 5, 13], ["Both SARS", "TEST", 0, 9], ["CoV", "TEST", 10, 13], ["tumor non-SARS", "PROBLEM", 20, 34], ["superior vena cava obstruction", "PROBLEM", 61, 91], ["lung metastasis", "PROBLEM", 93, 108], ["upper airway tumors", "PROBLEM", 113, 132], ["breathlessness", "PROBLEM", 146, 160], ["distress", "PROBLEM", 165, 173], ["SARS", "OBSERVATION", 5, 9], ["tumor", "OBSERVATION", 20, 25], ["superior vena cava", "ANATOMY", 61, 79], ["obstruction", "OBSERVATION", 80, 91], ["lung", "ANATOMY", 93, 97], ["metastasis", "OBSERVATION", 98, 108], ["upper", "ANATOMY_MODIFIER", 113, 118], ["airway", "ANATOMY", 119, 125], ["tumors", "OBSERVATION", 126, 132]]], ["The presenting characteristics of SARS-CoV-2, such as fever, fatigue, and dyspnea, are frequently analogous to those of subjects with tumors, particularly those undergoing therapy.", [["tumors", "ANATOMY", 134, 140], ["SARS", "DISEASE", 34, 38], ["fever", "DISEASE", 54, 59], ["fatigue", "DISEASE", 61, 68], ["dyspnea", "DISEASE", 74, 81], ["tumors", "DISEASE", 134, 140], ["tumors", "CANCER", 134, 140], ["SARS-CoV", "SPECIES", 34, 42], ["SARS", "PROBLEM", 34, 38], ["fever", "PROBLEM", 54, 59], ["fatigue", "PROBLEM", 61, 68], ["dyspnea", "PROBLEM", 74, 81], ["tumors", "PROBLEM", 134, 140], ["therapy", "TREATMENT", 172, 179], ["SARS", "OBSERVATION", 34, 38], ["fever", "OBSERVATION", 54, 59], ["tumors", "OBSERVATION", 134, 140]]], ["Therefore, the identification of SARS-CoV-2 symptoms in such subjects can be difficult (Table 2 ).", [["SARS", "DISEASE", 33, 37], ["SARS-CoV-2", "ORGANISM", 33, 43], ["SARS-CoV", "SPECIES", 33, 41], ["SARS", "PROBLEM", 33, 37], ["CoV", "PROBLEM", 38, 41], ["2 symptoms", "PROBLEM", 42, 52]]], ["Not only can the clinical appearance of SARS-CoV-2 in tumor subjects be unique, but identifying this disease is problematic due to several factors.", [["tumor", "ANATOMY", 54, 59], ["SARS", "DISEASE", 40, 44], ["tumor", "DISEASE", 54, 59], ["SARS-CoV-2", "ORGANISM", 40, 50], ["tumor", "CANCER", 54, 59], ["SARS", "PROBLEM", 40, 44], ["CoV", "PROBLEM", 45, 48], ["this disease", "PROBLEM", 96, 108], ["SARS", "OBSERVATION", 40, 44], ["tumor", "OBSERVATION", 54, 59]]], ["For instance, tumor subjects might have atypical radiographic features.", [["tumor", "ANATOMY", 14, 19], ["tumor", "DISEASE", 14, 19], ["tumor", "CANCER", 14, 19], ["tumor subjects", "PROBLEM", 14, 28], ["atypical radiographic features", "PROBLEM", 40, 70], ["tumor", "OBSERVATION", 14, 19], ["atypical", "OBSERVATION_MODIFIER", 40, 48]]], ["Qu et al. A study described the case of one subject affected by lung adenocarcinoma who had a laboratory established SARS-CoV-2 infection with irregular, diffuse, small ground-glass opacities and partial consolidation on chest CT-scan.", [["lung adenocarcinoma", "ANATOMY", 64, 83], ["chest", "ANATOMY", 221, 226], ["lung adenocarcinoma", "DISEASE", 64, 83], ["SARS-CoV-2 infection", "DISEASE", 117, 137], ["lung adenocarcinoma", "CANCER", 64, 83], ["chest", "ORGAN", 221, 226], ["A study", "TEST", 10, 17], ["lung adenocarcinoma", "PROBLEM", 64, 83], ["a laboratory", "TEST", 92, 104], ["CoV", "TEST", 122, 125], ["2 infection", "PROBLEM", 126, 137], ["irregular, diffuse, small ground-glass opacities", "PROBLEM", 143, 191], ["partial consolidation", "PROBLEM", 196, 217], ["chest CT", "TEST", 221, 229], ["scan", "TEST", 230, 234], ["et al", "OBSERVATION", 3, 8], ["lung", "ANATOMY", 64, 68], ["adenocarcinoma", "OBSERVATION", 69, 83], ["irregular", "OBSERVATION_MODIFIER", 143, 152], ["diffuse", "OBSERVATION_MODIFIER", 154, 161], ["small", "OBSERVATION_MODIFIER", 163, 168], ["ground-glass opacities", "OBSERVATION", 169, 191], ["partial", "OBSERVATION_MODIFIER", 196, 203], ["consolidation", "OBSERVATION", 204, 217], ["chest", "ANATOMY", 221, 226]]], ["This is not congruent with the typical peripheral subpleural ground-glass infiltrates seen in this infection [52] .", [["infection", "DISEASE", 99, 108], ["the typical peripheral subpleural ground-glass infiltrates", "PROBLEM", 27, 85], ["this infection", "PROBLEM", 94, 108], ["not", "UNCERTAINTY", 8, 11], ["congruent", "OBSERVATION_MODIFIER", 12, 21], ["typical", "OBSERVATION_MODIFIER", 31, 38], ["peripheral", "ANATOMY_MODIFIER", 39, 49], ["subpleural", "ANATOMY", 50, 60], ["ground-glass infiltrates", "OBSERVATION", 61, 85], ["infection", "OBSERVATION", 99, 108]]], ["Lung tumor subjects might have radiographic features alike to those of a SAR-CoV-2 infection, and this might be misleading.", [["Lung tumor", "ANATOMY", 0, 10], ["Lung tumor", "DISEASE", 0, 10], ["infection", "DISEASE", 83, 92], ["Lung tumor", "CANCER", 0, 10], ["CoV-2", "ORGANISM", 77, 82], ["Lung tumor subjects", "PROBLEM", 0, 19], ["radiographic features", "PROBLEM", 31, 52], ["a SAR-CoV-2 infection", "PROBLEM", 71, 92], ["tumor", "OBSERVATION", 5, 10], ["infection", "OBSERVATION", 83, 92]]], ["A study described the cases of five of 139 tumor subjects who had ground-glass opacities on baseline chest CT-scans.", [["tumor", "ANATOMY", 43, 48], ["tumor", "DISEASE", 43, 48], ["tumor", "CANCER", 43, 48], ["A study", "TEST", 0, 7], ["ground-glass opacities", "PROBLEM", 66, 88], ["baseline chest CT", "TEST", 92, 109], ["scans", "TEST", 110, 115], ["tumor", "OBSERVATION", 43, 48], ["glass opacities", "OBSERVATION", 73, 88], ["chest", "ANATOMY", 101, 106]]], ["Three of these subjects submitted to RT-PCR, had a negative test, and were judged negative for SARS-CoV-2 [53] .Common Features of SARS-CoV-2 and Tumor non-SARS-CoV-2 Common Markers of SARS-CoV-2 and Tumor non-SARS-CoV-2 Other Clinical Characteristics Common in SARS-CoV-2 and Tumor non-SARS-CoV-2Moreover, many cancer markers, such as carbohydrate antigens (CA) and carcinoembryonic antigens (CEA), increase during several inflammatory situations in the lungs.", [["Tumor", "ANATOMY", 146, 151], ["Tumor", "ANATOMY", 200, 205], ["cancer", "ANATOMY", 312, 318], ["lungs", "ANATOMY", 455, 460], ["SARS", "DISEASE", 131, 135], ["cancer", "DISEASE", 312, 318], ["carbohydrate", "CHEMICAL", 336, 348], ["Tumor", "CANCER", 146, 151], ["SARS-CoV-2", "ORGANISM", 185, 195], ["Tumor", "CANCER", 200, 205], ["Tumor", "CANCER", 277, 282], ["cancer", "CANCER", 312, 318], ["carbohydrate antigens", "GENE_OR_GENE_PRODUCT", 336, 357], ["CA", "GENE_OR_GENE_PRODUCT", 359, 361], ["carcinoembryonic antigens", "GENE_OR_GENE_PRODUCT", 367, 392], ["CEA", "GENE_OR_GENE_PRODUCT", 394, 397], ["lungs", "ORGAN", 455, 460], ["carbohydrate antigens", "PROTEIN", 336, 357], ["CA", "PROTEIN", 359, 361], ["carcinoembryonic antigens", "PROTEIN", 367, 392], ["CEA", "PROTEIN", 394, 397], ["SARS-CoV", "SPECIES", 95, 103], ["SARS-CoV", "SPECIES", 131, 139], ["SARS-CoV", "SPECIES", 185, 193], ["SARS-CoV", "SPECIES", 262, 270], ["RT-PCR", "TEST", 37, 43], ["SARS", "PROBLEM", 95, 99], ["CoV", "TEST", 100, 103], ["SARS", "TEST", 131, 135], ["CoV", "TEST", 136, 139], ["Tumor non-SARS", "TEST", 146, 160], ["CoV", "TEST", 161, 164], ["SARS", "TEST", 185, 189], ["CoV", "TEST", 190, 193], ["Tumor non-SARS", "TEST", 200, 214], ["CoV", "TEST", 215, 218], ["SARS", "TEST", 262, 266], ["CoV", "TEST", 267, 270], ["Tumor non-SARS", "TEST", 277, 291], ["CoV", "TEST", 292, 295], ["many cancer markers", "PROBLEM", 307, 326], ["carbohydrate antigens (CA) and carcinoembryonic antigens (CEA", "PROBLEM", 336, 397], ["several inflammatory situations in the lungs", "PROBLEM", 416, 460], ["SARS", "OBSERVATION", 131, 135], ["Tumor", "OBSERVATION", 146, 151], ["Tumor", "OBSERVATION", 200, 205], ["cancer", "OBSERVATION", 312, 318], ["CEA", "ANATOMY", 394, 397], ["increase", "OBSERVATION_MODIFIER", 400, 408], ["several", "OBSERVATION_MODIFIER", 416, 423], ["inflammatory", "OBSERVATION", 424, 436], ["lungs", "ANATOMY", 455, 460]]], ["Wei et al. postulated that SARS-CoV-2-provokes acute lung damage, which may be accompanied with augments of some tumor markers [54] .", [["lung", "ANATOMY", 53, 57], ["tumor", "ANATOMY", 113, 118], ["SARS", "DISEASE", 27, 31], ["lung damage", "DISEASE", 53, 64], ["tumor", "DISEASE", 113, 118], ["SARS-CoV-2", "ORGANISM", 27, 37], ["lung", "ORGAN", 53, 57], ["tumor", "CANCER", 113, 118], ["CoV", "TEST", 32, 35], ["acute lung damage", "PROBLEM", 47, 64], ["some tumor markers", "PROBLEM", 108, 126], ["SARS", "OBSERVATION", 27, 31], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["lung", "ANATOMY", 53, 57], ["damage", "OBSERVATION", 58, 64], ["may be", "UNCERTAINTY", 72, 78], ["some", "OBSERVATION_MODIFIER", 108, 112], ["tumor", "OBSERVATION", 113, 118]]], ["In this retrospective analysis, the concentrations of several serum biomarkers were performed in SARS-CoV-2 subjects (mild: 131; severe: 98; critical: 23).", [["serum", "ANATOMY", 62, 67], ["serum", "ORGANISM_SUBSTANCE", 62, 67], ["SARS-CoV", "SPECIES", 97, 105], ["this retrospective analysis", "TEST", 3, 30], ["several serum biomarkers", "TEST", 54, 78], ["SARS", "TEST", 97, 101], ["CoV", "TEST", 102, 105]]], ["They reported that there were relevant augments in concentrations of carcinoembryonic antigen (CEA), carbohydrate antigens (CA) 125 and 153, human epididymis protein 4 (HE4), and cytokeratin-19 fragment (CYFRA21-1) in SARS-CoV-2 mild cases with respect to normal controls; their concentrations exhibited constant and relevant augments in severe and critical cases.", [["SARS", "DISEASE", 218, 222], ["carbohydrate", "CHEMICAL", 101, 113], ["carcinoembryonic antigen", "GENE_OR_GENE_PRODUCT", 69, 93], ["CEA", "GENE_OR_GENE_PRODUCT", 95, 98], ["carbohydrate antigens", "GENE_OR_GENE_PRODUCT", 101, 122], ["CA) 125", "GENE_OR_GENE_PRODUCT", 124, 131], ["human epididymis protein 4", "GENE_OR_GENE_PRODUCT", 141, 167], ["HE4", "GENE_OR_GENE_PRODUCT", 169, 172], ["cytokeratin-19", "GENE_OR_GENE_PRODUCT", 179, 193], ["CYFRA21-1", "GENE_OR_GENE_PRODUCT", 204, 213], ["SARS-CoV", "ORGANISM", 218, 226], ["carcinoembryonic antigen", "PROTEIN", 69, 93], ["CEA", "PROTEIN", 95, 98], ["carbohydrate antigens", "PROTEIN", 101, 122], ["CA", "PROTEIN", 124, 126], ["human epididymis protein 4", "PROTEIN", 141, 167], ["HE4", "PROTEIN", 169, 172], ["cytokeratin-19 fragment", "PROTEIN", 179, 202], ["CYFRA21", "PROTEIN", 204, 211], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 141, 146], ["SARS-CoV", "SPECIES", 218, 226], ["carcinoembryonic antigen", "TEST", 69, 93], ["CEA", "TEST", 95, 98], ["carbohydrate antigens", "TEST", 101, 122], ["CA", "TEST", 124, 126], ["human epididymis protein", "TEST", 141, 165], ["HE4", "TEST", 169, 172], ["cytokeratin", "TEST", 179, 190], ["CYFRA21", "TEST", 204, 211], ["SARS", "TEST", 218, 222], ["CoV", "TEST", 223, 226], ["mild cases", "PROBLEM", 229, 239], ["epididymis", "ANATOMY", 147, 157], ["19 fragment", "OBSERVATION_MODIFIER", 191, 202], ["severe", "OBSERVATION_MODIFIER", 338, 344]]], ["CA199 and squamous cell carcinoma antigen (SCC) are augmented considerably only in critical cases of SARS-CoV-2, with respect to mild and severe cases and normal controls.", [["squamous cell carcinoma", "ANATOMY", 10, 33], ["SCC", "ANATOMY", 43, 46], ["squamous cell carcinoma", "DISEASE", 10, 33], ["SARS", "DISEASE", 101, 105], ["CA199", "GENE_OR_GENE_PRODUCT", 0, 5], ["squamous cell carcinoma", "CANCER", 10, 33], ["antigen", "GENE_OR_GENE_PRODUCT", 34, 41], ["SCC", "CANCER", 43, 46], ["CA199", "PROTEIN", 0, 5], ["SARS-CoV", "SPECIES", 101, 109], ["CA199", "TEST", 0, 5], ["squamous cell carcinoma antigen (SCC", "PROBLEM", 10, 46], ["SARS", "PROBLEM", 101, 105], ["CoV", "TEST", 106, 109], ["mild and severe cases", "PROBLEM", 129, 150], ["squamous cell carcinoma", "OBSERVATION", 10, 33], ["mild", "OBSERVATION_MODIFIER", 129, 133], ["severe", "OBSERVATION_MODIFIER", 138, 144], ["cases", "OBSERVATION", 145, 150], ["normal controls", "OBSERVATION", 155, 170]]], ["There were positive correlations between concentrations of C-reactive protein and concentrations of CEA, SCC, HE4, CYFRA21-1, CA153, and CA125 [54] .", [["CEA", "GENE_OR_GENE_PRODUCT", 100, 103], ["SCC", "GENE_OR_GENE_PRODUCT", 105, 108], ["HE4", "GENE_OR_GENE_PRODUCT", 110, 113], ["CYFRA21-1", "GENE_OR_GENE_PRODUCT", 115, 124], ["CA153", "GENE_OR_GENE_PRODUCT", 126, 131], ["CA125", "GENE_OR_GENE_PRODUCT", 137, 142], ["C-reactive protein", "PROTEIN", 59, 77], ["CEA", "PROTEIN", 100, 103], ["SCC", "PROTEIN", 105, 108], ["HE4", "PROTEIN", 110, 113], ["CYFRA21", "PROTEIN", 115, 122], ["CA153", "PROTEIN", 126, 131], ["CA125", "PROTEIN", 137, 142], ["C-reactive protein", "TEST", 59, 77], ["CEA", "TEST", 100, 103], ["SCC", "TEST", 105, 108], ["HE4", "TEST", 110, 113], ["CYFRA21", "TEST", 115, 122], ["CA153", "TEST", 126, 131], ["CA125", "TEST", 137, 142], ["CEA", "ANATOMY", 100, 103]]], ["In this analysis, the authors excluded any subjects with tumor diagnoses; therefore, the increase of these cancer markers was not correlated with pre-existing situations of tumorigenesis.", [["tumor", "ANATOMY", 57, 62], ["cancer", "ANATOMY", 107, 113], ["tumor", "DISEASE", 57, 62], ["cancer", "DISEASE", 107, 113], ["tumor", "CANCER", 57, 62], ["cancer", "CANCER", 107, 113], ["this analysis", "TEST", 3, 16], ["tumor diagnoses", "PROBLEM", 57, 72], ["these cancer markers", "PROBLEM", 101, 121], ["tumorigenesis", "PROBLEM", 173, 186], ["tumor", "OBSERVATION", 57, 62], ["increase", "OBSERVATION_MODIFIER", 89, 97], ["cancer", "OBSERVATION", 107, 113], ["tumorigenesis", "OBSERVATION", 173, 186]]], ["Moreover, numerous previous studies have established that cancer biomarkers are also elevated in various inflammatory conditions in the lungs [55] [56] [57] [58] [59] [60] (Table 2) .Common Features of SARS-CoV-2 and Tumor non-SARS-CoV-2 Common Markers of SARS-CoV-2 and Tumor non-SARS-CoV-2 Other Clinical Characteristics Common in SARS-CoV-2 and Tumor non-SARS-CoV-2Finally, other biological and clinical characteristics can disguise SARS-CoV-2's presentation in tumor subjects.", [["cancer", "ANATOMY", 58, 64], ["lungs", "ANATOMY", 136, 141], ["Tumor", "ANATOMY", 217, 222], ["Tumor", "ANATOMY", 271, 276], ["tumor", "ANATOMY", 465, 470], ["cancer", "DISEASE", 58, 64], ["SARS", "DISEASE", 202, 206], ["SARS", "DISEASE", 436, 440], ["tumor", "DISEASE", 465, 470], ["[55] [56] [57] [58] [59] [60]", "CHEMICAL", 142, 171], ["cancer", "CANCER", 58, 64], ["lungs", "ORGAN", 136, 141], ["56] [57] [58] [59", "SIMPLE_CHEMICAL", 148, 165], ["Tumor", "CANCER", 217, 222], ["SARS-CoV-2", "ORGANISM", 256, 266], ["Tumor", "CANCER", 271, 276], ["Tumor", "CANCER", 348, 353], ["tumor", "CANCER", 465, 470], ["SARS-CoV", "SPECIES", 202, 210], ["SARS-CoV", "SPECIES", 256, 264], ["SARS-CoV", "SPECIES", 333, 341], ["numerous previous studies", "TEST", 10, 35], ["cancer biomarkers", "TEST", 58, 75], ["elevated in various inflammatory conditions in the lungs", "PROBLEM", 85, 141], ["SARS", "TEST", 202, 206], ["CoV", "TEST", 207, 210], ["Tumor non-SARS", "TEST", 217, 231], ["CoV", "TEST", 232, 235], ["SARS", "TEST", 256, 260], ["CoV", "TEST", 261, 264], ["Tumor non-SARS", "TEST", 271, 285], ["CoV", "TEST", 286, 289], ["SARS", "TEST", 333, 337], ["CoV", "TEST", 338, 341], ["Tumor non-SARS", "TEST", 348, 362], ["CoV", "TEST", 363, 366], ["SARS", "PROBLEM", 436, 440], ["tumor subjects", "PROBLEM", 465, 479], ["cancer", "OBSERVATION", 58, 64], ["elevated", "OBSERVATION_MODIFIER", 85, 93], ["various", "OBSERVATION_MODIFIER", 97, 104], ["inflammatory", "OBSERVATION_MODIFIER", 105, 117], ["lungs", "ANATOMY", 136, 141], ["SARS", "OBSERVATION", 202, 206], ["Tumor", "OBSERVATION", 217, 222], ["Tumor", "OBSERVATION", 271, 276], ["tumor", "OBSERVATION", 465, 470]]], ["For instance, hematologic malignancies can cause laboratory results to be misleading.Common Features of SARS-CoV-2 and Tumor non-SARS-CoV-2 Common Markers of SARS-CoV-2 and Tumor non-SARS-CoV-2 Other Clinical Characteristics Common in SARS-CoV-2 and Tumor non-SARS-CoV-2The presence of one of the two pathologies, or both in the same subject, can therefore make the diagnostic process more difficult.Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaThe aim of this review was not to analyze in detail the therapy of individual neoplastic pathologies in patients with SARS-CoV-2, nor to suggest how the presence of infection should change the approach to neoplastic disease.", [["hematologic malignancies", "ANATOMY", 14, 38], ["Tumor", "ANATOMY", 119, 124], ["Tumor", "ANATOMY", 173, 178], ["Tumor", "ANATOMY", 250, 255], ["neoplastic", "ANATOMY", 550, 560], ["neoplastic", "ANATOMY", 677, 687], ["malignancies", "DISEASE", 26, 38], ["SARS", "DISEASE", 104, 108], ["Neoplasia", "DISEASE", 463, 472], ["SARS", "DISEASE", 590, 594], ["infection", "DISEASE", 637, 646], ["neoplastic disease", "DISEASE", 677, 695], ["hematologic malignancies", "CANCER", 14, 38], ["Tumor", "CANCER", 119, 124], ["Tumor", "CANCER", 173, 178], ["Tumor", "CANCER", 250, 255], ["Patients", "ORGANISM", 449, 457], ["patients", "ORGANISM", 576, 584], ["CoV-2", "ORGANISM", 595, 600], ["neoplastic disease", "CANCER", 677, 695], ["Patients", "SPECIES", 449, 457], ["patients", "SPECIES", 576, 584], ["SARS-CoV", "SPECIES", 104, 112], ["SARS-CoV", "SPECIES", 235, 243], ["hematologic malignancies", "PROBLEM", 14, 38], ["SARS", "TEST", 104, 108], ["CoV", "TEST", 109, 112], ["Tumor non-SARS", "TEST", 119, 133], ["CoV", "TEST", 134, 137], ["SARS", "TEST", 158, 162], ["CoV", "TEST", 163, 166], ["Tumor non-SARS", "TEST", 173, 187], ["CoV", "TEST", 188, 191], ["SARS", "TEST", 235, 239], ["CoV", "TEST", 240, 243], ["Tumor non-SARS-CoV", "TEST", 250, 268], ["the two pathologies", "PROBLEM", 293, 312], ["Antineoplastic", "TREATMENT", 400, 414], ["Antiviral Therapy", "TREATMENT", 419, 436], ["Neoplasia", "PROBLEM", 463, 472], ["individual neoplastic pathologies", "PROBLEM", 539, 572], ["SARS", "PROBLEM", 590, 594], ["infection", "PROBLEM", 637, 646], ["neoplastic disease", "PROBLEM", 677, 695], ["SARS", "OBSERVATION", 104, 108], ["Tumor", "OBSERVATION", 119, 124], ["Tumor", "OBSERVATION", 173, 178], ["Tumor", "OBSERVATION", 250, 255], ["one", "OBSERVATION_MODIFIER", 286, 289], ["two", "OBSERVATION_MODIFIER", 297, 300], ["pathologies", "OBSERVATION", 301, 312], ["Antiviral Therapy", "OBSERVATION", 419, 436], ["Neoplasia", "OBSERVATION", 463, 472], ["neoplastic", "OBSERVATION_MODIFIER", 550, 560], ["pathologies", "OBSERVATION", 561, 572], ["infection", "OBSERVATION", 637, 646], ["neoplastic", "OBSERVATION", 677, 687]]], ["In the next paragraphs we will evaluate instead those drugs used in the oncology field that can interfere with the clinical evolution of SARS-CoV-2 infection (Figure 2 ).Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaFor instance, Chinese trials are currently evaluating the action of the anti-vascular endothelial growth factor (VEGF) bevacizumab on SARS-CoV-2 patients (NCT04275414).", [["SARS-CoV-2 infection", "DISEASE", 137, 157], ["bevacizumab", "CHEMICAL", 361, 372], ["SARS", "DISEASE", 376, 380], ["SARS-CoV-2", "ORGANISM", 137, 147], ["Patients", "ORGANISM", 219, 227], ["anti-vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 314, 353], ["VEGF", "GENE_OR_GENE_PRODUCT", 355, 359], ["bevacizumab", "SIMPLE_CHEMICAL", 361, 372], ["SARS-CoV-2", "ORGANISM", 376, 386], ["patients", "ORGANISM", 387, 395], ["anti-vascular endothelial growth factor", "PROTEIN", 314, 353], ["VEGF", "PROTEIN", 355, 359], ["Patients", "SPECIES", 219, 227], ["patients", "SPECIES", 387, 395], ["SARS-CoV-2", "SPECIES", 137, 147], ["those drugs", "TREATMENT", 48, 59], ["SARS", "PROBLEM", 137, 141], ["CoV-2 infection", "PROBLEM", 142, 157], ["Antineoplastic", "TREATMENT", 170, 184], ["Antiviral Therapy", "TREATMENT", 189, 206], ["NeoplasiaFor instance", "TREATMENT", 233, 254], ["Chinese trials", "TREATMENT", 256, 270], ["the anti-vascular endothelial growth factor", "PROBLEM", 310, 353], ["bevacizumab", "TREATMENT", 361, 372], ["Antiviral Therapy", "OBSERVATION", 189, 206], ["anti-vascular endothelial", "ANATOMY", 314, 339]]], ["VEGF is the most potent vascular permeability inducer, and higher levels of VEGF have been found in SARS-CoV-2 patients compared with healthy controls.", [["vascular", "ANATOMY", 24, 32], ["VEGF", "GENE_OR_GENE_PRODUCT", 0, 4], ["vascular", "MULTI-TISSUE_STRUCTURE", 24, 32], ["VEGF", "GENE_OR_GENE_PRODUCT", 76, 80], ["SARS-CoV-2", "ORGANISM", 100, 110], ["patients", "ORGANISM", 111, 119], ["VEGF", "PROTEIN", 0, 4], ["VEGF", "PROTEIN", 76, 80], ["patients", "SPECIES", 111, 119], ["SARS-CoV", "SPECIES", 100, 108], ["higher levels of VEGF", "PROBLEM", 59, 80], ["SARS", "PROBLEM", 100, 104], ["CoV", "TEST", 105, 108], ["most potent", "OBSERVATION_MODIFIER", 12, 23], ["vascular", "ANATOMY", 24, 32], ["permeability", "OBSERVATION", 33, 45]]], ["Other studies will try to evaluate the effects of drugs, such as the myeloma drug thalidomide (NCT04273581), the programmed death-1 (PD-1) inhibitor camrelizumab (NCT04268537), and other anti-TNF tNFkumor drugs in the therapy of SARS-CoV-2 infection.", [["myeloma", "ANATOMY", 69, 76], ["myeloma", "DISEASE", 69, 76], ["thalidomide", "CHEMICAL", 82, 93], ["NCT04273581", "CHEMICAL", 95, 106], ["camrelizumab", "CHEMICAL", 149, 161], ["NCT04268537", "CHEMICAL", 163, 174], ["SARS-CoV-2 infection", "DISEASE", 229, 249], ["thalidomide", "CHEMICAL", 82, 93], ["NCT04273581", "CHEMICAL", 95, 106], ["camrelizumab", "CHEMICAL", 149, 161], ["NCT04268537", "CHEMICAL", 163, 174], ["myeloma", "CANCER", 69, 76], ["thalidomide", "SIMPLE_CHEMICAL", 82, 93], ["NCT04273581", "SIMPLE_CHEMICAL", 95, 106], ["programmed death-1", "GENE_OR_GENE_PRODUCT", 113, 131], ["PD-1", "GENE_OR_GENE_PRODUCT", 133, 137], ["camrelizumab", "SIMPLE_CHEMICAL", 149, 161], ["NCT04268537", "SIMPLE_CHEMICAL", 163, 174], ["anti-TNF tNFkumor drugs", "SIMPLE_CHEMICAL", 187, 210], ["SARS-CoV-2", "ORGANISM", 229, 239], ["SARS-CoV-2", "SPECIES", 229, 239], ["Other studies", "TEST", 0, 13], ["drugs", "TREATMENT", 50, 55], ["the myeloma drug thalidomide", "TREATMENT", 65, 93], ["the programmed death", "TREATMENT", 109, 129], ["other anti-TNF tNFkumor drugs", "TREATMENT", 181, 210], ["the therapy", "TREATMENT", 214, 225], ["SARS", "PROBLEM", 229, 233], ["CoV", "PROBLEM", 234, 237], ["2 infection", "PROBLEM", 238, 249], ["infection", "OBSERVATION", 240, 249]]], ["The possible value of other targeted substances, such as carfilzomib, afatinib, and ixazomib, will also be assessed [61] .Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaRegarding molecules that target the immune check points PD-1 and its ligand (PD-L1), these drugs have changed the therapy and outcome of numerous forms of tumors.", [["tumors", "ANATOMY", 349, 355], ["carfilzomib", "CHEMICAL", 57, 68], ["afatinib", "CHEMICAL", 70, 78], ["ixazomib", "CHEMICAL", 84, 92], ["tumors", "DISEASE", 349, 355], ["carfilzomib", "CHEMICAL", 57, 68], ["afatinib", "CHEMICAL", 70, 78], ["ixazomib", "CHEMICAL", 84, 92], ["carfilzomib", "SIMPLE_CHEMICAL", 57, 68], ["afatinib", "SIMPLE_CHEMICAL", 70, 78], ["ixazomib", "SIMPLE_CHEMICAL", 84, 92], ["Patients", "ORGANISM", 171, 179], ["PD-1", "GENE_OR_GENE_PRODUCT", 250, 254], ["PD-L1", "GENE_OR_GENE_PRODUCT", 271, 276], ["tumors", "CANCER", 349, 355], ["Patients", "SPECIES", 171, 179], ["other targeted substances", "PROBLEM", 22, 47], ["carfilzomib", "TREATMENT", 57, 68], ["afatinib", "TREATMENT", 70, 78], ["ixazomib", "TREATMENT", 84, 92], ["Antineoplastic", "TREATMENT", 122, 136], ["Antiviral Therapy", "TREATMENT", 141, 158], ["NeoplasiaRegarding molecules", "TREATMENT", 185, 213], ["PD", "TEST", 250, 252], ["these drugs", "TREATMENT", 279, 290], ["the therapy", "TREATMENT", 304, 315], ["tumors", "PROBLEM", 349, 355], ["Antiviral Therapy", "OBSERVATION", 141, 158], ["L1", "ANATOMY", 274, 276], ["tumors", "OBSERVATION", 349, 355]]], ["These monoclonal antibodies are able to restore antitumor immunity, and have received approval for the treatment of several forms of tumors, including lung cancer, breast cancer, melanoma, and urological tumors [62] [63] [64] [65] .", [["antitumor", "ANATOMY", 48, 57], ["tumors", "ANATOMY", 133, 139], ["lung cancer", "ANATOMY", 151, 162], ["breast cancer", "ANATOMY", 164, 177], ["melanoma", "ANATOMY", 179, 187], ["urological tumors", "ANATOMY", 193, 210], ["tumors", "DISEASE", 133, 139], ["lung cancer", "DISEASE", 151, 162], ["breast cancer", "DISEASE", 164, 177], ["melanoma", "DISEASE", 179, 187], ["urological tumors", "DISEASE", 193, 210], ["antitumor", "CANCER", 48, 57], ["tumors", "CANCER", 133, 139], ["lung cancer", "CANCER", 151, 162], ["breast cancer", "CANCER", 164, 177], ["melanoma", "CANCER", 179, 187], ["urological tumors", "CANCER", 193, 210], ["monoclonal antibodies", "PROTEIN", 6, 27], ["These monoclonal antibodies", "TEST", 0, 27], ["the treatment", "TREATMENT", 99, 112], ["tumors", "PROBLEM", 133, 139], ["lung cancer", "PROBLEM", 151, 162], ["breast cancer", "PROBLEM", 164, 177], ["melanoma", "PROBLEM", 179, 187], ["urological tumors", "PROBLEM", 193, 210], ["tumors", "OBSERVATION", 133, 139], ["lung", "ANATOMY", 151, 155], ["cancer", "OBSERVATION", 156, 162], ["breast", "ANATOMY", 164, 170], ["cancer", "OBSERVATION", 171, 177], ["melanoma", "OBSERVATION", 179, 187]]], ["For instance, Chinese trials are currently evaluating the action of the anti-vascular endothelial growth factor (VEGF) bevacizumab on SARS-CoV-2 patients (NCT04275414).", [["bevacizumab", "CHEMICAL", 119, 130], ["SARS", "DISEASE", 134, 138], ["anti-vascular endothelial growth factor", "GENE_OR_GENE_PRODUCT", 72, 111], ["VEGF", "GENE_OR_GENE_PRODUCT", 113, 117], ["bevacizumab", "SIMPLE_CHEMICAL", 119, 130], ["SARS-CoV-2", "ORGANISM", 134, 144], ["patients", "ORGANISM", 145, 153], ["anti-vascular endothelial growth factor", "PROTEIN", 72, 111], ["VEGF", "PROTEIN", 113, 117], ["patients", "SPECIES", 145, 153], ["Chinese trials", "TREATMENT", 14, 28], ["the anti-vascular endothelial growth factor", "PROBLEM", 68, 111], ["bevacizumab", "TREATMENT", 119, 130]]], ["VEGF is the most potent vascular permeability inducer, and higher levels of VEGF have been found in SARS-CoV-2 patients compared with healthy controls.", [["vascular", "ANATOMY", 24, 32], ["VEGF", "GENE_OR_GENE_PRODUCT", 0, 4], ["vascular", "MULTI-TISSUE_STRUCTURE", 24, 32], ["VEGF", "GENE_OR_GENE_PRODUCT", 76, 80], ["SARS-CoV-2", "ORGANISM", 100, 110], ["patients", "ORGANISM", 111, 119], ["VEGF", "PROTEIN", 0, 4], ["VEGF", "PROTEIN", 76, 80], ["patients", "SPECIES", 111, 119], ["SARS-CoV", "SPECIES", 100, 108], ["higher levels of VEGF", "PROBLEM", 59, 80], ["SARS", "PROBLEM", 100, 104], ["CoV", "TEST", 105, 108], ["most potent", "OBSERVATION_MODIFIER", 12, 23], ["vascular", "ANATOMY", 24, 32], ["permeability", "OBSERVATION", 33, 45]]], ["Other studies will try to evaluate the effects of drugs, such as the myeloma drug thalidomide (NCT04273581), the programmed death-1 (PD-1) inhibitor camrelizumab (NCT04268537), and other anti-TNF tNFkumor drugs in the therapy of SARS-CoV-2 infection.", [["myeloma", "ANATOMY", 69, 76], ["myeloma", "DISEASE", 69, 76], ["thalidomide", "CHEMICAL", 82, 93], ["NCT04273581", "CHEMICAL", 95, 106], ["camrelizumab", "CHEMICAL", 149, 161], ["NCT04268537", "CHEMICAL", 163, 174], ["SARS-CoV-2 infection", "DISEASE", 229, 249], ["thalidomide", "CHEMICAL", 82, 93], ["NCT04273581", "CHEMICAL", 95, 106], ["camrelizumab", "CHEMICAL", 149, 161], ["NCT04268537", "CHEMICAL", 163, 174], ["myeloma", "CANCER", 69, 76], ["thalidomide", "SIMPLE_CHEMICAL", 82, 93], ["NCT04273581", "SIMPLE_CHEMICAL", 95, 106], ["programmed death-1", "GENE_OR_GENE_PRODUCT", 113, 131], ["PD-1", "GENE_OR_GENE_PRODUCT", 133, 137], ["camrelizumab", "SIMPLE_CHEMICAL", 149, 161], ["NCT04268537", "SIMPLE_CHEMICAL", 163, 174], ["anti-TNF tNFkumor drugs", "SIMPLE_CHEMICAL", 187, 210], ["SARS-CoV-2", "ORGANISM", 229, 239], ["SARS-CoV-2", "SPECIES", 229, 239], ["Other studies", "TEST", 0, 13], ["drugs", "TREATMENT", 50, 55], ["the myeloma drug thalidomide", "TREATMENT", 65, 93], ["the programmed death", "TREATMENT", 109, 129], ["other anti-TNF tNFkumor drugs", "TREATMENT", 181, 210], ["the therapy", "TREATMENT", 214, 225], ["SARS", "PROBLEM", 229, 233], ["CoV", "PROBLEM", 234, 237], ["2 infection", "PROBLEM", 238, 249], ["infection", "OBSERVATION", 240, 249]]], ["The possible value of other targeted substances, such as carfilzomib, afatinib, and ixazomib, will also be assessed [61] .Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaRegarding molecules that target the immune check points PD-1 and its ligand (PD-L1), these drugs have changed the therapy and outcome of numerous forms of tumors.", [["tumors", "ANATOMY", 349, 355], ["carfilzomib", "CHEMICAL", 57, 68], ["afatinib", "CHEMICAL", 70, 78], ["ixazomib", "CHEMICAL", 84, 92], ["tumors", "DISEASE", 349, 355], ["carfilzomib", "CHEMICAL", 57, 68], ["afatinib", "CHEMICAL", 70, 78], ["ixazomib", "CHEMICAL", 84, 92], ["carfilzomib", "SIMPLE_CHEMICAL", 57, 68], ["afatinib", "SIMPLE_CHEMICAL", 70, 78], ["ixazomib", "SIMPLE_CHEMICAL", 84, 92], ["Patients", "ORGANISM", 171, 179], ["PD-1", "GENE_OR_GENE_PRODUCT", 250, 254], ["PD-L1", "GENE_OR_GENE_PRODUCT", 271, 276], ["tumors", "CANCER", 349, 355], ["Patients", "SPECIES", 171, 179], ["other targeted substances", "PROBLEM", 22, 47], ["carfilzomib", "TREATMENT", 57, 68], ["afatinib", "TREATMENT", 70, 78], ["ixazomib", "TREATMENT", 84, 92], ["Antineoplastic", "TREATMENT", 122, 136], ["Antiviral Therapy", "TREATMENT", 141, 158], ["NeoplasiaRegarding molecules", "TREATMENT", 185, 213], ["PD", "TEST", 250, 252], ["these drugs", "TREATMENT", 279, 290], ["the therapy", "TREATMENT", 304, 315], ["tumors", "PROBLEM", 349, 355], ["Antiviral Therapy", "OBSERVATION", 141, 158], ["L1", "ANATOMY", 274, 276], ["tumors", "OBSERVATION", 349, 355]]], ["These monoclonal antibodies are able to restore antitumor immunity, and have received approval for the treatment of several forms of tumors, including lung cancer, breast cancer, melanoma, and urological tumors [62] [63] [64] [65] .Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaThe immune-related adverse events (irAEs) of anti-PD-1 or anti-PD-L1 substances are generally inflammation against organ-specific targets.", [["antitumor", "ANATOMY", 48, 57], ["tumors", "ANATOMY", 133, 139], ["lung cancer", "ANATOMY", 151, 162], ["breast cancer", "ANATOMY", 164, 177], ["melanoma", "ANATOMY", 179, 187], ["urological tumors", "ANATOMY", 193, 210], ["organ", "ANATOMY", 419, 424], ["tumors", "DISEASE", 133, 139], ["lung cancer", "DISEASE", 151, 162], ["breast cancer", "DISEASE", 164, 177], ["melanoma", "DISEASE", 179, 187], ["urological tumors", "DISEASE", 193, 210], ["inflammation", "DISEASE", 398, 410], ["antitumor", "CANCER", 48, 57], ["tumors", "CANCER", 133, 139], ["lung cancer", "CANCER", 151, 162], ["breast cancer", "CANCER", 164, 177], ["melanoma", "CANCER", 179, 187], ["urological tumors", "CANCER", 193, 210], ["Patients", "ORGANISM", 281, 289], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 349, 358], ["anti-PD-L1 substances", "SIMPLE_CHEMICAL", 362, 383], ["organ", "ORGAN", 419, 424], ["monoclonal antibodies", "PROTEIN", 6, 27], ["Patients", "SPECIES", 281, 289], ["These monoclonal antibodies", "TEST", 0, 27], ["the treatment", "TREATMENT", 99, 112], ["tumors", "PROBLEM", 133, 139], ["lung cancer", "PROBLEM", 151, 162], ["breast cancer", "PROBLEM", 164, 177], ["melanoma", "PROBLEM", 179, 187], ["urological tumors", "PROBLEM", 193, 210], ["Antineoplastic", "TREATMENT", 232, 246], ["Antiviral Therapy", "TREATMENT", 251, 268], ["NeoplasiaThe immune", "PROBLEM", 295, 314], ["adverse events", "PROBLEM", 323, 337], ["anti-PD", "TEST", 349, 356], ["anti-PD-L1 substances", "TREATMENT", 362, 383], ["generally inflammation", "PROBLEM", 388, 410], ["tumors", "OBSERVATION", 133, 139], ["lung", "ANATOMY", 151, 155], ["cancer", "OBSERVATION", 156, 162], ["breast", "ANATOMY", 164, 170], ["cancer", "OBSERVATION", 171, 177], ["melanoma", "OBSERVATION", 179, 187], ["Antiviral Therapy", "OBSERVATION", 251, 268], ["L1", "ANATOMY", 370, 372], ["inflammation", "OBSERVATION", 398, 410]]], ["Patients can present with irAEs such as pneumonitis, hepatitis, myocarditis, nephritis, and encephalitis.", [["irAEs", "DISEASE", 26, 31], ["pneumonitis", "DISEASE", 40, 51], ["hepatitis", "DISEASE", 53, 62], ["myocarditis", "DISEASE", 64, 75], ["nephritis", "DISEASE", 77, 86], ["encephalitis", "DISEASE", 92, 104], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["irAEs", "PROBLEM", 26, 31], ["pneumonitis", "PROBLEM", 40, 51], ["hepatitis", "PROBLEM", 53, 62], ["myocarditis", "PROBLEM", 64, 75], ["nephritis", "PROBLEM", 77, 86], ["encephalitis", "PROBLEM", 92, 104], ["pneumonitis", "OBSERVATION", 40, 51], ["hepatitis", "OBSERVATION", 53, 62], ["myocarditis", "OBSERVATION", 64, 75], ["nephritis", "OBSERVATION", 77, 86], ["encephalitis", "OBSERVATION", 92, 104]]], ["There is no augmented occurrence of hepatitis in patients with chronic hepatitis or immune reconstitution in subjects with HIV infection [66, 67] .", [["hepatitis", "DISEASE", 36, 45], ["chronic hepatitis", "DISEASE", 63, 80], ["HIV infection", "DISEASE", 123, 136], ["patients", "ORGANISM", 49, 57], ["HIV", "ORGANISM", 123, 126], ["patients", "SPECIES", 49, 57], ["HIV", "SPECIES", 123, 126], ["HIV", "SPECIES", 123, 126], ["hepatitis", "PROBLEM", 36, 45], ["chronic hepatitis", "PROBLEM", 63, 80], ["immune reconstitution", "TREATMENT", 84, 105], ["HIV infection", "PROBLEM", 123, 136], ["no", "UNCERTAINTY", 9, 11], ["augmented", "OBSERVATION_MODIFIER", 12, 21], ["hepatitis", "OBSERVATION", 36, 45], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["hepatitis", "OBSERVATION", 71, 80], ["immune reconstitution", "OBSERVATION", 84, 105]]], ["However, there have been cases of reactivation of latent tuberculosis via an augment in the immune response [68] .", [["tuberculosis", "DISEASE", 57, 69], ["latent tuberculosis", "ORGANISM", 50, 69], ["latent tuberculosis", "PROBLEM", 50, 69], ["latent", "OBSERVATION_MODIFIER", 50, 56], ["tuberculosis", "OBSERVATION", 57, 69]]], ["Reports of fatal encephalitis or myocarditis found in Epstein-Barr virus positive lymphocytes in the affected histological region have been released, suggesting some role of the infection in this irAE [69] .", [["lymphocytes", "ANATOMY", 82, 93], ["encephalitis", "DISEASE", 17, 29], ["myocarditis", "DISEASE", 33, 44], ["infection", "DISEASE", 178, 187], ["Epstein-Barr virus", "ORGANISM", 54, 72], ["lymphocytes", "CELL", 82, 93], ["Epstein-Barr virus", "SPECIES", 54, 72], ["fatal encephalitis", "PROBLEM", 11, 29], ["myocarditis", "PROBLEM", 33, 44], ["Barr virus positive lymphocytes", "PROBLEM", 62, 93], ["the infection", "PROBLEM", 174, 187], ["fatal", "OBSERVATION_MODIFIER", 11, 16], ["encephalitis", "OBSERVATION", 17, 29], ["myocarditis", "OBSERVATION", 33, 44], ["Barr virus", "OBSERVATION", 62, 72], ["affected", "ANATOMY_MODIFIER", 101, 109], ["histological", "ANATOMY_MODIFIER", 110, 122], ["region", "ANATOMY_MODIFIER", 123, 129], ["infection", "OBSERVATION", 178, 187]]], ["However, differently to chemotherapy, which is immunosuppressive, immune checkpoint inhibitors may be a safer possibility, as one case series of tumor subjects with SARS-CoV-2 infection did not report any cases among those submitted to immunotherapy [10] .", [["tumor", "ANATOMY", 145, 150], ["tumor", "DISEASE", 145, 150], ["SARS-CoV-2 infection", "DISEASE", 165, 185], ["tumor", "CANCER", 145, 150], ["SARS-CoV-2", "ORGANISM", 165, 175], ["chemotherapy", "TREATMENT", 24, 36], ["immunosuppressive", "TREATMENT", 47, 64], ["immune checkpoint inhibitors", "TREATMENT", 66, 94], ["tumor subjects", "PROBLEM", 145, 159], ["SARS", "PROBLEM", 165, 169], ["CoV-2 infection", "PROBLEM", 170, 185], ["tumor", "OBSERVATION", 145, 150]]], ["Thus, patients may be less inclined towards grave infections, but are at risk of a cytokine release syndrome that would aggravate a SARS-CoV-2 infection [70] [71] [72] .", [["infections", "DISEASE", 50, 60], ["infection", "DISEASE", 143, 152], ["patients", "ORGANISM", 6, 14], ["CoV-2", "ORGANISM", 137, 142], ["cytokine", "PROTEIN", 83, 91], ["patients", "SPECIES", 6, 14], ["grave infections", "PROBLEM", 44, 60], ["a cytokine release syndrome", "PROBLEM", 81, 108], ["a SARS", "PROBLEM", 130, 136], ["infection", "PROBLEM", 143, 152], ["infections", "OBSERVATION", 50, 60]]], ["PD-1 blockade is anticipated to reduce the development of sepsis secondary to severe pneumonia and excessive inflammatory response syndrome in COVID-19 patients, by reversing sepsis-associated T cell depletion.Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaHowever, the management must be cautiously calculated on a case-by-case scenario, given the possible augmentation in the risk of side-effects or death from the SARS-CoV-2 infection [73] .", [["T cell", "ANATOMY", 193, 199], ["sepsis", "DISEASE", 58, 64], ["pneumonia", "DISEASE", 85, 94], ["excessive inflammatory response syndrome", "DISEASE", 99, 139], ["sepsis", "DISEASE", 175, 181], ["death", "DISEASE", 427, 432], ["SARS", "DISEASE", 442, 446], ["infection", "DISEASE", 453, 462], ["PD-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 152, 160], ["T cell", "CELL", 193, 199], ["Patients", "ORGANISM", 259, 267], ["SARS-CoV-2", "ORGANISM", 442, 452], ["patients", "SPECIES", 152, 160], ["Patients", "SPECIES", 259, 267], ["PD-1 blockade", "TREATMENT", 0, 13], ["sepsis", "PROBLEM", 58, 64], ["severe pneumonia", "PROBLEM", 78, 94], ["excessive inflammatory response syndrome", "PROBLEM", 99, 139], ["reversing sepsis", "PROBLEM", 165, 181], ["T cell depletion", "PROBLEM", 193, 209], ["Antineoplastic", "TREATMENT", 210, 224], ["Antiviral Therapy", "TREATMENT", 229, 246], ["augmentation", "TREATMENT", 383, 395], ["side-effects", "PROBLEM", 411, 423], ["death", "PROBLEM", 427, 432], ["the SARS", "PROBLEM", 438, 446], ["CoV-2 infection", "PROBLEM", 447, 462], ["sepsis", "OBSERVATION", 58, 64], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["pneumonia", "OBSERVATION", 85, 94], ["excessive", "OBSERVATION_MODIFIER", 99, 108], ["inflammatory response syndrome", "OBSERVATION", 109, 139], ["sepsis", "OBSERVATION", 175, 181], ["T cell depletion", "OBSERVATION", 193, 209], ["Antiviral Therapy", "OBSERVATION", 229, 246]]], ["Checkpoint inhibitors (ICIs) appear to be more supportable than other chemotherapeutic drugs [74, 75] .", [["Checkpoint inhibitors", "TREATMENT", 0, 21], ["chemotherapeutic drugs", "TREATMENT", 70, 92]]], ["If the studies on camrelizumab in patients with SARS-CoV-2 infection give comforting results [61] , the use of this drug could be an important element for the treatment of the disease in many neoplastic patients.", [["neoplastic", "ANATOMY", 192, 202], ["camrelizumab", "CHEMICAL", 18, 30], ["SARS-CoV-2 infection", "DISEASE", 48, 68], ["camrelizumab", "CHEMICAL", 18, 30], ["camrelizumab", "SIMPLE_CHEMICAL", 18, 30], ["patients", "ORGANISM", 34, 42], ["SARS-CoV-2", "ORGANISM", 48, 58], ["patients", "ORGANISM", 203, 211], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 203, 211], ["the studies", "TEST", 3, 14], ["camrelizumab", "TEST", 18, 30], ["SARS", "PROBLEM", 48, 52], ["CoV-2 infection", "PROBLEM", 53, 68], ["this drug", "TREATMENT", 111, 120], ["the treatment", "TREATMENT", 155, 168], ["the disease", "PROBLEM", 172, 183], ["disease", "OBSERVATION", 176, 183], ["neoplastic", "OBSERVATION_MODIFIER", 192, 202]]], ["The immune-related adverse events (irAEs) of anti-PD-1 or anti-PD-L1 substances are generally inflammation against organ-specific targets.", [["organ", "ANATOMY", 115, 120], ["inflammation", "DISEASE", 94, 106], ["anti-PD-1", "GENE_OR_GENE_PRODUCT", 45, 54], ["anti-PD-L1", "SIMPLE_CHEMICAL", 58, 68], ["organ", "ORGAN", 115, 120], ["adverse events", "PROBLEM", 19, 33], ["anti-PD", "TEST", 45, 52], ["anti-PD-L1 substances", "TREATMENT", 58, 79], ["generally inflammation", "PROBLEM", 84, 106], ["L1", "ANATOMY", 66, 68], ["inflammation", "OBSERVATION", 94, 106]]], ["Patients can present with irAEs such as pneumonitis, hepatitis, myocarditis, nephritis, and encephalitis.", [["irAEs", "DISEASE", 26, 31], ["pneumonitis", "DISEASE", 40, 51], ["hepatitis", "DISEASE", 53, 62], ["myocarditis", "DISEASE", 64, 75], ["nephritis", "DISEASE", 77, 86], ["encephalitis", "DISEASE", 92, 104], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["irAEs", "PROBLEM", 26, 31], ["pneumonitis", "PROBLEM", 40, 51], ["hepatitis", "PROBLEM", 53, 62], ["myocarditis", "PROBLEM", 64, 75], ["nephritis", "PROBLEM", 77, 86], ["encephalitis", "PROBLEM", 92, 104], ["pneumonitis", "OBSERVATION", 40, 51], ["hepatitis", "OBSERVATION", 53, 62], ["myocarditis", "OBSERVATION", 64, 75], ["nephritis", "OBSERVATION", 77, 86], ["encephalitis", "OBSERVATION", 92, 104]]], ["There is no augmented occurrence of hepatitis in patients with chronic hepatitis or immune reconstitution in subjects with HIV infection [66, 67] .", [["hepatitis", "DISEASE", 36, 45], ["chronic hepatitis", "DISEASE", 63, 80], ["HIV infection", "DISEASE", 123, 136], ["patients", "ORGANISM", 49, 57], ["HIV", "ORGANISM", 123, 126], ["patients", "SPECIES", 49, 57], ["HIV", "SPECIES", 123, 126], ["HIV", "SPECIES", 123, 126], ["hepatitis", "PROBLEM", 36, 45], ["chronic hepatitis", "PROBLEM", 63, 80], ["immune reconstitution", "TREATMENT", 84, 105], ["HIV infection", "PROBLEM", 123, 136], ["no", "UNCERTAINTY", 9, 11], ["augmented", "OBSERVATION_MODIFIER", 12, 21], ["hepatitis", "OBSERVATION", 36, 45], ["chronic", "OBSERVATION_MODIFIER", 63, 70], ["hepatitis", "OBSERVATION", 71, 80], ["immune reconstitution", "OBSERVATION", 84, 105]]], ["However, there have been cases of reactivation of latent tuberculosis via an augment in the immune response [68] .", [["tuberculosis", "DISEASE", 57, 69], ["latent tuberculosis", "ORGANISM", 50, 69], ["latent tuberculosis", "PROBLEM", 50, 69], ["latent", "OBSERVATION_MODIFIER", 50, 56], ["tuberculosis", "OBSERVATION", 57, 69]]], ["Reports of fatal encephalitis or myocarditis found in Epstein-Barr virus positive lymphocytes in the affected histological region have been released, suggesting some role of the infection in this irAE [69] .", [["lymphocytes", "ANATOMY", 82, 93], ["encephalitis", "DISEASE", 17, 29], ["myocarditis", "DISEASE", 33, 44], ["infection", "DISEASE", 178, 187], ["Epstein-Barr virus", "ORGANISM", 54, 72], ["lymphocytes", "CELL", 82, 93], ["Epstein-Barr virus", "SPECIES", 54, 72], ["fatal encephalitis", "PROBLEM", 11, 29], ["myocarditis", "PROBLEM", 33, 44], ["Barr virus positive lymphocytes", "PROBLEM", 62, 93], ["the infection", "PROBLEM", 174, 187], ["fatal", "OBSERVATION_MODIFIER", 11, 16], ["encephalitis", "OBSERVATION", 17, 29], ["myocarditis", "OBSERVATION", 33, 44], ["Barr virus", "OBSERVATION", 62, 72], ["affected", "ANATOMY_MODIFIER", 101, 109], ["histological", "ANATOMY_MODIFIER", 110, 122], ["region", "ANATOMY_MODIFIER", 123, 129], ["infection", "OBSERVATION", 178, 187]]], ["However, differently to chemotherapy, which is immunosuppressive, immune checkpoint inhibitors may be a safer possibility, as one case series of tumor subjects with SARS-CoV-2 infection did not report any cases among those submitted to immunotherapy [10] .", [["tumor", "ANATOMY", 145, 150], ["tumor", "DISEASE", 145, 150], ["SARS-CoV-2 infection", "DISEASE", 165, 185], ["tumor", "CANCER", 145, 150], ["SARS-CoV-2", "ORGANISM", 165, 175], ["chemotherapy", "TREATMENT", 24, 36], ["immunosuppressive", "TREATMENT", 47, 64], ["immune checkpoint inhibitors", "TREATMENT", 66, 94], ["tumor subjects", "PROBLEM", 145, 159], ["SARS", "PROBLEM", 165, 169], ["CoV-2 infection", "PROBLEM", 170, 185], ["tumor", "OBSERVATION", 145, 150]]], ["Thus, patients may be less inclined towards grave infections, but are at risk of a cytokine release syndrome that would aggravate a SARS-CoV-2 infection [70] [71] [72] .", [["infections", "DISEASE", 50, 60], ["infection", "DISEASE", 143, 152], ["patients", "ORGANISM", 6, 14], ["CoV-2", "ORGANISM", 137, 142], ["cytokine", "PROTEIN", 83, 91], ["patients", "SPECIES", 6, 14], ["grave infections", "PROBLEM", 44, 60], ["a cytokine release syndrome", "PROBLEM", 81, 108], ["a SARS", "PROBLEM", 130, 136], ["infection", "PROBLEM", 143, 152], ["infections", "OBSERVATION", 50, 60]]], ["PD-1 blockade is anticipated to reduce the development of sepsis secondary to severe pneumonia and excessive inflammatory response syndrome in COVID-19 patients, by reversing sepsis-associated T cell depletion.Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaHowever, the management must be cautiously calculated on a case-by-case scenario, given the possible augmentation in the risk of side-effects or death from the SARS-CoV-2 infection [73] .", [["T cell", "ANATOMY", 193, 199], ["sepsis", "DISEASE", 58, 64], ["pneumonia", "DISEASE", 85, 94], ["excessive inflammatory response syndrome", "DISEASE", 99, 139], ["sepsis", "DISEASE", 175, 181], ["death", "DISEASE", 427, 432], ["SARS", "DISEASE", 442, 446], ["infection", "DISEASE", 453, 462], ["PD-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 152, 160], ["T cell", "CELL", 193, 199], ["Patients", "ORGANISM", 259, 267], ["SARS-CoV-2", "ORGANISM", 442, 452], ["patients", "SPECIES", 152, 160], ["Patients", "SPECIES", 259, 267], ["PD-1 blockade", "TREATMENT", 0, 13], ["sepsis", "PROBLEM", 58, 64], ["severe pneumonia", "PROBLEM", 78, 94], ["excessive inflammatory response syndrome", "PROBLEM", 99, 139], ["reversing sepsis", "PROBLEM", 165, 181], ["T cell depletion", "PROBLEM", 193, 209], ["Antineoplastic", "TREATMENT", 210, 224], ["Antiviral Therapy", "TREATMENT", 229, 246], ["augmentation", "TREATMENT", 383, 395], ["side-effects", "PROBLEM", 411, 423], ["death", "PROBLEM", 427, 432], ["the SARS", "PROBLEM", 438, 446], ["CoV-2 infection", "PROBLEM", 447, 462], ["sepsis", "OBSERVATION", 58, 64], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["pneumonia", "OBSERVATION", 85, 94], ["excessive", "OBSERVATION_MODIFIER", 99, 108], ["inflammatory response syndrome", "OBSERVATION", 109, 139], ["sepsis", "OBSERVATION", 175, 181], ["T cell depletion", "OBSERVATION", 193, 209], ["Antiviral Therapy", "OBSERVATION", 229, 246]]], ["Checkpoint inhibitors (ICIs) appear to be more supportable than other chemotherapeutic drugs [74, 75] .", [["Checkpoint inhibitors", "TREATMENT", 0, 21], ["chemotherapeutic drugs", "TREATMENT", 70, 92]]], ["If the studies on camrelizumab in patients with SARS-CoV-2 infection give comforting results [61] , the use of this drug could be an important element for the treatment of the disease in many neoplastic patients.Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaA different substance that seems to have surprising implications for subjects with SARS-CoV-2 infection is ibrutinib.", [["neoplastic", "ANATOMY", 192, 202], ["camrelizumab", "CHEMICAL", 18, 30], ["SARS-CoV-2 infection", "DISEASE", 48, 68], ["SARS-CoV-2 infection", "DISEASE", 367, 387], ["ibrutinib", "CHEMICAL", 391, 400], ["camrelizumab", "CHEMICAL", 18, 30], ["ibrutinib", "CHEMICAL", 391, 400], ["camrelizumab", "SIMPLE_CHEMICAL", 18, 30], ["patients", "ORGANISM", 34, 42], ["SARS-CoV-2", "ORGANISM", 48, 58], ["patients", "ORGANISM", 203, 211], ["Patients", "ORGANISM", 261, 269], ["SARS-CoV-2", "ORGANISM", 367, 377], ["ibrutinib", "SIMPLE_CHEMICAL", 391, 400], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 203, 211], ["Patients", "SPECIES", 261, 269], ["SARS-CoV", "SPECIES", 367, 375], ["the studies", "TEST", 3, 14], ["camrelizumab", "TEST", 18, 30], ["SARS", "PROBLEM", 48, 52], ["CoV-2 infection", "PROBLEM", 53, 68], ["this drug", "TREATMENT", 111, 120], ["the treatment", "TREATMENT", 155, 168], ["the disease", "PROBLEM", 172, 183], ["Antineoplastic", "TREATMENT", 212, 226], ["Antiviral Therapy", "TREATMENT", 231, 248], ["NeoplasiaA different substance", "PROBLEM", 275, 305], ["SARS", "PROBLEM", 367, 371], ["CoV-2 infection", "PROBLEM", 372, 387], ["ibrutinib", "PROBLEM", 391, 400], ["disease", "OBSERVATION", 176, 183], ["neoplastic", "OBSERVATION_MODIFIER", 192, 202], ["Antiviral Therapy", "OBSERVATION", 231, 248], ["infection", "OBSERVATION", 378, 387], ["ibrutinib", "OBSERVATION", 391, 400]]], ["Ibrutinib is a powerful covalent inhibitor of Bruton tyrosine kinase (BTK).", [["Ibrutinib", "CHEMICAL", 0, 9], ["tyrosine", "CHEMICAL", 53, 61], ["Ibrutinib", "CHEMICAL", 0, 9], ["tyrosine", "CHEMICAL", 53, 61], ["Ibrutinib", "SIMPLE_CHEMICAL", 0, 9], ["Bruton tyrosine kinase", "GENE_OR_GENE_PRODUCT", 46, 68], ["BTK", "GENE_OR_GENE_PRODUCT", 70, 73], ["Bruton tyrosine kinase", "PROTEIN", 46, 68], ["BTK", "PROTEIN", 70, 73], ["Ibrutinib", "TREATMENT", 0, 9], ["a powerful covalent inhibitor", "TREATMENT", 13, 42], ["Bruton tyrosine kinase", "TREATMENT", 46, 68]]], ["Ibrutinib is also a strong reversible inhibitor of hematopoietic cell kinase (HCK).Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaThe possibility for ibrutinib to reduce lung damage, pulmonary inflammatory cytokines, and death has in the past been established in a lethal flu experimental animal model, in which animals were challenged with an intranasal inoculum of H1N1 influenza virus.", [["hematopoietic cell", "ANATOMY", 51, 69], ["lung", "ANATOMY", 195, 199], ["pulmonary", "ANATOMY", 208, 217], ["Ibrutinib", "CHEMICAL", 0, 9], ["Neoplasia", "DISEASE", 146, 155], ["ibrutinib", "CHEMICAL", 175, 184], ["lung damage", "DISEASE", 195, 206], ["death", "DISEASE", 246, 251], ["influenza virus", "DISEASE", 397, 412], ["Ibrutinib", "CHEMICAL", 0, 9], ["ibrutinib", "CHEMICAL", 175, 184], ["Ibrutinib", "SIMPLE_CHEMICAL", 0, 9], ["hematopoietic cell kinase", "GENE_OR_GENE_PRODUCT", 51, 76], ["HCK", "GENE_OR_GENE_PRODUCT", 78, 81], ["Patients", "ORGANISM", 132, 140], ["ibrutinib", "SIMPLE_CHEMICAL", 175, 184], ["lung", "ORGAN", 195, 199], ["pulmonary", "ORGAN", 208, 217], ["animals", "ORGANISM", 337, 344], ["H1N1 influenza virus", "ORGANISM", 392, 412], ["hematopoietic cell kinase", "PROTEIN", 51, 76], ["HCK", "PROTEIN", 78, 81], ["pulmonary inflammatory cytokines", "PROTEIN", 208, 240], ["Patients", "SPECIES", 132, 140], ["H1N1 influenza virus", "SPECIES", 392, 412], ["H1N1 influenza virus", "SPECIES", 392, 412], ["Ibrutinib", "PROBLEM", 0, 9], ["a strong reversible inhibitor of hematopoietic cell kinase", "PROBLEM", 18, 76], ["Antineoplastic", "TREATMENT", 83, 97], ["Antiviral Therapy", "TREATMENT", 102, 119], ["Neoplasia", "PROBLEM", 146, 155], ["ibrutinib", "TREATMENT", 175, 184], ["lung damage", "PROBLEM", 195, 206], ["pulmonary inflammatory cytokines", "PROBLEM", 208, 240], ["death", "PROBLEM", 246, 251], ["a lethal flu experimental animal model", "PROBLEM", 288, 326], ["an intranasal inoculum", "TREATMENT", 366, 388], ["H1N1 influenza virus", "PROBLEM", 392, 412], ["strong", "OBSERVATION_MODIFIER", 20, 26], ["reversible", "OBSERVATION_MODIFIER", 27, 37], ["inhibitor", "OBSERVATION", 38, 47], ["hematopoietic cell kinase", "OBSERVATION", 51, 76], ["Antiviral Therapy", "OBSERVATION", 102, 119], ["Neoplasia", "OBSERVATION", 146, 155], ["possibility for", "UNCERTAINTY", 159, 174], ["ibrutinib", "OBSERVATION", 175, 184], ["lung", "ANATOMY", 195, 199], ["damage", "OBSERVATION", 200, 206], ["pulmonary", "ANATOMY", 208, 217], ["inflammatory cytokines", "OBSERVATION", 218, 240], ["H1N1", "OBSERVATION", 392, 396]]], ["Control animals presented with respiratory failure, with histological and Computed Tomography (CT) features coherent with relevant lung damage, in contrast to the animals treated with ibrutinib.", [["respiratory", "ANATOMY", 31, 42], ["lung", "ANATOMY", 131, 135], ["respiratory failure", "DISEASE", 31, 50], ["lung damage", "DISEASE", 131, 142], ["ibrutinib", "CHEMICAL", 184, 193], ["ibrutinib", "CHEMICAL", 184, 193], ["lung", "ORGAN", 131, 135], ["ibrutinib", "SIMPLE_CHEMICAL", 184, 193], ["respiratory failure", "PROBLEM", 31, 50], ["Computed Tomography (CT)", "TEST", 74, 98], ["relevant lung damage", "PROBLEM", 122, 142], ["ibrutinib", "TREATMENT", 184, 193], ["respiratory failure", "OBSERVATION", 31, 50], ["lung", "ANATOMY", 131, 135], ["damage", "OBSERVATION", 136, 142], ["ibrutinib", "OBSERVATION", 184, 193]]], ["Non-treated animals died, while those treated with ibrutinib recuperated and regained their weight after an initial loss, and all survived [76] .Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaSome experimental investigations have allowed elucidation of the mechanisms of action of ibrutinib.", [["ibrutinib", "CHEMICAL", 51, 60], ["ibrutinib", "CHEMICAL", 306, 315], ["ibrutinib", "CHEMICAL", 51, 60], ["ibrutinib", "CHEMICAL", 306, 315], ["animals", "ORGANISM", 12, 19], ["ibrutinib", "SIMPLE_CHEMICAL", 51, 60], ["Patients", "ORGANISM", 194, 202], ["ibrutinib", "SIMPLE_CHEMICAL", 306, 315], ["Patients", "SPECIES", 194, 202], ["ibrutinib", "TREATMENT", 51, 60], ["an initial loss", "PROBLEM", 105, 120], ["Antineoplastic", "TREATMENT", 145, 159], ["Antiviral Therapy", "TREATMENT", 164, 181], ["NeoplasiaSome experimental investigations", "PROBLEM", 208, 249], ["ibrutinib", "TREATMENT", 306, 315], ["Antiviral Therapy", "OBSERVATION", 164, 181]]], ["It was demonstrated that BTK, and its activator HCK, are implicated in Toll-like receptor (TLR) mediated signaling [77] [78] [79] .", [["BTK", "GENE_OR_GENE_PRODUCT", 25, 28], ["HCK", "GENE_OR_GENE_PRODUCT", 48, 51], ["Toll-like receptor", "GENE_OR_GENE_PRODUCT", 71, 89], ["TLR", "GENE_OR_GENE_PRODUCT", 91, 94], ["BTK", "PROTEIN", 25, 28], ["HCK", "PROTEIN", 48, 51], ["Toll-like receptor", "PROTEIN", 71, 89], ["TLR", "PROTEIN", 91, 94], ["BTK", "TEST", 25, 28], ["its activator HCK", "TEST", 34, 51]]], ["Both BTK and HCK are stimulated by Myeloid differentiation factor 88 (MyD88), a TLR-adaptor protein that acts on all Toll receptors excluding TLR3 in response to viruses, including coronaviruses [80] .", [["BTK", "GENE_OR_GENE_PRODUCT", 5, 8], ["HCK", "GENE_OR_GENE_PRODUCT", 13, 16], ["Myeloid differentiation factor 88", "GENE_OR_GENE_PRODUCT", 35, 68], ["MyD88", "GENE_OR_GENE_PRODUCT", 70, 75], ["TLR", "GENE_OR_GENE_PRODUCT", 80, 83], ["TLR3", "GENE_OR_GENE_PRODUCT", 142, 146], ["BTK", "PROTEIN", 5, 8], ["HCK", "PROTEIN", 13, 16], ["Myeloid differentiation factor 88", "PROTEIN", 35, 68], ["MyD88", "PROTEIN", 70, 75], ["TLR", "PROTEIN", 80, 83], ["adaptor protein", "PROTEIN", 84, 99], ["Toll receptors", "PROTEIN", 117, 131], ["TLR3", "PROTEIN", 142, 146], ["Myeloid differentiation factor", "TEST", 35, 65], ["a TLR-adaptor protein", "TREATMENT", 78, 99], ["all Toll receptors", "TREATMENT", 113, 131], ["TLR3", "PROBLEM", 142, 146], ["viruses", "PROBLEM", 162, 169], ["coronaviruses", "PROBLEM", 181, 194], ["BTK", "ANATOMY", 5, 8], ["HCK", "OBSERVATION", 13, 16]]], ["ATII cells have TLRs, as do the alveolar macrophages that regulate inflammatory responses.", [["ATII cells", "ANATOMY", 0, 10], ["alveolar macrophages", "ANATOMY", 32, 52], ["ATII cells", "CELL", 0, 10], ["TLRs", "GENE_OR_GENE_PRODUCT", 16, 20], ["alveolar macrophages", "CELL", 32, 52], ["ATII cells", "CELL_LINE", 0, 10], ["TLRs", "PROTEIN", 16, 20], ["alveolar macrophages", "CELL_TYPE", 32, 52], ["TLRs", "TEST", 16, 20], ["the alveolar macrophages", "PROBLEM", 28, 52], ["alveolar", "ANATOMY", 32, 40], ["macrophages", "OBSERVATION", 41, 52], ["inflammatory", "OBSERVATION_MODIFIER", 67, 79]]], ["As central elements of TLR/MYD88 signaling, BTK and HCK can control inflammatory cytokine generation via Extracellular signal-regulated kinases (ERK)1/2 [81] .Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaIn a transgenic animal model, stimulation of HCK caused serious pulmonary inflammation and an increase of the innate immune response, especially in older animals [82] .", [["pulmonary", "ANATOMY", 295, 304], ["HCK", "CHEMICAL", 276, 279], ["pulmonary inflammation", "DISEASE", 295, 317], ["TLR", "GENE_OR_GENE_PRODUCT", 23, 26], ["MYD88", "GENE_OR_GENE_PRODUCT", 27, 32], ["BTK", "GENE_OR_GENE_PRODUCT", 44, 47], ["HCK", "GENE_OR_GENE_PRODUCT", 52, 55], ["Extracellular signal-regulated kinases", "GENE_OR_GENE_PRODUCT", 105, 143], ["ERK", "GENE_OR_GENE_PRODUCT", 145, 148], ["Patients", "ORGANISM", 208, 216], ["HCK", "GENE_OR_GENE_PRODUCT", 276, 279], ["pulmonary", "ORGAN", 295, 304], ["TLR", "PROTEIN", 23, 26], ["MYD88", "PROTEIN", 27, 32], ["BTK", "PROTEIN", 44, 47], ["HCK", "PROTEIN", 52, 55], ["inflammatory cytokine", "PROTEIN", 68, 89], ["Extracellular signal-regulated kinases", "PROTEIN", 105, 143], ["ERK", "PROTEIN", 145, 148], ["Patients", "SPECIES", 208, 216], ["BTK", "TEST", 44, 47], ["HCK", "TEST", 52, 55], ["inflammatory cytokine generation", "PROBLEM", 68, 100], ["Extracellular signal", "TEST", 105, 125], ["Antineoplastic", "TREATMENT", 159, 173], ["Antiviral Therapy", "TREATMENT", 178, 195], ["NeoplasiaIn a transgenic animal model", "TREATMENT", 222, 259], ["serious pulmonary inflammation", "PROBLEM", 287, 317], ["Antiviral Therapy", "OBSERVATION", 178, 195], ["serious", "OBSERVATION_MODIFIER", 287, 294], ["pulmonary", "ANATOMY", 295, 304], ["inflammation", "OBSERVATION", 305, 317], ["increase", "OBSERVATION_MODIFIER", 325, 333]]], ["Augmented concentrations of TNF-a were found in the bronchoalveolar lavage fluids of these animals.", [["bronchoalveolar lavage fluids", "ANATOMY", 52, 81], ["TNF", "GENE_OR_GENE_PRODUCT", 28, 31], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 52, 74], ["TNF", "PROTEIN", 28, 31], ["Augmented concentrations of TNF", "PROBLEM", 0, 31], ["the bronchoalveolar lavage fluids", "TEST", 48, 81], ["concentrations", "OBSERVATION_MODIFIER", 10, 24], ["bronchoalveolar lavage", "OBSERVATION", 52, 74]]], ["The pulmonary alterations evidenced in these mice looked very similar to those reported in the lungs of subjects with SARS-CoV-2 infection, which presented with fibrin exudation with alveolar infiltration of monocytes and macrophages [83] .Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaTreon et al. tried to elucidate the effect of ibrutinib in SARS-CoV-2 subjects [84] .", [["pulmonary", "ANATOMY", 4, 13], ["lungs", "ANATOMY", 95, 100], ["alveolar", "ANATOMY", 183, 191], ["monocytes", "ANATOMY", 208, 217], ["macrophages", "ANATOMY", 222, 233], ["pulmonary alterations", "DISEASE", 4, 25], ["SARS-CoV-2 infection", "DISEASE", 118, 138], ["ibrutinib", "CHEMICAL", 358, 367], ["SARS", "DISEASE", 371, 375], ["ibrutinib", "CHEMICAL", 358, 367], ["pulmonary", "ORGAN", 4, 13], ["mice", "ORGANISM", 45, 49], ["lungs", "ORGAN", 95, 100], ["SARS-CoV-2", "ORGANISM", 118, 128], ["fibrin", "GENE_OR_GENE_PRODUCT", 161, 167], ["alveolar", "TISSUE", 183, 191], ["monocytes", "CELL", 208, 217], ["macrophages", "CELL", 222, 233], ["Patients", "ORGANISM", 289, 297], ["ibrutinib", "SIMPLE_CHEMICAL", 358, 367], ["SARS-CoV-2", "ORGANISM", 371, 381], ["monocytes", "CELL_TYPE", 208, 217], ["macrophages", "CELL_TYPE", 222, 233], ["mice", "SPECIES", 45, 49], ["Patients", "SPECIES", 289, 297], ["mice", "SPECIES", 45, 49], ["SARS-CoV-2", "SPECIES", 118, 128], ["The pulmonary alterations", "PROBLEM", 0, 25], ["SARS", "PROBLEM", 118, 122], ["CoV-2 infection", "PROBLEM", 123, 138], ["fibrin exudation", "PROBLEM", 161, 177], ["alveolar infiltration of monocytes", "PROBLEM", 183, 217], ["macrophages", "PROBLEM", 222, 233], ["Antineoplastic", "TREATMENT", 240, 254], ["Antiviral Therapy", "TREATMENT", 259, 276], ["NeoplasiaTreon et al", "TREATMENT", 303, 323], ["ibrutinib in SARS", "PROBLEM", 358, 375], ["CoV", "TEST", 376, 379], ["pulmonary", "ANATOMY", 4, 13], ["alterations", "OBSERVATION", 14, 25], ["lungs", "ANATOMY", 95, 100], ["infection", "OBSERVATION", 129, 138], ["fibrin", "OBSERVATION_MODIFIER", 161, 167], ["exudation", "OBSERVATION_MODIFIER", 168, 177], ["alveolar", "ANATOMY_MODIFIER", 183, 191], ["infiltration", "OBSERVATION", 192, 204], ["monocytes", "OBSERVATION_MODIFIER", 208, 217], ["macrophages", "OBSERVATION_MODIFIER", 222, 233], ["Antiviral Therapy", "OBSERVATION", 259, 276]]], ["They evaluated 300 Waldenstrom's macroglobulinemia (WM) patients treated with a BTK-inhibitor.", [["WM", "ANATOMY", 52, 54], ["Waldenstrom's macroglobulinemia", "DISEASE", 19, 50], ["Waldenstrom's macroglobulinemia", "CANCER", 19, 50], ["patients", "ORGANISM", 56, 64], ["BTK", "GENE_OR_GENE_PRODUCT", 80, 83], ["BTK", "PROTEIN", 80, 83], ["patients", "SPECIES", 56, 64], ["Waldenstrom's macroglobulinemia", "PROBLEM", 19, 50], ["a BTK-inhibitor", "TREATMENT", 78, 93]]], ["They investigated six subjects receiving ibrutinib (five patients received 420 mg/day; one patient received 140 mg/day) who were diagnosed with SARS-CoV-2 infection.", [["ibrutinib", "CHEMICAL", 41, 50], ["SARS-CoV-2 infection", "DISEASE", 144, 164], ["ibrutinib", "CHEMICAL", 41, 50], ["ibrutinib", "SIMPLE_CHEMICAL", 41, 50], ["patients", "ORGANISM", 57, 65], ["patient", "ORGANISM", 91, 98], ["CoV-2", "ORGANISM", 149, 154], ["patients", "SPECIES", 57, 65], ["patient", "SPECIES", 91, 98], ["SARS-CoV-2", "SPECIES", 144, 154], ["ibrutinib", "TREATMENT", 41, 50], ["SARS", "PROBLEM", 144, 148], ["CoV", "PROBLEM", 149, 152], ["2 infection", "PROBLEM", 153, 164], ["infection", "OBSERVATION", 155, 164]]], ["Their median time with SARS-CoV-2 correlated symptoms prior to diagnostic analysis was five days.", [["SARS", "PROBLEM", 23, 27], ["correlated symptoms", "PROBLEM", 34, 53], ["diagnostic analysis", "TEST", 63, 82]]], ["All six subjects had fever and a cough as prodromal signs.", [["fever", "DISEASE", 21, 26], ["cough", "DISEASE", 33, 38], ["fever", "PROBLEM", 21, 26], ["a cough as prodromal signs", "PROBLEM", 31, 57], ["fever", "OBSERVATION", 21, 26], ["cough", "OBSERVATION", 33, 38]]], ["The five patients on ibrutinib at 420 mg/day had no dyspnea, and did not need hospitalization.", [["ibrutinib", "CHEMICAL", 21, 30], ["dyspnea", "DISEASE", 52, 59], ["ibrutinib", "CHEMICAL", 21, 30], ["patients", "ORGANISM", 9, 17], ["ibrutinib", "SIMPLE_CHEMICAL", 21, 30], ["patients", "SPECIES", 9, 17], ["ibrutinib", "TREATMENT", 21, 30], ["dyspnea", "PROBLEM", 52, 59], ["no", "UNCERTAINTY", 49, 51], ["dyspnea", "OBSERVATION", 52, 59]]], ["Their course was characterized by constant improvement, and disappearance of SARS-CoV-2 correlated symptoms.", [["SARS", "DISEASE", 77, 81], ["SARS", "PROBLEM", 77, 81], ["correlated symptoms", "PROBLEM", 88, 107], ["constant", "OBSERVATION_MODIFIER", 34, 42], ["improvement", "OBSERVATION_MODIFIER", 43, 54]]], ["The subject on treatment with ibrutinib 140 mg/day presented with increasing dyspnea and hypoxia, provoking hospitalization.", [["ibrutinib", "CHEMICAL", 30, 39], ["dyspnea", "DISEASE", 77, 84], ["hypoxia", "DISEASE", 89, 96], ["ibrutinib", "CHEMICAL", 30, 39], ["ibrutinib", "SIMPLE_CHEMICAL", 30, 39], ["treatment", "TREATMENT", 15, 24], ["ibrutinib", "TREATMENT", 30, 39], ["increasing dyspnea", "PROBLEM", 66, 84], ["hypoxia", "PROBLEM", 89, 96], ["increasing", "OBSERVATION_MODIFIER", 66, 76], ["dyspnea", "OBSERVATION", 77, 84], ["hypoxia", "OBSERVATION", 89, 96]]], ["Chest CT demonstrated bilateral ground glass opacities.", [["Chest CT", "TEST", 0, 8], ["bilateral ground glass opacities", "PROBLEM", 22, 54], ["bilateral", "ANATOMY_MODIFIER", 22, 31], ["ground glass opacities", "OBSERVATION", 32, 54]]], ["This induced a hold on ibrutinib administration, with a severe worsening of hypoxia [84] .Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaAlthough the study included only a small series of patients, it surely offers interesting possibilities.", [["ibrutinib", "CHEMICAL", 23, 32], ["hypoxia", "DISEASE", 76, 83], ["ibrutinib", "CHEMICAL", 23, 32], ["ibrutinib", "SIMPLE_CHEMICAL", 23, 32], ["Patients", "ORGANISM", 139, 147], ["patients", "ORGANISM", 213, 221], ["Patients", "SPECIES", 139, 147], ["patients", "SPECIES", 213, 221], ["ibrutinib administration", "TREATMENT", 23, 47], ["a severe worsening of hypoxia", "PROBLEM", 54, 83], ["Antineoplastic", "TREATMENT", 90, 104], ["Antiviral Therapy", "TREATMENT", 109, 126], ["the study", "TEST", 171, 180], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["worsening", "OBSERVATION_MODIFIER", 63, 72], ["hypoxia", "OBSERVATION", 76, 83], ["Antiviral Therapy", "OBSERVATION", 109, 126]]], ["Subjects on ibrutinib may benefit from maintenance of their treatment, despite the presence of SARS-CoV-2 infection, although it will be essential to confirm these data in other subjects on BTK-inhibitors, including CLL patients.Antineoplastic and Antiviral Therapy in Infected Patients with NeoplasiaLow-dose selinexor will be evaluated in a randomized clinical trial for hospitalized subjects with severe SARS-CoV-2 infection (NCT04349098).", [["CLL", "ANATOMY", 216, 219], ["ibrutinib", "CHEMICAL", 12, 21], ["infection", "DISEASE", 106, 115], ["CLL", "DISEASE", 216, 219], ["SARS-CoV-2 infection", "DISEASE", 407, 427], ["ibrutinib", "CHEMICAL", 12, 21], ["ibrutinib", "SIMPLE_CHEMICAL", 12, 21], ["SARS-CoV-2", "ORGANISM", 95, 105], ["BTK", "GENE_OR_GENE_PRODUCT", 190, 193], ["CLL", "CANCER", 216, 219], ["patients", "ORGANISM", 220, 228], ["Patients", "ORGANISM", 278, 286], ["BTK", "PROTEIN", 190, 193], ["patients", "SPECIES", 220, 228], ["Patients", "SPECIES", 278, 286], ["SARS-CoV", "SPECIES", 95, 103], ["SARS-CoV-2", "SPECIES", 407, 417], ["ibrutinib", "TREATMENT", 12, 21], ["their treatment", "TREATMENT", 54, 69], ["SARS", "PROBLEM", 95, 99], ["CoV-2 infection", "PROBLEM", 100, 115], ["these data", "TEST", 158, 168], ["BTK-inhibitors", "TREATMENT", 190, 204], ["CLL patients", "TREATMENT", 216, 228], ["Antineoplastic", "TREATMENT", 229, 243], ["Antiviral Therapy", "TREATMENT", 248, 265], ["NeoplasiaLow-dose selinexor", "TREATMENT", 292, 319], ["severe SARS", "PROBLEM", 400, 411], ["CoV-2 infection", "PROBLEM", 412, 427], ["SARS", "OBSERVATION", 95, 99], ["infection", "OBSERVATION", 106, 115], ["Antiviral Therapy", "OBSERVATION", 248, 265]]], ["This oral drug has been approved for the treatment of subjects with relapsed/refractory multiple myeloma [85] .", [["oral", "ANATOMY", 5, 9], ["myeloma", "ANATOMY", 97, 104], ["multiple myeloma", "DISEASE", 88, 104], ["oral", "ORGANISM_SUBDIVISION", 5, 9], ["myeloma", "CANCER", 97, 104], ["relapsed/refractory multiple myeloma", "PROBLEM", 68, 104], ["refractory", "OBSERVATION_MODIFIER", 77, 87], ["multiple", "OBSERVATION_MODIFIER", 88, 96], ["myeloma", "OBSERVATION", 97, 104]]], ["It is a selective inhibitor of nuclear export (SINE) compound that acts on cellular protein Exportin (XPO1).", [["nuclear", "ANATOMY", 31, 38], ["cellular", "ANATOMY", 75, 83], ["cellular", "CELL", 75, 83], ["Exportin", "GENE_OR_GENE_PRODUCT", 92, 100], ["XPO1", "GENE_OR_GENE_PRODUCT", 102, 106], ["nuclear export (SINE) compound", "PROTEIN", 31, 61], ["cellular protein", "PROTEIN", 75, 91], ["Exportin", "PROTEIN", 92, 100], ["XPO1", "PROTEIN", 102, 106], ["a selective inhibitor", "TREATMENT", 6, 27]]], ["The protein supports the transportation of numerous essential proteins from the nucleus to the cytoplasm, increasing the actions of pro-inflammatory transcription factors.", [["nucleus", "ANATOMY", 80, 87], ["cytoplasm", "ANATOMY", 95, 104], ["nucleus", "CELLULAR_COMPONENT", 80, 87], ["cytoplasm", "ORGANISM_SUBSTANCE", 95, 104], ["essential proteins", "PROTEIN", 52, 70], ["pro-inflammatory transcription factors", "PROTEIN", 132, 170], ["pro-inflammatory transcription factors", "TREATMENT", 132, 170], ["increasing", "OBSERVATION_MODIFIER", 106, 116], ["pro-inflammatory transcription", "OBSERVATION", 132, 162]]], ["SINE elements have also shown the capability to reduce the proliferation of several viruses, such as RNA viruses, influenza, and respiratory syncytial virus, in vitro and in vivo.", [["influenza", "DISEASE", 114, 123], ["respiratory syncytial virus", "DISEASE", 129, 156], ["respiratory syncytial virus", "ORGANISM", 129, 156], ["SINE elements", "DNA", 0, 13], ["respiratory syncytial virus", "SPECIES", 129, 156], ["respiratory syncytial virus", "SPECIES", 129, 156], ["the capability", "PROBLEM", 30, 44], ["the proliferation", "PROBLEM", 55, 72], ["several viruses", "PROBLEM", 76, 91], ["RNA viruses", "PROBLEM", 101, 112], ["influenza", "PROBLEM", 114, 123], ["respiratory syncytial virus", "PROBLEM", 129, 156], ["proliferation", "OBSERVATION_MODIFIER", 59, 72], ["several", "OBSERVATION_MODIFIER", 76, 83], ["viruses", "OBSERVATION", 84, 91], ["respiratory", "ANATOMY", 129, 140], ["syncytial virus", "OBSERVATION", 141, 156]]], ["Moreover, these elements have been able to provoke anti-inflammatory and anti-viral activities in several animal models, including showing effects in respiratory infections.", [["respiratory", "ANATOMY", 150, 161], ["respiratory infections", "DISEASE", 150, 172], ["anti-inflammatory", "TREATMENT", 51, 68], ["anti-viral activities", "TREATMENT", 73, 94], ["respiratory infections", "PROBLEM", 150, 172], ["respiratory", "ANATOMY", 150, 161], ["infections", "OBSERVATION", 162, 172]]], ["Finally, SINE compounds have been demonstrated to be able to inhibit relevant host protein interactions with SARS-CoV-2 [86] .The Management of Cancer Patients with SARS-CoV2 InfectionThe present SARS-CoV-2 pandemic is modifying how we face tumors in several ways.", [["Cancer", "ANATOMY", 144, 150], ["tumors", "ANATOMY", 241, 247], ["Cancer", "DISEASE", 144, 150], ["SARS-CoV2 Infection", "DISEASE", 165, 184], ["SARS-CoV-2 pandemic", "DISEASE", 196, 215], ["tumors", "DISEASE", 241, 247], ["Cancer", "CANCER", 144, 150], ["Patients", "ORGANISM", 151, 159], ["SARS-CoV-2", "ORGANISM", 196, 206], ["tumors", "CANCER", 241, 247], ["Patients", "SPECIES", 151, 159], ["Cancer", "PROBLEM", 144, 150], ["SARS", "PROBLEM", 165, 169], ["CoV2 Infection", "PROBLEM", 170, 184], ["face tumors", "PROBLEM", 236, 247], ["Cancer", "OBSERVATION", 144, 150], ["tumors", "OBSERVATION", 241, 247]]], ["In the context of SARS-CoV-2, greater importance is being placed upon the therapy of cancer patients who may be at augmented risk for having serious and potentially fatal events [87] .The Management of Cancer Patients with SARS-CoV2 InfectionCytotoxic therapies employed for hematological malignancies can provoke a reduction of lymphocyte subsets, possibly making subjects more vulnerable to infection [88, 89] .The Management of Cancer Patients with SARS-CoV2 InfectionAnalogous reflections must be formulated for the employment of radiotherapy.", [["cancer", "ANATOMY", 85, 91], ["Cancer", "ANATOMY", 202, 208], ["hematological malignancies", "ANATOMY", 275, 301], ["lymphocyte", "ANATOMY", 329, 339], ["Cancer", "ANATOMY", 431, 437], ["SARS", "DISEASE", 18, 22], ["cancer", "DISEASE", 85, 91], ["Cancer", "DISEASE", 202, 208], ["hematological malignancies", "DISEASE", 275, 301], ["infection", "DISEASE", 393, 402], ["Cancer", "DISEASE", 431, 437], ["SARS-CoV2 Infection", "DISEASE", 452, 471], ["SARS-CoV-2", "ORGANISM", 18, 28], ["cancer", "CANCER", 85, 91], ["patients", "ORGANISM", 92, 100], ["Cancer", "CANCER", 202, 208], ["Patients", "ORGANISM", 209, 217], ["hematological malignancies", "CANCER", 275, 301], ["lymphocyte", "CELL", 329, 339], ["Cancer", "CANCER", 431, 437], ["Patients", "ORGANISM", 438, 446], ["lymphocyte subsets", "CELL_TYPE", 329, 347], ["patients", "SPECIES", 92, 100], ["Patients", "SPECIES", 209, 217], ["Patients", "SPECIES", 438, 446], ["SARS-CoV", "SPECIES", 18, 26], ["SARS", "PROBLEM", 18, 22], ["Cancer", "PROBLEM", 202, 208], ["SARS-CoV2 InfectionCytotoxic therapies", "TREATMENT", 223, 261], ["hematological malignancies", "PROBLEM", 275, 301], ["lymphocyte subsets", "PROBLEM", 329, 347], ["infection", "PROBLEM", 393, 402], ["Cancer", "PROBLEM", 431, 437], ["SARS", "PROBLEM", 452, 456], ["CoV2 Infection", "PROBLEM", 457, 471], ["radiotherapy", "TREATMENT", 534, 546], ["SARS", "OBSERVATION", 18, 22], ["Cancer", "OBSERVATION", 202, 208], ["lymphocyte subsets", "OBSERVATION", 329, 347], ["Cancer", "OBSERVATION", 431, 437]]], ["This type of treatment may worsen myelosuppression and augment the risk of SARS-CoC-2 infection.", [["myelosuppression", "DISEASE", 34, 50], ["SARS", "DISEASE", 75, 79], ["infection", "DISEASE", 86, 95], ["CoC-2", "GENE_OR_GENE_PRODUCT", 80, 85], ["treatment", "TREATMENT", 13, 22], ["myelosuppression", "PROBLEM", 34, 50], ["SARS", "PROBLEM", 75, 79], ["CoC-2 infection", "PROBLEM", 80, 95], ["SARS", "OBSERVATION", 75, 79], ["infection", "OBSERVATION", 86, 95]]], ["Nevertheless, there are several possibilities for radiotherapy timing, and suitable single fraction or short courses of radiation are recommended [90] .The Management of Cancer Patients with SARS-CoV2 InfectionAlthough the effects of viral pandemics on tumor subjects are far from certain, the choice to continue with anti-tumor treatment, including surgery, during the conditions of the SARS-CoV-2 outbreak should be cautiously evaluated given the possibility of immunosuppression, critical respiratory complications, or death.", [["Cancer", "ANATOMY", 170, 176], ["tumor", "ANATOMY", 253, 258], ["anti-tumor", "ANATOMY", 318, 328], ["respiratory", "ANATOMY", 492, 503], ["Cancer", "DISEASE", 170, 176], ["viral pandemics", "DISEASE", 234, 249], ["tumor", "DISEASE", 253, 258], ["SARS", "DISEASE", 388, 392], ["respiratory complications", "DISEASE", 492, 517], ["death", "DISEASE", 522, 527], ["Cancer", "CANCER", 170, 176], ["Patients", "ORGANISM", 177, 185], ["tumor", "CANCER", 253, 258], ["anti-tumor", "CANCER", 318, 328], ["Patients", "SPECIES", 177, 185], ["radiotherapy timing", "TREATMENT", 50, 69], ["radiation", "TREATMENT", 120, 129], ["Cancer", "PROBLEM", 170, 176], ["SARS-CoV2", "PROBLEM", 191, 200], ["viral pandemics", "PROBLEM", 234, 249], ["tumor subjects", "PROBLEM", 253, 267], ["anti-tumor treatment", "TREATMENT", 318, 338], ["surgery", "TREATMENT", 350, 357], ["the SARS", "PROBLEM", 384, 392], ["immunosuppression", "TREATMENT", 464, 481], ["critical respiratory complications", "PROBLEM", 483, 517], ["death", "PROBLEM", 522, 527], ["Cancer", "OBSERVATION", 170, 176], ["immunosuppression", "OBSERVATION", 464, 481], ["respiratory complications", "OBSERVATION", 492, 517]]], ["An analysis of 34 asymptomatic subjects who undertook diverse elective surgeries during the course of the SARS-CoV-2 incubation period helped to clarify these risks [91] .", [["SARS", "DISEASE", 106, 110], ["An analysis", "TEST", 0, 11], ["34 asymptomatic subjects", "PROBLEM", 15, 39], ["diverse elective surgeries", "TREATMENT", 54, 80], ["the SARS", "PROBLEM", 102, 110]]], ["All 34 subjects developed SARS-CoV-2 pneumonia just after surgery (median time to SARS-CoV-2 onset, 3.5 days), with 44% requiring ICU admission.", [["SARS-CoV-2 pneumonia", "DISEASE", 26, 46], ["SARS", "PROBLEM", 26, 30], ["CoV-2 pneumonia", "PROBLEM", 31, 46], ["surgery", "TREATMENT", 58, 65], ["SARS", "OBSERVATION", 26, 30], ["pneumonia", "OBSERVATION", 37, 46]]], ["Half of these subjects died in the ICU.The Management of Cancer Patients with SARS-CoV2 InfectionHowever, delaying specific tumor surgeries may be correlated with an augmented risk of progression.The Management of Cancer Patients with SARS-CoV2 InfectionSeveral solid cancers, such as pancreatic or lung cancer and some hematologic diseases, such as acute leukemia, require urgent therapy.", [["Cancer", "ANATOMY", 57, 63], ["tumor", "ANATOMY", 124, 129], ["Cancer", "ANATOMY", 214, 220], ["solid cancers", "ANATOMY", 262, 275], ["pancreatic", "ANATOMY", 285, 295], ["lung cancer", "ANATOMY", 299, 310], ["hematologic", "ANATOMY", 320, 331], ["acute leukemia", "ANATOMY", 350, 364], ["Cancer", "DISEASE", 57, 63], ["SARS", "DISEASE", 78, 82], ["tumor", "DISEASE", 124, 129], ["Cancer", "DISEASE", 214, 220], ["SARS-CoV2 InfectionSeveral solid cancers", "DISEASE", 235, 275], ["pancreatic or lung cancer", "DISEASE", 285, 310], ["hematologic diseases", "DISEASE", 320, 340], ["acute leukemia", "DISEASE", 350, 364], ["subjects", "ORGANISM", 14, 22], ["Cancer", "CANCER", 57, 63], ["Patients", "ORGANISM", 64, 72], ["tumor", "CANCER", 124, 129], ["Cancer", "CANCER", 214, 220], ["Patients", "ORGANISM", 221, 229], ["SARS-CoV2 InfectionSeveral", "CANCER", 235, 261], ["solid cancers", "CANCER", 262, 275], ["pancreatic", "CANCER", 285, 295], ["lung cancer", "CANCER", 299, 310], ["acute leukemia", "CANCER", 350, 364], ["Patients", "SPECIES", 64, 72], ["Patients", "SPECIES", 221, 229], ["Cancer", "PROBLEM", 57, 63], ["SARS", "PROBLEM", 78, 82], ["CoV2 InfectionHowever", "PROBLEM", 83, 104], ["specific tumor surgeries", "TREATMENT", 115, 139], ["progression", "PROBLEM", 184, 195], ["Cancer", "PROBLEM", 214, 220], ["SARS", "PROBLEM", 235, 239], ["CoV2 InfectionSeveral solid cancers", "PROBLEM", 240, 275], ["pancreatic or lung cancer", "PROBLEM", 285, 310], ["some hematologic diseases", "PROBLEM", 315, 340], ["acute leukemia", "PROBLEM", 350, 364], ["urgent therapy", "TREATMENT", 374, 388], ["Cancer", "OBSERVATION", 57, 63], ["tumor", "OBSERVATION", 124, 129], ["progression", "OBSERVATION_MODIFIER", 184, 195], ["Cancer", "OBSERVATION", 214, 220], ["solid cancers", "OBSERVATION", 262, 275], ["pancreatic", "ANATOMY", 285, 295], ["lung", "ANATOMY", 299, 303], ["cancer", "OBSERVATION", 304, 310], ["hematologic diseases", "OBSERVATION", 320, 340], ["acute", "OBSERVATION_MODIFIER", 350, 355], ["leukemia", "OBSERVATION", 356, 364]]], ["However, other early-stage tumors, such as prostate, cervical, breast, and nonmelanoma skin tumors, may be able to be treated with a certain delay.The Management of Cancer Patients with SARS-CoV2 InfectionConsequently, the risk:benefit ratio of a systemic antitumor therapy has to be evaluated.", [["early-stage tumors", "ANATOMY", 15, 33], ["prostate", "ANATOMY", 43, 51], ["cervical", "ANATOMY", 53, 61], ["breast", "ANATOMY", 63, 69], ["nonmelanoma skin tumors", "ANATOMY", 75, 98], ["Cancer", "ANATOMY", 165, 171], ["antitumor", "ANATOMY", 256, 265], ["tumors", "DISEASE", 27, 33], ["prostate, cervical, breast", "DISEASE", 43, 69], ["nonmelanoma skin tumors", "DISEASE", 75, 98], ["Cancer", "DISEASE", 165, 171], ["SARS-CoV2 Infection", "DISEASE", 186, 205], ["early-stage tumors", "CANCER", 15, 33], ["prostate", "CANCER", 43, 51], ["cervical", "CANCER", 53, 61], ["breast", "CANCER", 63, 69], ["nonmelanoma skin tumors", "CANCER", 75, 98], ["Cancer", "CANCER", 165, 171], ["Patients", "ORGANISM", 172, 180], ["antitumor", "CANCER", 256, 265], ["Patients", "SPECIES", 172, 180], ["other early-stage tumors", "PROBLEM", 9, 33], ["prostate, cervical, breast, and nonmelanoma skin tumors", "PROBLEM", 43, 98], ["Cancer", "PROBLEM", 165, 171], ["SARS", "PROBLEM", 186, 190], ["CoV2 Infection", "PROBLEM", 191, 205], ["a systemic antitumor therapy", "TREATMENT", 245, 273], ["early", "OBSERVATION_MODIFIER", 15, 20], ["-stage", "OBSERVATION_MODIFIER", 20, 26], ["tumors", "OBSERVATION", 27, 33], ["prostate", "ANATOMY", 43, 51], ["cervical", "ANATOMY", 53, 61], ["breast", "ANATOMY", 63, 69], ["nonmelanoma", "OBSERVATION", 75, 86], ["skin", "ANATOMY", 87, 91], ["tumors", "OBSERVATION", 92, 98], ["Cancer", "OBSERVATION", 165, 171], ["Infection", "OBSERVATION", 196, 205]]], ["For each cancer subject, numerous elements, such as performance status, age, comorbidities, and the number of hospital visits required for the therapy, can modify this risk [92] .The Management of Cancer Patients with SARS-CoV2 InfectionAs a result of the pandemics, elective medical care has been de-prioritized in many places, and a logical framework to evaluate patient prioritization is required.", [["cancer", "ANATOMY", 9, 15], ["Cancer", "ANATOMY", 197, 203], ["cancer", "DISEASE", 9, 15], ["Cancer", "DISEASE", 197, 203], ["SARS-CoV2 InfectionAs", "DISEASE", 218, 239], ["cancer", "CANCER", 9, 15], ["Cancer", "CANCER", 197, 203], ["Patients", "ORGANISM", 204, 212], ["patient", "ORGANISM", 365, 372], ["Patients", "SPECIES", 204, 212], ["patient", "SPECIES", 365, 372], ["each cancer subject", "PROBLEM", 4, 23], ["comorbidities", "PROBLEM", 77, 90], ["the therapy", "TREATMENT", 139, 150], ["Cancer", "PROBLEM", 197, 203], ["SARS", "PROBLEM", 218, 222], ["CoV2 InfectionAs", "PROBLEM", 223, 239], ["elective medical care", "TREATMENT", 267, 288], ["cancer", "OBSERVATION", 9, 15], ["Cancer", "OBSERVATION", 197, 203]]], ["Oncology societies and national authorities have been quick to release guidelines on tumor care during the outbreak [93] .The Management of Cancer Patients with SARS-CoV2 InfectionFor example, the NHS in England has defined a prioritization of systemic anticancer treatments, as displayed in Table 3 .", [["tumor", "ANATOMY", 85, 90], ["Cancer", "ANATOMY", 140, 146], ["anticancer", "ANATOMY", 253, 263], ["tumor", "DISEASE", 85, 90], ["Cancer", "DISEASE", 140, 146], ["tumor", "CANCER", 85, 90], ["Cancer", "CANCER", 140, 146], ["Patients", "ORGANISM", 147, 155], ["anticancer", "CANCER", 253, 263], ["Patients", "SPECIES", 147, 155], ["tumor care", "TREATMENT", 85, 95], ["Cancer", "PROBLEM", 140, 146], ["SARS-CoV2 Infection", "PROBLEM", 161, 180], ["systemic anticancer treatments", "TREATMENT", 244, 274], ["Cancer", "OBSERVATION", 140, 146], ["Infection", "OBSERVATION", 171, 180], ["systemic anticancer", "OBSERVATION", 244, 263]]], ["Prioritizing systemic anticancer treatments (extracted and adapted from National Health System England's clinical guide for the management of non-coronavirus patients requiring acute treatment: cancer [94] ).Priority Level Treatment1 Curative treatment with high chance of success (>50%) Adjuvant/neoadjuvant treatment which adds at least 50% chance of cure to surgery/radiotherapy alone/treatment given at relapse 2 Curative treatment with an intermediate chance of success (20-50%) Adjuvant/neoadjuvant treatment which adds 20-50% chance of cure to surgery/radiotherapy alone/treatment given at relapse 3 Curative treatment with a low chance of success (10-20%) Adjuvant/neoadjuvant treatment which adds 10-20% chance of cure to surgery/radiotherapy alone/treatment given at relapse Non-curative treatment with a high chance of more than 1 year extension (>50%) 4 Curative treatment with a very low chance of success (0-10%) Adjuvant/neoadjuvant treatment which adds less than 10% chance of cure to surgery/radiotherapy alone/treatment given at relapse Non-curative treatment with an intermediate chance of more than 1 year extension to life (15% to 50%) 5 Non-curative treatment with a high chance of palliation or temporary tumor control (>50%) and less than 1 year expected extension to life 6 Non-curative treatment with an intermediate chance of palliation or temporary tumor control (15-50%) and less than 1 year expected extension to life Chemotherapy in a local hospital is suggested to decrease population movement.", [["anticancer", "ANATOMY", 22, 32], ["cancer", "ANATOMY", 194, 200], ["tumor", "ANATOMY", 1228, 1233], ["tumor", "ANATOMY", 1377, 1382], ["non-coronavirus", "DISEASE", 142, 157], ["cancer", "DISEASE", 194, 200], ["tumor", "DISEASE", 1228, 1233], ["tumor", "DISEASE", 1377, 1382], ["anticancer", "CANCER", 22, 32], ["patients", "ORGANISM", 158, 166], ["cancer", "CANCER", 194, 200], ["tumor", "CANCER", 1228, 1233], ["tumor", "CANCER", 1377, 1382], ["patients", "SPECIES", 158, 166], ["Prioritizing systemic anticancer treatments", "TREATMENT", 0, 43], ["the management", "TREATMENT", 124, 138], ["acute treatment", "TREATMENT", 177, 192], ["cancer", "PROBLEM", 194, 200], ["Curative treatment", "TREATMENT", 234, 252], ["Adjuvant/neoadjuvant treatment", "TREATMENT", 288, 318], ["surgery", "TREATMENT", 361, 368], ["radiotherapy", "TREATMENT", 369, 381], ["treatment", "TREATMENT", 388, 397], ["Curative treatment", "TREATMENT", 417, 435], ["Adjuvant/neoadjuvant treatment", "TREATMENT", 484, 514], ["surgery", "TREATMENT", 551, 558], ["radiotherapy", "TREATMENT", 559, 571], ["treatment", "TREATMENT", 578, 587], ["Curative treatment", "TREATMENT", 607, 625], ["Adjuvant/neoadjuvant treatment", "TREATMENT", 664, 694], ["surgery", "TREATMENT", 731, 738], ["radiotherapy", "TREATMENT", 739, 751], ["treatment", "TREATMENT", 758, 767], ["Non-curative treatment", "TREATMENT", 785, 807], ["Curative treatment", "TREATMENT", 866, 884], ["Adjuvant/neoadjuvant treatment", "TREATMENT", 927, 957], ["surgery", "TREATMENT", 1001, 1008], ["radiotherapy", "TREATMENT", 1009, 1021], ["treatment", "TREATMENT", 1028, 1037], ["Non-curative treatment", "TREATMENT", 1055, 1077], ["Non-curative treatment", "TREATMENT", 1159, 1181], ["palliation", "TREATMENT", 1204, 1214], ["temporary tumor control", "TREATMENT", 1218, 1241], ["Non-curative treatment", "TREATMENT", 1299, 1321], ["palliation", "TREATMENT", 1353, 1363], ["temporary tumor control", "TREATMENT", 1367, 1390], ["life Chemotherapy", "TREATMENT", 1443, 1460], ["tumor", "OBSERVATION", 1228, 1233], ["palliation", "OBSERVATION", 1353, 1363], ["temporary", "OBSERVATION_MODIFIER", 1367, 1376], ["tumor", "OBSERVATION", 1377, 1382]]], ["High-dosage chemotherapy or protocols with relevant myelotoxicity should be avoided, while Granulocyte Colony-Stimulating Factor (G-CSF) should be administered.", [["myelotoxicity", "DISEASE", 52, 65], ["Granulocyte Colony-Stimulating Factor", "GENE_OR_GENE_PRODUCT", 91, 128], ["G-CSF", "GENE_OR_GENE_PRODUCT", 130, 135], ["Granulocyte Colony-Stimulating Factor", "PROTEIN", 91, 128], ["CSF", "PROTEIN", 132, 135], ["High-dosage chemotherapy", "TREATMENT", 0, 24], ["protocols", "TREATMENT", 28, 37], ["relevant myelotoxicity", "PROBLEM", 43, 65], ["Granulocyte Colony", "TEST", 91, 109], ["Stimulating Factor (G-CSF)", "TREATMENT", 110, 136]]], ["Oral chemotherapy drugs suitable for home-based therapy are preferred, particularly for palliative therapy.Priority Level TreatmentThe creation of a mathematical framework might permit a quantitative analysis to balance conflicting risks and support treatment decision making.", [["Oral", "ANATOMY", 0, 4], ["Oral chemotherapy drugs", "TREATMENT", 0, 23], ["home-based therapy", "TREATMENT", 37, 55], ["palliative therapy", "TREATMENT", 88, 106], ["a quantitative analysis", "TEST", 185, 208], ["treatment decision", "TREATMENT", 250, 268]]], ["Incorporation of SARS-CoV-2-correlated risk models into the analysis of randomized trials could guide clinical decisions during this outbreak [95] .ConclusionsSARS-CoV-2 is seriously interfering with tumor therapy, and nullifying attempts to treat cancer patients adequately [96] .ConclusionsThe combination of these two health problems, tumors and the outbreak, could become a catastrophe if not correctly handled.", [["tumor", "ANATOMY", 200, 205], ["cancer", "ANATOMY", 248, 254], ["tumors", "ANATOMY", 338, 344], ["tumor", "DISEASE", 200, 205], ["cancer", "DISEASE", 248, 254], ["tumors", "DISEASE", 338, 344], ["tumor", "CANCER", 200, 205], ["cancer", "CANCER", 248, 254], ["patients", "ORGANISM", 255, 263], ["tumors", "CANCER", 338, 344], ["patients", "SPECIES", 255, 263], ["SARS", "PROBLEM", 17, 21], ["CoV", "TEST", 22, 25], ["randomized trials", "TREATMENT", 72, 89], ["ConclusionsSARS", "TEST", 148, 163], ["tumor therapy", "TREATMENT", 200, 213], ["cancer", "PROBLEM", 248, 254], ["these two health problems", "PROBLEM", 311, 336], ["tumors", "PROBLEM", 338, 344], ["a catastrophe", "PROBLEM", 376, 389], ["tumor", "OBSERVATION", 200, 205], ["tumors", "OBSERVATION", 338, 344], ["catastrophe", "OBSERVATION", 378, 389]]], ["The ultimate objective of all treatment options is to decrease the damage as much as possible [97] .ConclusionsMoreover, the negative effects of the outbreak on tumor patients are not restrained to direct effects only.", [["tumor", "ANATOMY", 161, 166], ["tumor", "DISEASE", 161, 166], ["tumor", "CANCER", 161, 166], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 167, 175], ["all treatment options", "TREATMENT", 26, 47], ["the damage", "PROBLEM", 63, 73], ["the outbreak on tumor", "PROBLEM", 145, 166], ["tumor", "OBSERVATION", 161, 166]]], ["This pandemic has reduced the activities of several research centers and oncological clinical units, has stopped patient enrolment into clinical trials, and has halted novel clinical studies.", [["patient", "ORGANISM", 113, 120], ["patient", "SPECIES", 113, 120], ["oncological clinical units", "TREATMENT", 73, 99], ["clinical studies", "TEST", 174, 190], ["reduced", "OBSERVATION_MODIFIER", 18, 25]]], ["Most trials need supplementary visits and tests, further augmenting the possibility for diffusion of infection.", [["infection", "DISEASE", 101, 110], ["tests", "TEST", 42, 47], ["infection", "PROBLEM", 101, 110], ["infection", "OBSERVATION", 101, 110]]], ["Finally, the amount of new drugs able to be released, both in terms of production and delivery, may be reduced [98] .ConclusionsCareful and judicious management of cancer patients with SARS-Cov2 could guarantee a better outcome for these patients, and a less dramatic impact due to the current pandemic.Conflicts of Interest:The authors declare no conflict of interest.", [["cancer", "ANATOMY", 164, 170], ["cancer", "DISEASE", 164, 170], ["SARS", "DISEASE", 185, 189], ["cancer", "CANCER", 164, 170], ["patients", "ORGANISM", 171, 179], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 171, 179], ["patients", "SPECIES", 238, 246], ["new drugs", "TREATMENT", 23, 32], ["delivery", "TREATMENT", 86, 94], ["judicious management", "TREATMENT", 140, 160], ["cancer", "PROBLEM", 164, 170], ["SARS", "PROBLEM", 185, 189], ["amount", "OBSERVATION_MODIFIER", 13, 19], ["new", "OBSERVATION_MODIFIER", 23, 26], ["drugs", "OBSERVATION", 27, 32], ["cancer", "OBSERVATION", 164, 170]]]], "PMC7316427": [["IntroductionTowards the end of December, 2019, an outbreak of a novel coronavirus disease (COVID-19) was reported in Wuhan, People\u2019s Republic of China [1].", [["coronavirus disease", "DISEASE", 70, 89], ["coronavirus", "ORGANISM", 70, 81], ["coronavirus", "SPECIES", 70, 81], ["a novel coronavirus disease", "PROBLEM", 62, 89], ["COVID", "TEST", 91, 96], ["coronavirus disease", "OBSERVATION", 70, 89]]], ["As of 25 May 2020, the virus had spread to countries around the world and affected over 5.43 million people with more than 345,000 deaths reported [2].", [["deaths", "DISEASE", 131, 137], ["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107], ["the virus", "PROBLEM", 19, 28]]], ["To curb the rapid transmission of COVID-19, various health organizations and responsible government ministries recommended people to use face masks to cover their nose and mouth when outside their homes.", [["people", "ORGANISM", 123, 129], ["nose", "ORGANISM_SUBDIVISION", 163, 167], ["mouth", "ORGANISM_SUBDIVISION", 172, 177], ["people", "SPECIES", 123, 129], ["COVID", "TEST", 34, 39], ["face masks", "TREATMENT", 137, 147], ["mouth", "ANATOMY", 172, 177]]], ["Moreover, the use of face mask is a standard safety procedure in some places and is a standard operating procedure for some workers, such as those in healthcare.", [["face mask", "TREATMENT", 21, 30], ["a standard safety procedure", "TREATMENT", 34, 61], ["a standard operating procedure", "TREATMENT", 84, 114]]], ["The commonly used masks are the face (surgical) masks and respirator masks-P2 and N95 (Fig. 1a)[3].", [["P2", "DNA", 75, 77], ["The commonly used masks", "TREATMENT", 0, 23], ["the face (surgical) masks", "TREATMENT", 28, 53], ["respirator masks", "TREATMENT", 58, 74], ["respirator masks", "OBSERVATION", 58, 74]]], ["Respirator masks are specially designed for high-risk medical settings and have the capability to protect the wearer from viruses and bacteria, whereas, surgical masks are designed for light medical settings and do not necessarily protect the wearer from bacteria and viruses.", [["Respirator masks", "TREATMENT", 0, 16], ["high-risk medical settings", "TREATMENT", 44, 70], ["the capability", "PROBLEM", 80, 94], ["viruses", "PROBLEM", 122, 129], ["bacteria", "PROBLEM", 134, 142], ["surgical masks", "TREATMENT", 153, 167], ["light medical settings", "TREATMENT", 185, 207], ["bacteria", "PROBLEM", 255, 263], ["viruses", "PROBLEM", 268, 275]]], ["According to the world health organization, we quote that \u201cWearing a medical mask can limit the spread of certain respiratory viral diseases, including COVID-19.", [["respiratory viral diseases", "DISEASE", 114, 140], ["a medical mask", "TREATMENT", 67, 81], ["certain respiratory viral diseases", "PROBLEM", 106, 140], ["COVID", "TEST", 152, 157], ["viral diseases", "OBSERVATION", 126, 140]]], ["However, the use of a mask alone is not sufficient to provide an adequate level of protection.", [["a mask", "TREATMENT", 20, 26]]], ["Other measures such as physical distancing and hand hygiene should be adopted\u201d [4].", [["hand", "ANATOMY", 47, 51], ["hand", "ORGANISM_SUBDIVISION", 47, 51], ["Other measures", "TREATMENT", 0, 14], ["physical distancing and hand hygiene", "TREATMENT", 23, 59]]], ["This makes it clear that a surgical mask alone cannot protect one from COVID-19 but can play some role in one\u2019s protection.", [["a surgical mask", "TREATMENT", 25, 40]]], ["This renders them important in the fight against COVID-19.How Face Masks Work?Face masks are made up of fine microscopic sieves which are the active layers driving the mask\u2019s working mechanism.", [["layers", "TISSUE", 149, 155], ["COVID", "TEST", 49, 54], ["Face masks", "TREATMENT", 78, 88], ["the mask", "TREATMENT", 164, 172], ["active", "OBSERVATION_MODIFIER", 142, 148], ["layers", "OBSERVATION_MODIFIER", 149, 155]]], ["The fine microscopic sieve is made up of entangled mats of very fine fibers capable of creating convoluted pathways that the air along with any particle or viruses and bacteria one inhales has to take when in use.", [["fibers", "ANATOMY", 69, 75], ["viruses", "PROBLEM", 156, 163], ["bacteria", "PROBLEM", 168, 176], ["air", "OBSERVATION", 125, 128], ["viruses", "OBSERVATION", 156, 163]]], ["When the face mask is in use, three different types of particles can be blocked from reaching the wearer in four separate mechanisms (Fig. 1b).", [["the face mask", "TREATMENT", 5, 18]]], ["Theses particles are separately classified in three sizes, macro, micro, and nano (Fig. 1c).", [["macro, micro", "TREATMENT", 59, 71], ["nano (Fig. 1c", "TREATMENT", 77, 90], ["sizes", "OBSERVATION_MODIFIER", 52, 57]]], ["Bigger macro-particles (above 600 nm) usually with sizes above the pore sizes of the mats cannot be permitted through the filters and are immediately blocked outside the masks in a mechanism called the interception mechanism.", [["pore", "ANATOMY", 67, 71], ["Bigger macro-particles", "TEST", 0, 22], ["the filters", "TREATMENT", 118, 129], ["above 600 nm", "OBSERVATION_MODIFIER", 24, 36], ["sizes", "OBSERVATION_MODIFIER", 51, 56], ["pore", "OBSERVATION_MODIFIER", 67, 71], ["sizes", "OBSERVATION_MODIFIER", 72, 77], ["mats", "OBSERVATION", 85, 89], ["filters", "OBSERVATION", 122, 129]]], ["For micro fine particles, (~ 300\u2013600 nm) these can possibly move through the mat pores of the mask sieve, but there is higher probability for them to crash (just like any object moving in a non-straight path at high velocities) on the fiber walls on their course through the fiber entanglements.", [["fiber walls", "ANATOMY", 235, 246], ["the mask sieve", "TREATMENT", 90, 104], ["fiber entanglements", "OBSERVATION", 275, 294]]], ["This is highly dictated by the particles\u2019 mass and velocity, hence making the particle to never reach the wearer.", [["mass", "OBSERVATION", 42, 46], ["velocity", "OBSERVATION_MODIFIER", 51, 59]]], ["For nano-sized particles (below 300 nm), due to their very small sizes, they can easily move through the pores without even colliding with the pore walls with the help of air but are easily bombarded by the air molecules around them.", [["pore walls", "ANATOMY", 143, 153], ["nano-sized particles", "TREATMENT", 4, 24], ["sized", "OBSERVATION_MODIFIER", 9, 14], ["particles", "OBSERVATION", 15, 24], ["small", "OBSERVATION_MODIFIER", 59, 64], ["sizes", "OBSERVATION_MODIFIER", 65, 70], ["air", "OBSERVATION", 171, 174], ["air molecules", "OBSERVATION", 207, 220]]], ["For such particles to be captured, diffusion-based capture mechanism is followed which only happens in finer fibers (in nanometer sizes) and branched nanofibers.", [["fibers", "ANATOMY", 109, 115], ["fibers", "CELLULAR_COMPONENT", 109, 115], ["such particles", "PROBLEM", 4, 18], ["branched nanofibers", "TREATMENT", 141, 160], ["nanometer", "OBSERVATION_MODIFIER", 120, 129], ["sizes", "OBSERVATION_MODIFIER", 130, 135], ["branched", "OBSERVATION_MODIFIER", 141, 149], ["nanofibers", "OBSERVATION_MODIFIER", 150, 160]]], ["Electrospun nanofibers in this case prove more efficient.", [["Electrospun nanofibers", "TREATMENT", 0, 22]]], ["However, there are particles just between micro and nano ranges in a tune of ~ 300 nm, they hardly respect the impact/collision mechanism and the diffusion-based capture mechanism, and thus prove hard to filter in many face masks.", [["many face masks", "TREATMENT", 214, 229], ["particles", "OBSERVATION_MODIFIER", 19, 28], ["300 nm", "OBSERVATION_MODIFIER", 79, 85], ["collision mechanism", "OBSERVATION", 118, 137]]], ["This, therefore, requires multiple layers of the mats to delay such particles and let them obey one of the mechanisms.", [["multiple", "OBSERVATION_MODIFIER", 26, 34], ["layers", "OBSERVATION_MODIFIER", 35, 41]]], ["The presence of multiple filtration layers creates new different engineering problem of breathability of the final product.", [["multiple filtration layers", "PROBLEM", 16, 42], ["multiple", "OBSERVATION_MODIFIER", 16, 24], ["filtration", "OBSERVATION", 25, 35], ["layers", "OBSERVATION_MODIFIER", 36, 42], ["new", "OBSERVATION_MODIFIER", 51, 54], ["different", "OBSERVATION_MODIFIER", 55, 64], ["engineering", "OBSERVATION_MODIFIER", 65, 76]]], ["It is therefore important for an engineer to address the two competing demands of air filterability and air breathability to meet the ideal performance of a face mask.", [["air filterability", "TREATMENT", 82, 99], ["air breathability", "TREATMENT", 104, 121], ["a face mask", "TREATMENT", 155, 166], ["air filterability", "OBSERVATION", 82, 99], ["air breathability", "OBSERVATION", 104, 121]]], ["Electrospun nanofibers provide the needed balance with right process control during electrospinning.", [["Electrospun nanofibers", "TREATMENT", 0, 22], ["right process control", "TREATMENT", 55, 76], ["electrospinning", "TREATMENT", 84, 99]]], ["The last mechanism is electrostatic driven filtration, where the filter is made up of charged mats which are capable of attracting the oppositely charged particles as a means of them not reaching the wearer.Uniqueness of Electrospun NanofibersThe porosity and surface area of the fibers in the face mask dictate their breathability and filterability.", [["surface area", "ANATOMY", 260, 272], ["fibers", "ANATOMY", 280, 286], ["face", "ANATOMY", 294, 298], ["fibers", "CELLULAR_COMPONENT", 280, 286], ["electrostatic driven filtration", "PROBLEM", 22, 53], ["the filter", "TREATMENT", 61, 71], ["Electrospun NanofibersThe porosity and surface area", "TREATMENT", 221, 272], ["the face mask", "TREATMENT", 290, 303], ["electrostatic driven filtration", "OBSERVATION", 22, 53], ["filter", "OBSERVATION", 65, 71], ["Electrospun Nanofibers", "OBSERVATION", 221, 243], ["porosity", "OBSERVATION_MODIFIER", 247, 255], ["surface", "OBSERVATION_MODIFIER", 260, 267], ["area", "OBSERVATION_MODIFIER", 268, 272], ["fibers", "OBSERVATION_MODIFIER", 280, 286], ["face", "ANATOMY", 294, 298]]], ["Thus, to overcome these two competing properties, one has to find ways to engineer and balance the pores in the active filtration layer as well as the surface area of the fibers making up the mat.", [["surface area", "ANATOMY", 151, 163], ["fibers", "ANATOMY", 171, 177], ["fibers", "CELLULAR_COMPONENT", 171, 177], ["active", "OBSERVATION_MODIFIER", 112, 118], ["filtration", "OBSERVATION", 119, 129]]], ["With electrospinning (Fig. 2a), it is possible to control these two properties in situ during the preparation of the nanofibers.", [["the nanofibers", "TREATMENT", 113, 127]]], ["Porosity of the mats can be controlled by changing the spinning nozzles, polymer solutions and the collection geometry of the nanofibers, which rationally defines the resultant fiber diameters and their packing density [5].", [["fiber", "ANATOMY", 177, 182], ["the spinning nozzles, polymer solutions", "TREATMENT", 51, 90], ["the collection geometry of the nanofibers", "TREATMENT", 95, 136], ["the resultant fiber diameters", "TREATMENT", 163, 192], ["mats", "OBSERVATION", 16, 20], ["resultant", "OBSERVATION_MODIFIER", 167, 176], ["fiber", "OBSERVATION_MODIFIER", 177, 182], ["diameters", "OBSERVATION_MODIFIER", 183, 192], ["packing density", "OBSERVATION", 203, 218]]], ["Breathability of the filtration layer in the electrospun nanofibers can also be controlled in situ by controlling the fiber collection time, and collection geometry of the nanofibers during spinning which both dictate the final thickness of the mat and areal weight.", [["fiber", "ANATOMY", 118, 123], ["the filtration layer", "TREATMENT", 17, 37], ["the electrospun nanofibers", "TREATMENT", 41, 67], ["the nanofibers", "TREATMENT", 168, 182], ["filtration", "OBSERVATION_MODIFIER", 21, 31], ["layer", "OBSERVATION_MODIFIER", 32, 37]]], ["The method of collection the nanofibers can result into random nonwoven mats, aligned or meshed structures (see examples in Fig. 2b).", [["The method of collection the nanofibers", "TREATMENT", 0, 39], ["random nonwoven mats, aligned or meshed structures", "PROBLEM", 56, 106]]], ["Each arrangement is known to provide special breathability factor.Uniqueness of Electrospun NanofibersElectrospun nanofibers exist as nonwoven mats welded together physically with their parent polymer joints.", [["polymer joints", "MULTI-TISSUE_STRUCTURE", 193, 207], ["breathability factor", "PROTEIN", 45, 65], ["Electrospun NanofibersElectrospun nanofibers", "TREATMENT", 80, 124], ["joints", "ANATOMY", 201, 207]]], ["This is due to the fact that during the rapid electrospinning process in the high-field zone, the nanofibers continuously pile on each other when not perfectly dry, but in a wet state.", [["the rapid electrospinning process", "TREATMENT", 36, 69], ["rapid", "OBSERVATION_MODIFIER", 40, 45], ["electrospinning", "OBSERVATION", 46, 61], ["high", "OBSERVATION_MODIFIER", 77, 81], ["field", "OBSERVATION_MODIFIER", 82, 87], ["zone", "OBSERVATION_MODIFIER", 88, 92], ["dry", "OBSERVATION", 160, 163]]], ["This is not the case in the common commercial face masks on market, whose active filter employs polypropylene (PP) fibers with small diameters in the range of ~ 500\u20131000 nm.", [["polypropylene", "CHEMICAL", 96, 109], ["active filter employs polypropylene (PP) fibers", "TREATMENT", 74, 121], ["active", "OBSERVATION_MODIFIER", 74, 80], ["filter", "OBSERVATION", 81, 87], ["small", "OBSERVATION_MODIFIER", 127, 132], ["diameters", "OBSERVATION_MODIFIER", 133, 142]]], ["The PP fibers filters achieves the three named filtration mechanisms with the fiber web kept together with the help of electrostatic charge responsible for keeping it in the required shape for maximum efficiency.", [["PP fibers", "ANATOMY", 4, 13], ["The PP fibers filters", "TREATMENT", 0, 21], ["the fiber web", "TREATMENT", 74, 87], ["electrostatic charge", "TREATMENT", 119, 139], ["fibers filters", "OBSERVATION", 7, 21], ["maximum efficiency", "OBSERVATION", 193, 211]]], ["Indeed, such filters lose static electricity when exposed to water and moisture, thus diminishing their filtering effect to almost half the original performance.", [["moisture", "TREATMENT", 71, 79]]], ["Here, we propose to use electrospun non-woven fibers (with diameter below 100 nm) as filter.", [["fibers", "ANATOMY", 46, 52], ["electrospun non-woven fibers", "TREATMENT", 24, 52]]], ["These fibers as explained are physically bundled and welded onto each other in a durable web, thus overcoming the limitation of static loss mechanism-based filters.", [["fibers", "ANATOMY", 6, 12], ["fibers", "CELLULAR_COMPONENT", 6, 12], ["static loss mechanism", "PROBLEM", 128, 149], ["based filters", "TREATMENT", 150, 163]]], ["Thus, even in presence of fluids and moisture (if hydrophobic), and with the same porosity, these filters can maintain the same breathability as conventional PP filters while sustaining filtration efficiency of more of than 90%.Uniqueness of Electrospun NanofibersTo balance the two competing properties of breathability and filterability, therefore, electrospinning as a technique can be employed.", [["fluids and moisture", "TREATMENT", 26, 45], ["these filters", "TREATMENT", 92, 105], ["conventional PP filters", "TREATMENT", 145, 168], ["Electrospun Nanofibers", "TREATMENT", 242, 264], ["electrospinning", "TREATMENT", 351, 366], ["a technique", "TREATMENT", 370, 381], ["fluids", "OBSERVATION", 26, 32], ["Electrospun Nanofibers", "OBSERVATION", 242, 264]]], ["With the right nozzle spinning gauges, collector geometry and polymer solution, it is possible to achieve balance between porosity and breathability of the mask filters at once in situ, thus making electrospinning technique favorable.Assembling Nanofibers-Based Face Mask At HomeA wide range of portable, safe, battery-operated, and easy-to-use electrospinners are available on the market which can be used to obtain the electrospun nanofiber mats with ease [9].", [["the right nozzle spinning gauges", "TREATMENT", 5, 37], ["collector geometry and polymer solution", "TREATMENT", 39, 78], ["the mask filters", "TREATMENT", 152, 168], ["electrospinning technique", "TREATMENT", 198, 223], ["Assembling Nanofibers", "TREATMENT", 234, 255], ["Based Face Mask", "TREATMENT", 256, 271], ["electrospinners", "TREATMENT", 345, 360], ["the electrospun nanofiber mats", "TREATMENT", 417, 447], ["right", "ANATOMY_MODIFIER", 9, 14]]], ["Then, after obtaining the right electrospun filter mats, they can be utilized when in a fully assembled working face mask.", [["the right electrospun filter mats", "TREATMENT", 22, 55], ["working face mask", "TREATMENT", 104, 121], ["right", "ANATOMY_MODIFIER", 26, 31], ["filter mats", "OBSERVATION", 44, 55]]], ["A do-it-yourself (DIY) approach to obtain a functional mask has been provided which can be followed at home (Fig. 3).Assembling Nanofibers-Based Face Mask At HomeIt is important to note that face mask should be made to conform to certain set standards.", [["a functional mask", "TREATMENT", 42, 59], ["Assembling Nanofibers", "TREATMENT", 117, 138], ["Based Face Mask", "TREATMENT", 139, 154], ["face mask", "TREATMENT", 191, 200]]], ["For example, breathability test MIL-M-36954 C: \u0394P [10] -which quantifies the face mask\u2019s resistance to airflow, fluid resistance test ASTM F1862 [11]- which determines the resistance of the face mask to fluid penetration, particulate filtration test ASTM F2299 [12]- which evaluates the filterability of the face mask, bacterial filtration test ASTM F2101 [13]- which determines the amount of bacteria larger than 3000 nm that can possibly be filtered by the mask, flammability test 16 CFR Part 1610: flame spread [14]- which measures the flame resistance properties of the mask.", [["fluid", "ANATOMY", 203, 208], ["MIL-M-36954", "CHEMICAL", 32, 43], ["breathability test MIL", "TEST", 13, 35], ["\u0394P", "TEST", 47, 49], ["the face mask", "TREATMENT", 73, 86], ["airflow", "TEST", 103, 110], ["fluid resistance test ASTM", "TEST", 112, 138], ["the face mask", "TREATMENT", 186, 199], ["fluid penetration", "PROBLEM", 203, 220], ["particulate filtration test ASTM", "TEST", 222, 254], ["the face mask", "TREATMENT", 304, 317], ["bacterial filtration test ASTM F2101", "TEST", 319, 355], ["bacteria", "PROBLEM", 393, 401], ["flammability test", "TEST", 465, 482], ["flame spread", "PROBLEM", 501, 513], ["the mask", "TREATMENT", 570, 578], ["fluid resistance", "OBSERVATION", 112, 128], ["fluid penetration", "OBSERVATION", 203, 220], ["bacteria", "OBSERVATION", 393, 401], ["flame resistance", "OBSERVATION", 539, 555]]], ["Beyond these, other important regular tests can be carried out which include; biocidal efficiency, viricidal efficiency, skin sensitivity, allergy, toxicity, etc.SummaryUntil an effective vaccine is developed and made widely available, wearing protective face masks, maintaining personal hygiene and safe social distancing should be followed to prevent the spread of the COVID-19, and to provide a sense of security and well-being to everyone.", [["skin", "ANATOMY", 121, 125], ["allergy", "DISEASE", 139, 146], ["toxicity", "DISEASE", 148, 156], ["skin", "ORGAN", 121, 125], ["regular tests", "TEST", 30, 43], ["biocidal efficiency", "PROBLEM", 78, 97], ["viricidal efficiency", "PROBLEM", 99, 119], ["skin sensitivity", "PROBLEM", 121, 137], ["allergy", "PROBLEM", 139, 146], ["toxicity", "PROBLEM", 148, 156], ["an effective vaccine", "TREATMENT", 175, 195], ["protective face masks", "TREATMENT", 244, 265], ["skin", "ANATOMY", 121, 125]]], ["This is leading to a worldwide surge in the use of billions of face masks every day-causing high demand for materials making them.", [["billions of face masks", "TREATMENT", 51, 73]]], ["In this work we have proposed the use of durable and yet reliable electrospun nonwoven filters with very small-fiber diameters (below 100 nm).", [["reliable electrospun nonwoven filters", "TREATMENT", 57, 94], ["nonwoven filters", "OBSERVATION", 78, 94], ["fiber diameters", "OBSERVATION_MODIFIER", 111, 126]]], ["The filter can be processed by suitable disinfection methods and protocols to achieve reuse (increased usage time) without compromising the filtration efficiency.", [["The filter", "TREATMENT", 0, 10], ["suitable disinfection methods", "TREATMENT", 31, 60], ["the filtration efficiency", "PROBLEM", 136, 161], ["filter", "OBSERVATION", 4, 10], ["filtration efficiency", "OBSERVATION", 140, 161]]], ["Beyond these, future face masks need to be anti-viral as well as viricidal.", [["future face masks", "TREATMENT", 14, 31], ["anti-viral", "TREATMENT", 43, 53], ["viricidal", "TREATMENT", 65, 74]]], ["The current electrospinning technology is mature [15], making the proposed strategy relatively low-cost with mass production capacity.", [["mass production capacity", "PROBLEM", 109, 133], ["mass", "OBSERVATION", 109, 113]]]], "e655c2ad915c4b181014f112510c6a17b08b04bd": [["BackgroundCirculating in China and 94 other countries and territories, the COVID-19 epidemic has resulted in 103,168 confirmed cases including 22,355 outside mainland China, with 3,507 deaths reported (March 7, 2020).", [["deaths", "DISEASE", 185, 191], ["the COVID", "TEST", 71, 80]]], ["Due to its increasing threat to global health, WHO has declared that the COVID-19 epidemic was a global public health emergency.", [["the COVID", "TEST", 69, 78], ["increasing", "OBSERVATION_MODIFIER", 11, 21]]], ["The causative pathogen of the COVID-19 outbreak has been identified as a highly infectious novel coronavirus which is referred to as the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).", [["coronavirus", "DISEASE", 97, 108], ["Acute Respiratory Syndrome Coronavirus", "DISEASE", 144, 182], ["COVID-19", "ORGANISM", 30, 38], ["coronavirus", "ORGANISM", 97, 108], ["SARS-CoV-2", "ORGANISM", 186, 196], ["COVID-19", "SPECIES", 30, 38], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 137, 196], ["the COVID", "TEST", 26, 35], ["a highly infectious novel coronavirus", "PROBLEM", 71, 108], ["the Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 133, 182], ["SARS", "TEST", 186, 190], ["CoV", "TEST", 191, 194], ["pathogen", "OBSERVATION_MODIFIER", 14, 22], ["highly", "OBSERVATION_MODIFIER", 73, 79], ["infectious", "OBSERVATION", 80, 90], ["Severe", "OBSERVATION_MODIFIER", 137, 143], ["Acute", "OBSERVATION_MODIFIER", 144, 149], ["Respiratory Syndrome", "OBSERVATION", 150, 170]]], ["[1] [2] [3] The transmission of SARS-CoV-2 in humans is thought to be via at least 3 sources: 1) inhalation of liquid droplets produced by and/or 2) close contact with infected persons and 3) contact with surfaces contaminated with SARS-CoV-2.", [["SARS", "DISEASE", 32, 36], ["SARS", "DISEASE", 232, 236], ["SARS-CoV-2", "ORGANISM", 32, 42], ["humans", "ORGANISM", 46, 52], ["persons", "ORGANISM", 177, 184], ["humans", "SPECIES", 46, 52], ["persons", "SPECIES", 177, 184], ["humans", "SPECIES", 46, 52], ["SARS-CoV", "SPECIES", 232, 240], ["SARS", "PROBLEM", 32, 36], ["CoV", "TEST", 37, 40], ["inhalation of liquid droplets", "TREATMENT", 97, 126]]], ["4 Moreover, aerosol transmission of pathogens has been shown in confined spaces.", [["pathogens", "PROBLEM", 36, 45], ["pathogens", "OBSERVATION", 36, 45]]], ["5, 6 There are many respiratory diseases spread by the airborne route such as tuberculosis, measles and chickenpox.", [["respiratory", "ANATOMY", 20, 31], ["respiratory diseases", "DISEASE", 20, 40], ["tuberculosis", "DISEASE", 78, 90], ["measles", "DISEASE", 92, 99], ["chickenpox", "DISEASE", 104, 114], ["many respiratory diseases", "PROBLEM", 15, 40], ["the airborne route", "TREATMENT", 51, 69], ["tuberculosis", "PROBLEM", 78, 90], ["measles", "PROBLEM", 92, 99], ["chickenpox", "PROBLEM", 104, 114], ["many", "OBSERVATION_MODIFIER", 15, 19], ["respiratory diseases", "OBSERVATION", 20, 40], ["tuberculosis", "OBSERVATION", 78, 90]]], ["7, 8 A retrospective cohort study conducted after the SARS epidemic in Hong Kong in 2003 suggested that airborne spread may have played an important role in the transmission of that disease.", [["SARS", "DISEASE", 54, 58], ["A retrospective cohort study", "TEST", 5, 33], ["the SARS epidemic", "PROBLEM", 50, 67], ["airborne spread", "PROBLEM", 104, 119], ["that disease", "PROBLEM", 177, 189], ["airborne spread", "OBSERVATION", 104, 119], ["disease", "OBSERVATION", 182, 189]]], ["9 At present, there is little information on the characteristics of airborne SARS-CoV-2 containing aerosols, their concentration patterns and behaviour during airborne transmission due to the difficulties in sampling virus-laden aerosols and challenges in their quantification at low concentration.", [["SARS", "DISEASE", 77, 81], ["airborne SARS", "PROBLEM", 68, 81], ["airborne transmission", "TREATMENT", 159, 180], ["the difficulties", "PROBLEM", 188, 204], ["sampling virus", "TREATMENT", 208, 222], ["laden aerosols", "TREATMENT", 223, 237]]], ["Such a lack of understanding limits effective risk assessment, prevention and control of COVID-19 disease outbreaks.", [["risk assessment", "TEST", 46, 61], ["COVID-19 disease outbreaks", "PROBLEM", 89, 115]]], ["This study on airborne SARS-CoV-2 was conducted in different areas inside two hospitals and public areas in Wuhan, China, the epicenter city during the initial disease outbreak.", [["This study", "TEST", 0, 10], ["airborne SARS", "TEST", 14, 27], ["CoV", "TEST", 28, 31], ["the initial disease outbreak", "PROBLEM", 148, 176]]], ["We aimed to 1) quantify the concentrations of airborne SARS-CoV-2 both inside the hospitals and in outdoor public areas, 2) evaluate the aerodynamic size distributions of SARS-CoV-2 aerosols that may mediate its airborne transmission, and 3) determine the dry deposition rate of the airborne SARS-CoV-2 in a patient ward room.Study designThis study is an experimental investigation on the concentration and aerodynamic characteristics of airborne SARS-CoV-2 aerosol in different areas of two hospitals: the Renmin Hospital of Wuhan University, designated for treatment of severe symptom COVID-19 patient during the disease outbreak and the Wuchang Fangcang Field Hospital, one of the first temporary hospitals which was renovated from an indoor sports stadium to quarantine and treat mildly symptom patients, and outdoor public areas in Wuhan during the coronavirus outbreak.", [["SARS", "DISEASE", 55, 59], ["SARS", "DISEASE", 171, 175], ["SARS", "DISEASE", 292, 296], ["SARS-CoV-2 aerosol", "CHEMICAL", 447, 465], ["coronavirus", "DISEASE", 854, 865], ["patient", "ORGANISM", 308, 315], ["patient", "ORGANISM", 596, 603], ["patients", "ORGANISM", 799, 807], ["patient", "SPECIES", 308, 315], ["patient", "SPECIES", 596, 603], ["patients", "SPECIES", 799, 807], ["coronavirus", "SPECIES", 854, 865], ["SARS-CoV", "SPECIES", 171, 179], ["SARS-CoV", "SPECIES", 292, 300], ["airborne SARS", "TEST", 46, 59], ["SARS", "PROBLEM", 171, 175], ["CoV-2 aerosols", "TREATMENT", 176, 190], ["the dry deposition rate", "PROBLEM", 252, 275], ["This study", "TEST", 338, 348], ["an experimental investigation", "TEST", 352, 381], ["airborne SARS", "TEST", 438, 451], ["CoV-2 aerosol", "TREATMENT", 452, 465], ["severe symptom COVID", "PROBLEM", 572, 592], ["the disease outbreak", "PROBLEM", 611, 631], ["mildly symptom patients", "PROBLEM", 784, 807], ["the coronavirus outbreak", "PROBLEM", 850, 874], ["size", "OBSERVATION_MODIFIER", 149, 153], ["airborne SARS", "OBSERVATION", 438, 451], ["coronavirus", "OBSERVATION", 854, 865]]], ["We further classified the sampling locations into three categories according to their accessibility by different groups: 1) Patient Areas (PAA), where the COVID-19 patients have physical presence.", [["patients", "ORGANISM", 164, 172], ["Patient", "SPECIES", 124, 131], ["patients", "SPECIES", 164, 172]]], ["These include the Intensive Care Units (ICU), Coronary Care Units (CCU) and ward rooms inside Renmin Hospital, a toilet and staff workstations inside Fangcang Hospital; 2) Medical Staff Areas (MSA), the workplaces in the two hospitals exclusively accessed by the medical staff who had direct contact with the patients and 3) Public Areas (PUA), which were venues open for the general public.", [["Coronary", "ANATOMY", 46, 54], ["patients", "ORGANISM", 309, 317], ["patients", "SPECIES", 309, 317], ["Coronary", "ANATOMY", 46, 54]]], ["The description and characteristics of sampling sites are shown in Table S1 .Study designThree types of aerosol samples were collected: 1) Aerosol samples of total suspended particles (TSP) with no upper size limit to quantify RNA concentration of SARS-CoV-2 aerosol; 2) Aerodynamic size segregated aerosol samples to determine the size distribution of airborne SARS-CoV-2; 3) Aerosol deposition samples to determine the deposition rate of airborne SARS-CoV-2.Sample collectionThe sampling was conducted between February 17 and March 2, 2020 in the locations by two batches as shown in Table 1 .", [["samples", "ANATOMY", 112, 119], ["samples", "ANATOMY", 307, 314], ["SARS", "DISEASE", 449, 453], ["SARS-CoV", "SPECIES", 449, 457], ["sampling sites", "TEST", 39, 53], ["aerosol samples", "TREATMENT", 104, 119], ["total suspended particles (TSP", "TREATMENT", 158, 188], ["SARS", "TEST", 248, 252], ["CoV-2 aerosol", "TREATMENT", 253, 266], ["Aerodynamic size segregated aerosol samples", "TREATMENT", 271, 314], ["airborne SARS", "PROBLEM", 353, 366], ["Aerosol deposition samples", "TREATMENT", 377, 403], ["the deposition rate", "TEST", 417, 436], ["airborne SARS", "TEST", 440, 453], ["Sample collection", "TEST", 460, 477], ["upper size", "OBSERVATION_MODIFIER", 198, 208], ["size", "OBSERVATION_MODIFIER", 332, 336], ["collection", "OBSERVATION", 467, 477]]], ["All aerosol samples were collected on presterilized gelatin filters (Sartorius, Germany).", [["samples", "ANATOMY", 12, 19], ["All aerosol samples", "TREATMENT", 0, 19], ["presterilized gelatin filters", "TREATMENT", 38, 67]]], ["Total of 30 TSP aerosol samples were collected on 25 mm diameter filters loaded into styrene filter cassettes (SKC Inc, US) and sampled air at a fixed flow rate of 5.0 litre per minute (LPM) using a portable pump (APEX2, Casella, US).", [["samples", "ANATOMY", 24, 31], ["styrene", "CHEMICAL", 85, 92], ["styrene", "CHEMICAL", 85, 92], ["30 TSP aerosol samples", "TREATMENT", 9, 31], ["25 mm diameter filters", "TREATMENT", 50, 72], ["styrene filter cassettes", "TREATMENT", 85, 109], ["US", "TEST", 120, 122], ["a fixed flow rate", "TEST", 143, 160], ["a portable pump", "TEST", 197, 212], ["styrene filter", "OBSERVATION", 85, 99]]], ["Total of 3 size segregated aerosol samples were collected using a miniature cascade impactor (Sioutas impactor, SKC Inc., US) that separate aerosol into five ranges (> 2.5 Table S1 .", [["samples", "ANATOMY", 35, 42], ["3 size segregated aerosol samples", "TREATMENT", 9, 42], ["a miniature cascade impactor (Sioutas impactor", "TREATMENT", 64, 110], ["size", "OBSERVATION_MODIFIER", 11, 15]]], ["Prior to the field sampling, the integrity and robustness of experiment protocol was examined in the laboratory and described in Supplementary Appendix (Table S2 ).Analytical method and data analysisAfter aerosol sample collection, all samples were handled immediately in the BSL-2 laboratory of Wuhan University.", [["samples", "ANATOMY", 236, 243], ["the field sampling", "TEST", 9, 27], ["experiment protocol", "TEST", 61, 80], ["Analytical method", "TEST", 164, 181], ["data analysis", "TEST", 186, 199], ["aerosol sample collection", "TREATMENT", 205, 230], ["all samples", "TEST", 232, 243], ["Appendix", "ANATOMY", 143, 151]]], ["The 25, 37mm and 80 mm filter samples were dissolved in deionized water, then TRIzol LS Reagent (Invitrogen) was added to inactivate SARS-CoV-2 viruses and extract RNA according to the manufacturer's instruction.", [["samples", "ANATOMY", 30, 37], ["SARS-CoV-2 viruses", "SPECIES", 133, 151], ["80 mm filter samples", "TREATMENT", 17, 37], ["TRIzol LS Reagent (Invitrogen)", "TREATMENT", 78, 108], ["SARS", "PROBLEM", 133, 137], ["extract RNA", "TREATMENT", 156, 167]]], ["First strand cDNA was synthesized using PrimeScript RT kit (TakaRa).", [["strand cDNA", "DNA", 6, 17], ["TakaRa", "PROTEIN", 60, 66], ["First strand cDNA", "TREATMENT", 0, 17], ["PrimeScript RT kit (TakaRa)", "TREATMENT", 40, 67]]], ["Optimized ddPCR was used to detect the presence of SARS-CoV-2 viruses following our previous study.", [["SARS-CoV-2 viruses", "ORGANISM", 51, 69], ["SARS-CoV-2 viruses", "SPECIES", 51, 69], ["Optimized ddPCR", "TEST", 0, 15], ["SARS", "PROBLEM", 51, 55], ["our previous study", "TEST", 80, 98]]], ["10 Analysis of the ddPCR data was performed with QuantaSoft software (Bio-Rad).", [["ddPCR", "DNA", 19, 24], ["the ddPCR data", "TEST", 15, 29], ["QuantaSoft software", "TEST", 49, 68]]], ["The concentration reported by the procedure equals copies of template per microliter of the final 1x ddPCR reaction, which was normalized to copies m -3 in all the results, and hence the virus or viral RNA concentration in aerosol is expressed in copies m -3 hereafter.", [["the final 1x ddPCR reaction", "TEST", 88, 115], ["the virus", "PROBLEM", 183, 192], ["viral RNA concentration", "TREATMENT", 196, 219]]], ["A detailed protocol is provided in Supplementary Appendix.Airborne SARS-CoV-2 concentrationsThe airborne SARS-CoV-2 concentrations in different categorized sites are shown in Table 1 .", [["SARS", "DISEASE", 105, 109], ["A detailed protocol", "TEST", 0, 19], ["Airborne SARS", "TEST", 58, 71], ["The airborne SARS", "TEST", 92, 109], ["Appendix", "ANATOMY", 49, 57]]], ["The ICU, CCU and ward room in PAA of Renmin Hospital had negative test results.", [["PAA", "CHEMICAL", 30, 33]]], ["Fangcang Hospital workstations in different zones had low concentrations (1-9 copies m -3 ) of SARS-CoV-2 aerosol.", [["SARS", "DISEASE", 95, 99], ["low concentrations", "PROBLEM", 54, 72], ["SARS", "PROBLEM", 95, 99], ["low concentrations", "OBSERVATION_MODIFIER", 54, 72]]], ["The highest concentration in PAA of two hospitals was observed inside the patient mobile toilet room (19 copies m -3 ).", [["PAA", "CHEMICAL", 29, 32], ["PAA", "CHEMICAL", 29, 32], ["PAA", "SIMPLE_CHEMICAL", 29, 32], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["concentration", "OBSERVATION_MODIFIER", 12, 25], ["PAA", "OBSERVATION_MODIFIER", 29, 32]]], ["In MSAs, the two sampling sites in Renmin Hospital had low concentration of 6 copies m -3 , while the sites in Fangcang Hospital in general had higher concentrations.", [["higher concentrations", "OBSERVATION", 144, 165]]], ["Particularly, the Protective Apparel Removal Rooms (PARRs) in three different zones inside Fangcang Hospital are among the upper range of airborne SARS-CoV-2 concentration from 18 to 42 copies m -3 in the first batch of sampling.", [["SARS", "DISEASE", 147, 151], ["airborne SARS", "TEST", 138, 151], ["upper range", "OBSERVATION_MODIFIER", 123, 134]]], ["During the second batch of sampling, the two TSP samples in the PARRs had negative test results with reduced number of medical staff and more rigorous sanitization processes in Fangcang.", [["the two TSP samples", "TEST", 37, 56]]], ["In PUA, SARS-CoV-2 aerosol concentrations were below 3 copies m -3 , except for two occasions: one crowd gathering site near the entrance of a department store with frequent customer flow and one outdoor site next to Renmin Hospital with outpatients and passengers passing by.", [["SARS", "DISEASE", 8, 12], ["PUA", "SIMPLE_CHEMICAL", 3, 6], ["SARS", "TEST", 8, 12], ["CoV", "TEST", 13, 16], ["2 aerosol concentrations", "TREATMENT", 17, 41]]], ["The peak concentration of SARS-CoV-2 aerosols appears in two distinct size ranges, one in the submicron region with aerodynamic diameter dominant between 0.25 to 1.0 \u00b5m, and the other peak in supermicron region with diameter larger than 2.5 \u00b5m.", [["SARS", "DISEASE", 26, 30], ["The peak concentration", "TEST", 0, 22], ["SARS", "TEST", 26, 30], ["CoV", "TEST", 31, 34], ["peak", "OBSERVATION_MODIFIER", 4, 8], ["concentration", "OBSERVATION_MODIFIER", 9, 22], ["two distinct", "OBSERVATION_MODIFIER", 57, 69], ["size", "OBSERVATION_MODIFIER", 70, 74], ["ranges", "OBSERVATION_MODIFIER", 75, 81], ["one", "OBSERVATION_MODIFIER", 83, 86], ["submicron", "ANATOMY_MODIFIER", 94, 103], ["region", "ANATOMY_MODIFIER", 104, 110], ["aerodynamic", "OBSERVATION_MODIFIER", 116, 127], ["diameter", "OBSERVATION_MODIFIER", 128, 136], ["0.25 to 1.0 \u00b5m", "OBSERVATION_MODIFIER", 154, 168], ["peak", "OBSERVATION_MODIFIER", 184, 188], ["supermicron", "ANATOMY_MODIFIER", 192, 203], ["region", "ANATOMY_MODIFIER", 204, 210], ["diameter", "OBSERVATION_MODIFIER", 216, 224], ["larger", "OBSERVATION_MODIFIER", 225, 231]]], ["The submicron region was dominantly noted in PARRs in Zone B and C of Fangcang Hospital (Figure 1a and 1b) with peak concentration of 40 and 9 copies m -3 in 0.25 to 0.5 \u00b5m and 0.5 to 1.0 \u00b5m, respectively.", [["peak concentration", "TEST", 112, 130], ["submicron", "OBSERVATION_MODIFIER", 4, 13], ["dominantly", "OBSERVATION_MODIFIER", 25, 35]]], ["Whereas the supermicron region was observed in Fangcang Hospital Zone C PARR and Medical Staff's Office (Figure 1b and 1c) with 7 and 9 copies m -3 .", [["supermicron region", "DNA", 12, 30]]], ["The two concentration peaks in sub-and supermicron ranges have independent existence in SARS-CoV-2 aerosols and they do not necessarily co-exist indicating possible different formation mechanisms.", [["The two concentration peaks", "PROBLEM", 0, 27], ["two", "OBSERVATION_MODIFIER", 4, 7], ["concentration", "OBSERVATION_MODIFIER", 8, 21], ["peaks", "OBSERVATION_MODIFIER", 22, 27], ["sub", "OBSERVATION_MODIFIER", 31, 34]]], ["The aerosol deposition sample collected from the Renmin Hospital ICU room had raw counts of SARS-CoV-2 RNA significantly above the detection limit as shown in Table S1 , although the TSP aerosol sample concentration inside this ICU room was below detection limit during the 3 hour sampling period.", [["sample", "ANATOMY", 23, 29], ["TSP", "GENE_OR_GENE_PRODUCT", 183, 186], ["SARS-CoV-2 RNA", "RNA", 92, 106], ["SARS-CoV", "SPECIES", 92, 100], ["The aerosol deposition sample", "TEST", 0, 29], ["SARS", "TEST", 92, 96], ["CoV", "TEST", 97, 100], ["the TSP aerosol sample concentration", "TREATMENT", 179, 215]]], ["The much longer integration time of 7 days for the deposition sample has contributed to the accumulation of virus sediment.", [["the deposition sample", "PROBLEM", 47, 68], ["the accumulation of virus sediment", "PROBLEM", 88, 122], ["accumulation of", "OBSERVATION", 92, 107], ["virus sediment", "OBSERVATION", 108, 122]]], ["The area normalized deposition rate inside the ICU room is calculated to be 31 and 113 copies m -2 hour -1 .", [["area", "OBSERVATION_MODIFIER", 4, 8], ["normalized", "OBSERVATION", 9, 19], ["deposition", "OBSERVATION_MODIFIER", 20, 30], ["rate", "OBSERVATION_MODIFIER", 31, 35]]], ["The sample with the higher deposition rate was placed in the hindrance-free corner of the room, approximately 3 meters from the patient's bed.", [["sample", "ANATOMY", 4, 10], ["patient", "ORGANISM", 128, 135], ["patient", "SPECIES", 128, 135], ["The sample", "TEST", 0, 10], ["the higher deposition rate", "TREATMENT", 16, 42], ["higher", "OBSERVATION_MODIFIER", 20, 26], ["deposition", "OBSERVATION_MODIFIER", 27, 37]]], ["The other sample recorded lower virus copies and it was placed in another corner with medical equipment above, and approximately 2 meters from the patient's bed.", [["patient", "ORGANISM", 147, 154], ["patient", "SPECIES", 147, 154], ["The other sample", "TEST", 0, 16], ["lower virus copies", "PROBLEM", 26, 44]]], ["This may have blocked the path of virus aerosol sediment.DiscussionGenerally undetectable or very low concentrations of airborne SARS-CoV-2 were found in most PAA inside the two hospitals in Wuhan.", [["SARS", "DISEASE", 129, 133], ["PAA", "CHEMICAL", 159, 162], ["PAA", "CHEMICAL", 159, 162], ["virus aerosol sediment", "PROBLEM", 34, 56], ["virus aerosol sediment", "OBSERVATION", 34, 56]]], ["The negative pressure ventilation and high air exchange rate inside ICU, CCU and ward room of Renmin Hospital are effective in minimizing airborne SARS-CoV-2.", [["SARS", "DISEASE", 147, 151], ["The negative pressure ventilation", "TREATMENT", 0, 33], ["pressure ventilation", "OBSERVATION", 13, 33]]], ["Fangcang Hospital hosted over 200 mild symptom patients in each zone during the peak of the COVID-19 outbreak.", [["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["the COVID", "TEST", 88, 97]]], ["However, the SARS-CoV-2 aerosol concentrations inside the patient hall were very low during the two batches of sampling periods, showing the protective and preventive measures taken in Fangcang Hospital are effective in hindering the aerosol transmission and reducing the potential infection risks of the medical staff.", [["SARS", "DISEASE", 13, 17], ["infection", "DISEASE", 282, 291], ["SARS-CoV-2", "ORGANISM", 13, 23], ["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["the SARS", "TEST", 9, 17], ["CoV-2 aerosol concentrations", "TREATMENT", 18, 46], ["preventive measures", "TREATMENT", 156, 175], ["the aerosol transmission", "TREATMENT", 230, 254]]], ["Inside the Renmin Hospital ICU rooms, the two aerosol deposition samples tested positive with an estimated deposition rate of 31 and 113 copies m -2 hr -1 .", [["the two aerosol deposition samples", "TEST", 38, 72], ["an estimated deposition rate", "TEST", 94, 122]]], ["The deposited virus may come from respiratory droplet or virus-laden aerosol transmission.", [["The deposited virus", "PROBLEM", 0, 19], ["respiratory droplet", "PROBLEM", 34, 53], ["virus", "OBSERVATION", 14, 19], ["respiratory droplet", "OBSERVATION", 34, 53]]], ["Our findings add support to a hypothesis that virus-laden aerosol deposition may play a role in surface contamination and subsequent contact by susceptible people resulting in human infection.DiscussionThis study also recorded an elevated airborne SARS-CoV-2 concentration inside the patient mobile toilet of Fangcang Hospital.", [["surface", "ANATOMY", 96, 103], ["infection", "DISEASE", 182, 191], ["surface", "CELLULAR_COMPONENT", 96, 103], ["people", "ORGANISM", 156, 162], ["human", "ORGANISM", 176, 181], ["patient", "ORGANISM", 284, 291], ["people", "SPECIES", 156, 162], ["human", "SPECIES", 176, 181], ["patient", "SPECIES", 284, 291], ["human", "SPECIES", 176, 181], ["a hypothesis that virus", "PROBLEM", 28, 51], ["laden aerosol deposition", "TREATMENT", 52, 76], ["surface contamination", "PROBLEM", 96, 117], ["human infection", "PROBLEM", 176, 191], ["This study", "TEST", 202, 212], ["an elevated airborne SARS", "PROBLEM", 227, 252], ["laden", "OBSERVATION_MODIFIER", 52, 57], ["aerosol deposition", "OBSERVATION", 58, 76], ["infection", "OBSERVATION", 182, 191]]], ["This may come from either the patient's breath or the aerosolization of the virus-laden aerosol from patient's faeces or urine during use.", [["faeces", "ANATOMY", 111, 117], ["urine", "ANATOMY", 121, 126], ["patient", "ORGANISM", 30, 37], ["patient", "ORGANISM", 101, 108], ["faeces", "ORGANISM_SUBSTANCE", 111, 117], ["urine", "ORGANISM_SUBSTANCE", 121, 126], ["patient", "SPECIES", 30, 37], ["patient", "SPECIES", 101, 108], ["the virus", "TREATMENT", 72, 81], ["laden aerosol", "TREATMENT", 82, 95]]], ["Ong et al. has found the wipe samples from room surfaces of toilets used by SARS-CoV-2 patients tested positive.", [["samples", "ANATOMY", 30, 37], ["SARS", "DISEASE", 76, 80], ["SARS-CoV-2", "ORGANISM", 76, 86], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["SARS-CoV", "SPECIES", 76, 84], ["CoV", "TEST", 81, 84]]], ["11 Our finding has confirmed the aerosol transmission as an important pathway for surface contamination.", [["surface", "ANATOMY", 82, 89], ["surface", "CELLULAR_COMPONENT", 82, 89], ["the aerosol transmission", "TREATMENT", 29, 53], ["surface contamination", "PROBLEM", 82, 103]]], ["We call for extra care and attention on the proper design, use and disinfection of the toilets in hospitals and in communities to minimize the potential source of the virus-laden aerosol.DiscussionMSAs in general have higher concentration of SARS-CoV-2 aerosol with biomodal size distributions compared to PAA in both hospitals during the first batch of sampling in the peak of COVID-19 outbreak.", [["SARS", "DISEASE", 242, 246], ["PAA", "CHEMICAL", 306, 309], ["PAA", "CHEMICAL", 306, 309], ["the virus", "TREATMENT", 163, 172], ["laden aerosol", "TREATMENT", 173, 186], ["SARS", "PROBLEM", 242, 246], ["CoV", "TEST", 247, 250], ["biomodal size distributions", "TREATMENT", 266, 293], ["COVID", "TEST", 378, 383], ["size", "OBSERVATION_MODIFIER", 275, 279]]], ["For Renmin Hospital sampling sites, the air circulation in MSA by design is isolated from that of the patient rooms.", [["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 102, 109], ["the air circulation in MSA", "PROBLEM", 36, 62], ["air circulation", "OBSERVATION", 40, 55]]], ["While for Fangcang Hospital, the nonventilated temporary PARR has limited air penetration from the patient hall where the SARS-CoV-2 aerosol concentration was generally low.", [["PARR", "CHEMICAL", 57, 61], ["SARS", "DISEASE", 122, 126], ["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["the nonventilated temporary PARR", "TREATMENT", 29, 61], ["limited air penetration", "PROBLEM", 66, 89], ["the SARS", "TEST", 118, 126], ["CoV-2 aerosol concentration", "TREATMENT", 127, 154], ["air penetration", "OBSERVATION", 74, 89]]], ["We believe one direct source of the high SARS-CoV-2 aerosol concentration may be the resuspension of virus-laden aerosol from the surface of medical staff protective apparel while they are being removed.", [["surface", "ANATOMY", 130, 137], ["SARS", "DISEASE", 41, 45], ["the high SARS", "PROBLEM", 32, 45], ["CoV-2 aerosol concentration", "TREATMENT", 46, 73], ["virus-laden aerosol", "TREATMENT", 101, 120]]], ["These resuspended virus-laden aerosol originally may come from the direct deposition of respiratory droplets or virus-laden aerosol onto the protective apparel while medical staff having long working hours inside PAA, as shown from the SARS-CoV-2 deposition results in ICU room.", [["PAA", "CHEMICAL", 213, 216], ["SARS", "DISEASE", 236, 240], ["PAA", "CHEMICAL", 213, 216], ["PAA", "SIMPLE_CHEMICAL", 213, 216], ["These resuspended virus", "TREATMENT", 0, 23], ["laden aerosol", "TREATMENT", 24, 37], ["respiratory droplets", "TREATMENT", 88, 108], ["virus", "TREATMENT", 112, 117], ["the SARS", "TEST", 232, 240], ["respiratory droplets", "OBSERVATION", 88, 108]]], ["Another possible source is the resuspension of floor dust aerosol containing virus that were transferred from PAA to MSA.", [["PAA", "CHEMICAL", 110, 113], ["PAA", "CHEMICAL", 110, 113], ["PAA", "SIMPLE_CHEMICAL", 110, 113], ["floor dust aerosol containing virus", "PROBLEM", 47, 82], ["possible", "UNCERTAINTY", 8, 16]]], ["The two virus-laden aerosol sources also appear to correspond to the sub-and supermicron peaks found in size-segregated samples.", [["samples", "ANATOMY", 120, 127], ["samples", "TISSUE", 120, 127], ["the sub", "TEST", 65, 72], ["two", "OBSERVATION_MODIFIER", 4, 7], ["virus", "OBSERVATION", 8, 13], ["laden", "OBSERVATION_MODIFIER", 14, 19], ["aerosol sources", "OBSERVATION", 20, 35], ["sub", "OBSERVATION_MODIFIER", 69, 72], ["size", "OBSERVATION_MODIFIER", 104, 108]]], ["We hypothesize the submicron aerosol may come from the resuspension of virus-laden aerosol from staff apparel due to its higher mobility while the supermicron virus-laden aerosol may come from the resuspension of dust particles from the floors or other hard surfaces.", [["supermicron virus", "ORGANISM", 147, 164], ["the submicron aerosol", "TREATMENT", 15, 36], ["virus-laden aerosol", "TREATMENT", 71, 90], ["its higher mobility", "PROBLEM", 117, 136], ["the supermicron virus-laden aerosol", "TREATMENT", 143, 178], ["dust particles", "PROBLEM", 213, 227], ["dust particles", "OBSERVATION", 213, 227]]], ["The findings suggest virus-laden aerosols could first deposit on the surface of medical staff protective apparel and the floors in patient areas and are then resuspended by the movements of medical staff.", [["surface", "ANATOMY", 69, 76], ["patient", "ORGANISM", 131, 138], ["patient", "SPECIES", 131, 138], ["virus-laden aerosols", "PROBLEM", 21, 41], ["suggest", "UNCERTAINTY", 13, 20], ["virus", "OBSERVATION", 21, 26], ["laden aerosols", "OBSERVATION", 27, 41]]], ["The second batch of TSP samples taken in Fangcang MSAs all tested negative with reduced number of patients from > 200 to 100 per zone and implementation of more rigorous and thorough sanitization measures in Fangcang.", [["samples", "ANATOMY", 24, 31], ["TSP samples", "CANCER", 20, 31], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["TSP samples", "TEST", 20, 31], ["Fangcang MSAs", "TEST", 41, 54], ["thorough sanitization measures", "TREATMENT", 174, 204], ["reduced", "OBSERVATION_MODIFIER", 80, 87], ["number", "OBSERVATION_MODIFIER", 88, 94]]], ["The comparison of the two batches of samples showed the effectiveness and importance of sanitization in reducing the airborne SARS-CoV-2 in high risk areas.DiscussionIn PUA outside the hospitals, we found the majority of the sites have undetectable or very low concentrations of SARS-CoV-2 aerosol, except for one crowd gathering site about 1 meter to the entrance of a department store with customers frequently passing through, and the other site next to Renmin Hospital where the outpatients and passengers passed by.", [["samples", "ANATOMY", 37, 44], ["SARS", "DISEASE", 126, 130], ["SARS", "DISEASE", 279, 283], ["outpatients", "ORGANISM", 483, 494], ["sanitization", "TREATMENT", 88, 100], ["the airborne SARS", "TEST", 113, 130], ["CoV", "TEST", 131, 134], ["high risk", "OBSERVATION_MODIFIER", 140, 149]]], ["It is possible that asymptomatic carriers of COVID-19 in the crowd may have contributed as the source of virus-laden aerosol during the sampling period.", [["COVID-19", "ORGANISM", 45, 53], ["COVID-19", "DNA", 45, 53], ["COVID", "TEST", 45, 50], ["virus-laden aerosol", "TREATMENT", 105, 124]]], ["12, 13 The results showed overall low risks in the public venues but do reinforce the importance of avoiding crowded gatherings and implementing early identification and diagnosis of asymptomatic carriers for early quarantine or treatment.", [["asymptomatic carriers", "PROBLEM", 183, 204], ["treatment", "TREATMENT", 229, 238], ["low risks", "OBSERVATION", 34, 43]]], ["Personal protection equipment such as wearing masks in public places or while in transit may reduce aerosol exposure and transmission.DiscussionThe results from this study provide the first field report on the characteristics of airborne SARS-CoV-2 in Wuhan with important implications for the public health prevention and medical staff protection.", [["SARS", "DISEASE", 238, 242], ["SARS-CoV", "SPECIES", 238, 246], ["Personal protection equipment", "TREATMENT", 0, 29], ["this study", "TEST", 161, 171], ["the public health prevention", "TREATMENT", 290, 318], ["medical staff protection", "TREATMENT", 323, 347]]], ["We call for particular attentions on 1) the proper use and cleaning of toilets (e.g. ventilation and sterilization), as a potential spread source of coronavirus with relatively high risk caused by aerosolization of virus and contamination of surfaces after use; 2) for the general public, the proper use of personal protection measures, such as wearing masks and avoiding busy crowds; 3) the effective sanitization of the high risk area and the use of high level protection masks for medical staff with direct contact with the COVID-19 patients or with long stay in high risk area; 4) the renovation of large stadiums as field hospitals with nature ventilation and protective measures is an effective approach to quarantine and treat mild symptom patients so as to reduce the COVID-19 transmission among the public; 5) the virus may be resuspended from the contaminated protective apparel surface to the air while taking off and from the floor surface with the movement of medical staff.", [["floor surface", "ANATOMY", 938, 951], ["coronavirus", "DISEASE", 149, 160], ["coronavirus", "ORGANISM", 149, 160], ["patients", "ORGANISM", 536, 544], ["patients", "ORGANISM", 747, 755], ["patients", "SPECIES", 536, 544], ["patients", "SPECIES", 747, 755], ["cleaning of toilets", "TREATMENT", 59, 78], ["ventilation", "TREATMENT", 85, 96], ["sterilization", "TREATMENT", 101, 114], ["coronavirus", "PROBLEM", 149, 160], ["virus", "PROBLEM", 215, 220], ["personal protection measures", "TREATMENT", 307, 335], ["wearing masks", "TREATMENT", 345, 358], ["high level protection masks", "TREATMENT", 452, 479], ["large stadiums", "TREATMENT", 603, 617], ["nature ventilation", "TREATMENT", 642, 660], ["protective measures", "TREATMENT", 665, 684], ["mild symptom", "PROBLEM", 734, 746], ["the COVID", "TEST", 772, 781], ["the virus", "PROBLEM", 819, 828], ["large", "OBSERVATION_MODIFIER", 603, 608], ["air", "OBSERVATION", 904, 907]]], ["Thus, surface sanitization of the apparel before they are taken off may also help reduce the infection risk for medical staff.", [["surface", "ANATOMY", 6, 13], ["infection", "DISEASE", 93, 102], ["surface", "CELLULAR_COMPONENT", 6, 13], ["the infection risk", "PROBLEM", 89, 107], ["infection", "OBSERVATION", 93, 102]]], ["Note: * The reported values are virus aerosol deposition rate in copies m -2 hour -1 . # Two batches of sampling were conducted for the sites.", [["virus aerosol deposition rate", "TREATMENT", 32, 61], ["Two batches of sampling", "TREATMENT", 89, 112]]], ["Detailed information is shown in Table S1 . a The samples taken during the first batch of sampling from Feb 17 to Feb 24, 2020. b The samples taken during the second batch of sampling on Mar 2, 2020.", [["samples", "ANATOMY", 50, 57], ["samples", "ANATOMY", 134, 141], ["The samples", "TEST", 46, 57], ["The samples", "TEST", 130, 141]]]], "PMC5144900": [["THE 2015 MERS OUTBREAK IN SOUTH KOREAOur first example of the use of Internet-based information draws from a recent large-scale outbreak of infection due to MERS coronavirus, a zoonotic virus that has caused sporadic but recurrent outbreaks in humans since March 2012, particularly in the Middle East [9].", [["infection", "DISEASE", 140, 149], ["MERS coronavirus", "DISEASE", 157, 173], ["zoonotic virus", "DISEASE", 177, 191], ["MERS coronavirus", "ORGANISM", 157, 173], ["humans", "ORGANISM", 244, 250], ["humans", "SPECIES", 244, 250], ["MERS coronavirus", "SPECIES", 157, 173], ["humans", "SPECIES", 244, 250], ["infection", "PROBLEM", 140, 149], ["MERS coronavirus", "PROBLEM", 157, 173], ["a zoonotic virus", "PROBLEM", 175, 191], ["large", "OBSERVATION_MODIFIER", 116, 121], ["infection", "OBSERVATION", 140, 149], ["recurrent", "OBSERVATION_MODIFIER", 221, 230], ["outbreaks", "OBSERVATION", 231, 240], ["Middle", "ANATOMY_MODIFIER", 289, 295]]], ["The concentration of human infections has been linked to the local population of dromedary camels, which may serve as an intermediate host for MERS [10, 11].", [["infections", "DISEASE", 27, 37], ["human", "ORGANISM", 21, 26], ["camels", "ORGANISM_SUBDIVISION", 91, 97], ["human", "SPECIES", 21, 26], ["human", "SPECIES", 21, 26], ["human infections", "PROBLEM", 21, 37], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["infections", "OBSERVATION", 27, 37], ["local", "OBSERVATION_MODIFIER", 61, 66]]], ["The human-to-human transmission potential of MERS in the community at large appears to remain subcritical; however, outbreaks tend to be amplified via nosocomial transmission [9, 12, 13].", [["human", "ORGANISM", 4, 9], ["human", "ORGANISM", 13, 18], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 13, 18], ["MERS", "PROBLEM", 45, 49], ["subcritical", "OBSERVATION", 94, 105]]], ["Case importation from the Middle East continues to represent a substantial risk for outbreaks, as recently exemplified by the 2015 MERS outbreak in South Korea.", [["outbreaks", "PROBLEM", 84, 93]]], ["We concentrate on this large outbreak, sparked by a single index case who arrived in South Korea on 4 May 2015.", [["large", "OBSERVATION_MODIFIER", 23, 28], ["outbreak", "OBSERVATION", 29, 37]]], ["The index case developed symptoms 7 days later and did not receive a diagnosis of MERS until 20 May 2015, after having sought treatment in several healthcare facilities [14].THE 2015 MERS OUTBREAK IN SOUTH KOREAIn the case of the 2015 South Korean MERS outbreak, epidemiological information was available from traditional surveillance systems, but detailed, high-resolution data had to be parsed out from online reports emanating from disparate health authorities, including the Korean Centers for Disease Control, the Ministry of Health and Welfare of South Korea, and the World Health Organization [14\u201317].", [["MERS", "DISEASE", 82, 86], ["symptoms", "PROBLEM", 25, 33], ["traditional surveillance systems", "TEST", 310, 342], ["Disease Control", "TREATMENT", 498, 513]]], ["Systematic near real-time analysis of these online reports allowed reconstruction of MERS transmission chains, which can be considered a single giant cluster in this outbreak (Supplementary Figure 1) [18].", [["reconstruction of MERS transmission chains", "TREATMENT", 67, 109]]], ["The full transmission tree comprised 150 cases linked to nosocomial events, where each case was classified according to occupational and social exposure.", [["nosocomial events", "PROBLEM", 57, 74]]], ["It became clear relatively early on that all cases were linked to exposure in the healthcare setting: 150 cases, included 107 hospital patients (including the index patient), 28 visitors or family members, 12 healthcare workers, and 3 nonclinical staff.THE 2015 MERS OUTBREAK IN SOUTH KOREAThe South Korean MERS outbreak comprised 3 disease generations, with the index patient representing generation 0.", [["patients", "ORGANISM", 135, 143], ["patient", "ORGANISM", 165, 172], ["patient", "ORGANISM", 369, 376], ["patients", "SPECIES", 135, 143], ["patient", "SPECIES", 165, 172], ["patient", "SPECIES", 369, 376], ["3 disease generations", "PROBLEM", 331, 352], ["clear", "OBSERVATION", 10, 15]]], ["The average reproduction number followed a declining trend, from 30 cases in the first generation to 3.8 in the second generation and 0.1 in the third generation (Supplementary Figure 1).", [["average", "OBSERVATION_MODIFIER", 4, 11]]], ["Overall, this outbreak followed a similar trajectory to previous hospital clusters involving coronaviruses [18], with early super-spreading events generating a disproportionate number of secondary infections, followed by a rapid decline of the reproduction number to <1.0 in subsequent generations as infection control measures gained strength.THE 2014\u20132015 EBOLA EPIDEMIC IN WEST AFRICAOur second example of using Internet data to characterize transmission dynamics is based on the 2014\u20132015 Ebola outbreak in West Africa.", [["coronaviruses", "DISEASE", 93, 106], ["infections", "DISEASE", 197, 207], ["decline of the reproduction number", "DISEASE", 229, 263], ["infection", "DISEASE", 301, 310], ["Ebola", "DISEASE", 493, 498], ["coronaviruses", "PROBLEM", 93, 106], ["early super-spreading events", "PROBLEM", 118, 146], ["secondary infections", "PROBLEM", 187, 207], ["a rapid decline", "PROBLEM", 221, 236], ["infection control measures", "TREATMENT", 301, 327], ["Internet data", "TEST", 415, 428], ["disproportionate", "OBSERVATION_MODIFIER", 160, 176], ["number", "OBSERVATION_MODIFIER", 177, 183], ["secondary", "OBSERVATION_MODIFIER", 187, 196], ["infections", "OBSERVATION", 197, 207], ["rapid", "OBSERVATION_MODIFIER", 223, 228], ["decline", "OBSERVATION_MODIFIER", 229, 236], ["infection", "OBSERVATION", 301, 310]]], ["In contrast to the MERS outbreak previously described, scarce epidemiological data were available throughout the Ebola outbreak from traditional surveillance systems.", [["Ebola", "DISEASE", 113, 118], ["traditional surveillance systems", "TEST", 133, 165]]], ["To alleviate the need for solid epidemiological information and assess Ebola transmission characteristics, we designed an approach to systematically collect information on Ebola case clusters from Internet news reports published during the outbreak [19].", [["Ebola", "DISEASE", 71, 76], ["Ebola", "DISEASE", 172, 177], ["Ebola", "ORGANISM", 71, 76], ["Ebola", "ORGANISM", 172, 177], ["Ebola", "SPECIES", 71, 76]]], ["Below we extend and update this work and reflect on future developments needed to generalize Internet-based approaches to study transmission dynamics more broadly.THE 2014\u20132015 EBOLA EPIDEMIC IN WEST AFRICATo obtain detailed information on Ebola transmission chains, we reviewed news stories and investigative reports published between January 2014 and January 2016 and describing suspected, probable, and confirmed cases of Ebola in the 3 most affected countries (Guinea, Sierra Leone, and Liberia).", [["Ebola", "DISEASE", 240, 245], ["Ebola", "DISEASE", 425, 430], ["Ebola", "ORGANISM", 240, 245], ["Ebola", "ORGANISM", 425, 430], ["Ebola", "PROBLEM", 425, 430], ["Ebola", "OBSERVATION", 425, 430]]], ["We focused on reports available from the World Health Organization Web site, particularly news segments published in the section \u201cStories from the field on Ebola,\u201d and Ebola situational reports, as well as online authoritative media outlets (see Supplementary Table 1 for a complete list of case clusters, their characteristics and corresponding sources).THE 2014\u20132015 EBOLA EPIDEMIC IN WEST AFRICAWe manually reviewed and selected articles that contained detailed stories about Ebola case clusters arising within families or via funerals or hospital exposure.", [["Ebola", "DISEASE", 156, 161], ["Ebola", "DISEASE", 479, 484], ["Ebola", "ORGANISM", 479, 484]]], ["Each patient with Ebola was assigned one or several types of exposure (family/household, hospital, sexual, or funeral).", [["Ebola", "DISEASE", 18, 23], ["patient", "ORGANISM", 5, 12], ["Ebola", "ORGANISM", 18, 23], ["patient", "SPECIES", 5, 12], ["Ebola", "PROBLEM", 18, 23]]], ["We also analyzed Ebola transmission dynamics for a subset of clusters for which transmission chains were explicitly described in the articles or could be inferred based on chronological information on the timing of symptoms of successive cases (Figure 1).", [["Ebola", "ORGANISM", 17, 22], ["symptoms", "PROBLEM", 215, 223]]]], "ff56926b9a45fe14f061e2df3f573214d73e4e6b": [["IntroductionThe coronavirus virion possesses two or three major envelope glycoproteins [40] .", [["coronavirus virion", "ORGANISM", 16, 34], ["envelope glycoproteins", "PROTEIN", 64, 86], ["The coronavirus virion possesses", "TREATMENT", 12, 44], ["coronavirus virion", "OBSERVATION", 16, 34]]], ["The latter are synthesized from different virus-specific subgenomic RNAs which are translated at the level Of membrane-bound ribosomes [34, 35] , and then undergo post-translational processing at the level of rough endoplasmic reticulum or Golgi apparatus [40, 42] .", [["membrane", "ANATOMY", 110, 118], ["ribosomes", "ANATOMY", 125, 134], ["endoplasmic reticulum", "ANATOMY", 215, 236], ["Golgi apparatus", "ANATOMY", 240, 255], ["membrane", "CELLULAR_COMPONENT", 110, 118], ["ribosomes", "CELLULAR_COMPONENT", 125, 134], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 215, 236], ["Golgi apparatus", "CELLULAR_COMPONENT", 240, 255], ["virus-specific subgenomic RNAs", "RNA", 42, 72], ["different virus-specific subgenomic RNAs", "PROBLEM", 32, 72], ["different virus", "OBSERVATION", 32, 47], ["subgenomic RNAs", "OBSERVATION", 57, 72], ["rough", "ANATOMY_MODIFIER", 209, 214], ["endoplasmic reticulum", "OBSERVATION", 215, 236]]], ["The peplomeric (E2) protein precursors of mouse hepatitis (MHV) and avian infectious bronchitis (IBV) viruses are cotranslationally N-glycosylated and have then an apparent mol.wt, of 150,000 [27, 32, 36] .", [["E2", "CHEMICAL", 16, 18], ["mouse hepatitis (MHV)", "DISEASE", 42, 63], ["infectious bronchitis (IBV) viruses", "DISEASE", 74, 109], ["N", "CHEMICAL", 132, 133], ["E2", "GENE_OR_GENE_PRODUCT", 16, 18], ["mouse hepatitis (MHV)", "ORGANISM", 42, 63], ["avian infectious bronchitis", "ORGANISM", 68, 95], ["IBV", "ORGANISM", 97, 100], ["peplomeric (E2) protein precursors", "PROTEIN", 4, 38], ["mouse", "SPECIES", 42, 47], ["avian infectious bronchitis", "SPECIES", 68, 95], ["mouse", "SPECIES", 42, 47], ["MHV", "SPECIES", 59, 62], ["IBV", "SPECIES", 97, 100], ["The peplomeric (E2) protein precursors", "TREATMENT", 0, 38], ["mouse hepatitis (MHV)", "PROBLEM", 42, 63], ["avian infectious bronchitis (IBV) viruses", "PROBLEM", 68, 109], ["an apparent mol.wt", "TEST", 161, 179], ["mouse hepatitis", "OBSERVATION", 42, 57], ["infectious", "OBSERVATION_MODIFIER", 74, 84], ["bronchitis", "OBSERVATION", 85, 95]]], ["The polypeptides synthesized in vitro or in tunicamycin-treated cells have a mol.wt, of approximately 120,000 [3, 28, 33] .", [["cells", "ANATOMY", 64, 69], ["tunicamycin", "CHEMICAL", 44, 55], ["tunicamycin", "CHEMICAL", 44, 55], ["tunicamycin", "SIMPLE_CHEMICAL", 44, 55], ["cells", "CELL", 64, 69], ["tunicamycin-treated cells", "CELL_LINE", 44, 69], ["The polypeptides", "TREATMENT", 0, 16], ["tunicamycin-treated cells", "TREATMENT", 44, 69]]], ["This agrees with the mol.wts, of the polypeptide moieties predicted from nucleotide sequences of their E2 genes [1, 20, 31] .", [["nucleotide", "CHEMICAL", 73, 83], ["E2", "CHEMICAL", 103, 105], ["nucleotide", "CHEMICAL", 73, 83], ["E2", "GENE_OR_GENE_PRODUCT", 103, 105], ["polypeptide moieties", "PROTEIN", 37, 57], ["E2 genes", "DNA", 103, 111], ["the polypeptide moieties", "TREATMENT", 33, 57], ["nucleotide sequences", "TEST", 73, 93]]], ["A glycoprotein with a mol.wt, of approximately 170,000 has been identified as the intracellular precursor of the E2 protein of bovine enteric coronavirus (BCV), and hemagglutinating mammalian coronavirus [9, 10] .", [["intracellular", "ANATOMY", 82, 95], ["E2", "CHEMICAL", 113, 115], ["enteric coronavirus", "DISEASE", 134, 153], ["mol.wt", "GENE_OR_GENE_PRODUCT", 22, 28], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 82, 95], ["E2", "GENE_OR_GENE_PRODUCT", 113, 115], ["bovine enteric coronavirus", "ORGANISM", 127, 153], ["BCV", "ORGANISM", 155, 158], ["hemagglutinating mammalian coronavirus", "ORGANISM", 165, 203], ["glycoprotein", "PROTEIN", 2, 14], ["mol.wt", "PROTEIN", 22, 28], ["E2 protein", "PROTEIN", 113, 123], ["bovine", "SPECIES", 127, 133], ["enteric coronavirus", "SPECIES", 134, 153], ["mammalian coronavirus", "SPECIES", 182, 203], ["bovine enteric coronavirus", "SPECIES", 127, 153], ["BCV", "SPECIES", 155, 158], ["hemagglutinating mammalian coronavirus", "SPECIES", 165, 203], ["A glycoprotein", "TREATMENT", 0, 14], ["bovine enteric coronavirus", "PROBLEM", 127, 153], ["hemagglutinating mammalian coronavirus", "PROBLEM", 165, 203], ["enteric coronavirus", "ANATOMY", 134, 153]]], ["Unglycosylated precursors have not been yet identified for BCV, but concomitant with the loss of its surface projections, the virus is neither infectious nor hemagglutinating, after cultivation in the presence of TM [10] .", [["surface", "ANATOMY", 101, 108], ["BCV", "ORGANISM", 59, 62], ["BCV", "SPECIES", 59, 62], ["Unglycosylated precursors", "PROBLEM", 0, 25], ["BCV", "PROBLEM", 59, 62], ["the loss of its surface projections", "PROBLEM", 85, 120], ["the virus", "PROBLEM", 122, 131], ["infectious", "PROBLEM", 143, 153], ["hemagglutinating", "PROBLEM", 158, 174], ["cultivation", "TREATMENT", 182, 193], ["infectious", "OBSERVATION_MODIFIER", 143, 153]]], ["Following further glycosylation, the peplomeric protein of these coronaviruses undergoes proteolytic cleavage to yield two subunits with mol.wts, of 85-100,000 [9, 20, 41] .", [["coronaviruses", "ORGANISM", 65, 78], ["peplomeric protein", "PROTEIN", 37, 55], ["further glycosylation", "TREATMENT", 10, 31], ["the peplomeric protein", "TREATMENT", 33, 55], ["these coronaviruses", "PROBLEM", 59, 78], ["proteolytic cleavage", "TREATMENT", 89, 109]]], ["This proteolytic cleavage is a host-cell dependent event and is required for activation of the cell-fusing activity, and therefore appears to be an important determinant of viral pathogenesis [12] .", [["cell", "ANATOMY", 36, 40], ["cell", "ANATOMY", 95, 99], ["cell", "CELL", 36, 40], ["cell", "CELL", 95, 99], ["This proteolytic cleavage", "PROBLEM", 0, 25], ["a host-cell dependent event", "PROBLEM", 29, 56], ["viral pathogenesis", "PROBLEM", 173, 191], ["host-cell dependent", "OBSERVATION_MODIFIER", 31, 50]]], ["The precursor proteins to the BCV hemagglutinating protein (gp 124/gp62) are gp59 (monomer) and gp 118 (disulfide-linked dimer) [9, 10] .IntroductionThe N-terminal regions of the matrix E 1 proteins of MHV and BCV bear oligosaccharides chains that lack mannose and fucose, and are O-linked to serine or threonine residues, an unusual feature among viral glycoproteins [18, 22, 27] .", [["fucose", "CHEMICAL", 265, 271], ["threonine", "CHEMICAL", 303, 312], ["disulfide", "CHEMICAL", 104, 113], ["mannose", "CHEMICAL", 253, 260], ["fucose", "CHEMICAL", 265, 271], ["O", "CHEMICAL", 281, 282], ["serine", "CHEMICAL", 293, 299], ["threonine", "CHEMICAL", 303, 312], ["BCV hemagglutinating protein", "GENE_OR_GENE_PRODUCT", 30, 58], ["gp 124/gp62", "GENE_OR_GENE_PRODUCT", 60, 71], ["gp59", "GENE_OR_GENE_PRODUCT", 77, 81], ["gp 118", "GENE_OR_GENE_PRODUCT", 96, 102], ["matrix E 1", "GENE_OR_GENE_PRODUCT", 179, 189], ["MHV", "ORGANISM", 202, 205], ["BCV", "ORGANISM", 210, 213], ["mannose", "SIMPLE_CHEMICAL", 253, 260], ["fucose", "SIMPLE_CHEMICAL", 265, 271], ["serine", "AMINO_ACID", 293, 299], ["threonine", "AMINO_ACID", 303, 312], ["precursor proteins", "PROTEIN", 4, 22], ["BCV hemagglutinating protein", "PROTEIN", 30, 58], ["gp 124", "PROTEIN", 60, 66], ["gp62", "PROTEIN", 67, 71], ["gp59", "PROTEIN", 77, 81], ["monomer", "PROTEIN", 83, 90], ["gp 118", "PROTEIN", 96, 102], ["disulfide-linked dimer", "PROTEIN", 104, 126], ["N-terminal regions", "PROTEIN", 153, 171], ["matrix E 1 proteins", "PROTEIN", 179, 198], ["MHV and BCV bear oligosaccharides chains", "PROTEIN", 202, 242], ["viral glycoproteins", "PROTEIN", 348, 367], ["MHV", "SPECIES", 202, 205], ["The precursor proteins", "TEST", 0, 22], ["the BCV hemagglutinating protein", "TEST", 26, 58], ["gp", "TEST", 60, 62], ["gp", "TEST", 96, 98], ["The N-terminal regions", "TREATMENT", 149, 171], ["MHV", "TREATMENT", 202, 205], ["BCV bear oligosaccharides chains", "TREATMENT", 210, 242], ["threonine residues", "PROBLEM", 303, 321], ["MHV", "ANATOMY", 202, 205]]], ["Therefore, the glycosylation process of the p20-23 intracellular precursors does not depend on transfer of oligosaccharides from dolichol phosphate intermediates and is not inhibited by tunicamycin, but by sodium monensin, an inhibitor of the Golgi function [18, 27] .", [["intracellular", "ANATOMY", 51, 64], ["Golgi", "ANATOMY", 243, 248], ["dolichol phosphate", "CHEMICAL", 129, 147], ["tunicamycin", "CHEMICAL", 186, 197], ["sodium monensin", "CHEMICAL", 206, 221], ["p20-23", "CHEMICAL", 44, 50], ["dolichol phosphate", "CHEMICAL", 129, 147], ["tunicamycin", "CHEMICAL", 186, 197], ["sodium monensin", "CHEMICAL", 206, 221], ["p20-23", "GENE_OR_GENE_PRODUCT", 44, 50], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 51, 64], ["dolichol phosphate intermediates", "SIMPLE_CHEMICAL", 129, 161], ["tunicamycin", "SIMPLE_CHEMICAL", 186, 197], ["sodium monensin", "SIMPLE_CHEMICAL", 206, 221], ["Golgi", "CELLULAR_COMPONENT", 243, 248], ["p20", "PROTEIN", 44, 47], ["the glycosylation process", "TREATMENT", 11, 36], ["the p20", "TEST", 40, 47], ["oligosaccharides", "PROBLEM", 107, 123], ["dolichol phosphate intermediates", "TREATMENT", 129, 161], ["tunicamycin", "TREATMENT", 186, 197], ["sodium monensin", "TREATMENT", 206, 221], ["the Golgi function", "TEST", 239, 257]]], ["The matrix glycoprotein of the avian infectious bronchitis virus (IBV) and the porcine transmissible gastroenteritis virus (TGEV), unlike that of MHV and BCV, has N-linked complex oligosaccharides like those found on the peplomeric glycoproteins [3, 19, 37] .", [["infectious bronchitis virus", "DISEASE", 37, 64], ["transmissible gastroenteritis", "DISEASE", 87, 116], ["N", "CHEMICAL", 163, 164], ["matrix", "CELLULAR_COMPONENT", 4, 10], ["avian infectious bronchitis virus", "ORGANISM", 31, 64], ["IBV", "ORGANISM", 66, 69], ["porcine transmissible gastroenteritis virus", "ORGANISM", 79, 122], ["TGEV", "ORGANISM", 124, 128], ["MHV", "ORGANISM", 146, 149], ["BCV", "ORGANISM", 154, 157], ["matrix glycoprotein", "PROTEIN", 4, 23], ["peplomeric glycoproteins", "PROTEIN", 221, 245], ["avian infectious bronchitis virus", "SPECIES", 31, 64], ["porcine transmissible gastroenteritis virus", "SPECIES", 79, 122], ["infectious bronchitis virus", "SPECIES", 37, 64], ["IBV", "SPECIES", 66, 69], ["porcine transmissible gastroenteritis virus", "SPECIES", 79, 122], ["TGEV", "SPECIES", 124, 128], ["MHV", "SPECIES", 146, 149], ["BCV", "SPECIES", 154, 157], ["The matrix glycoprotein", "TREATMENT", 0, 23], ["the avian infectious bronchitis virus", "PROBLEM", 27, 64], ["the porcine transmissible gastroenteritis virus", "PROBLEM", 75, 122], ["N-linked complex oligosaccharides", "PROBLEM", 163, 196], ["infectious", "OBSERVATION_MODIFIER", 37, 47], ["bronchitis", "OBSERVATION", 48, 58], ["gastroenteritis virus", "OBSERVATION", 101, 122], ["BCV", "ANATOMY", 154, 157]]], ["Indeed, two potential N-glycosylated sites are available near the N-terminus of the sequence of the E 1 gene of both viruses [2, 19] .", [["N", "CHEMICAL", 22, 23], ["N", "CHEMICAL", 66, 67], ["E 1", "GENE_OR_GENE_PRODUCT", 100, 103], ["N-glycosylated sites", "DNA", 22, 42], ["N-terminus", "PROTEIN", 66, 76], ["E 1 gene", "DNA", 100, 108], ["potential N-glycosylated sites", "TREATMENT", 12, 42], ["both", "ANATOMY_MODIFIER", 112, 116], ["viruses", "OBSERVATION", 117, 124]]], ["The significance of this diversity of glycosylation patterns among coronaviruses is not known.IntroductionTurkey enteric coronavirus (TCV), a major etiological agent of epidemic diarrhea in turkey poults [5, 25] , possesses an hemagglutinating activity, surface projections of two different types, and biochemical characteristics that resemble those of mammalian hemagglutinating coronaviruses [4, 6, 17, 19] .", [["surface", "ANATOMY", 254, 261], ["enteric coronavirus (TCV)", "DISEASE", 113, 138], ["diarrhea", "DISEASE", 178, 186], ["5, 25]", "CHEMICAL", 205, 211], ["IntroductionTurkey enteric coronavirus", "ORGANISM", 94, 132], ["TCV", "ORGANISM", 134, 137], ["turkey poults", "ORGANISM", 190, 203], ["mammalian hemagglutinating coronaviruses", "ORGANISM", 353, 393], ["enteric coronavirus", "SPECIES", 113, 132], ["turkey poults", "SPECIES", 190, 203], ["TCV", "SPECIES", 134, 137], ["turkey", "SPECIES", 190, 196], ["glycosylation patterns among coronaviruses", "PROBLEM", 38, 80], ["epidemic diarrhea", "PROBLEM", 169, 186], ["an hemagglutinating activity", "PROBLEM", 224, 252], ["mammalian hemagglutinating coronaviruses", "PROBLEM", 353, 393], ["coronavirus", "OBSERVATION", 121, 132], ["hemagglutinating activity", "OBSERVATION", 227, 252], ["surface", "OBSERVATION_MODIFIER", 254, 261], ["two different", "OBSERVATION_MODIFIER", 277, 290], ["types", "OBSERVATION_MODIFIER", 291, 296]]], ["TCV isolates also can be propagated in HRT-18 cells, an established cell line originated from a human rectal adenocarcinoma [4, 7, 15, 17] .", [["HRT-18 cells", "ANATOMY", 39, 51], ["cell line", "ANATOMY", 68, 77], ["rectal adenocarcinoma", "ANATOMY", 102, 123], ["rectal adenocarcinoma", "DISEASE", 102, 123], ["TCV", "ORGANISM", 0, 3], ["HRT-18 cells", "CELL", 39, 51], ["cell line", "CELL", 68, 77], ["human", "ORGANISM", 96, 101], ["rectal adenocarcinoma", "CANCER", 102, 123], ["HRT-18 cells", "CELL_LINE", 39, 51], ["human", "SPECIES", 96, 101], ["TCV", "SPECIES", 0, 3], ["human", "SPECIES", 96, 101], ["TCV isolates", "TEST", 0, 12], ["HRT", "TEST", 39, 42], ["an established cell line", "TREATMENT", 53, 77], ["a human rectal adenocarcinoma", "PROBLEM", 94, 123], ["cell line", "OBSERVATION", 68, 77], ["rectal", "ANATOMY", 102, 108], ["adenocarcinoma", "OBSERVATION", 109, 123]]], ["In the present study, we have investigated the intracellular synthesis and post-translational modifications of virus-coded polypeptides in cultures of HRT-18 infected with TCV in the presence or the absence of glycosylation inhibitors.", [["intracellular", "ANATOMY", 47, 60], ["cultures", "ANATOMY", 139, 147], ["HRT-18", "CHEMICAL", 151, 157], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 47, 60], ["HRT-18", "CELL", 151, 157], ["TCV", "ORGANISM", 172, 175], ["TCV", "SPECIES", 172, 175], ["the present study", "TEST", 3, 20], ["the intracellular synthesis", "PROBLEM", 43, 70], ["post-translational modifications of virus", "PROBLEM", 75, 116], ["cultures", "TEST", 139, 147], ["HRT", "TEST", 151, 154], ["TCV", "PROBLEM", 172, 175], ["glycosylation inhibitors", "TREATMENT", 210, 234]]], ["Putative intracellular glycosylated and unglycosylated precursors have been identified for glycoproteins associated with both types of surface projections, and the matrix protein of T C V was f o u n d to be glycosylated by a process which was sensitive to tunicamycin, but resistant to sodium monensin.", [["intracellular", "ANATOMY", 9, 22], ["surface", "ANATOMY", 135, 142], ["tunicamycin", "CHEMICAL", 257, 268], ["sodium monensin", "CHEMICAL", 287, 302], ["tunicamycin", "CHEMICAL", 257, 268], ["sodium monensin", "CHEMICAL", 287, 302], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 9, 22], ["matrix", "CELLULAR_COMPONENT", 164, 170], ["T C V", "GENE_OR_GENE_PRODUCT", 182, 187], ["tunicamycin", "SIMPLE_CHEMICAL", 257, 268], ["sodium monensin", "SIMPLE_CHEMICAL", 287, 302], ["glycoproteins", "PROTEIN", 91, 104], ["matrix protein", "PROTEIN", 164, 178], ["T C V", "PROTEIN", 182, 187], ["Putative intracellular glycosylated", "TREATMENT", 0, 35], ["unglycosylated precursors", "TREATMENT", 40, 65], ["glycoproteins", "PROBLEM", 91, 104], ["the matrix protein", "TEST", 160, 178], ["T C V", "PROBLEM", 182, 187], ["tunicamycin", "TREATMENT", 257, 268], ["sodium monensin", "TREATMENT", 287, 302], ["intracellular glycosylated", "OBSERVATION", 9, 35], ["unglycosylated precursors", "OBSERVATION", 40, 65], ["surface", "OBSERVATION_MODIFIER", 135, 142]]], ["The effects of these glycosylation inhibitors on the viral morphogenesis was confirmed by electron microscopy of TCVinfected cells.", [["TCVinfected cells", "ANATOMY", 113, 130], ["TCVinfected cells", "CELL", 113, 130], ["TCVinfected cells", "CELL_LINE", 113, 130], ["these glycosylation inhibitors", "TREATMENT", 15, 45], ["the viral morphogenesis", "PROBLEM", 49, 72], ["electron microscopy", "TEST", 90, 109], ["TCVinfected cells", "PROBLEM", 113, 130], ["TCVinfected cells", "OBSERVATION", 113, 130]]], ["Glycosylation of the matrix protein was apparently not required for the formation of the TCV virions.Virus and cell culturesThe Minnesota strain [21 ] of TCV and virus stocks were obtained and propagated in HRT-18 cells, in the presence of trypsin, as previously described [-4, 7] .", [["virions", "ANATOMY", 93, 100], ["cell cultures", "ANATOMY", 111, 124], ["HRT-18 cells", "ANATOMY", 207, 219], ["matrix", "CELLULAR_COMPONENT", 21, 27], ["TCV", "ORGANISM", 89, 92], ["Virus", "ORGANISM", 101, 106], ["cell cultures", "CELL", 111, 124], ["TCV", "ORGANISM", 154, 157], ["HRT-18 cells", "CELL", 207, 219], ["trypsin", "GENE_OR_GENE_PRODUCT", 240, 247], ["matrix protein", "PROTEIN", 21, 35], ["cell cultures", "CELL_LINE", 111, 124], ["HRT-18 cells", "CELL_LINE", 207, 219], ["trypsin", "PROTEIN", 240, 247], ["TCV", "SPECIES", 154, 157], ["Glycosylation of the matrix protein", "TREATMENT", 0, 35], ["the TCV virions", "PROBLEM", 85, 100], ["Virus", "PROBLEM", 101, 106], ["cell cultures", "TEST", 111, 124], ["The Minnesota strain", "TREATMENT", 124, 144], ["TCV and virus stocks", "TREATMENT", 154, 174], ["HRT", "TEST", 207, 210], ["trypsin", "PROBLEM", 240, 247], ["TCV virions", "OBSERVATION", 89, 100], ["cell cultures", "OBSERVATION", 111, 124], ["trypsin", "OBSERVATION", 240, 247]]], ["After five successive passages, the virus was cloned twice by the limiting dilution method.", [["five successive passages", "TREATMENT", 6, 30], ["the virus", "PROBLEM", 32, 41], ["successive", "OBSERVATION_MODIFIER", 11, 21], ["passages", "OBSERVATION_MODIFIER", 22, 30]]], ["Cloned virus was passaged at a multiplicity of infection of 0.1 to 5 TCID 50 per cell.AntiserumThe origin of the rabbit anti-TCV hyperimmune serum was described previously [4] .Radioisotopic labeling of intracellular proteinsTo analyse intracellular synthesis of viral polypeptides, HRT-18 cells were infected at a multiplicity of 10 TCID 50/cell.", [["cell", "ANATOMY", 81, 85], ["serum", "ANATOMY", 141, 146], ["intracellular", "ANATOMY", 203, 216], ["intracellular", "ANATOMY", 236, 249], ["HRT-18 cells", "ANATOMY", 283, 295], ["cell", "ANATOMY", 342, 346], ["infection", "DISEASE", 47, 56], ["cell", "CELL", 81, 85], ["AntiserumThe", "SIMPLE_CHEMICAL", 86, 98], ["rabbit", "ORGANISM", 113, 119], ["hyperimmune", "ORGANISM", 129, 140], ["serum", "ORGANISM_SUBSTANCE", 141, 146], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 203, 216], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 236, 249], ["HRT-18 cells", "CELL", 283, 295], ["cell", "CELL", 342, 346], ["intracellular proteins", "PROTEIN", 203, 225], ["HRT-18 cells", "CELL_LINE", 283, 295], ["rabbit", "SPECIES", 113, 119], ["hyperimmune", "SPECIES", 129, 140], ["Cloned virus", "SPECIES", 0, 12], ["rabbit", "SPECIES", 113, 119], ["anti-TCV", "SPECIES", 120, 128], ["Cloned virus", "PROBLEM", 0, 12], ["infection", "PROBLEM", 47, 56], ["the rabbit anti-TCV hyperimmune serum", "TEST", 109, 146], ["intracellular proteins", "PROBLEM", 203, 225], ["intracellular synthesis", "TEST", 236, 259], ["viral polypeptides", "PROBLEM", 263, 281], ["HRT", "TEST", 283, 286], ["virus", "OBSERVATION", 7, 12], ["infection", "OBSERVATION", 47, 56], ["intracellular proteins", "OBSERVATION", 203, 225]]], ["At given times, indicated in Results and figure legends, the maintenance medium was replaced by medium without methionine.", [["methionine", "CHEMICAL", 111, 121], ["methionine", "CHEMICAL", 111, 121], ["methionine", "SIMPLE_CHEMICAL", 111, 121], ["the maintenance medium", "TREATMENT", 57, 79], ["methionine", "TREATMENT", 111, 121]]], ["After 30 min of methionine starvation, the cells were pulse-labeled for 30 min by the addition of 1 ml/flask of methionine-free RPMI containing 50gCi/ml [35S]methionine.", [["cells", "ANATOMY", 43, 48], ["methionine", "CHEMICAL", 16, 26], ["methionine", "CHEMICAL", 112, 122], ["[35S]methionine", "CHEMICAL", 153, 168], ["methionine", "CHEMICAL", 16, 26], ["methionine", "CHEMICAL", 112, 122], ["[35S]methionine", "CHEMICAL", 153, 168], ["methionine", "SIMPLE_CHEMICAL", 16, 26], ["cells", "CELL", 43, 48], ["methionine", "SIMPLE_CHEMICAL", 112, 122], ["[35S]methionine", "SIMPLE_CHEMICAL", 153, 168], ["methionine starvation", "TREATMENT", 16, 37], ["methionine-free RPMI", "TREATMENT", 112, 132], ["methionine", "TREATMENT", 158, 168]]], ["Replicate cultures were chased for 1 hour by replacing pulse-medium with complete RPMI containing 5% FBS and then harvested in ice-cold PBS.", [["FBS", "ANATOMY", 101, 104], ["FBS", "ORGANISM_SUBSTANCE", 101, 104], ["Replicate cultures", "TEST", 0, 18], ["complete RPMI", "TREATMENT", 73, 86], ["5% FBS", "TREATMENT", 98, 104]]], ["In experiments where tunicamycin (0.01 to 10.0 gg/ ml) or sodium monensin (0.5 to 5 gM) was used, the inhibitor was added at the beginning of the starvation period and was present throughout the rest of the experiment.Radioisotopic labeling of intracellular proteinsFor pulse-chase labeling of intracellular polypeptides, the infected cells were starved for methionine for 30min and then labeled by adding 50 ~tCi/ml of [35S]methionine to methionine-free medium, beginning at 6 to 9 hours p.i. for different experiments.", [["intracellular", "ANATOMY", 244, 257], ["intracellular", "ANATOMY", 294, 307], ["cells", "ANATOMY", 335, 340], ["tunicamycin", "CHEMICAL", 21, 32], ["sodium monensin", "CHEMICAL", 58, 73], ["methionine", "CHEMICAL", 358, 368], ["[35S]methionine", "CHEMICAL", 420, 435], ["methionine", "CHEMICAL", 439, 449], ["tunicamycin", "CHEMICAL", 21, 32], ["sodium monensin", "CHEMICAL", 58, 73], ["methionine", "CHEMICAL", 358, 368], ["[35S]methionine", "CHEMICAL", 420, 435], ["methionine", "CHEMICAL", 439, 449], ["tunicamycin", "SIMPLE_CHEMICAL", 21, 32], ["sodium monensin", "SIMPLE_CHEMICAL", 58, 73], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 244, 257], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 294, 307], ["cells", "CELL", 335, 340], ["methionine", "SIMPLE_CHEMICAL", 358, 368], ["[35S]methionine", "SIMPLE_CHEMICAL", 420, 435], ["methionine", "SIMPLE_CHEMICAL", 439, 449], ["intracellular proteins", "PROTEIN", 244, 266], ["infected cells", "CELL_TYPE", 326, 340], ["tunicamycin", "TREATMENT", 21, 32], ["sodium monensin", "TREATMENT", 58, 73], ["the inhibitor", "TREATMENT", 98, 111], ["intracellular polypeptides", "TREATMENT", 294, 320], ["the infected cells", "PROBLEM", 322, 340], ["methionine", "TREATMENT", 358, 368], ["methionine", "TREATMENT", 425, 435], ["methionine-free medium", "TREATMENT", 439, 461], ["infected cells", "OBSERVATION", 326, 340]]], ["After a 30 min pulse period, the cells were rinsed twice in complete RPMI and then further incubated with this medium for 15 rain to 4 h before harvesting.", [["cells", "ANATOMY", 33, 38], ["cells", "CELL", 33, 38], ["the cells", "PROBLEM", 29, 38], ["this medium", "TREATMENT", 106, 117]]], ["The cell sheets were rinsed twice in PBS, and scraped into ice-cold lysis buffer (RIPA) made of 20 mM Tris-HC1, pH 6.8, 150 mM NaC1, 1 mM EDTA, 0.6M KC1, 0.5mM MgC12, 1% Triton X-100, 0.1% SDS, 1% NP40, 103 units aprotinin/ml and 200gg PMSF/ml.", [["cell sheets", "ANATOMY", 4, 15], ["NaC1", "CHEMICAL", 127, 131], ["MgC12", "CHEMICAL", 160, 165], ["Triton X-100", "CHEMICAL", 170, 182], ["Tris-HC1", "CHEMICAL", 102, 110], ["NaC1", "CHEMICAL", 127, 131], ["EDTA", "CHEMICAL", 138, 142], ["MgC12", "CHEMICAL", 160, 165], ["NP40", "CHEMICAL", 197, 201], ["PMSF", "CHEMICAL", 236, 240], ["cell sheets", "CELL", 4, 15], ["Tris-HC1", "SIMPLE_CHEMICAL", 102, 110], ["NaC1", "SIMPLE_CHEMICAL", 127, 131], ["EDTA", "SIMPLE_CHEMICAL", 138, 142], ["KC1", "SIMPLE_CHEMICAL", 149, 152], ["MgC12", "SIMPLE_CHEMICAL", 160, 165], ["Triton X-100", "SIMPLE_CHEMICAL", 170, 182], ["NP40", "SIMPLE_CHEMICAL", 197, 201], ["aprotinin", "GENE_OR_GENE_PRODUCT", 213, 222], ["The cell sheets", "TREATMENT", 0, 15], ["cold lysis buffer", "TREATMENT", 63, 80], ["Tris", "TEST", 102, 106], ["pH", "TEST", 112, 114], ["NaC1", "TEST", 127, 131], ["EDTA", "TEST", 138, 142], ["KC1", "TEST", 149, 152], ["MgC12", "TEST", 160, 165], ["cell sheets", "OBSERVATION", 4, 15]]], ["The cell lysate was immediately passed 10 times through a 26-Gauge syringe needle, heated to 100 \u00b0C for 3 rain, clarified by centrifugation at 15,000 x g for 20min, and stored at --70\u00b0C. Uninfected HRT-18 cells were similarly radiolabeled, and mock lysates were prepared as control samples.ImmunoprecipitationThe immunoprecipitation assays were performed according to Deregt et al. [9] .", [["cell lysate", "ANATOMY", 4, 15], ["HRT-18 cells", "ANATOMY", 198, 210], ["lysates", "ANATOMY", 249, 256], ["samples", "ANATOMY", 282, 289], ["cell lysate", "CELL", 4, 15], ["HRT-18 cells", "CELL", 198, 210], ["lysates", "ORGANISM_SUBSTANCE", 249, 256], ["HRT-18 cells", "CELL_LINE", 198, 210], ["The cell lysate", "TREATMENT", 0, 15], ["a 26-Gauge syringe needle", "TREATMENT", 56, 81], ["Uninfected HRT", "TEST", 187, 201], ["mock lysates", "TEST", 244, 256], ["Immunoprecipitation", "TEST", 290, 309], ["The immunoprecipitation assays", "TEST", 309, 339], ["cell lysate", "OBSERVATION", 4, 15], ["18 cells", "OBSERVATION_MODIFIER", 202, 210]]], ["Briefly, samples of 50 to 100 gl of clarified radiolabeled cytosol extracts (1 \u00d7 10 6 c.p.m.) were mixed with the anti-TCV serum bound to protein A-Sepharose and incubated for 2 h at 37 \u00b0CWestern immunoblottingReplicas were prepared by electrophoresis transfer of proteins separated by SDS-PAGE to nitrocellulose sheets (0.45 ~tm pore size, Schteicher et Sch/ill) as previously described [6] .", [["samples", "ANATOMY", 9, 16], ["cytosol extracts", "ANATOMY", 59, 75], ["serum", "ANATOMY", 123, 128], ["SDS-PAGE", "CHEMICAL", 286, 294], ["nitrocellulose", "CHEMICAL", 298, 312], ["cytosol extracts", "ORGANISM_SUBSTANCE", 59, 75], ["anti-TCV", "ORGANISM", 114, 122], ["serum", "ORGANISM_SUBSTANCE", 123, 128], ["A-Sepharose", "GENE_OR_GENE_PRODUCT", 146, 157], ["protein A-Sepharose", "PROTEIN", 138, 157], ["anti-TCV", "SPECIES", 114, 122], ["samples", "TEST", 9, 16], ["radiolabeled cytosol extracts", "TEST", 46, 75], ["the anti-TCV serum bound", "PROBLEM", 110, 134], ["protein A-Sepharose", "TEST", 138, 157], ["CWestern immunoblottingReplicas", "TREATMENT", 187, 218], ["nitrocellulose sheets", "TREATMENT", 298, 319], ["Schteicher et Sch/ill", "TREATMENT", 341, 362]]], ["After saturation with bovine serum albumin (grade V), the nitrocellulose sheets were incubated for 2 h at room temperature in rabbit hyperimmune sera diluted 1:500 in TBS with 0.05% (V/V) Tween 20 (TBS-T).", [["serum", "ANATOMY", 29, 34], ["sera", "ANATOMY", 145, 149], ["nitrocellulose", "CHEMICAL", 58, 72], ["Tween 20", "CHEMICAL", 188, 196], ["bovine", "ORGANISM", 22, 28], ["serum", "ORGANISM_SUBSTANCE", 29, 34], ["albumin", "ORGANISM_SUBSTANCE", 35, 42], ["rabbit", "ORGANISM", 126, 132], ["hyperimmune", "ORGANISM", 133, 144], ["sera", "ORGANISM_SUBSTANCE", 145, 149], ["bovine", "SPECIES", 22, 28], ["rabbit", "SPECIES", 126, 132], ["bovine", "SPECIES", 22, 28], ["rabbit", "SPECIES", 126, 132], ["saturation", "TEST", 6, 16], ["bovine serum albumin", "TEST", 22, 42], ["the nitrocellulose sheets", "TREATMENT", 54, 79], ["TBS", "TEST", 167, 170]]], ["The nitrocellulose sheets were subsequently washed 3 times for 10 min in TBS-T, and then incubated with 1 : 1000 dilution of peroxidase-labeled goat anti-rabbit IgG (Boehringer-Mannheim) in TBS-T for 90 rain.", [["nitrocellulose", "CHEMICAL", 4, 18], ["peroxidase", "GENE_OR_GENE_PRODUCT", 125, 135], ["goat", "ORGANISM", 144, 148], ["TBS-T", "CELL", 190, 195], ["peroxidase", "PROTEIN", 125, 135], ["goat anti-rabbit IgG", "PROTEIN", 144, 164], ["goat", "SPECIES", 144, 148], ["anti-rabbit", "SPECIES", 149, 160], ["goat", "SPECIES", 144, 148], ["The nitrocellulose sheets", "TREATMENT", 0, 25], ["peroxidase-labeled goat anti-rabbit IgG", "TREATMENT", 125, 164]]], ["After washing, blots were developed by reaction for 30 to 45min with 0.05% 4-chloro-l-naphthol (Sigma) substrate, prepared in TBS containing 20% (V/V) methanol.Polyacrylamide gel electrophoresisSamples were mixed with equal volumes of double strength sample buffer with or without 2-mercaptoethanol, boiled for 3 min, and clarified at 10,000 x g for 15 min before electrophoresis in 8.5 or 10 percent SDS-polyacrylamide slab gels, as previously described [6] .", [["4-chloro-l-naphthol", "CHEMICAL", 75, 94], ["2-mercaptoethanol", "CHEMICAL", 281, 298], ["4-chloro-l-naphthol", "CHEMICAL", 75, 94], ["methanol", "CHEMICAL", 151, 159], ["2-mercaptoethanol", "CHEMICAL", 281, 298], ["SDS", "CHEMICAL", 401, 404], ["polyacrylamide", "CHEMICAL", 405, 419], ["4-chloro-l-naphthol", "SIMPLE_CHEMICAL", 75, 94], ["Sigma) substrate", "SIMPLE_CHEMICAL", 96, 112], ["Polyacrylamide", "SIMPLE_CHEMICAL", 160, 174], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 281, 298], ["blots", "TEST", 15, 20], ["chloro-l-naphthol (Sigma) substrate", "TREATMENT", 77, 112], ["methanol", "TREATMENT", 151, 159], ["Polyacrylamide gel electrophoresisSamples", "TREATMENT", 160, 201], ["double strength sample buffer", "TREATMENT", 235, 264], ["mercaptoethanol", "TREATMENT", 283, 298], ["electrophoresis", "TEST", 364, 379], ["polyacrylamide slab gels", "TREATMENT", 405, 429]]], ["High and low molecular weight marker proteins or 14C-methylated marker proteins were run on each gel to allow molecular weight estimates of viral proteins.", [["14C", "CHEMICAL", 49, 52], ["14C", "SIMPLE_CHEMICAL", 49, 52], ["low molecular weight marker proteins", "PROTEIN", 9, 45], ["14C-methylated marker proteins", "PROTEIN", 49, 79], ["viral proteins", "PROTEIN", 140, 154], ["High and low molecular weight marker proteins", "PROBLEM", 0, 45], ["methylated marker proteins", "TREATMENT", 53, 79], ["each gel", "TREATMENT", 92, 100], ["viral proteins", "PROBLEM", 140, 154], ["low molecular", "OBSERVATION_MODIFIER", 9, 22], ["viral proteins", "OBSERVATION", 140, 154]]], ["Gels were analyzed by autoradiography or fluorography after \"Amplify\" (Amersham) treatment.", [["Gels", "SIMPLE_CHEMICAL", 0, 4], ["fluorography", "TEST", 41, 53], ["Amplify\" (Amersham) treatment", "TREATMENT", 61, 90]]], ["Dried gels were exposed to Kodak X-OMAT RP films at --70 \u00b0C.Electron microscopyEM of infected cells, cultivated in the presence of tunicamycin or sodium monensin, was done by fixation with 2.5% glutaraldehyde followed by post-fixation with 1% osmium tetroxide, dehydration in graded ethanol and embedding in Epoxy 512, as previously described [7] .", [["cells", "ANATOMY", 94, 99], ["tunicamycin", "CHEMICAL", 131, 142], ["sodium monensin", "CHEMICAL", 146, 161], ["glutaraldehyde", "CHEMICAL", 194, 208], ["osmium tetroxide", "CHEMICAL", 243, 259], ["dehydration", "DISEASE", 261, 272], ["ethanol", "CHEMICAL", 283, 290], ["Epoxy 512", "CHEMICAL", 308, 317], ["tunicamycin", "CHEMICAL", 131, 142], ["sodium monensin", "CHEMICAL", 146, 161], ["glutaraldehyde", "CHEMICAL", 194, 208], ["osmium tetroxide", "CHEMICAL", 243, 259], ["ethanol", "CHEMICAL", 283, 290], ["cells", "CELL", 94, 99], ["tunicamycin", "SIMPLE_CHEMICAL", 131, 142], ["sodium monensin", "SIMPLE_CHEMICAL", 146, 161], ["glutaraldehyde", "SIMPLE_CHEMICAL", 194, 208], ["osmium tetroxide", "SIMPLE_CHEMICAL", 243, 259], ["ethanol", "SIMPLE_CHEMICAL", 283, 290], ["infected cells", "CELL_TYPE", 85, 99], ["RP films", "TEST", 40, 48], ["infected cells", "PROBLEM", 85, 99], ["tunicamycin", "TREATMENT", 131, 142], ["sodium monensin", "TREATMENT", 146, 161], ["fixation", "TREATMENT", 175, 183], ["2.5% glutaraldehyde", "TREATMENT", 189, 208], ["1% osmium tetroxide", "TREATMENT", 240, 259], ["dehydration", "PROBLEM", 261, 272], ["infected cells", "OBSERVATION", 85, 99]]], ["Thin sections were stained with lead-citrate and uranyl acetate [11] and examined on a EM 300 Philips microscope.Chemicals and isotopesTunicamycin (TM), sodium monensin (SM), phenylmethylsulfonyl fluoride (PMSF), aprotinin were purchased from Boehringer-Mannheim Canada Ltd., Dorval, Quebec.", [["Thin sections", "ANATOMY", 0, 13], ["lead-citrate", "CHEMICAL", 32, 44], ["uranyl acetate", "CHEMICAL", 49, 63], ["Tunicamycin", "CHEMICAL", 135, 146], ["sodium monensin", "CHEMICAL", 153, 168], ["SM", "CHEMICAL", 170, 172], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 175, 204], ["PMSF", "CHEMICAL", 206, 210], ["citrate", "CHEMICAL", 37, 44], ["uranyl acetate", "CHEMICAL", 49, 63], ["Tunicamycin", "CHEMICAL", 135, 146], ["sodium monensin", "CHEMICAL", 153, 168], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 175, 204], ["PMSF", "CHEMICAL", 206, 210], ["aprotinin", "CHEMICAL", 213, 222], ["Thin sections", "CANCER", 0, 13], ["lead-citrate", "SIMPLE_CHEMICAL", 32, 44], ["uranyl acetate", "SIMPLE_CHEMICAL", 49, 63], ["Tunicamycin", "SIMPLE_CHEMICAL", 135, 146], ["TM", "SIMPLE_CHEMICAL", 148, 150], ["sodium monensin", "SIMPLE_CHEMICAL", 153, 168], ["SM", "SIMPLE_CHEMICAL", 170, 172], ["phenylmethylsulfonyl fluoride", "SIMPLE_CHEMICAL", 175, 204], ["PMSF", "SIMPLE_CHEMICAL", 206, 210], ["aprotinin", "SIMPLE_CHEMICAL", 213, 222], ["Thin sections", "TEST", 0, 13], ["lead-citrate and uranyl acetate", "TREATMENT", 32, 63], ["isotopesTunicamycin (TM)", "TREATMENT", 127, 151], ["sodium monensin (SM), phenylmethylsulfonyl fluoride (PMSF", "TREATMENT", 153, 210], ["aprotinin", "TREATMENT", 213, 222]]], ["Stock solutions of TM (2mg/ml) and sodium monensin (1,000gM) were prepared in dimethylsulfoxide and in methanol, respectively.", [["TM", "CHEMICAL", 19, 21], ["sodium monensin", "CHEMICAL", 35, 50], ["1,000gM", "CHEMICAL", 52, 59], ["dimethylsulfoxide", "CHEMICAL", 78, 95], ["sodium monensin", "CHEMICAL", 35, 50], ["dimethylsulfoxide", "CHEMICAL", 78, 95], ["methanol", "CHEMICAL", 103, 111], ["sodium monensin", "SIMPLE_CHEMICAL", 35, 50], ["dimethylsulfoxide", "SIMPLE_CHEMICAL", 78, 95], ["methanol", "SIMPLE_CHEMICAL", 103, 111], ["TM", "TREATMENT", 19, 21], ["sodium monensin", "TREATMENT", 35, 50], ["dimethylsulfoxide", "TREATMENT", 78, 95]]], ["These inhibitors were also purchased from Calbiochem, La Jolta, CA.", [["These inhibitors", "TREATMENT", 0, 16], ["La Jolta", "ANATOMY", 54, 62], ["CA", "OBSERVATION", 64, 66]]], ["Bovine pancreatic trypsin (TPCK treated, 12,300 units/mg) and 4chloro-l-naphthol were purchased from Sigma Chemical Co, St. Louis, MO.", [["pancreatic", "ANATOMY", 7, 17], ["TPCK", "CHEMICAL", 27, 31], ["4chloro-l-naphthol", "CHEMICAL", 62, 80], ["4chloro-l-naphthol", "CHEMICAL", 62, 80], ["Bovine", "ORGANISM", 0, 6], ["pancreatic trypsin", "GENE_OR_GENE_PRODUCT", 7, 25], ["TPCK", "SIMPLE_CHEMICAL", 27, 31], ["4chloro-l-naphthol", "SIMPLE_CHEMICAL", 62, 80], ["St. Louis", "ORGANISM", 120, 129], ["Bovine pancreatic trypsin", "PROTEIN", 0, 25], ["Bovine", "SPECIES", 0, 6], ["Bovine", "SPECIES", 0, 6], ["Bovine pancreatic trypsin (TPCK", "TREATMENT", 0, 31], ["4chloro", "TREATMENT", 62, 69], ["naphthol", "TREATMENT", 72, 80], ["pancreatic", "ANATOMY", 7, 17]]], ["Reagents for SDS-PAGE were purchased from BIO-RAD Laboratories, Richmond, CA.", [["SDS", "TEST", 13, 16]]], ["Protein A Sepharose CL-4B and molecular weight marker proteins were purchased from Pharmacia, Uppsala, Sweden.", [["CL-4B", "GENE_OR_GENE_PRODUCT", 20, 25], ["Sepharose CL-4B and molecular weight marker proteins", "PROTEIN", 10, 62], ["Protein", "TEST", 0, 7], ["A Sepharose CL", "TEST", 8, 22], ["molecular weight marker proteins", "TEST", 30, 62]]], ["L-[35S]methionine (1,120 Ci/mmole) and a mixture of 14C-methylated marker proteins were purchasesd from Amersham Searle Co., Oakville, Ontario.", [["L-[35S]methionine", "CHEMICAL", 0, 17], ["14C", "CHEMICAL", 52, 55], ["L-[35S]methionine", "CHEMICAL", 0, 17], ["14C", "CHEMICAL", 52, 55], ["L-[35S]methionine", "SIMPLE_CHEMICAL", 0, 17], ["14C", "SIMPLE_CHEMICAL", 52, 55], ["14C-methylated marker proteins", "PROTEIN", 52, 82], ["methionine", "TREATMENT", 7, 17], ["a mixture", "TREATMENT", 39, 48], ["methylated marker proteins", "TREATMENT", 56, 82]]], ["D-[6-3H]glucosamine hydrochloride (2%20 Ci/mmole) was purchased from ICN Biochemical Canada Ltd, Montreal, Quebec.Intracellular protein synthesisPulse labeling of cells with [35S]methionine at different times after infection, followed by S D S -P A G E was used to resolve and to identify polypeptides designated as specific to TCV-infected HRT-18 cell cultures (Fig. 1A) .", [["Intracellular", "ANATOMY", 114, 127], ["cells", "ANATOMY", 163, 168], ["HRT-18 cell cultures", "ANATOMY", 341, 361], ["D-[6-3H]glucosamine hydrochloride", "CHEMICAL", 0, 33], ["2%20 Ci/mmole", "CHEMICAL", 35, 48], ["[35S]methionine", "CHEMICAL", 174, 189], ["infection", "DISEASE", 215, 224], ["D-[6-3H]glucosamine hydrochloride", "CHEMICAL", 0, 33], ["mmole", "CHEMICAL", 43, 48], ["[35S]methionine", "CHEMICAL", 174, 189], ["D-[6-3H]glucosamine hydrochloride", "SIMPLE_CHEMICAL", 0, 33], ["2%20 Ci/mmole", "SIMPLE_CHEMICAL", 35, 48], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["cells", "CELL", 163, 168], ["[35S]methionine", "SIMPLE_CHEMICAL", 174, 189], ["TCV", "ORGANISM", 328, 331], ["HRT-18 cell cultures", "CELL", 341, 361], ["Fig. 1A", "CELL", 363, 370], ["TCV-infected HRT-18 cell cultures", "CELL_LINE", 328, 361], ["glucosamine hydrochloride", "TREATMENT", 8, 33], ["Intracellular protein synthesis", "PROBLEM", 114, 145], ["Pulse labeling of cells", "PROBLEM", 145, 168], ["methionine", "TREATMENT", 179, 189], ["infection", "PROBLEM", 215, 224], ["A G E", "TREATMENT", 247, 252], ["TCV", "TEST", 328, 331], ["infected HRT", "TEST", 332, 344], ["cell cultures", "TEST", 348, 361], ["protein synthesis", "OBSERVATION", 128, 145], ["infection", "OBSERVATION", 215, 224]]], ["Late in infection, it was possible to detect the synthesis of four major TCV-induced polypeptides with apparent mol.wt, of 140,000, 100,000, 52,000, and 24,000 which were not present in mock-infected control cultures (lane M).", [["cultures", "ANATOMY", 208, 216], ["infection", "DISEASE", 8, 17], ["TCV", "ORGANISM", 73, 76], ["mol.wt", "GENE_OR_GENE_PRODUCT", 112, 118], ["mock-infected control cultures", "CELL_LINE", 186, 216], ["Late in infection", "PROBLEM", 0, 17], ["infection", "OBSERVATION", 8, 17]]], ["The 170,000 minor polypeptide was reproducibly resolved as a doublet.", [["a doublet", "TREATMENT", 59, 68], ["reproducibly", "OBSERVATION_MODIFIER", 34, 46], ["resolved", "OBSERVATION_MODIFIER", 47, 55]]], ["The predominant 52,000 nucleoprotein could be detected as soon as 6 to 8 hours post-infection and was initially resolved as a group of 3 closely migrating bands; the two other polypeptides migrated with estimated mol.wt, of 46,000 and 48,000, respectively.", [["3 closely migrating bands", "PROBLEM", 135, 160], ["the two other polypeptides", "TREATMENT", 162, 188], ["wt", "TEST", 217, 219]]], ["By 12 hours, all four major TCVinduced polypeptides were present; they persisted until virus and host cell protein synthesis was reduced due to extensive cytopathic changes (between 48 and 72 hours post-infection).", [["cell", "ANATOMY", 102, 106], ["infection", "DISEASE", 203, 212], ["host cell", "CELL", 97, 106], ["all four major TCVinduced polypeptides", "PROBLEM", 13, 51], ["virus", "PROBLEM", 87, 92], ["host cell protein synthesis", "TEST", 97, 124], ["extensive cytopathic changes", "PROBLEM", 144, 172], ["infection", "PROBLEM", 203, 212], ["extensive", "OBSERVATION_MODIFIER", 144, 153], ["cytopathic", "OBSERVATION", 154, 164], ["infection", "OBSERVATION", 203, 212]]], ["Between 12 and 24 hours, all polypeptides appeared to be synthesized at a relatively constant rate, without any apparent shut-off of host cell protein synthesis.", [["cell", "ANATOMY", 138, 142], ["cell", "CELL", 138, 142], ["all polypeptides", "PROBLEM", 25, 41], ["host cell protein synthesis", "TREATMENT", 133, 160], ["host cell protein synthesis", "OBSERVATION", 133, 160]]], ["The four major intracellular polypeptide species comigrated with the viral polypeptides (lane V), as well as the 200,000 and the 36-38,000 polypeptide species.", [["intracellular", "ANATOMY", 15, 28], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 28], ["lane V", "GENE_OR_GENE_PRODUCT", 89, 95], ["intracellular polypeptide species", "PROTEIN", 15, 48], ["viral polypeptides", "PROTEIN", 69, 87], ["lane V", "PROTEIN", 89, 95], ["The four major intracellular polypeptide species", "PROBLEM", 0, 48], ["the viral polypeptides", "PROBLEM", 65, 87], ["polypeptide species", "OBSERVATION", 29, 48], ["viral polypeptides", "OBSERVATION", 69, 87]]], ["The latter co-migrated also with a polypeptide having similar mol.wt, which also was present in mock-infected cells.", [["cells", "ANATOMY", 110, 115], ["cells", "CELL", 110, 115], ["mock-infected cells", "CELL_LINE", 96, 115], ["wt", "TEST", 66, 68], ["infected cells", "PROBLEM", 101, 115], ["infected cells", "OBSERVATION", 101, 115]]], ["All these polypeptides, as well as the 2 species that closely migrated with the nucleocapsid protein, were revealed by Western-immunoblotting using the anti-TCV rabbit hyperimmune serum (Fig. 1 C) .", [["serum", "ANATOMY", 180, 185], ["rabbit", "ORGANISM", 161, 167], ["hyperimmune", "ORGANISM", 168, 179], ["serum", "ORGANISM_SUBSTANCE", 180, 185], ["nucleocapsid protein", "PROTEIN", 80, 100], ["rabbit", "SPECIES", 161, 167], ["anti-TCV", "SPECIES", 152, 160], ["rabbit", "SPECIES", 161, 167], ["the 2 species", "PROBLEM", 35, 48], ["the nucleocapsid protein", "TEST", 76, 100], ["the anti-TCV rabbit hyperimmune serum", "TREATMENT", 148, 185], ["polypeptides", "OBSERVATION", 10, 22]]], ["The 30-32,000 polypeptide was not revealed by the antiserum and may represent a non-structural polypeptide.Intracellular protein synthesisUnder reducing conditions ( Fig. 1 B) , the major 140,000 intracellular polypeptide was not present, but replaced by another major component with mol.wt. of approximately 60-65,000.", [["Intracellular", "ANATOMY", 107, 120], ["intracellular", "ANATOMY", 196, 209], ["antiserum", "ORGANISM_SUBSTANCE", 50, 59], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 107, 120], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 196, 209], ["The 30-32,000 polypeptide", "TEST", 0, 25], ["a non-structural polypeptide", "TREATMENT", 78, 106], ["Intracellular protein synthesisUnder reducing conditions", "PROBLEM", 107, 163], ["wt", "TEST", 288, 290], ["may represent", "UNCERTAINTY", 64, 77], ["non-structural polypeptide", "OBSERVATION", 80, 106], ["protein synthesisUnder", "OBSERVATION", 121, 143]]], ["The intracellular polypeptide corresponding to the viral matrix protein was usually resolved as a doublet (22,000 and 24,000).Intracellular processing of TCV glycoproteinsTo investigate the intracellular processing of the viral structural proteins, TCVinfected and mock-infected HRT-18 cells were pulse-labeled from 6 to 12 hours after infection for 30 min with [35S]methionine, and the label was chased for various times.", [["intracellular", "ANATOMY", 4, 17], ["Intracellular", "ANATOMY", 126, 139], ["intracellular", "ANATOMY", 190, 203], ["HRT-18 cells", "ANATOMY", 279, 291], ["infection", "DISEASE", 336, 345], ["[35S]methionine", "CHEMICAL", 362, 377], ["[35S]methionine", "CHEMICAL", 362, 377], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["matrix", "CELLULAR_COMPONENT", 57, 63], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 126, 139], ["TCV", "ORGANISM", 154, 157], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 190, 203], ["HRT-18 cells", "CELL", 279, 291], ["[35S]methionine", "SIMPLE_CHEMICAL", 362, 377], ["viral matrix protein", "PROTEIN", 51, 71], ["TCV glycoproteins", "PROTEIN", 154, 171], ["viral structural proteins", "PROTEIN", 222, 247], ["TCVinfected and mock-infected HRT-18 cells", "CELL_LINE", 249, 291], ["The intracellular polypeptide", "PROBLEM", 0, 29], ["the viral matrix protein", "TEST", 47, 71], ["Intracellular processing of TCV glycoproteins", "PROBLEM", 126, 171], ["the viral structural proteins", "PROBLEM", 218, 247], ["infected HRT", "TEST", 270, 282], ["pulse", "TEST", 297, 302], ["infection", "PROBLEM", 336, 345], ["35S]methionine", "TREATMENT", 363, 377], ["viral", "OBSERVATION_MODIFIER", 51, 56], ["matrix protein", "OBSERVATION", 57, 71], ["TCV glycoproteins", "OBSERVATION", 154, 171]]], ["Polypeptides specific to TCV-infected cell cultures were then immunoprecipitated with the rabbit anti-TCV hyperimmune serum, and the precipitates were analyzed by SDS-PAGE.", [["cell cultures", "ANATOMY", 38, 51], ["serum", "ANATOMY", 118, 123], ["TCV", "ORGANISM", 25, 28], ["cell cultures", "CELL", 38, 51], ["rabbit", "ORGANISM", 90, 96], ["hyperimmune", "ORGANISM", 106, 117], ["serum", "ORGANISM_SUBSTANCE", 118, 123], ["TCV-infected cell cultures", "CELL_LINE", 25, 51], ["rabbit", "SPECIES", 90, 96], ["hyperimmune", "SPECIES", 106, 117], ["TCV", "SPECIES", 25, 28], ["rabbit", "SPECIES", 90, 96], ["anti-TCV", "SPECIES", 97, 105], ["Polypeptides", "TREATMENT", 0, 12], ["TCV", "TEST", 25, 28], ["infected cell cultures", "PROBLEM", 29, 51], ["the rabbit anti-TCV hyperimmune serum", "TEST", 86, 123], ["infected cell cultures", "OBSERVATION", 29, 51]]], ["As shown in Fig. 2 , pulse-chase experiments conducted at 7 and 8 hours after infection permitted the identification of new immunoprecipitable protein species with mol.wts, of approximately 150,000 to 170,000, 120,000, 90,000, 62,000, and 22-24,000.", [["infection", "DISEASE", 78, 87], ["immunoprecipitable protein species", "PROTEIN", 124, 158], ["infection", "PROBLEM", 78, 87], ["new immunoprecipitable protein species", "PROBLEM", 120, 158], ["mol.wts", "TEST", 164, 171], ["new", "OBSERVATION_MODIFIER", 120, 123], ["immunoprecipitable protein species", "OBSERVATION", 124, 158]]], ["No processing of the major p52 nucleocapsid protein was apparent during the 4 hourchase period, but significant variation was noted in the intensity of the 200,000, 140,000, and 100,000 protein bands.", [["p52", "GENE_OR_GENE_PRODUCT", 27, 30], ["p52 nucleocapsid protein", "PROTEIN", 27, 51], ["the major p52 nucleocapsid protein", "TEST", 17, 51], ["significant variation", "PROBLEM", 100, 121], ["protein bands", "TEST", 186, 199], ["nucleocapsid protein", "OBSERVATION", 31, 51], ["significant", "OBSERVATION_MODIFIER", 100, 111], ["variation", "OBSERVATION_MODIFIER", 112, 121]]], ["The 62,000 mol.wt, species was present during the first hour of the chase period and then disappeared from the gel, concomitant with the appearance of a weak band corresponding to a polypeptide with an approximative mol.wt, of 130,000, which later seemed to be converted into the gp 140 species.", [["gp 140 species", "PROTEIN", 280, 294], ["a weak band", "PROBLEM", 151, 162], ["a polypeptide", "TREATMENT", 180, 193], ["wt", "TEST", 220, 222]]], ["The 90,000 mol.wt, species, present since the beginning of the chase period, was progressively chased to give the final gp 100 species.", [["gp 100 species", "PROTEIN", 120, 134]]], ["The 120,000 protein species was also present from the beginning of the chase period and increased in intensity without any apparent change in its electrophoretic mobility.", [["120,000 protein species", "PROTEIN", 4, 27], ["The 120,000 protein species", "TEST", 0, 27], ["any apparent change in its electrophoretic mobility", "PROBLEM", 119, 170], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["apparent", "OBSERVATION_MODIFIER", 123, 131], ["change", "OBSERVATION_MODIFIER", 132, 138], ["electrophoretic mobility", "OBSERVATION", 146, 170]]], ["The 200,000 protein band intensified as the infection progressed, concomitant with an increase in the intensity of gp 100 and the 120,000 mol.wt, species.", [["infection", "DISEASE", 44, 53], ["gp 100", "PROTEIN", 115, 121], ["The 200,000 protein band", "TREATMENT", 0, 24], ["the infection", "PROBLEM", 40, 53], ["infection", "OBSERVATION", 44, 53], ["increase", "OBSERVATION_MODIFIER", 86, 94]]], ["The higher mol.wt. polypeptide disappeared later during the infection.Intracellular processing of TCV glycoproteinsProcessing seemed also to occurred among lower mol.wt, proteins.", [["Intracellular", "ANATOMY", 70, 83], ["infection", "DISEASE", 60, 69], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 70, 83], ["TCV", "ORGANISM", 98, 101], ["TCV glycoproteins", "PROTEIN", 98, 115], ["wt", "TEST", 15, 17], ["polypeptide", "TREATMENT", 19, 30], ["the infection", "PROBLEM", 56, 69], ["Intracellular processing of TCV glycoproteins", "PROBLEM", 70, 115], ["wt", "TEST", 166, 168], ["higher mol", "OBSERVATION", 4, 14], ["infection", "OBSERVATION", 60, 69], ["TCV glycoproteins", "OBSERVATION", 98, 115], ["lower mol", "OBSERVATION_MODIFIER", 156, 165]]], ["A 36,000 mol.wt, protein, co-migrating with a protein present in mock-infected cell lysates (data not shown), appeared to be chased into a 38,000 mol.wt, species.", [["cell lysates", "ANATOMY", 79, 91], ["mol.wt", "GENE_OR_GENE_PRODUCT", 9, 15], ["cell lysates", "CELL", 79, 91], ["36,000 mol.wt, protein", "PROTEIN", 2, 24], ["protein", "TEST", 17, 24], ["a protein", "TEST", 44, 53], ["infected cell lysates", "TEST", 70, 91], ["infected cell lysates", "OBSERVATION", 70, 91]]], ["A minor band of 44,000 also appeared in the gels after the first hour of the chase period.Intracellular processing of TCV glycoproteinsProcessing of the small matrix glycoproteins could hardly be demonstrated by immunoprecipitation.", [["Intracellular", "ANATOMY", 90, 103], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 90, 103], ["TCV", "ORGANISM", 118, 121], ["small matrix glycoproteins", "GENE_OR_GENE_PRODUCT", 153, 179], ["TCV glycoproteins", "PROTEIN", 118, 135], ["small matrix glycoproteins", "PROTEIN", 153, 179], ["A minor band", "TEST", 0, 12], ["Intracellular processing of TCV glycoproteins", "PROBLEM", 90, 135], ["the small matrix glycoproteins", "PROBLEM", 149, 179], ["minor", "OBSERVATION_MODIFIER", 2, 7], ["band", "OBSERVATION_MODIFIER", 8, 12], ["TCV glycoproteins", "OBSERVATION", 118, 135], ["small", "OBSERVATION_MODIFIER", 153, 158], ["matrix glycoproteins", "OBSERVATION", 159, 179], ["could hardly be", "UNCERTAINTY", 180, 195], ["immunoprecipitation", "OBSERVATION", 212, 231]]], ["However, by SDS-PAGE analysis of cell lysates obtained after various chase periods, an increase in the intensity of the 24,000 protein band was noted concomitant with a decrease in the 20-22,000 protein band, presumably due to the glycosylation of the p20-22 to form the gp24 (Fig. 2B) .", [["cell lysates", "ANATOMY", 33, 45], ["cell lysates", "CELL", 33, 45], ["p20-22", "GENE_OR_GENE_PRODUCT", 252, 258], ["gp24", "GENE_OR_GENE_PRODUCT", 271, 275], ["p20-22", "PROTEIN", 252, 258], ["gp24 (Fig. 2B)", "PROTEIN", 271, 285], ["SDS", "TEST", 12, 15], ["cell lysates", "TEST", 33, 45], ["the 24,000 protein band", "TEST", 116, 139], ["protein band", "TEST", 195, 207], ["the glycosylation", "TEST", 227, 244], ["increase", "OBSERVATION_MODIFIER", 87, 95], ["decrease", "OBSERVATION_MODIFIER", 169, 177]]], ["The immunoprecipitations of chased lysates with pre-immune serum were all negative, as was the immunoprecipitation of uninfected lysates with the specific hyperimmune serum (data not shown).Effects of glycosylation inhibitors on TCV-induced intracellular proteins synthesisTo determine the nature of the glycosidic bonds present on each TCV glycoprotein, infected and mock-infected cells were maintained in media supplemented with either tunicamycin (TM) or sodium monensin (SM) and pulselabeled with [35S]methionine or [3H]glucosamine to follow the effects of the inhibitors on synthesis and glycosylation of TCV-induced intracellular proteins.", [["lysates", "ANATOMY", 35, 42], ["serum", "ANATOMY", 59, 64], ["lysates", "ANATOMY", 129, 136], ["serum", "ANATOMY", 167, 172], ["intracellular", "ANATOMY", 241, 254], ["cells", "ANATOMY", 382, 387], ["intracellular", "ANATOMY", 622, 635], ["tunicamycin", "CHEMICAL", 438, 449], ["sodium monensin", "CHEMICAL", 458, 473], ["SM", "CHEMICAL", 475, 477], ["[35S]methionine", "CHEMICAL", 501, 516], ["[3H]glucosamine", "CHEMICAL", 520, 535], ["tunicamycin", "CHEMICAL", 438, 449], ["sodium monensin", "CHEMICAL", 458, 473], ["[35S]methionine", "CHEMICAL", 501, 516], ["[3H]glucosamine", "CHEMICAL", 520, 535], ["lysates", "ORGANISM_SUBSTANCE", 35, 42], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["lysates", "ORGANISM_SUBSTANCE", 129, 136], ["hyperimmune", "ORGANISM", 155, 166], ["serum", "ORGANISM_SUBSTANCE", 167, 172], ["TCV", "ORGANISM", 229, 232], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 241, 254], ["TCV", "ORGANISM", 337, 340], ["cells", "CELL", 382, 387], ["tunicamycin", "SIMPLE_CHEMICAL", 438, 449], ["sodium monensin", "SIMPLE_CHEMICAL", 458, 473], ["SM", "SIMPLE_CHEMICAL", 475, 477], ["[35S]methionine", "SIMPLE_CHEMICAL", 501, 516], ["[3H]glucosamine", "SIMPLE_CHEMICAL", 520, 535], ["TCV", "ORGANISM", 610, 613], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 622, 635], ["intracellular proteins", "PROTEIN", 241, 263], ["TCV glycoprotein", "PROTEIN", 337, 353], ["infected and mock-infected cells", "CELL_TYPE", 355, 387], ["TCV-induced intracellular proteins", "PROTEIN", 610, 644], ["The immunoprecipitations", "TEST", 0, 24], ["chased lysates", "PROBLEM", 28, 42], ["pre-immune serum", "TEST", 48, 64], ["uninfected lysates", "PROBLEM", 118, 136], ["the specific hyperimmune serum", "TEST", 142, 172], ["glycosylation inhibitors", "TREATMENT", 201, 225], ["TCV", "TREATMENT", 229, 232], ["intracellular proteins synthesis", "PROBLEM", 241, 273], ["the glycosidic bonds", "PROBLEM", 300, 320], ["each TCV glycoprotein", "TREATMENT", 332, 353], ["infected cells", "PROBLEM", 373, 387], ["tunicamycin (TM", "TREATMENT", 438, 453], ["sodium monensin", "TREATMENT", 458, 473], ["methionine", "TREATMENT", 506, 516], ["glucosamine", "TREATMENT", 524, 535], ["the inhibitors", "TREATMENT", 561, 575], ["synthesis", "TREATMENT", 579, 588], ["glycosylation of TCV", "TREATMENT", 593, 613], ["intracellular proteins", "PROBLEM", 622, 644], ["proteins synthesis", "OBSERVATION", 255, 273], ["glycosidic bonds", "OBSERVATION", 304, 320], ["infected cells", "OBSERVATION", 373, 387]]], ["No cytopathic changes or polycaryocytosis were observed when TCV-infected cell cultures were grown in the presence of 0.5 or 1.0 ~tg/ml of TM.", [["cell cultures", "ANATOMY", 74, 87], ["TCV", "ORGANISM", 61, 64], ["cell cultures", "CELL", 74, 87], ["TCV-infected cell cultures", "CELL_LINE", 61, 87], ["TCV", "SPECIES", 61, 64], ["cytopathic changes", "PROBLEM", 3, 21], ["polycaryocytosis", "PROBLEM", 25, 41], ["TCV", "TEST", 61, 64], ["infected cell cultures", "TEST", 65, 87], ["TM", "TEST", 139, 141], ["cytopathic", "OBSERVATION", 3, 13]]], ["In contrast, the addition of 0.5 to 2.5 ~tM sodium monensin did not interfere with Tunicamycin at a concentration of 0.5 lag/ml slightly decreased the overall intracellular protein synthesis, as suggested by the intensity of bands of [35S]methionine-labeled proteins resolved by SDS-PAGE of cell lysates.", [["intracellular", "ANATOMY", 159, 172], ["cell lysates", "ANATOMY", 291, 303], ["sodium monensin", "CHEMICAL", 44, 59], ["Tunicamycin", "CHEMICAL", 83, 94], ["[35S]methionine", "CHEMICAL", 234, 249], ["sodium monensin", "CHEMICAL", 44, 59], ["Tunicamycin", "CHEMICAL", 83, 94], ["[35S]methionine", "CHEMICAL", 234, 249], ["sodium monensin", "SIMPLE_CHEMICAL", 44, 59], ["Tunicamycin", "SIMPLE_CHEMICAL", 83, 94], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 159, 172], ["[35S]methionine", "SIMPLE_CHEMICAL", 234, 249], ["cell lysates", "ORGANISM_SUBSTANCE", 291, 303], ["[35S]methionine-labeled proteins", "PROTEIN", 234, 266], ["~tM sodium monensin", "TREATMENT", 40, 59], ["Tunicamycin", "TREATMENT", 83, 94], ["the overall intracellular protein synthesis", "PROBLEM", 147, 190], ["methionine-labeled proteins", "TREATMENT", 239, 266], ["cell lysates", "PROBLEM", 291, 303], ["intracellular protein synthesis", "OBSERVATION", 159, 190]]], ["Polypeptides corresponding to TCV peplomeric glycoproteins showed a drastic decrease in their apparent molecular weights, yielding 90,000, 120-130,000, and 150,000 polypeptide species (Fig. 3 A, arrowheads) .", [["TCV", "ORGANISM", 30, 33], ["TCV peplomeric glycoproteins", "PROTEIN", 30, 58], ["TCV", "SPECIES", 30, 33], ["Polypeptides", "TREATMENT", 0, 12], ["TCV peplomeric glycoproteins", "TEST", 30, 58], ["a drastic decrease in their apparent molecular weights", "PROBLEM", 66, 120], ["polypeptide species", "TEST", 164, 183], ["drastic", "OBSERVATION_MODIFIER", 68, 75], ["decrease", "OBSERVATION_MODIFIER", 76, 84]]], ["These new intracellular polypeptides were also resolved by Western immunoblotting (Fig. 3 B) .", [["intracellular", "ANATOMY", 10, 23], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 23], ["These new intracellular polypeptides", "PROBLEM", 0, 36], ["new", "OBSERVATION_MODIFIER", 6, 9], ["intracellular polypeptides", "OBSERVATION", 10, 36]]], ["Radioim-munoprecipitation experiments using the anti-TCV hyperimmune serum, after [35S]methionine and [3H]glucosamine labeling, confirmed the absence of the peplomeric glycoproteins from TM-treated cells, whereas the relative amount of the unglycosylated high mol.wt, polypeptide species increased (Fig. 4A, lanes 5 and 7) .", [["serum", "ANATOMY", 69, 74], ["cells", "ANATOMY", 198, 203], ["[35S]methionine", "CHEMICAL", 82, 97], ["[3H]glucosamine", "CHEMICAL", 102, 117], ["[35S]methionine", "CHEMICAL", 82, 97], ["[3H]glucosamine", "CHEMICAL", 102, 117], ["hyperimmune", "ORGANISM", 57, 68], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["[35S]methionine", "SIMPLE_CHEMICAL", 82, 97], ["[3H]glucosamine", "SIMPLE_CHEMICAL", 102, 117], ["TM", "GENE_OR_GENE_PRODUCT", 187, 189], ["cells", "CELL", 198, 203], ["peplomeric glycoproteins", "PROTEIN", 157, 181], ["TM-treated cells", "CELL_LINE", 187, 203], ["hyperimmune", "SPECIES", 57, 68], ["anti-TCV", "SPECIES", 48, 56], ["Radioim", "TREATMENT", 0, 7], ["the anti-TCV hyperimmune serum", "TREATMENT", 44, 74], ["methionine", "TREATMENT", 87, 97], ["glucosamine labeling", "TREATMENT", 106, 126], ["the peplomeric glycoproteins", "PROBLEM", 153, 181], ["TM-treated cells", "TREATMENT", 187, 203], ["wt", "TEST", 264, 266], ["polypeptide species", "TEST", 268, 287], ["high mol.", "OBSERVATION", 255, 264], ["increased", "OBSERVATION_MODIFIER", 288, 297]]], ["A major non-glycosylated polypeptide having a mol.wt, of 60,000 was also revealed in the presence of TM.Effects of glycosylation inhibitors on TCV-induced intracellular proteins synthesisIn contrast, both types of surface glycoproteins (gpl80-200/gpl00 and gp 140) were immunoprecipitated from extracts of SM-treated TCV-infected cells and strongly labeled with [3H]glucosamine (Fig. 4A, lane 9) .", [["intracellular", "ANATOMY", 155, 168], ["surface", "ANATOMY", 214, 221], ["extracts", "ANATOMY", 294, 302], ["cells", "ANATOMY", 330, 335], ["SM", "CHEMICAL", 306, 308], ["[3H]glucosamine", "CHEMICAL", 362, 377], ["[3H]glucosamine", "CHEMICAL", 362, 377], ["TCV", "ORGANISM", 143, 146], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 155, 168], ["gpl80-200", "GENE_OR_GENE_PRODUCT", 237, 246], ["gpl00", "GENE_OR_GENE_PRODUCT", 247, 252], ["gp 140", "GENE_OR_GENE_PRODUCT", 257, 263], ["extracts", "ORGANISM_SUBSTANCE", 294, 302], ["SM", "SIMPLE_CHEMICAL", 306, 308], ["TCV", "ORGANISM", 317, 320], ["cells", "CELL", 330, 335], ["[3H]glucosamine", "SIMPLE_CHEMICAL", 362, 377], ["TM", "PROTEIN", 101, 103], ["intracellular proteins", "PROTEIN", 155, 177], ["surface glycoproteins", "PROTEIN", 214, 235], ["gpl80", "PROTEIN", 237, 242], ["gpl00", "PROTEIN", 247, 252], ["gp 140", "PROTEIN", 257, 263], ["SM-treated TCV-infected cells", "CELL_LINE", 306, 335], ["glycosylation inhibitors", "TREATMENT", 115, 139], ["TCV", "TEST", 143, 146], ["surface glycoproteins", "TREATMENT", 214, 235], ["gpl80", "TEST", 237, 242], ["SM", "PROBLEM", 306, 308], ["infected cells", "PROBLEM", 321, 335], ["glucosamine", "TREATMENT", 366, 377], ["infected cells", "OBSERVATION", 321, 335]]], ["A major polypeptide with an approximate mol.wt, of 150-170,000 was also immunoprecipitated after treatment with SM, but appeared slightly labeled with [3H]glucosamine (Fig. 4A, lanes 4 and 6) .Effects of glycosylation inhibitors on TCV-induced intracellular proteins synthesisGlycosylation of the matrix protein of TCV was also affected by TM.", [["intracellular", "ANATOMY", 244, 257], ["[3H]glucosamine", "CHEMICAL", 151, 166], ["[3H]glucosamine", "CHEMICAL", 151, 166], ["[3H]glucosamine", "SIMPLE_CHEMICAL", 151, 166], ["TCV", "ORGANISM", 232, 235], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 244, 257], ["matrix", "CELLULAR_COMPONENT", 297, 303], ["TCV", "ORGANISM", 315, 318], ["SM", "PROTEIN", 112, 114], ["intracellular proteins", "PROTEIN", 244, 266], ["matrix protein", "PROTEIN", 297, 311], ["A major polypeptide", "TREATMENT", 0, 19], ["wt", "TEST", 44, 46], ["treatment", "TREATMENT", 97, 106], ["SM", "TREATMENT", 112, 114], ["glucosamine", "TREATMENT", 155, 166], ["glycosylation inhibitors", "TREATMENT", 204, 228], ["TCV", "TREATMENT", 232, 235], ["intracellular proteins synthesisGlycosylation", "TREATMENT", 244, 289], ["the matrix protein of TCV", "TREATMENT", 293, 318]]], ["Neither the major gp24, nor the 36-38,000 and 44,000 mol.wt, species could be immunoprecipitated after TM treatment (Fig. 4A) .", [["gp24", "GENE_OR_GENE_PRODUCT", 18, 22], ["major gp24", "PROTEIN", 12, 22], ["TM treatment", "TREATMENT", 103, 115]]], ["In contrast, all these protein species were identified in immunoprecipitates from extracts of untreated and SM-treated TCV-infected cells (Fig. 4A, B) .Effects of glycosylation inhibitors on TCV maturationThe maturation of TCV in the absence or presence of glycosylation inhibitors was followed by sequential analysis by EM of ultrathin sections of TCV-infected cells.", [["immunoprecipitates", "ANATOMY", 58, 76], ["extracts", "ANATOMY", 82, 90], ["cells", "ANATOMY", 132, 137], ["sections", "ANATOMY", 337, 345], ["cells", "ANATOMY", 362, 367], ["SM", "CHEMICAL", 108, 110], ["TCV-infected", "DISEASE", 349, 361], ["extracts", "ORGANISM_SUBSTANCE", 82, 90], ["TCV", "ORGANISM", 119, 122], ["cells", "CELL", 132, 137], ["B", "CELL", 148, 149], ["TCV", "ORGANISM", 191, 194], ["TCV", "ORGANISM", 223, 226], ["TCV", "ORGANISM", 349, 352], ["cells", "CELL", 362, 367], ["SM-treated TCV-infected cells", "CELL_LINE", 108, 137], ["TCV-infected cells", "CELL_LINE", 349, 367], ["all these protein species", "PROBLEM", 13, 38], ["infected cells", "PROBLEM", 123, 137], ["glycosylation inhibitors", "TREATMENT", 163, 187], ["TCV maturation", "TREATMENT", 191, 205], ["glycosylation inhibitors", "TREATMENT", 257, 281], ["sequential analysis", "TEST", 298, 317], ["infected cells", "PROBLEM", 353, 367], ["infected cells", "OBSERVATION", 123, 137], ["infected cells", "OBSERVATION", 353, 367]]], ["Electron microscopic examination of negatively stained untreated TCVinfected cells, at 18 hours after inoculation, revealed budding of coronavirus particles through intracytoplasmic membranes and their accumulation in the lumen of smooth-walled vesicles (Fig. 5A) .", [["TCVinfected cells", "ANATOMY", 65, 82], ["intracytoplasmic membranes", "ANATOMY", 165, 191], ["lumen", "ANATOMY", 222, 227], ["smooth-walled vesicles", "ANATOMY", 231, 253], ["TCVinfected cells", "CELL", 65, 82], ["coronavirus", "ORGANISM", 135, 146], ["intracytoplasmic membranes", "CELLULAR_COMPONENT", 165, 191], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 222, 227], ["vesicles", "CELLULAR_COMPONENT", 245, 253], ["TCVinfected cells", "CELL_LINE", 65, 82], ["Electron microscopic examination", "TEST", 0, 32], ["negatively stained untreated TCVinfected cells", "PROBLEM", 36, 82], ["inoculation", "PROBLEM", 102, 113], ["budding of coronavirus particles", "PROBLEM", 124, 156], ["intracytoplasmic membranes", "PROBLEM", 165, 191], ["coronavirus particles", "OBSERVATION", 135, 156], ["intracytoplasmic membranes", "OBSERVATION", 165, 191], ["accumulation", "OBSERVATION_MODIFIER", 202, 214], ["lumen", "ANATOMY_MODIFIER", 222, 227], ["smooth", "OBSERVATION_MODIFIER", 231, 237], ["walled vesicles", "OBSERVATION", 238, 253]]], ["Progeny viral particles were shown at the outer surface of infected cells, but none have been observed to be budding from the plasma membrane.", [["outer surface", "ANATOMY", 42, 55], ["cells", "ANATOMY", 68, 73], ["plasma membrane", "ANATOMY", 126, 141], ["outer surface", "CELLULAR_COMPONENT", 42, 55], ["cells", "CELL", 68, 73], ["plasma membrane", "CELLULAR_COMPONENT", 126, 141], ["infected cells", "CELL_TYPE", 59, 73], ["Progeny viral particles", "PROBLEM", 0, 23], ["infected cells", "PROBLEM", 59, 73], ["viral particles", "OBSERVATION", 8, 23], ["infected cells", "OBSERVATION", 59, 73], ["plasma membrane", "OBSERVATION", 126, 141]]], ["The intracellular and extracellular viral particles were spherical in shape with an electron-lucent center and possessed large bulbous surface projections (Fig. 5 B) .Effects of glycosylation inhibitors on TCV maturationThe formation ofvirions was not inhibited by 0.1 to 1.0 gg/ml of TM (Fig. 6 ).", [["intracellular", "ANATOMY", 4, 17], ["extracellular", "ANATOMY", 22, 35], ["bulbous surface", "ANATOMY", 127, 142], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 4, 17], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 35], ["TCV", "ORGANISM", 206, 209], ["The intracellular and extracellular viral particles", "TEST", 0, 51], ["an electron-lucent center", "PROBLEM", 81, 106], ["glycosylation inhibitors", "TREATMENT", 178, 202], ["TCV maturation", "TREATMENT", 206, 220], ["intracellular", "OBSERVATION_MODIFIER", 4, 17], ["extracellular", "OBSERVATION_MODIFIER", 22, 35], ["viral particles", "OBSERVATION", 36, 51], ["spherical", "OBSERVATION_MODIFIER", 57, 66], ["shape", "OBSERVATION_MODIFIER", 70, 75], ["lucent", "OBSERVATION_MODIFIER", 93, 99], ["large", "OBSERVATION_MODIFIER", 121, 126], ["bulbous", "OBSERVATION_MODIFIER", 127, 134], ["surface", "OBSERVATION_MODIFIER", 135, 142]]], ["Complete virions were observed in dilated cytoplasmic vacuoles, but there was also an important accumulation of amorphous material, suggesting at least a partial interference with the viral assembly (Fig. 6A) .", [["virions", "ANATOMY", 9, 16], ["cytoplasmic vacuoles", "ANATOMY", 42, 62], ["cytoplasmic", "ORGANISM_SUBSTANCE", 42, 53], ["vacuoles", "CELLULAR_COMPONENT", 54, 62], ["Complete virions", "PROBLEM", 0, 16], ["dilated cytoplasmic vacuoles", "PROBLEM", 34, 62], ["an important accumulation of amorphous material", "PROBLEM", 83, 130], ["a partial interference", "PROBLEM", 152, 174], ["virions", "OBSERVATION", 9, 16], ["dilated", "OBSERVATION", 34, 41], ["cytoplasmic vacuoles", "OBSERVATION", 42, 62], ["important", "OBSERVATION_MODIFIER", 86, 95], ["accumulation", "OBSERVATION_MODIFIER", 96, 108], ["amorphous material", "OBSERVATION", 112, 130], ["at least", "OBSERVATION_MODIFIER", 143, 151], ["partial", "OBSERVATION_MODIFIER", 154, 161], ["interference", "OBSERVATION", 162, 174]]], ["Virions that were present in the cytoplasmic vacuoles migrating to the cell surface apparently lacked the characteristic large peplomers of coronaviruses (Fig. 6 B) .", [["cytoplasmic vacuoles", "ANATOMY", 33, 53], ["cell surface", "ANATOMY", 71, 83], ["Virions", "GENE_OR_GENE_PRODUCT", 0, 7], ["cytoplasmic vacuoles", "CELLULAR_COMPONENT", 33, 53], ["cell surface", "CELLULAR_COMPONENT", 71, 83], ["Virions", "PROTEIN", 0, 7], ["Virions", "PROBLEM", 0, 7], ["the characteristic large peplomers of coronaviruses", "PROBLEM", 102, 153], ["cytoplasmic", "OBSERVATION_MODIFIER", 33, 44], ["vacuoles", "OBSERVATION_MODIFIER", 45, 53], ["migrating", "OBSERVATION_MODIFIER", 54, 63], ["cell surface", "OBSERVATION", 71, 83], ["characteristic", "OBSERVATION_MODIFIER", 106, 120], ["large", "OBSERVATION_MODIFIER", 121, 126], ["peplomers", "OBSERVATION", 127, 136], ["coronaviruses", "OBSERVATION_MODIFIER", 140, 153]]], ["The virions were released from TM-treated cells, but usually none were adsorbed to the plasma membrane.Effects of glycosylation inhibitors on TCV maturationThe addition of SM to the medium of TCV-infected cell cultures did not interfere with the normal maturation of the virus (Fig. 7) .", [["virions", "ANATOMY", 4, 11], ["cells", "ANATOMY", 42, 47], ["plasma membrane", "ANATOMY", 87, 102], ["cell cultures", "ANATOMY", 205, 218], ["SM", "CHEMICAL", 172, 174], ["TM", "GENE_OR_GENE_PRODUCT", 31, 33], ["cells", "CELL", 42, 47], ["plasma membrane", "CELLULAR_COMPONENT", 87, 102], ["TCV", "ORGANISM", 142, 145], ["TCV", "ORGANISM", 192, 195], ["cell cultures", "CELL", 205, 218], ["TM-treated cells", "CELL_LINE", 31, 47], ["SM", "PROTEIN", 172, 174], ["TCV-infected cell cultures", "CELL_LINE", 192, 218], ["TCV", "SPECIES", 192, 195], ["The virions", "PROBLEM", 0, 11], ["TM-treated cells", "TREATMENT", 31, 47], ["glycosylation inhibitors", "TREATMENT", 114, 138], ["TCV maturation", "TREATMENT", 142, 156], ["infected cell cultures", "TEST", 196, 218], ["the virus", "PROBLEM", 267, 276], ["virions", "OBSERVATION", 4, 11], ["infected cell", "OBSERVATION", 196, 209], ["normal", "OBSERVATION", 246, 252]]], ["Large numbers of progeny viral particles could be observed in the cytosol even at a SM concentration of 5 gM/ml.", [["cytosol", "ANATOMY", 66, 73], ["cytosol", "ORGANISM_SUBSTANCE", 66, 73], ["SM", "PROTEIN", 84, 86], ["Large numbers of progeny viral particles", "PROBLEM", 0, 40], ["numbers", "OBSERVATION_MODIFIER", 6, 13], ["progeny viral particles", "OBSERVATION", 17, 40]]], ["However, such high concentration of SM seemed to be very toxic for HRT-18 cells, as suggested by the intensive vacuolisation (Fig. 7 B) .", [["HRT-18 cells", "ANATOMY", 67, 79], ["SM", "CHEMICAL", 36, 38], ["SM", "SIMPLE_CHEMICAL", 36, 38], ["HRT-18 cells", "CELL", 67, 79], ["SM", "PROTEIN", 36, 38], ["HRT-18 cells", "CELL_LINE", 67, 79], ["such high concentration of SM", "PROBLEM", 9, 38], ["very toxic", "PROBLEM", 52, 62], ["HRT", "TEST", 67, 70]]], ["The viral particles that accumulated in the lumen of smooth-walled vesicles of (Fig. 7A ).", [["lumen", "ANATOMY", 44, 49], ["smooth-walled vesicles", "ANATOMY", 53, 75], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 44, 49], ["The viral particles", "PROBLEM", 0, 19], ["viral particles", "OBSERVATION", 4, 19], ["lumen", "ANATOMY_MODIFIER", 44, 49], ["smooth", "OBSERVATION_MODIFIER", 53, 59], ["walled", "ANATOMY_MODIFIER", 60, 66], ["vesicles", "ANATOMY_MODIFIER", 67, 75]]], ["N u m e r o u s viral particles were observed in the intercellular spaces and, m a n y were adsorbed to the plasma membrane.", [["intercellular spaces", "ANATOMY", 53, 73], ["plasma membrane", "ANATOMY", 108, 123], ["plasma membrane", "CELLULAR_COMPONENT", 108, 123], ["u m e r o u s", "TEST", 2, 15], ["viral particles", "PROBLEM", 16, 31], ["viral particles", "OBSERVATION", 16, 31], ["intercellular spaces", "ANATOMY", 53, 73], ["plasma membrane", "ANATOMY", 108, 123]]], ["These virions possessed the characteristic surface peplomers.", [["virions", "ANATOMY", 6, 13], ["surface", "ANATOMY", 43, 50], ["These virions", "TREATMENT", 0, 13], ["characteristic", "OBSERVATION_MODIFIER", 28, 42], ["surface peplomers", "OBSERVATION", 43, 60]]], ["Long tubules, 25 to 3 0 n m in diameter, accumulated in dilated cysternae or in cytoplasmic vacuoles (Fig. 7 B) .DiscussionPrevious studies on the structural proteins of the TCV virions, produced in cell cultures or in ovo, have revealed a polypeptide pattern described so far only for viruses belonging to the subgroup of mammalian hemagglutinating coronaviruses [6] .", [["Long tubules", "ANATOMY", 0, 12], ["cysternae", "ANATOMY", 64, 73], ["cytoplasmic vacuoles", "ANATOMY", 80, 100], ["cell cultures", "ANATOMY", 199, 212], ["Long tubules", "TISSUE", 0, 12], ["cysternae", "CANCER", 64, 73], ["cytoplasmic", "ORGANISM_SUBSTANCE", 80, 91], ["vacuoles", "CELLULAR_COMPONENT", 92, 100], ["TCV virions", "ORGANISM", 174, 185], ["cell cultures", "CELL", 199, 212], ["mammalian hemagglutinating coronaviruses", "ORGANISM", 323, 363], ["structural proteins", "PROTEIN", 147, 166], ["cell cultures", "CELL_LINE", 199, 212], ["Long tubules", "PROBLEM", 0, 12], ["dilated cysternae", "PROBLEM", 56, 73], ["DiscussionPrevious studies", "TEST", 113, 139], ["the TCV virions", "PROBLEM", 170, 185], ["cell cultures", "TEST", 199, 212], ["a polypeptide pattern", "PROBLEM", 238, 259], ["viruses", "PROBLEM", 286, 293], ["mammalian hemagglutinating coronaviruses", "PROBLEM", 323, 363], ["25 to 3 0", "OBSERVATION_MODIFIER", 14, 23], ["diameter", "OBSERVATION_MODIFIER", 31, 39], ["dilated", "OBSERVATION", 56, 63], ["cytoplasmic vacuoles", "OBSERVATION", 80, 100], ["hemagglutinating coronaviruses", "OBSERVATION", 333, 363]]], ["In addition to the peplomeric and matrix glycoproteins, TCV virions contain an envelope glycoprotein, having a mol.wt, of 140,000, which behaves as a disulfide-linked dimer of 60-65,000 subunits, and which has been associated to the hemagglutinin (accompanying paper).", [["disulfide", "CHEMICAL", 150, 159], ["matrix", "CELLULAR_COMPONENT", 34, 40], ["TCV virions", "ORGANISM", 56, 67], ["peplomeric and matrix glycoproteins", "PROTEIN", 19, 54], ["envelope glycoprotein", "PROTEIN", 79, 100], ["disulfide-linked dimer", "PROTEIN", 150, 172], ["60-65,000 subunits", "PROTEIN", 176, 194], ["hemagglutinin", "PROTEIN", 233, 246], ["TCV", "SPECIES", 56, 59], ["the peplomeric and matrix glycoproteins", "TREATMENT", 15, 54], ["TCV virions", "TREATMENT", 56, 67], ["an envelope glycoprotein", "TREATMENT", 76, 100], ["wt", "TEST", 115, 117]]], ["In this paper, we described the identification of virus-induced intracellular polypeptides in TCV-infected HRT-18 cells, the kinetic of their synthesis, their post-translational processing in the presence of glycosylation inhibitors and their significance with respect to the production of mature virions.", [["intracellular", "ANATOMY", 64, 77], ["HRT-18 cells", "ANATOMY", 107, 119], ["virions", "ANATOMY", 297, 304], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 77], ["TCV", "ORGANISM", 94, 97], ["HRT-18 cells", "CELL", 107, 119], ["TCV-infected HRT-18 cells", "CELL_LINE", 94, 119], ["virus", "PROBLEM", 50, 55], ["intracellular polypeptides", "PROBLEM", 64, 90], ["TCV", "TEST", 94, 97], ["infected HRT", "PROBLEM", 98, 110], ["their synthesis", "PROBLEM", 136, 151], ["glycosylation inhibitors", "TREATMENT", 208, 232], ["mature virions", "PROBLEM", 290, 304], ["glycosylation inhibitors", "OBSERVATION", 208, 232], ["mature virions", "OBSERVATION", 290, 304]]], ["We found that TCV had a modest inhibitory effect on cell protein synthesis, making the analysis of virus-specific proteins difficult.", [["cell", "ANATOMY", 52, 56], ["TCV", "ORGANISM", 14, 17], ["cell", "CELL", 52, 56], ["virus-specific proteins", "PROTEIN", 99, 122], ["TCV", "PROBLEM", 14, 17], ["a modest inhibitory effect", "PROBLEM", 22, 48], ["cell protein synthesis", "TREATMENT", 52, 74], ["the analysis", "TEST", 83, 95], ["virus", "PROBLEM", 99, 104], ["cell protein synthesis", "OBSERVATION", 52, 74]]], ["Nevertheless, new intracellular protein species could be detected as soon as 6 h post-infection either by SDS-PAGE analysis of pulse-labeled TCV-infected cell extracts or by Western-immunoblotting, using anti-TCV hyperimmune serum produced to the eggadapted Minnesota strain.", [["intracellular", "ANATOMY", 18, 31], ["cell extracts", "ANATOMY", 154, 167], ["serum", "ANATOMY", 225, 230], ["infection", "DISEASE", 86, 95], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 18, 31], ["TCV", "ORGANISM", 141, 144], ["cell extracts", "ORGANISM_SUBSTANCE", 154, 167], ["hyperimmune", "ORGANISM", 213, 224], ["serum", "ORGANISM_SUBSTANCE", 225, 230], ["anti-TCV", "SPECIES", 204, 212], ["new intracellular protein species", "PROBLEM", 14, 47], ["infection", "PROBLEM", 86, 95], ["SDS", "TEST", 106, 109], ["pulse", "TEST", 127, 132], ["TCV", "TEST", 141, 144], ["infected cell extracts", "PROBLEM", 145, 167], ["anti-TCV hyperimmune serum", "TREATMENT", 204, 230], ["protein species", "OBSERVATION", 32, 47], ["infected cell", "OBSERVATION", 145, 158]]], ["The TCV structural proteins were all detected by 9 h post-infection, in agreement with the one-step growth curve that was determined in a previous study [7] and the replication cycle of coronaviruses [40] .", [["infection", "DISEASE", 58, 67], ["TCV", "ORGANISM", 4, 7], ["coronaviruses", "ORGANISM", 186, 199], ["TCV structural proteins", "PROTEIN", 4, 27], ["The TCV structural proteins", "PROBLEM", 0, 27], ["infection", "PROBLEM", 58, 67], ["a previous study", "TEST", 136, 152], ["the replication cycle of coronaviruses", "TREATMENT", 161, 199], ["infection", "OBSERVATION", 58, 67]]], ["At least 12 to 14 polypeptides immunoprecipitated from lysates of TCVinfected cells.", [["lysates", "ANATOMY", 55, 62], ["TCVinfected cells", "ANATOMY", 66, 83], ["lysates", "ORGANISM_SUBSTANCE", 55, 62], ["TCVinfected cells", "CELL", 66, 83], ["TCVinfected cells", "CELL_LINE", 66, 83], ["14 polypeptides immunoprecipitated", "PROBLEM", 15, 49], ["lysates of TCVinfected cells", "PROBLEM", 55, 83], ["TCVinfected cells", "OBSERVATION", 66, 83]]], ["Six of these polypeptides, with approximate mol.wts, of t 50-170,000, 130,000, 90,000, 48,000, 46,000, and 30-32,000, did not co-migrate with virion proteins.", [["virion proteins", "PROTEIN", 142, 157], ["these polypeptides", "TEST", 7, 25], ["virion proteins", "TREATMENT", 142, 157]]], ["Although a definitive relationship could not be established among these various intracellular polypeptides, pulse-chased experiments and analysis of infected cell extracts after cultivation in the presence of glycosylation inhibitors suggested that some of these products correspond to intracellular precursors, cleavage products or aggregated forms of structural glycoproteins.DiscussionNo processing of the p52 nucleocapsid (N) protein was apparent.", [["intracellular", "ANATOMY", 80, 93], ["cell extracts", "ANATOMY", 158, 171], ["intracellular", "ANATOMY", 286, 299], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 80, 93], ["cell extracts", "ORGANISM_SUBSTANCE", 158, 171], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 286, 299], ["p52", "GENE_OR_GENE_PRODUCT", 409, 412], ["cleavage products", "PROTEIN", 312, 329], ["structural glycoproteins", "PROTEIN", 353, 377], ["p52 nucleocapsid (N) protein", "PROTEIN", 409, 437], ["infected cell extracts", "TREATMENT", 149, 171], ["cultivation", "TREATMENT", 178, 189], ["glycosylation inhibitors", "TREATMENT", 209, 233], ["intracellular precursors", "PROBLEM", 286, 310], ["cleavage products", "TREATMENT", 312, 329], ["structural glycoproteins", "PROBLEM", 353, 377], ["the p52 nucleocapsid (N) protein", "TEST", 405, 437], ["infected cell", "OBSERVATION", 149, 162], ["intracellular precursors", "OBSERVATION", 286, 310], ["structural glycoproteins", "OBSERVATION", 353, 377]]], ["Two additional virus-specific binding proteins (48,000 and 46,000) which migrated slightly ahead of N were also identified for MHV and IBV [27, 32, 37] .", [["MHV", "ORGANISM", 127, 130], ["IBV", "ORGANISM", 135, 138], ["virus-specific binding proteins", "PROTEIN", 15, 46], ["48,000 and 46,000", "PROTEIN", 48, 65], ["MHV", "SPECIES", 127, 130], ["IBV", "SPECIES", 135, 138], ["Two additional virus-specific binding proteins", "TEST", 0, 46], ["IBV", "TEST", 135, 138], ["virus", "OBSERVATION", 15, 20]]], ["These two species reacted with monospecific anti-N antibody and, in vitro translation studies of the N gene have Shown that they may correspond to degradation products of N [26, 28, 33] .DiscussionThe 30-32 K polypeptide species present in TCV-infected cell lysates is apparently a virus-induced host cell or non-structural protein, as it was not revealed by Western-immunoblotting.", [["cell lysates", "ANATOMY", 253, 265], ["cell", "ANATOMY", 301, 305], ["K", "CHEMICAL", 207, 208], ["K polypeptide", "GENE_OR_GENE_PRODUCT", 207, 220], ["TCV", "ORGANISM", 240, 243], ["cell lysates", "CELL", 253, 265], ["host cell", "CELL", 296, 305], ["monospecific anti-N antibody", "PROTEIN", 31, 59], ["N gene", "DNA", 101, 107], ["non-structural protein", "PROTEIN", 309, 331], ["TCV", "SPECIES", 240, 243], ["These two species", "PROBLEM", 0, 17], ["monospecific anti-N antibody", "TEST", 31, 59], ["vitro translation studies", "TEST", 68, 93], ["K polypeptide species", "PROBLEM", 207, 228], ["TCV", "TEST", 240, 243], ["infected cell lysates", "PROBLEM", 244, 265], ["a virus", "PROBLEM", 280, 287], ["non-structural protein", "PROBLEM", 309, 331], ["infected cell lysates", "OBSERVATION", 244, 265], ["host cell", "OBSERVATION", 296, 305]]], ["A non-structural protein with a similar mol.wt. also has been detected in MHV-A59 infected cel lysates, and a protein with a mol.wt, of 28,000 was also obtained following cell-free translation of the virion genomic RNA [8, 32] .", [["cel lysates", "ANATOMY", 91, 102], ["cell", "ANATOMY", 171, 175], ["MHV-A59", "ORGANISM", 74, 81], ["cel lysates", "CELL", 91, 102], ["cell", "CELL", 171, 175], ["non-structural protein", "PROTEIN", 2, 24], ["virion genomic RNA", "RNA", 200, 218], ["MHV-A59", "SPECIES", 74, 81], ["A non-structural protein", "PROBLEM", 0, 24], ["wt", "TEST", 44, 46], ["a protein", "TEST", 108, 117], ["wt", "TEST", 129, 131], ["non-structural protein", "OBSERVATION", 2, 24], ["MHV", "ANATOMY", 74, 77]]], ["Since p28 is a basic protein which is most abundant in infected cells late in infection, it has been suggested that it may be involved in the processing of the genomic or subgenomic RNAs.DiscussionPulse-chased studies also revealed that TCV peplomeric glycoproteins undergo considerable post-translational changes before incorporation into the virion.", [["cells", "ANATOMY", 64, 69], ["virion", "ANATOMY", 344, 350], ["infection", "DISEASE", 78, 87], ["p28", "GENE_OR_GENE_PRODUCT", 6, 9], ["cells", "CELL", 64, 69], ["TCV", "ORGANISM", 237, 240], ["virion", "CELLULAR_COMPONENT", 344, 350], ["p28", "PROTEIN", 6, 9], ["basic protein", "PROTEIN", 15, 28], ["infected cells", "CELL_TYPE", 55, 69], ["genomic or subgenomic RNAs", "RNA", 160, 186], ["TCV peplomeric glycoproteins", "PROTEIN", 237, 265], ["TCV", "SPECIES", 237, 240], ["a basic protein", "PROBLEM", 13, 28], ["infected cells", "PROBLEM", 55, 69], ["infection", "PROBLEM", 78, 87], ["the genomic or subgenomic RNAs", "PROBLEM", 156, 186], ["TCV peplomeric glycoproteins", "TREATMENT", 237, 265], ["most abundant", "OBSERVATION_MODIFIER", 38, 51], ["infected cells", "OBSERVATION", 55, 69], ["late", "OBSERVATION_MODIFIER", 70, 74], ["infection", "OBSERVATION", 78, 87], ["may be", "UNCERTAINTY", 119, 125], ["subgenomic RNAs", "OBSERVATION", 171, 186]]], ["First glycosylation of the primary translation product from the E2 gene may result in the synthesis of the gp150-170,000 species, and further glycosylation yields gp 200.", [["E2", "CHEMICAL", 64, 66], ["E2", "GENE_OR_GENE_PRODUCT", 64, 66], ["primary translation product", "PROTEIN", 27, 54], ["E2 gene", "DNA", 64, 71], ["gp150", "PROTEIN", 107, 112], ["gp 200", "PROTEIN", 163, 169], ["the E2 gene", "TREATMENT", 60, 71]]], ["Subsequent proteolytic cleavage of gp 200 to yield gp 120 and gp 100, as demonstrated in the accompanying paper, appeared to occur quite efficiently, as these two species were the predominant species precipitated from TCV-infected cell extracts.", [["cell extracts", "ANATOMY", 231, 244], ["gp 200", "GENE_OR_GENE_PRODUCT", 35, 41], ["gp 120", "GENE_OR_GENE_PRODUCT", 51, 57], ["gp 100", "GENE_OR_GENE_PRODUCT", 62, 68], ["TCV", "ORGANISM", 218, 221], ["cell extracts", "ORGANISM_SUBSTANCE", 231, 244], ["gp 200", "PROTEIN", 35, 41], ["gp 120", "PROTEIN", 51, 57], ["gp 100", "PROTEIN", 62, 68], ["TCV", "SPECIES", 218, 221], ["Subsequent proteolytic cleavage of gp", "TREATMENT", 0, 37], ["the predominant species", "PROBLEM", 176, 199], ["infected cell extracts", "TREATMENT", 222, 244], ["infected cell extracts", "OBSERVATION", 222, 244]]], ["This pattern of processing of E2 is similar to the patterns proposed for the E2 of BCV, MHV, and IBV [9, 36, 403 .", [["E2", "CHEMICAL", 30, 32], ["E2", "CHEMICAL", 77, 79], ["E2", "GENE_OR_GENE_PRODUCT", 30, 32], ["E2", "GENE_OR_GENE_PRODUCT", 77, 79], ["BCV", "ORGANISM", 83, 86], ["MHV", "ORGANISM", 88, 91], ["MHV", "SPECIES", 88, 91], ["IBV", "SPECIES", 97, 100], ["processing of E2", "PROBLEM", 16, 32], ["IBV", "TEST", 97, 100]]], ["A primary glycosylated precursor with apparent mol.wt, of 170,000 also has been identified for BCV using anti-E2 monoclonal antibodies [9, 103.DiscussionIn case of TCV, proteolytic cleavage of E2 probably occurs also prior to the final glycosylation step.", [["TCV", "DISEASE", 164, 167], ["E2", "CHEMICAL", 193, 195], ["BCV", "ORGANISM", 95, 98], ["TCV", "ORGANISM", 164, 167], ["E2", "GENE_OR_GENE_PRODUCT", 193, 195], ["anti-E2 monoclonal antibodies", "PROTEIN", 105, 134], ["BCV", "SPECIES", 95, 98], ["A primary glycosylated precursor", "PROBLEM", 0, 32], ["wt", "TEST", 51, 53], ["BCV", "TEST", 95, 98], ["anti-E2 monoclonal antibodies", "TEST", 105, 134], ["TCV, proteolytic cleavage of E2", "TREATMENT", 164, 195], ["the final glycosylation step", "TREATMENT", 226, 254]]], ["A 90,000 mol.wt, non-glycosylated polypeptide was revealed by immunoprecipitation prior to the appearance of gp 170 and, was apparently chased to give the TCV virion gp 100.", [["gp 170", "GENE_OR_GENE_PRODUCT", 109, 115], ["gp 170", "PROTEIN", 109, 115], ["TCV virion gp 100", "PROTEIN", 155, 172], ["non-glycosylated polypeptide", "TREATMENT", 17, 45], ["the TCV virion gp", "TREATMENT", 151, 168]]], ["Whether these two intracetlular polypeptides are in fact related remains to be demonstrated.", [["intracetlular polypeptides", "GENE_OR_GENE_PRODUCT", 18, 44], ["these two intracetlular polypeptides", "PROBLEM", 8, 44], ["two", "OBSERVATION_MODIFIER", 14, 17], ["intracetlular", "OBSERVATION_MODIFIER", 18, 31], ["polypeptides", "OBSERVATION", 32, 44]]], ["It may be possible that a certain amount of a primary E2 apoprotein is cleaved and then further glycosylated to give the final gp 100-120.", [["E2", "CHEMICAL", 54, 56], ["E2", "GENE_OR_GENE_PRODUCT", 54, 56], ["primary E2 apoprotein", "PROTEIN", 46, 67], ["gp 100-120", "PROTEIN", 127, 137], ["a primary E2 apoprotein", "TREATMENT", 44, 67], ["may be possible", "UNCERTAINTY", 3, 18]]], ["A recent study on the intracellular processing of measles virus F and HA proteins demonstrated that glycosylation was essential to the post-translation proteolytic cleavage to proceed [30] .", [["intracellular", "ANATOMY", 22, 35], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 22, 35], ["measles virus F", "ORGANISM", 50, 65], ["HA proteins", "GENE_OR_GENE_PRODUCT", 70, 81], ["measles virus F and HA proteins", "PROTEIN", 50, 81], ["measles virus", "SPECIES", 50, 63], ["measles virus", "SPECIES", 50, 63], ["A recent study", "TEST", 0, 14], ["the intracellular processing", "TEST", 18, 46], ["measles virus F", "TREATMENT", 50, 65], ["HA proteins", "PROBLEM", 70, 81], ["glycosylation", "TREATMENT", 100, 113]]], ["Similarly, results obtained with coronavirus MHV-A59 have suggested that the proteolytic cleavage of E2 was a post-translational event that occured only after assembling of the virion and further processing of the E2 protein in the Golgi apparatus [-12, 20, 273 .", [["Golgi apparatus", "ANATOMY", 232, 247], ["E2", "CHEMICAL", 101, 103], ["E2", "CHEMICAL", 214, 216], ["coronavirus MHV-A59", "ORGANISM", 33, 52], ["E2", "GENE_OR_GENE_PRODUCT", 101, 103], ["virion", "CELLULAR_COMPONENT", 177, 183], ["E2", "GENE_OR_GENE_PRODUCT", 214, 216], ["Golgi", "CELLULAR_COMPONENT", 232, 237], ["E2 protein", "PROTEIN", 214, 224], ["coronavirus MHV", "SPECIES", 33, 48], ["coronavirus MHV-A59", "SPECIES", 33, 52], ["coronavirus MHV", "TEST", 33, 48], ["the proteolytic cleavage of E2", "PROBLEM", 73, 103], ["the virion", "PROBLEM", 173, 183], ["the E2 protein", "TEST", 210, 224]]], ["With TCV, gp 100 and gp 120 species were also demonstrated after treatment with monensin, an inhibitor of the Golgi function, suggesting that the first glycosylation acquired in the RER may be sufficient.DiscussionThe 90K protein may also represent a host cell component similar in mol.wt. to a group of resident proteins of the ER identified as putative receptors or carriers involved in the RER-Golgi translocation step [133.", [["Golgi", "ANATOMY", 110, 115], ["cell", "ANATOMY", 256, 260], ["RER-Golgi", "ANATOMY", 393, 402], ["monensin", "CHEMICAL", 80, 88], ["monensin", "CHEMICAL", 80, 88], ["TCV", "ORGANISM", 5, 8], ["gp 100", "GENE_OR_GENE_PRODUCT", 10, 16], ["gp", "GENE_OR_GENE_PRODUCT", 21, 23], ["monensin", "SIMPLE_CHEMICAL", 80, 88], ["Golgi", "CELLULAR_COMPONENT", 110, 115], ["RER", "CELLULAR_COMPONENT", 182, 185], ["cell", "CELL", 256, 260], ["ER", "GENE_OR_GENE_PRODUCT", 329, 331], ["Golgi", "CELLULAR_COMPONENT", 397, 402], ["gp 120 species", "PROTEIN", 21, 35], ["90K protein", "PROTEIN", 218, 229], ["resident proteins", "PROTEIN", 304, 321], ["ER", "PROTEIN", 329, 331], ["putative receptors", "PROTEIN", 346, 364], ["TCV", "TEST", 5, 8], ["gp", "TEST", 10, 12], ["gp 120 species", "TEST", 21, 35], ["monensin", "TREATMENT", 80, 88], ["an inhibitor", "TREATMENT", 90, 102], ["the Golgi function", "TEST", 106, 124], ["the first glycosylation", "PROBLEM", 142, 165], ["The 90K protein", "TEST", 214, 229], ["a host cell component", "PROBLEM", 249, 270], ["may also represent", "UNCERTAINTY", 230, 248], ["host cell", "OBSERVATION", 251, 260], ["component", "OBSERVATION_MODIFIER", 261, 270], ["similar", "OBSERVATION_MODIFIER", 271, 278]]], ["The \"glucose-regulated proteins\" grp78 and grp94, for example, have been identified in the lumen of the ER of a large number of different types of mammalian cells [243.DiscussionRecently, it has been demonstrated that unassembled or incorrectly assembled HA protein of influenza virus is prevented from leaving ER, being complexed to a cellular protein with approximate mol.wt, of 90,000 resident in the lumen of ER [14] .", [["lumen", "ANATOMY", 91, 96], ["ER", "ANATOMY", 104, 106], ["cells", "ANATOMY", 157, 162], ["cellular", "ANATOMY", 336, 344], ["lumen", "ANATOMY", 404, 409], ["glucose", "CHEMICAL", 5, 12], ["influenza", "DISEASE", 269, 278], ["glucose", "CHEMICAL", 5, 12], ["glucose", "SIMPLE_CHEMICAL", 5, 12], ["grp78", "GENE_OR_GENE_PRODUCT", 33, 38], ["grp94", "GENE_OR_GENE_PRODUCT", 43, 48], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 91, 96], ["ER", "GENE_OR_GENE_PRODUCT", 104, 106], ["mammalian cells", "CELL", 147, 162], ["HA", "GENE_OR_GENE_PRODUCT", 255, 257], ["influenza virus", "ORGANISM", 269, 284], ["ER", "GENE_OR_GENE_PRODUCT", 311, 313], ["cellular", "CELL", 336, 344], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 404, 409], ["ER", "GENE_OR_GENE_PRODUCT", 413, 415], ["glucose-regulated proteins", "PROTEIN", 5, 31], ["grp78", "PROTEIN", 33, 38], ["grp94", "PROTEIN", 43, 48], ["ER", "PROTEIN", 104, 106], ["mammalian cells", "CELL_TYPE", 147, 162], ["HA protein", "PROTEIN", 255, 265], ["ER", "PROTEIN", 311, 313], ["cellular protein", "PROTEIN", 336, 352], ["ER", "PROTEIN", 413, 415], ["influenza virus", "SPECIES", 269, 284], ["The \"glucose", "TEST", 0, 12], ["grp78", "TEST", 33, 38], ["grp94", "TEST", 43, 48], ["mammalian cells", "PROBLEM", 147, 162], ["influenza virus", "PROBLEM", 269, 284], ["wt", "TEST", 374, 376], ["lumen", "ANATOMY_MODIFIER", 91, 96], ["large", "OBSERVATION_MODIFIER", 112, 117], ["number", "OBSERVATION_MODIFIER", 118, 124], ["different types", "OBSERVATION_MODIFIER", 128, 143], ["mammalian cells", "OBSERVATION", 147, 162], ["influenza virus", "OBSERVATION", 269, 284], ["lumen", "ANATOMY_MODIFIER", 404, 409]]], ["A host-cell protein with similar mol.wt, also co-precipitated from lysates of measles virus-infected and TM-treated cells [30] .DiscussionPropolypeptides or primary-translation products with approximate mol.wts. of 127,000 to 146,000 have been predicted from the amino acid sequences determined by sequencing analysis of the genes encoding the E2 of IBV and MHV [1, 20, 31] .", [["cell", "ANATOMY", 7, 11], ["lysates", "ANATOMY", 67, 74], ["cells", "ANATOMY", 116, 121], ["measles virus-infected", "DISEASE", 78, 100], ["amino acid", "CHEMICAL", 263, 273], ["E2", "CHEMICAL", 344, 346], ["amino acid", "CHEMICAL", 263, 273], ["host-cell", "CELL", 2, 11], ["lysates", "ORGANISM_SUBSTANCE", 67, 74], ["measles virus", "ORGANISM", 78, 91], ["TM", "CELL", 105, 107], ["cells", "CELL", 116, 121], ["amino acid", "AMINO_ACID", 263, 273], ["E2", "GENE_OR_GENE_PRODUCT", 344, 346], ["IBV", "ORGANISM", 350, 353], ["host-cell protein", "PROTEIN", 2, 19], ["TM-treated cells", "CELL_LINE", 105, 121], ["primary-translation products", "PROTEIN", 157, 185], ["measles virus", "SPECIES", 78, 91], ["measles virus", "SPECIES", 78, 91], ["IBV", "SPECIES", 350, 353], ["MHV", "SPECIES", 358, 361], ["wt", "TEST", 37, 39], ["lysates", "TEST", 67, 74], ["measles virus", "PROBLEM", 78, 91], ["DiscussionPropolypeptides", "TREATMENT", 128, 153], ["primary-translation products", "TREATMENT", 157, 185], ["the amino acid sequences", "TEST", 259, 283], ["sequencing analysis", "TEST", 298, 317]]], ["Non-glycosylated polypeptides with apparent mol.wts, of 120-130,000 and 150,000 were immunoprecipitated from extracts of TCV-infected, TM-treated cells.", [["extracts", "ANATOMY", 109, 117], ["cells", "ANATOMY", 146, 151], ["TCV-infected", "DISEASE", 121, 133], ["extracts", "ORGANISM_SUBSTANCE", 109, 117], ["TCV", "ORGANISM", 121, 124], ["TM", "CELL", 135, 137], ["cells", "CELL", 146, 151], ["TCV-infected, TM-treated cells", "CELL_LINE", 121, 151], ["TCV", "SPECIES", 121, 124], ["Non-glycosylated polypeptides", "TREATMENT", 0, 29], ["wts", "TEST", 48, 51], ["TCV", "TEST", 121, 124], ["infected", "PROBLEM", 125, 133], ["infected", "OBSERVATION", 125, 133]]], ["The new intracellular polypeptides were also identified by Western-immunoblotting.", [["intracellular", "ANATOMY", 8, 21], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 8, 21], ["The new intracellular polypeptides", "PROBLEM", 0, 34], ["new", "OBSERVATION_MODIFIER", 4, 7], ["intracellular polypeptides", "OBSERVATION", 8, 34]]], ["Although a definitive precursor-final product relationship was not demonstrated with E2 or E 3, the latter were not synthesized in the presence of TM.", [["E2", "CHEMICAL", 85, 87], ["E2 or E 3", "CHEMICAL", 85, 94], ["E2", "SIMPLE_CHEMICAL", 85, 87], ["E 3", "GENE_OR_GENE_PRODUCT", 91, 94]]], ["This was confirmed by radiolabeling with glucosamine and by EM.", [["glucosamine", "CHEMICAL", 41, 52], ["glucosamine", "CHEMICAL", 41, 52], ["glucosamine", "SIMPLE_CHEMICAL", 41, 52], ["glucosamine", "TREATMENT", 41, 52]]], ["Both surface glycoproteins of the TCV virions thus possess N-linked oligosaccharides.", [["surface", "ANATOMY", 5, 12], ["N", "CHEMICAL", 59, 60], ["TCV virions", "ORGANISM", 34, 45], ["surface glycoproteins", "PROTEIN", 5, 26], ["N-linked oligosaccharides", "PROTEIN", 59, 84], ["TCV", "SPECIES", 34, 37], ["the TCV virions", "TREATMENT", 30, 45], ["surface", "OBSERVATION_MODIFIER", 5, 12], ["glycoproteins", "OBSERVATION", 13, 26]]], ["The observation that the nonglycosylated polypeptides were only detected in the presence of this glycosylation inhibitor indicated that glycosylation of the E2 and E3 was initiated at the co-translational level.", [["E2", "CHEMICAL", 157, 159], ["E2", "GENE_OR_GENE_PRODUCT", 157, 159], ["E3", "GENE_OR_GENE_PRODUCT", 164, 166], ["E2", "PROTEIN", 157, 159], ["E3", "PROTEIN", 164, 166], ["the nonglycosylated polypeptides", "PROBLEM", 21, 53], ["this glycosylation inhibitor", "TREATMENT", 92, 120], ["glycosylation of the E2 and E3", "TREATMENT", 136, 166]]], ["This is, again, typical for N-glycosidic linkages.", [["N", "CHEMICAL", 28, 29], ["glycosidic linkages", "OBSERVATION", 30, 49]]], ["The accumulation of amorphous material in the cysternae of TCV-infected, TM-treated cells may result from the rapid degradation of these putative non-glycosylated precursors.", [["cysternae", "ANATOMY", 46, 55], ["cells", "ANATOMY", 84, 89], ["TCV-infected", "DISEASE", 59, 71], ["cysternae", "CANCER", 46, 55], ["TCV", "ORGANISM", 59, 62], ["TM", "CELL", 73, 75], ["cells", "CELL", 84, 89], ["TCV-infected, TM-treated cells", "CELL_LINE", 59, 89], ["The accumulation of amorphous material", "PROBLEM", 0, 38], ["TCV", "PROBLEM", 59, 62], ["infected", "PROBLEM", 63, 71], ["TM-treated cells", "TREATMENT", 73, 89], ["the rapid degradation of these putative non-glycosylated precursors", "PROBLEM", 106, 173], ["accumulation", "OBSERVATION_MODIFIER", 4, 16], ["amorphous material", "OBSERVATION", 20, 38], ["infected", "OBSERVATION", 63, 71], ["rapid", "OBSERVATION_MODIFIER", 110, 115], ["non-glycosylated precursors", "OBSERVATION", 146, 173]]], ["Monensin has been shown to produce an intra Golgi blockade of a number of secretory proteins by collapsing the hydrogen ion gradient across cellular membranes [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] .", [["Golgi", "ANATOMY", 44, 49], ["cellular membranes", "ANATOMY", 140, 158], ["Monensin", "CHEMICAL", 0, 8], ["hydrogen", "CHEMICAL", 111, 119], ["Monensin", "CHEMICAL", 0, 8], ["hydrogen", "CHEMICAL", 111, 119], ["Monensin", "SIMPLE_CHEMICAL", 0, 8], ["Golgi", "CELLULAR_COMPONENT", 44, 49], ["hydrogen", "SIMPLE_CHEMICAL", 111, 119], ["cellular membranes", "CELLULAR_COMPONENT", 140, 158], ["[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13]", "SIMPLE_CHEMICAL", 159, 214], ["secretory proteins", "PROTEIN", 74, 92], ["Monensin", "TREATMENT", 0, 8], ["collapsing the hydrogen ion gradient across cellular membranes", "PROBLEM", 96, 158]]], ["It thus blocks \"O\" glycosylation, but not N-glycosylation which occurs in the RER.", [["O", "CHEMICAL", 16, 17], ["N", "CHEMICAL", 42, 43], ["RER", "CELLULAR_COMPONENT", 78, 81], ["glycosylation", "TREATMENT", 19, 32], ["glycosylation", "TREATMENT", 44, 57]]], ["The 100K and t40K species were heavily labeled with glucosamine in the presence of monensin, which further supported the results obtained with TM.DiscussionThe unglycosylated 60,000 and 130,000 mol.wt, proteins species immunoprecipitated from extracts of TCV-infected cells, and the virion 62-65,000 and 140,000 mol.wt, glycoproteins appear to be different forms of the same viral protein.", [["extracts", "ANATOMY", 243, 251], ["cells", "ANATOMY", 268, 273], ["K", "CHEMICAL", 7, 8], ["glucosamine", "CHEMICAL", 52, 63], ["monensin", "CHEMICAL", 83, 91], ["glucosamine", "CHEMICAL", 52, 63], ["monensin", "CHEMICAL", 83, 91], ["glucosamine", "SIMPLE_CHEMICAL", 52, 63], ["monensin", "SIMPLE_CHEMICAL", 83, 91], ["mol.wt", "GENE_OR_GENE_PRODUCT", 194, 200], ["extracts", "ORGANISM_SUBSTANCE", 243, 251], ["TCV", "ORGANISM", 255, 258], ["cells", "CELL", 268, 273], ["mol.wt", "GENE_OR_GENE_PRODUCT", 312, 318], ["100K and t40K species", "PROTEIN", 4, 25], ["unglycosylated 60,000 and 130,000 mol.wt", "PROTEIN", 160, 200], ["TCV-infected cells", "CELL_TYPE", 255, 273], ["virion 62-65,000", "PROTEIN", 283, 299], ["viral protein", "PROTEIN", 375, 388], ["TCV", "SPECIES", 255, 258], ["The 100K and t40K species", "TEST", 0, 25], ["glucosamine", "TREATMENT", 52, 63], ["monensin", "TREATMENT", 83, 91], ["The unglycosylated", "TEST", 156, 174], ["proteins species", "TEST", 202, 218], ["TCV", "TEST", 255, 258], ["infected cells", "PROBLEM", 259, 273], ["the virion", "TEST", 279, 289], ["glycoproteins", "TREATMENT", 320, 333], ["infected cells", "OBSERVATION", 259, 273]]], ["The non-glycosylated p60 may correspond to the precursor protein, which undergoes glycosylation to yield the gp62-65 species, before rapid dimerization by disulfide bonds to yield gp 130, as suggested by electrophoresis in the presence of 2-ME.", [["gp62-65", "CHEMICAL", 109, 116], ["disulfide", "CHEMICAL", 155, 164], ["p60", "GENE_OR_GENE_PRODUCT", 21, 24], ["disulfide bonds", "SIMPLE_CHEMICAL", 155, 170], ["gp 130", "GENE_OR_GENE_PRODUCT", 180, 186], ["non-glycosylated p60", "PROTEIN", 4, 24], ["precursor protein", "PROTEIN", 47, 64], ["gp62-65 species", "PROTEIN", 109, 124], ["gp 130", "PROTEIN", 180, 186], ["the precursor protein", "PROBLEM", 43, 64], ["glycosylation", "TREATMENT", 82, 95], ["the gp62", "TEST", 105, 113]]], ["A further glycosylation step would result to the final E3 protein, as described for BCV [9, 10] .DiscussionThe fact that E 1 was not detected in lysates of methionine labeled TCVinfected, TM-treated cells, is suggestive of a N-linked glycosylation.", [["lysates", "ANATOMY", 145, 152], ["cells", "ANATOMY", 199, 204], ["methionine", "CHEMICAL", 156, 166], ["TCVinfected", "CHEMICAL", 175, 186], ["methionine", "CHEMICAL", 156, 166], ["N", "CHEMICAL", 225, 226], ["E3", "GENE_OR_GENE_PRODUCT", 55, 57], ["E 1", "GENE_OR_GENE_PRODUCT", 121, 124], ["lysates", "ORGANISM_SUBSTANCE", 145, 152], ["methionine", "SIMPLE_CHEMICAL", 156, 166], ["TCVinfected", "SIMPLE_CHEMICAL", 175, 186], ["cells", "CELL", 199, 204], ["E3 protein", "PROTEIN", 55, 65], ["E 1", "DNA", 121, 124], ["methionine labeled TCVinfected, TM-treated cells", "CELL_LINE", 156, 204], ["A further glycosylation step", "TREATMENT", 0, 28], ["BCV", "TEST", 84, 87], ["methionine", "TEST", 156, 166], ["a N-linked glycosylation", "PROBLEM", 223, 247], ["suggestive of", "UNCERTAINTY", 209, 222]]], ["The absence in the same gel of the 36-42,000 mol.wt, species, probably corresponding to an aggregated form of E1 [10, 15, 38, 39] , and the presence of E1 in lysates of TCV-infected, SM-treated cells, further supported this notion.", [["lysates", "ANATOMY", 158, 165], ["cells", "ANATOMY", 194, 199], ["TCV-infected", "DISEASE", 169, 181], ["SM", "CHEMICAL", 183, 185], ["E1", "GENE_OR_GENE_PRODUCT", 110, 112], ["E1", "GENE_OR_GENE_PRODUCT", 152, 154], ["lysates", "ORGANISM_SUBSTANCE", 158, 165], ["TCV", "ORGANISM", 169, 172], ["SM", "CELL", 183, 185], ["cells", "CELL", 194, 199], ["E1", "PROTEIN", 152, 154], ["TCV-infected, SM-treated cells", "CELL_LINE", 169, 199], ["TCV", "SPECIES", 169, 172], ["TCV", "TEST", 169, 172], ["infected", "PROBLEM", 173, 181], ["SM-treated cells", "PROBLEM", 183, 199]]], ["In this respect, TCV differs from viruses of the subgroup of mammalian hemagglutinating coronaviruses [9, 18] , but resembles IBV [2, 3, 37] .", [["hemagglutinating coronaviruses", "DISEASE", 71, 101], ["TCV", "ORGANISM", 17, 20], ["mammalian hemagglutinating coronaviruses", "ORGANISM", 61, 101], ["IBV", "ORGANISM", 126, 129], ["TCV", "SPECIES", 17, 20], ["IBV", "SPECIES", 126, 129], ["mammalian hemagglutinating coronaviruses", "PROBLEM", 61, 101], ["hemagglutinating coronaviruses", "OBSERVATION", 71, 101]]], ["Whereas glycosylation of glycoproteins with N-glycosidic linkages is generally initiated at the co-translational level, glycosylation of E 1 of TCV appears to be exclusively a posttranslational event.", [["N-glycosidic", "CHEMICAL", 44, 56], ["N", "CHEMICAL", 44, 45], ["E 1", "GENE_OR_GENE_PRODUCT", 137, 140], ["TCV", "ORGANISM", 144, 147], ["E 1", "PROTEIN", 137, 140], ["glycosylation of glycoproteins", "TREATMENT", 8, 38], ["N-glycosidic linkages", "TREATMENT", 44, 65], ["glycosylation of E", "TREATMENT", 120, 138], ["TCV", "TREATMENT", 144, 147], ["a posttranslational event", "PROBLEM", 174, 199]]], ["This is suggested by the observation that apoprotein precursor of E 1 (p20) was present in TCV-infected cells prior gp24.", [["cells", "ANATOMY", 104, 109], ["apoprotein precursor of E 1", "GENE_OR_GENE_PRODUCT", 42, 69], ["p20", "GENE_OR_GENE_PRODUCT", 71, 74], ["TCV", "ORGANISM", 91, 94], ["cells", "CELL", 104, 109], ["gp24", "GENE_OR_GENE_PRODUCT", 116, 120], ["E 1", "PROTEIN", 66, 69], ["p20", "PROTEIN", 71, 74], ["TCV-infected cells", "CELL_LINE", 91, 109], ["gp24", "PROTEIN", 116, 120], ["apoprotein precursor of E", "TEST", 42, 67], ["infected cells", "OBSERVATION", 95, 109]]], ["For TCV and IBV, E 1 therefore constitutes an example of a membrane glycoprotein that is targeted to the ER and is not subsequently directed further along the secretory pathway.", [["membrane", "ANATOMY", 59, 67], ["ER", "ANATOMY", 105, 107], ["TCV", "ORGANISM", 4, 7], ["IBV", "ORGANISM", 12, 15], ["E 1", "GENE_OR_GENE_PRODUCT", 17, 20], ["membrane", "CELLULAR_COMPONENT", 59, 67], ["ER", "GENE_OR_GENE_PRODUCT", 105, 107], ["E 1", "DNA", 17, 20], ["membrane glycoprotein", "PROTEIN", 59, 80], ["ER", "PROTEIN", 105, 107], ["TCV", "SPECIES", 4, 7], ["IBV", "SPECIES", 12, 15], ["TCV", "PROBLEM", 4, 7], ["a membrane glycoprotein", "PROBLEM", 57, 80]]], ["As previously reported for IBV and MHV [3, 16, 37] , E 1 appeared to be the only glycoprotein required for the formation of TCV virions, and its glycosylation is apparently not essential [3, 37] .", [["IBV", "ORGANISM", 27, 30], ["MHV", "ORGANISM", 35, 38], ["E 1", "GENE_OR_GENE_PRODUCT", 53, 56], ["TCV", "ORGANISM", 124, 127], ["glycoprotein", "PROTEIN", 81, 93], ["IBV", "SPECIES", 27, 30], ["MHV", "SPECIES", 35, 38], ["TCV", "SPECIES", 124, 127], ["IBV", "PROBLEM", 27, 30], ["MHV", "TEST", 35, 38], ["TCV virions", "TREATMENT", 124, 135]]], ["Arrest of virus budding, as demonstrated in MHV-infected cells cultivated in the presence of monensin [23] , was not demonstrated in TCV-infected cells in the presence of TM.", [["cells", "ANATOMY", 57, 62], ["cells", "ANATOMY", 146, 151], ["MHV-infected", "DISEASE", 44, 56], ["monensin", "CHEMICAL", 93, 101], ["TCV-infected", "DISEASE", 133, 145], ["monensin", "CHEMICAL", 93, 101], ["MHV", "ORGANISM", 44, 47], ["cells", "CELL", 57, 62], ["monensin [23]", "SIMPLE_CHEMICAL", 93, 106], ["TCV", "ORGANISM", 133, 136], ["cells", "CELL", 146, 151], ["MHV-infected cells", "CELL_LINE", 44, 62], ["TCV-infected cells", "CELL_LINE", 133, 151], ["MHV", "SPECIES", 44, 47], ["TCV", "SPECIES", 133, 136], ["Arrest of virus budding", "PROBLEM", 0, 23], ["infected cells", "PROBLEM", 48, 62], ["monensin", "TREATMENT", 93, 101], ["infected cells", "PROBLEM", 137, 151], ["virus", "OBSERVATION", 10, 15], ["MHV", "ANATOMY", 44, 47], ["infected cells", "OBSERVATION", 48, 62], ["infected cells", "OBSERVATION", 137, 151]]], ["This strengthens the notion that glycosylation of E 1 is not necessary for virus budding.", [["E 1", "GENE_OR_GENE_PRODUCT", 50, 53], ["E 1", "PROTEIN", 50, 53], ["glycosylation of E", "TREATMENT", 33, 51], ["virus budding", "PROBLEM", 75, 88]]]]}